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Abstract 
 
Pathway based and genome wide association studies aim to identify alleles of 
low/moderate risk that may account for the development of EOC not attributed to high 
risk susceptibility genes. 
The aim of this study was to investigate the functional role of low/moderate 
susceptibility SNPs and candidate genes that emerge from candidate gene approaches 
and GWAS using tumour tissues or appropriate models from the proposed cells of 
origin for EOC, normal Ovarian Surface Epithelium (NOSE), Fallopian Tube Epithelium 
(FTE) respectively. Part of this study focused in establishing NOSE, FTE and EOC cell 
lines to study differential expression of candidate genes in post-GWAS functional 
characterisation studies. Additionally, I have established 3D FTE cultures and propose 
they more closely resemble the in vivo characteristics than 2D cultures.  
A candidate gene approach has identified nine candidate genes. I tested 301 
invasive EOC tumours and found frequent LOH for tagging SNPs in those genes. LOH 
was associated with worse survival for AXIN2, CASP5, RRBBP8 and AIFM2 but the 
result for AXIN2, CASP5 and AIFM2 were associated with stage. Additionally, one SNP 
in STAG3 showed significant preferential loss of the common allele. 
Six loci containing susceptibility SNPs were identified in an ovarian cancer 
GWAS. I found compelling evidence for the somatic role of several genes within these 
loci in EOC development based on their differential expression between normal (NOSE 
& FTE) and EOC cell lines. These genes included PVT1, SP2, CBX1, PNPO, HAUS8, 
USE1, SKAP1, MERIT40 and members of the HOXB family of genes with an observed 
gain of function role and TIPARP and BNC2 with an observed loss of function role in 
EOC development. Additionally, I found weak associations of susceptibility SNPs’ 
genotypes with CBX1, SNX11, SP2 and HOXD1 expression and compelling evidence 
of genotype specific methylation of HOXB5 using non tumour samples.  
I further knocked down MERIT40 in EOC cell lines to study the potential role of 
the gene in EOC development. I found that MERIT40 depletion led to increased 
accumulation of spontaneous DNA damage and cell cycle arrest characterised by 
reduction in ploidy of the mucinous EOC cell line EFO27. 
This study provides functional evidence that GWAS are powerful tools for 
identifying novel genes implicated with EOC and that further functional investigation of 
GWAS identified loci leads to a better understanding of the molecular players involved 
in EOC initiation, development and survival. 
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1 Literature review 
 
 Epithelial Ovarian Cancer: An overview 1.1
Epithelial ovarian cancer (EOC) constitutes up to 90% of primary ovarian 
tumours. It is the most common cause of gynaecological cancer deaths and the 
fifth most common cancer responsible for female fatalities due to cancer (Shan 
et al, 2009) with survival rates not improving over the last twenty years (Figure 
1.1). In 2002 EOC accounted for 125,000 deaths per year out of 200,000 
incidents occurring worldwide (Parkin et al, 2005), increasing to 225,000 
incidents and 140,200 deaths in 2008 (Jemal et al, 2011). The risk of incidence 
for EOC is as high as 1% for the total female population with a 60% risk of 
mortality for the inflicted population (Jemal et al, 2011).  
One of the reasons that the mortality rates for ovarian cancer are so high 
is that about 70% of the women are diagnosed at advanced stages of the 
disease (Goff et al, 2007). Early diagnosis can be difficult since the symptoms, 
in most cases, are not evident in early disease. Several studies have tried to 
identify a panel of symptoms in early disease that would help early referral of 
women to a gynaecologist. Most of the reported symptoms are gastrointestinal 
and urinary symptoms such as persistent abdominal distension, some loss of 
appetite, pain in the abdomen, fatigue, increased urinary frequency and 
constipation (Goff et al, 2007, Bankhead et al, 2008). Some studies report that 
gynaecological symptoms are not evident (Goff et al, 2007), which is 
contradicted by other studies that have proposed vaginal bleeding independent 
of menstrual cycle as a symptom (Lurie et al, 2009). 
When ovarian cancer is suspected, screening is performed by 
transvaginal ultrasonography and the measurement of tumour marker cancer 
antigen CA125 in the blood of the patients is taken (Cannistra et al, 2004). 
Epithelial ovarian cancer diagnosis is staged during laparotomic procedures and 
confirmed by biopsy and histopathological examination of the tumour by a 
pathologist where the grade of the disease is assigned to the tumour according 
to the International Federation of Gynaecology and Obstetrics (FIGO) (Nam et 
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al, 2010). Recent studies have shown that a more reliable method for 
diagnosing malignant EOC and revealing metastatic disease is positron 
emission tomography/computed tomography (Nam et al, 2009). 
According to FIGO there are 4 stages of EOC, Stage I is when the 
tumour is limited to the ovaries, stage II when there is pelvic extension of the 
ovarian tumour to structures like the uterus, fallopian tubes or pelvic 
peritoneum, stage III when the tumour involves the upper abdomen and lymph 
nodes are involved and Stage IV when there is apparent metastasis in distal 
organs (Cannistra, 2004). Unfortunately, early stages of EOC rarely exhibit 
symptoms that will alert the patient to proceed with screening and therefore 
diagnosis is made mostly at later stages of the disease when the survival rates 
are significantly reduced (Brun et al, 2000) as documented  by Cancer 
Research UK (Figure 1.1). 
 
 
 
 
 
 
 
 
 
Figure 1.1: Stage of epithelial ovarian cancer associated with survival from disease.
Five year stage specific relative survival rates in the UK over the last 20 years as 
published on March 2011 by Cancer research UK, [Adults (Ages 15-99),Anglia Cancer 
Network, 1987-2008)]. (http://www.cancerresearchuk.org/cancer-info/cancerstats/ 
types/ovary/survival/ovarian-cancer-survival-statistics). 
 
When EOC is confirmed and depending on the stage at diagnosis the 
patient would be subjected to total abdominal hysterectomy and/or combination 
chemotherapy. In early stage disease adjuvant platinum chemotherapy 
Access Restricted in the 
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including cisplatin and carboplatin is used post surgery whereas in advanced 
stage disease combination of platinum and taxane (the derivative paclitaxel) 
based chemotherapy is used pre and post surgery (Cannistra, 2004) and 
possibly radiotherapy as well (http://cancerhelp.cancerresearchuk.org/type/ 
ovarian-cancer/treatment/). 
EOC is a complex cancer regarding its initiation and also its metastasis 
due to the extreme molecular heterogeneity of the disease. Numerous studies 
have demonstrated several alterations in EOC that involve cell cycle regulation 
and DNA repair pathways as well as oncogenes and tumour suppressor genes 
(Darcy et al, 2010). Historically, the etiology for EOC has been studied through 
clinical observations but due to the lack of early stage specimens our 
understanding of the initiation and progression of the disease is still poor. The 
development of appropriate in vitro models and animal models is essential to 
study the underlying causes for EOC development. 
 
1.1.1 Subtypes of epithelial ovarian cancer  
EOC should not be treated as a single disease as it is stratified into 
various histological subtypes. All of the histological subtypes are distinct in their 
clinical behaviour as well genetic risk factors and molecular pathways 
implicated in their oncogenesis. Subtypes also have different responses to 
chemotherapy causing the 5-year survival time to be different for distinct 
subtypes (Kurian et al, 2005).  Reproducible sub-classification of EOC subtypes 
is very important and although classification of EOCs started as an empirical 
observation of traditional histomorphologic features, the classification has 
become more logical by linking these features with expression of particular 
biomarkers and mRNA profiling and clinical behaviour of the tumours. 
The most common histological subtypes of epithelial cancer are serous 
adenocarcinoma which is subdivided further into high grade serous and low-
grade serous, intestinal mucinous, endometrioid and clear-cell. All subtypes are 
characterised by mutations in different genes and expression of distinct 
biomarkers (Figure 1.2). Some subtypes are classed as undifferentiated or 
mixed which are most likely serous subtypes.  
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Serous carcinomas 
These are the most common amongst EOCs accounting for about 80% 
of all ovarian carcinomas and are evident in about 95% of patients diagnosed 
with FIGO stages III-IV (Soslow, 2008). The morphology of serous tumours is 
very heterogeneous which could possibly suggest that they arise from 
transformation or progression from other types of tumours. Their architecture is 
predominately papillary containing psammona bodies (Cannistra et al, 2005) 
mimicking yolk sack tumours but can also be glandular mimicking embryonal 
carcinomas or solid mimicking dysgerminomas (reviewed in Soslow, 2008).  
High grade serous carcinomas (HGSCs) and low grade serous 
carcinomas (LGSCs) exhibit very similar histologic appearance but as a first 
step for differential diagnosis, searching for a precursor lesion is indicative, as 
high grade have been associated with tubal intraepithelial tumours and low 
grade associated with borderline grade tumours (Soslow, 2008). The 
discrimination between them is mainly based on some differences on their 
immunophenotype, genetic profile and their clinical behaviour.  
Whereas Wilms tumour 1 (WT1), mesothelin, oestrogen receptor (ER) 
and cancer antigen 125 (CA125) are commonly over-expressed in all serous 
carcinomas (SCs), p53 (tumour protein 53) and progesterone receptor (PR) 
over-expression are uniquely found in the high grade and low grade SCs 
respectively. Another major difference between the two grades is the 
significantly higher expression of the E3-ubiquitin-protein ligase Ki-67 (encoded 
by Mib-1) in high grade SCs (Köbel et al, 2008). High grade SCs frequently 
have BRCA1, BRCA2, TP53 and KRAS mutations whereas low grade SCs 
have mutations on KRAS and BRAF genes (Sieben et al, 2004, Risch et al, 
2006, Ahhmed et al, 2010).  
Some studies show that SCs have the highest mortality rates between all 
the EOC subtypes (Brun et al, 2000) with high grade SCs having the poorest 
prognosis but there is a lot of controversy on that subject as other studies 
reported SCs to be more responsive to cisplatin treatment together with 
endometrioid carcinomas (Shimizu et al, 1997). The improved response to 
cisplatin based chemotherapy is seen especially in patients bearing BRCA1 and 
BRCA2 germline mutations (found in high grade SCs) and thus having better 3-
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year survival rates of 60% in mutations carriers compared to 40% in non 
carriers (Ben et al, 2002). Recent evidence have shown that BRCA1 and 
BRCA2 mutation carriers have improved 5-year survival, 44% and 52% 
respectively compared to 36% of non-carriers and BRCA2 mutation carriers 
have the best prognosis (Bolton et al, 2012). 
 
Intestinal mucinous carcinomas 
Primary ovarian mucinous carcinomas (MCs) account for less than 3% of 
all ovarian carcinomas. About 65% of MCs are FIGO stage I and about 30% of 
all FIGO stage I patients have MCs. Their morphology is mainly glandular, and 
presence of intracytoplasmic mucin and goblet cells resembling the lining of the 
intestine (hence the description intestinal) are essential for a pathologist to 
classify a tumour as being mucinous. Mucinous borderline and benign tumours 
also exist and can be distinguished by the absence of goblet cells. Most primary 
mucinous carcinomas show transitions from cystadenomas to intestinal 
mucinous borderline to carcinoma (Soslow, 2008). 
MCs lack expression of ER, WT1 and CA125 and have high expression 
of CK7. They often have KRAS mutations but they do not possess BRCA1, 
BRCA2 and TP53 mutations often seen in SCs (Cuatrecasas et al, 1997). 
Mucinous tumours have been reported to belong to a cisplatin resistant group 
(together with clear cell carcinomas) by demonstrating only a 5% response to 
cisplatin based chemotherapy (Shimizu et al, 1997). However, Harrison et al 
have reviewed retrospective studies and show early MCs have a 90% 5-year 
survival rate whereas only advanced stage MCs present relative resistance to 
platinum based therapy, with overall response rates of 26-42 % to cisplatin 
based first line chemotherapy (Harrison et al, 2008).  
 
Endometrioid Carcinomas    
Endometrioid carcinomas (ECs) comprise the second most prevalent 
EOC subtype accounting for about 10% of all EOCs. Most ECs are classified as 
FIGO stage I and  II and they are the most frequent carcinomas observed in 
FIGO stage I patients constituting about 50% of all stage I cases. Their 
morphology can be papillary or glandular mimicking Sertoli-Leydig cell tumours, 
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or solid mimicking granulosa cell tumours. Their architecture resembles the 
endometrium epithelium and ECs have been associated with endometriosis, 
endometrioid borderline tumours, or an endometrioid type of synchronous 
endometrial neoplasms. 
Genetic alterations contributing to the development of ECs are PTEN 
mutations (Obata et al, 1998) and mutations in the CTNNB1 gene encoding for 
b-catenin (Sagae et al, 1999). The biggest challenge for the pathologists has 
been to discriminate between SCs and ECs given their molecular and 
morphological similarity. Studies have shown that high grade ECs lack 
expression of WT1 and p53 but have high expression of b-catenin whereas 
about 30% of low grade ECs exhibit p53 over-expression (Madore et al, 2009). 
Köbel and colleagues have also reported that ECs present high expression of 
p21, PR and ER.  
Endometrioid histology is associated with a better survival compared with 
SCs, regardless of response to platinum based chemotherapy (Storey et al, 
2008) and regardless of the fact ECs have been classified as cisplatin resistant 
ovarian carcinomas (Shimizu et al, 1997). 
 
Clear cell carcinomas 
Clear cell carcinomas (CCCs) account for about 5% of all ovarian 
tumours. Most CCCs are classified as FIGO stage I and  II and they are the 
second most frequent carcinomas observed in FIGO stage I patients 
constituting about 35% of all stage I cases. Their architecture is mainly 
tubulocystic, and solid. Similar to ECs they are associated with an origin of 
epithelial endometriosis (Soslow, 2008). The molecular events characterising 
the progression of CCCs are not as well described as for other subtypes. Some 
studies have reported mutations in the PTEN gene (Sato et al, 2000) and 
ARID1A, a gene involved in chromatin remodelling (Wiegand et al, 2010). The 
latter report showed presence of ARID1A mutations in ECs as well. These 
reports suggest that clear cell tumours could arise from ovarian and pelvic 
endometriosis.    
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Figure 1.2: Representation of the morphology, proposed precursor lesions, 
immunophenotype, genetic alterations and clinical behaviour of the five main subtypes 
of epithelial ovarian cancer. The high grade serous picture shows a papillary pattern 
and high nuclear grade. The low grade serous picture shows stromal invasion of low 
grade carcinoma in a borderline serous tumour. The mucinous picture shows mucinous 
borderline tumour (right part of the picture) continuing to mucinous carcinoma (left part 
of the picture). The endometrioid picture shows endometrioid adenocarcinoma arising 
from endometriosis. The clear cell picture shows clear cell carcinoma with microcystic 
pattern. The pictures of the H&E stained tumours were taken from Soslow, 2008 (high 
grade serous and clear cell) and Bell, 2005 (low grade, mucinous, endometrioid). TIC: 
tubal intraepithelial carcinoma. OSE: Ovarian surface epithelium.  
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1.1.2 Recent models for classification of epithelial ovarian tumours  
The histological subtypes of EOC have been more recently categorised 
into 2 different types, Type I and Type II tumours. This model does not replace 
the traditional histopathological classification for ovarian carcinoma but provides 
a framework for the study of ovarian carcinogenesis that is believed to have an 
important clinical implication as it proposes that the two genetically distinct 
types of EOC should be differentially treated. 
Type I epithelial ovarian tumours comprise of the less frequent low grade 
and borderline serous tumours as well as endometrioid, mucinous and clear-cell 
cancers. These histological subtypes are characterised by a distinct mutation 
spectrum that includes PTEN, PIK3CA, KRAS, BRAF and CTNNB1 mutations 
(Kurman et al, 2008, Steffensen et al, 2011).  Type II epithelial ovarian tumours 
comprise of the high-grade serous carcinomas, mixed malignant mesodermal 
tumours, carcinosarcomas and undifferentiated tumours. The majority of these 
tumours exhibit high prevalence of TP53 mutations and loss of BRCA1 (Kurman 
et al, 2008, Steffensen et al, 2011). The best serological biomarkers to date for 
the distinction of type I for type II EOC patients are p53 autoantibodies in 
combination with CA125 levels, which are absent in the blood of type I patients 
(Lu et al, 2011).  
This classification theory is supported by the dualistic model of serous 
carcinogenesis according to which the precursors of low-grade serous 
carcinomas are well characterised precursor lesions called borderline tumours, 
whereas high-grade-serous carcinomas are genetically distinct and to not 
represent a transition from low-grade to a high-grade phenotype but arise de 
novo (Singer et al, 2005). 
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 Risk and protection factors for ovarian cancer 1.2
A great proportion of ovarian cancer cases is associated with several risk 
factors including the incessant ovulation and endometriosis. Risks associated 
with genetic factors and hereditability (family history) will be also discussed 
later. Non genetic risk factors include ageing, the use of fertility drugs and 
hormone replacement therapy (HRT), using talc powder, being overweight, 
dietary habits and smoking. Protective factors include pregnancy/childbearing, 
breastfeeding, tubal ligation, use of the oral contraceptive pill and consumption 
of some painkillers. 
 
1.2.1 Risk Factors for ovarian cancer  
Ageing and ovarian cancer: More than 45% of women diagnosed with 
ovarian cancer are above 65 years old and the older the woman is the highest 
the risk of being diagnosed with higher stage of the disease (Yancik, 1993). 
According to the American National Cancer Institute more than 70% US 
incidence of ovarian cancer over the last 25 years affected women aged 65 or 
more years old (Figure 1.3). 
Use of fertility drugs and ovarian cancer: Infertility has been long 
recognised as a risk factor for ovarian cancer. Epidemiological studies have 
reported an increased risk to ovarian cancer amongst infertile women (Risch et 
al, 1994). Fertility drugs such as human menopausal gonadotropin have been 
associated with an elevated risk especially in borderline ovarian tumour cases 
(Harris et al, 1992, Goldberg et al, 1992). 
Use of hormone replacement therapy (HRT) and ovarian cancer:  
There are several types of HRT and include oestrogen and/or progesterone. 
Several studies, have reported that for women taking HRT more than 5 years 
the risk of ovarian cancer increases and the longer the consumption is 
continued the higher the risk (Folsom et al,. 2004, Beral et al, 2007). The most 
comprehensive study to date, known as the Million Women study showed that 
since 1991, the use of HRT has contributed to the development of 1300 
additional ovarian cancers and 1000 additional deaths in the UK alone (Beral et 
al, 2007).    
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Figure 1.3: Epithelial ovarian cancer incidence associated with age. A) Age adjusted 
rates per 100,000 of population for ovarian cancer in 6 different age groups. The 
incidence rate is significantly higher in the age groups above 65 years old. B) 
Percentage of ovarian cancer incidence as distributed between the different age 
groups. These graphs were designed from data downloaded from the National Cancer 
Institute and are presenting US incidence from 1992 to 2008 in all ethnic groups as 
reported by April 2011.  
 
Use of talc powder and ovarian cancer: The association between use 
of talcum powder genitally or perineally and risk for ovarian cancer has not been 
consistent amongst studies. Some studies have reported 30% increased risk 
associated with talcum use (Cramer et al, 1999 May, Cramer et al, 1999 July) or 
more modest associations (Rosenblatt et al, 2011), but other epidemiological 
studies did not support a causal association (Huncharek  et al, 2011)   
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Excess weight, diet, smoking and other risk factors and ovarian 
cancer: There are controversial data showing an association between the use 
of intra-uterine device and increased risk (Zapata et al, 2010). Conflicting data 
have also been described for lactose, saturated fat, and also excess weight as 
ovarian cancer risk factors (Cancer Research UK). Smoking has been 
associated with increased risk of mucinous cancer in a systematic review of 30 
case studies that investigated subtype specific ovarian cancer risk linked with 
smoking (Jordan et al, 2006) but the data are controversial. 
 
1.2.2 Protective factors for ovarian cancer 
Pregnancy: Pregnancy confers protection against ovarian cancer in line 
with the incessant ovulation hypothesis which will be later discussed. The 
ovarian surface repair does not take place during pregnancy as there are no 
ovulatory cycles. 
Tubal ligation: It has been shown that women that undergo tubal 
ligation as a method of sterilisation have a reduced risk in developing ovarian 
cancer (Tworoger et al, 2007, Cibula et al, 2011). The protective mode of tubal 
ligation could be attributed either by not allowing ovulation and in turn post-
ovulatory repair and also stopping the flow of hormones that make the ovarian 
microenvironment more mitogenic or by not allowing the cells from 
endometrium or endosalpinx to transport in the ovary (Dubeau, 2008). 
Use of the oral contraceptive (OC) pill: It is well established that use of 
the OC pill reduces the risk for ovarian cancer. The more prolonged the intake 
of OC the greater the reduction of the risk for ovarian cancer (Ness et al, 2001, 
La Vecchia, 2006, Tworoger et al, 2007). 
Breastfeeding: A large cohort study has reported a weak association of 
breastfeeding with reduction in the risk for ovarian cancer compared to women 
that never breastfed (Danforth et al, 2004) and other studies further supported 
this evidence. 
Consumption of painkillers: There is conflicting data on whether the 
use of anti-inflammatory drugs such as aspirin or paracetamol confers a 
protective role against ovarian cancer (Cancer research UK).  
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 Origins of Epithelial Ovarian Cancer  1.3
The genetic, clinical and histological heterogeneity observed in EOC 
subtypes is likely to be in part due to different cellular origins from which each 
histotype is derived. The site of origin and the initial events for tumorigenesis in 
EOC is a question that must be studied to improve earlier detection and better 
targeted treatments for distinct subtypes.  
Ovarian and generally pelvic malignancies are proposed to have three 
distinct sites of origin: 
1. The ovarian surface epithelium (OSE) 
2. The Fallopian tube epithelium (FTE) 
3. The peritoneal surface 
In an attempt to better classify the origins for each EOC subtype an overview 
through developmental and reproductive biology is essential. 
1.3.1 Development of the female reproductive tract and ovulation in 
adults 
Soon after fertilisation of the oocyte with a sperm, a single diploid cell is 
formed called a zygote. The zygote then undergoes cleavage (cell division) to 
form a single layer sphere of cells called blastula. Gastrulation is that point of 
embryonic development where a three layered structure, called gastrula, is 
formed from the blastula. These three layers are the ectoderm (outer layer), the 
mesoderm (intermediate layer) and the endoderm (inner layer). The 
development of the urogenital system, including the reproductive tract, starts 
soon after the gastrulation event when the mesoderm differentiates. The 
mesoderm segregates into the pluripotent mesenchyme, which will later give 
rise to the connective tissues, and the coelomic (peritoneal) mesothelium that 
gives rise to the müllerian duct. The müllerian mesothelium (müllerian duct), 
also known as the paramesonephric duct, in turn differentiates into oviductal, 
endometrial and cervical epithelia (Acien et al, 1992, Murdoch and McDonnel, 
2002, Kobayashi et al, 2003, Sajjad, 2010). 
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The involvement of homeobox genes across the Mullerian duct in the 
differentiation of the distinct organs has been well established with HOXA9 
highly expressed where the fallopian tube will develop, HOXA10 is expressed 
as the endometrium develops and HOXA11 is expressed in the lower cervix. 
HOXA genes are also activated in the relevant tissue of the adult female 
reproductive system (Taylor et al, 1997, Du and Taylor, 2004). 
Distinct from this müllerian developmental pathway, the ovarian cortex 
originates from invagination of the coelomic mesothelium over the gonadal ridge 
which is the precursor to the gonads (Byskov, 1986). The outer layer of the 
ovarian cortex consists of a single layered germinal epithelium known as the 
ovarian surface epithelium (OSE). OSE cells are supported by a basal layer of 
connective tissue called the tunica albuginea which is enriched with fibroblasts, 
endothelial, smooth muscle and interstitial cells.  
 
1.3.2 Ovarian Surface Epithelium origin of EOC 
A single cell of origin for EOC being the OSE has been widely accepted 
for several decades but the resemblance of epithelial ovarian tumours to organs 
and epithelium that derive via Mullerian development raised the question on 
whether there are additional sites of EOC initiation. 
OSE is a single layer of epithelial cells with cuboidal or squamous 
morphology. They are often described as uncommitted mesothelial cells 
expressing mesenchymal and epithelial markers due to their shared 
characteristics with the mesothelial lining of the peritoneum and normal 
epithelium. OSE cells have been isolated (Auersperg et al 1984) and their 
culturing conditions have been optimised using a 105:199 media supplemented 
with foetal bovine serum (FBS), insulin, bovine pituitary extract (BPE), 
hydrocortisone (HC, Li et al, 2004). OSE immortalisation (Maeda et al 2005) 
has also been established and optimised over the past decades. The fact that 
OSE cells have a great phenotypic plasticity has been considered an argument 
for their potential to differentiate into cancer cells (Connolly et al, 2003). 
The OSE has a well-established role in transporting nutrients and 
mediating the repair of the ovarian epithelium after ovulation. During ovulation 
the cell-cell adhesions between the OSE cells are broken down by excreted 
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lysozymes for the mature oocyte to be released. Following ovulation the OSE 
drastically proliferate at the site of the trauma and repair the surface. This 
vigorous healing process causes the formation of clefts in the cortical stroma. 
These clefts have the tendency to close up and form invaginations at the 
cortical ovarian stroma, and are then called cortical inclusion cysts (ICs). Within 
the ovarian stroma, the OSE-lined inclusion cysts are exposed to a more 
mitogenic environment that might be promoting tumour development (Burdette 
et al, 2007, Risch, 2007). 
There are three main hypotheses that support the OSE origin of ovarian 
carcinogenesis and there is a large amount of molecular evidence that support 
these theories: 
A) The incessant ovulation hypothesis 
The first one to suggest this hypothesis was Fathalla et al in 1971. She 
performed an experiment where hens were subjected in hyperovulation by 
exposing them to prolonged photostimulation and reported the development of 
ovarian adenocarcinomas in 17 out of 19 experimental subjects with the control 
hens remaining healthy (Fathalla, 1971). This hypothesis proposes that the 
higher the number of ovulation cycles in a lifetime of a female the higher the 
chances are for the repair mechanisms of OSE cells to become deranged.  
The underlying mechanism behind this hypothesis is that hormone 
oestrogen produced during ovulation is thought to promote this inclusion of OSE 
within the ovarian stroma at the formation of the described inclusion cysts and 
also affect mitotic activity of OSE causing unrepaired DNA damage and further 
leading to malignancy (Auersperg et al, 1998). To further support Fathalla’s 
proposal it has been subsequently shown, that ovulation triggers inflammation 
responses and the release of several cytokines and chemokines and these may 
contribute to DNA damage of OSE cells which in that mitogenic environment 
may lead to neoplastic transformations (Ness et al, 1999). There is evidence 
which support that ovulation induction is implicated with ovarian carcinoma 
development whereas oral contraception and pregnancy as previously 
discussed has a protective role (Chene et al, 2009).  
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B) The gonadotropin stimulation hypothesis 
This theory is based on the observation that the levels of the hormone 
gonadotropin are higher during the menstrual cycle when women ovulate than 
during pregnancy or while on oral contraceptive pill. Receptors for gonadotropin 
have been identified on OSE cells (Kang et al, 2001) and several studies 
suggest that synergistically with oestrogen, gonadotropin stimulates OSE 
proliferation and causes the induction of unrepaired DNA damage leading to 
malignancies (Konishi et al, 1999). Gonadotropin stimulation of human OSE 
cells can lead to increased proliferation and DNA synthesis as well as 
decreased cell death (Edmondson et al, 2006). The latter study also reported 
different responses from OSE derived from different women and suggested that 
the risk of EOC development may be dependent on the ability of OSE cells to 
respond to elevated levels of gonadotropins (Edmondson et al, 2006). The 
gonadotropin theory is also supported by the observation of increased ovarian 
cancer risk in postmenopausal women and women with polycystic ovaries 
where in both cases the levels of gonadotropin are especially high (Rossing et 
al, 1994) 
 
C) The hormone stimulation hypothesis 
Several studies have proposed the influence of other hormones to the 
development of epithelial ovarian cancer linked with OSE. Androgen levels 
when elevated have been linked with an increased risk with EOC as the OSE 
has an enzyme that can convert a weak androgen hormone, androstenedione 
to testosterone. This conversion leads to elevated levels of androgen in the 
plasma during ovulation but also at post-menopausal women and women with 
polycystic ovary syndrome. The OSE within inclusion cysts also gets over 
exposed to paracrine androgen hormones rather than circulating androgens and 
the increased incidence of EOC when these androgen levels are elevated 
suggests a role for the OSE in EOC development (Risch, 1998). OSE also has 
been reported to exhibit stimulation of DNA synthesis and proliferation after 
exposure to androgens in vitro (Edmondson et al, 2002).  
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Progesterone is a hormone that has been demonstrated to have a protective 
effect for EOC. This was based on the observation that pregnant women 
although having elevated levels of androgens in their plasma, they have even 
more elevated oestrogen and progesterone levels. Following the discovery of 
progesterone receptors on the ovarian epithelium, defects of the expression of 
these receptors has been suggested to lead to increased ovarian 
carcinogenesis (Risch, 1998). Another study suggested that progesterone 
prevents increased proliferation of the OSE by showing that progesterone 
receptor antagonists caused increased proliferation of OSE (Ivarsson et al, 
2001). 
 
1.3.2.1 Molecular and phenotypic evidence supporting OSE origin 
The presence of cortical inclusion cysts lined with ovarian surface 
epithelium in patients diagnosed with epithelial ovarian cancer suggests that 
these germinal inclusion cysts may play a role in ovarian carcinogenesis (Mittal 
et al, 1993). Epithelial inclusion cysts of BRCA1 and BRCA2 mutation carriers 
display frequent accumulation of p53 which is known as the neoplastic p53 
expression signature (Kerner et al, 2005, Pothuri et al, 2010) and another 
earlier study has shown that p53 expression was significantly elevated in 
inclusion cysts from patients with serous adenocarcinoma compared to normal 
and borderline adenocarcinoma (Hutson et al, 1995). This unique expression 
signature in the ovarian epithelial inclusion cysts is a representation of the 
oncogenic stress that causes increased growth signals and DNA damage which 
in turn lead to accumulation of p53. The frequent mutation of TP53 seen in high 
grade serous carcinomas may be explained if their precursor lesions are the 
epithelial inclusion cysts. 
The relationship between the expression of homeobox genes implicated 
in Mullerian development and lineage differentiation in EOC has also been 
demonstrated in studies where OSE cells were transfected with HOXA9, 
HOXA10 and HOXA11 and gave rise to serous, endometrioid and mucinous 
tumours respectively, suggesting that alterations in the HOX gene family in OSE 
cells may be an early event in tumourigenesis (Cheng et al, 2005, reviewed in 
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Naora 2007). The expression of the HOX genes in OSE that shares a common 
origin with the Mullerian derived tissues in development may be assigning a 
progenitor cell role to uncommitted OSE into adapting a Mullerian morphology 
and that might be answering to the paradox that EOC subtypes resemble more 
the Mullerian epithelial tissues.  
 
1.3.2.2 The role of epithelial-to-mesenchymal transition and 
mesenchymal-to-epithelial transition in OSE derived 
carcinogenesis  
Epithelial to mesenchymal transition (EMT) is a fundamental and 
conserved process during embryonic development, remodelling and restitution 
of tissue and wound repair. During these processes loss of cell-cell adhesion 
and increased cell movement is achieved and is characterised by distinct 
morphology of epithelial cells that acquire a mesenchymal phenotype (Thieri et 
al, 2003). The observed loss of differentiation, increased cell motility and 
invasion during EMT are characteristics of malignancy and it is now well 
established that carcinoma cells (epithelial derived tumours) are exploiting this 
mechanism to assimilate an increasingly aggressive phenotype especially 
relating to invasion and metastasis (Arias el al, 2001). 
The molecule that linked EMT with carcinoma formation is E-Cadherin, a 
cell adhesion marker that is maintaining the adherent junctions of cells and 
guarantees their polarization and architecture of epithelial tissue. Loss of E-
Cadherin is defining the development of epithelial tumours by increasing the 
invasiveness of cells and decreasing the intercellular adhesiveness. The 
important role that EMT has in carcinoma progression is supported by reports of 
several transcriptional repressors of E-cadherin such as Snail and Slug playing 
a key role in invasion and metastasis (Perl et al, 1998, Yang et al, 2005). The 
process of EMT is defined by E-Cadherin reduction and it’s been demonstrated 
to contribute in carcinoma development for colorectal (reviewed in Bates, 2005), 
gastric and breast cancer (Yang et al, 2005).The cells of origin for most 
epithelial cancers are more differentiated than the resulting tumours.  
This is where the ovarian cancer paradox lies, with EOCs exhibiting an 
architectural organisation and appearing more differentiated than the proposed 
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OSE precursor cells. This presented the biggest argument regarding the origin 
of ovarian cancers along with the diversity of the subtypes resembling other 
reproductive tract organs. OSE, unlike other epithelial cells, have an 
uncommitted phenotype with mixed epithelial (keratin expression) and 
mesenchymal morphology (MUC-1, Vimentin, smooth muscle actin α) that 
differentiates into different types in response to environmental signals 
(Auersperg et al, 2001). Additionally, they rarely express E-Cadherin. During 
post-ovulatory remodelling of the ovarian surface, OSE cells migrate from the 
ovarian surface to the cortical stroma or are trapped in the ruptured follicle and 
undergo EMT under the influence of factors like EGF (Epidermal Growth Factor) 
and TGF-β (Transforming Growth Factor), IL-6 and other cytokines which are all 
well characterised EMT inducing factors (Salamanca et al, 2004, Zavadil and 
Böttinger, 2005, Ahmed et al, 2006).  
The mesenchymal migratory characteristics conveyed by EMT to OSE 
cells at the position of the wound repair are for the purpose of repairing the 
scarred OSE and for allowing the OSE cells migrated within the stroma to 
incorporate with the stromal cells. The OSE cells that fail to undergo EMT are 
forming ‘foreign’ epithelial cell aggregates within the stroma resulting in the 
formation of the inclusion cysts which have been deemed as precursor lesions 
of ovarian carcinomas as discussed before. It is conceivable that the OSE lining 
the inclusion cysts after prolonged contact with all the EMT inducing factors 
within the ovarian stroma, undergo EMT, which similarly to other epithelial 
cancers may lead to neoplastic transformation. 
 It is interesting that the markers CA125 and E-Cadherin are expressed 
by the OSE cells lining of the inclusion cysts but not from OSE and both E-
Cadherin and CA125 are markers found in EOC samples (Auersperg et al, 
2001). The expression of E- Cadherin in tumour progression is controversial as 
there are reports that show that early (benign and borderline) ovarian tumours 
express E-Cadherin but the expression decreases as the tumours become 
more advanced (malignant) (Sundfeldt, 2003, Yoshida et al, 2009) but there is 
also evidence suggesting that the expression of E-Cadherin during cancer 
progression may be dynamic and highly contextual (Kowalski et al, 2003). This 
observation has set a role of mesenchymal to epithelial transition in the 
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progression of EOCs and could suggest an explanation to the paradox of the 
well-differentiated EOCs compared to other epithelial cancers. To summarise 
the proposed model, uncommitted OSE cells do not express E-Cadherin and if 
they fail to undergo EMT post ovulation they form inclusion cysts during which 
formation they undergo mesenchymal to epithelial transition (MET) and express 
E-Cadherin and also CA125. The epithelial lining of the ICs exposed to stromal 
stimulators is in turn undergoing EMT leading to tumour progression and 
advanced or secondary tumours can switch back to MET a process seen in 
other cancer metastasis as well (Okamoto et al, 2009). CA125 is also a marker 
that is expressed in the epithelium of the Mullerian ducts during development 
and this Mullerian type differentiation-metaplasia that OSE undergo in an adult 
female can help in understanding the development of so many different EOC 
subtypes. This may well be the indication that the Mullerian metaplasia to 
malignant progression is regulated by the microenvironment of the tumour and 
can exploit EMT or MET accommodated by the plasticity of OSE cells to easily 
differentiate.  
 
1.3.3 Fallopian tube and other cell type origins for EOC  
The mucosal epithelium of the fallopian tube (FT) consists of two cell 
types: ciliated and secretory. The ciliated cells are responsible for transportation 
of the ovum, sperm cell and the zygote. Ciliated cells express LhS28, a marker 
of basal bodies within the cilia, and Fox1, a transcription factor involved in 
ciliogenesis. The secretory cells secrete mucous that delays the progression of 
the spermatozoa through the fallopian tube. The secretory cells express Bcl-2 a 
mitochondrial suppressor of apoptosis and PAX8 a transcription factor involved 
in the development of reproductive tract (Levanon et al, 2010). Early serous 
carcinogenesis in the fallopian tube has presented elevated levels of another 
transcription factor seen in reproductive tract development, PAX2 (Chen et al, 
2010). 
Previous studies have tried to isolate epithelial cells of the fallopian 
mucosa using methods such as enzymatic treatment with trypsin and/or 
pancreatin. The epithelial status of the isolated cells was checked with 
cytokeratin antibodies of CK7, CK8, CK18, CK19 and PKK1. The lifespan of the 
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isolated cells was reported to be extremely short and those studies have failed 
to successfully subculture FT isolated cells (Henriksen et al, 1990, Comer et al, 
1998). In a recent study Levanon et al have created the first reported FT model 
for studying EOC development where ex vivo cultures of secretory and ciliated 
epithelial cells of the fallopian mucosa were created to recapitulate FT function 
in vivo (Levanon et al, 2010). No study to date has successfully subcultured and 
fully characterised an in vitro FT model. 
 
1.3.3.1 Molecular and phenotypic evidence supporting FT origin 
Lately there is increasing debate about whether the fallopian tube is the 
predominant site of the origin for HGSCs. This debate initially derived from the 
morphologic discontinuum of the OSE with high grade SCs which resemble 
more the fallopian tube epithelium. This observation together with data that fail 
to assign a precise percentage of serous carcinomas arising from the OSE 
(Deligdisch et al, 1999) has led to more thorough investigation for the origin of 
HGSCs. 
In the quest for a link between early malignancies in the FT and EOC 
development several studies have reported arguments to support this theory. 
The expression profiles of high grade SCs and the FT epithelium from BRCA1 
mutation carriers have been compared and exhibit striking similarities but differ 
to the expression profile of ovarian surface epithelium (Tone et al, 2008). 
Several studies have shown that in BRCA1 mutation carriers who have 
undergone prophylactic surgery several were found to have an early 
malignancy, termed as tubal intraepithelial carcinoma (TIC) as this malignancy 
in 100% of the cases was found to originate in the fimbrial/distal region of the 
fallopian tube (FT) (Piek et al, 2003, Medeiros et al, 2006, Callahan et al, 2007). 
Other studies have shown that ~70% of early malignancies in women that 
underwent prophylactic surgery were neoplastic transformation of the salpingeal 
mucosa (Powell et al, 2005, Kindelberger et al, 2007). Mutational analysis in 
TIC revealed TP53 mutations further supporting the distal fallopian tube origin 
for EOC (Kindelberger et al, 2007). Several studies have also shown a 
dominant tubal p53 signature of about 40% of cases from prophylactic surgeries 
(Folkins et al, 2008), with 95% located at the distal/fimbrial end of the fallopian 
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tubes (Leonhardt et al, 2011) and more specifically within segments of secretory 
cells (Lee et al, 2007).  
Kindelberger et al have taken recent research into account to draw a 
preliminary model of pelvic carcinogenesis. In Figure 1.4 the proposed models 
of pelvic carcinogenesis including ovarian cancer are shown. One pathway 
shows the traditional Mullerian origin where OSE contribute in the formation of 
Mullerian inclusions in the ovary leading into carcinogenesis. The second 
scenario proposes that early malignancies are formed in the fallopian tube and 
these clones later invade the ovarian surfaces leading into carcinogenesis. 
Additionally within that scenario, following endometriosis the endometrial cells 
are transported ectopically to the ovary to give rise to endometrioid carcinomas 
(Kindelberger et al, 2007, reviewed by Dubeau, 2008). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: Model proposing a multiplicity of sites of origin for the pathogenesis of 
EOC. Some tumours may arise from the OSE through Mullerian metaplasia, some after 
ectopic transportation of tumour cells from TIC in the distal end of the fallopian tubes 
and others from another source close to the ovarian surface such as the endometrium 
(Kindelberger et al, 2007).   
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 Animal and in vitro models used to study EOC  1.4
Experimental animal models for human disease and cancer are essential 
to help elucidate the biological and genetic factors that govern the phenotypic 
characteristics of the disease. Animal models have the advantage of studying 
the disease in the mammalian environment where the mechanisms of the 
effects of steroids and hormones can be better studied in regards to EOC 
initiation.  
There are three types of animal models for EOC tumourigenesis 
(reviewed in Vanderhyden et al, 2003): i) Animal models that develop ovarian 
tumours spontaneously such as hens and some strains of mice, but their low 
incidence make them a poor tool for experimental studies. ii) Animal models 
with xenografts of OSE cells transformed in vitro. Although this approach has 
allowed for evaluation of oncogenes that contribute to the development of EOC, 
it can also be used in the investigation of the initiation and early events of 
ovarian tumourigenesis. iii) The development of transgenic animals that will 
develop EOC with approaches to transform their ovarian surface epithelium, to 
create defined genetic lesions that could be studied at various stages as they 
inevitably develop ovarian cancer in situ. 
The first in vitro tool for studying molecular markers thought to be 
implicated with ovarian cancer development and progression as well as 
chemoresistance, are ovarian cancer cell lines that have been established by 
primary ovarian tumours or ascites. However, a limitation of this approach, 
though cheap and easily controlled, is that there is always the risk that 
alterations observed might have been introduced through prolonged tissue 
culture and cannot resemble the microenvironment in the tumour.  
Another in vitro model for studying EOC transformation is achieved by 
introducing the molecular alterations to study in primary normal ovarian surface 
epithelial (NOSE) cell lines from the OSE as it is one of the proposed cells of 
origin for EOC, known as transformation models. Using primary cell lines is 
challenging as they have a limited lifespan in culture using hTERT (Yang et al, 
2007). Attempts to create in vitro transformation models using immortalised 
NOSE cells with knocked down TP53 and Rb have been made but did not lead 
into a neoplastic phenotype (Yang, 2007).  
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However, all these studies have used in vitro two dimensional (2D) cell 
models. 2D cell cultures are cell monolayers that do not exhibit the complex cell 
- cell and cell - extracellular matrix (ECM) interactions that are observed in 
tissue in vivo. This is a major limitation, so 3D culturing of cells can be used to 
try and re-capitulate tissue architecture and thus improve the biological 
relevance of in vitro models. There are several studies that have provided 
substantial evidence proposing that 3D cultures more closely resemble the in 
vivo architectural organisation and microenvironment than 2D cultures, and that 
culturing cells in 3D can lead to phenotypic and molecular changes that reflect 
the in vivo biology of the cell more closely than 2D cultures (Knuechel et al, 
1990, Ghosh et al, 2005, Zietarska et al, 2007). 
In an attempt to create an in vitro model to resemble the genetic 
heterogeneity in EOC and study the initiation and early stage neoplastic 
progression an in vitro transformation model has been created within our group 
by firstly creating three dimensional (3D) models of normal OSE (NOSE) cells, 
which better resemble the microenvironment of the ovary. Lawrenson et al 
subsequently created 3D models of partially transformed immortalised NOSE 
(IOSE) cell lines by overexpressing the MYC oncogene to later create double 
mutant cell lines by subsequent expression of KRAS and BRAF and showed 
neoplastic progression in vitro and differential gene expression profiles between 
the transformed cell lines (Lawrenson et al, 2009, Lawrenson et al, 2011). 
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 Genetics of epithelial ovarian cancer  1.5
1.5.1 Heritability in Ovarian Cancer  
EOC is a polygenic disease that can be caused by mutations, alterations 
and duplications of genes and 90% of the cases are sporadic with no family 
history. The remaining 10% of cases are inherited and this is termed as familial 
ovarian cancer (Holschneider and Berek, 2000). 
Family studies have well-established that the cumulative risk of 
developing ovarian cancer for a woman with a family history of ovarian cancer is 
significantly higher than women of the general population where the risk is 
estimated as 1% by the age of 70. An extensive meta-analysis of such studies 
has been performed by Stratton and colleagues, which reported that the relative 
risk of a woman with one affected first degree relative is 3.1% (95% CI 2.6-3.7), 
with the risk being higher to sisters and daughters, 3.8 and 6 respectively, than 
to mothers 1.1%, the nature of the difference is still not understood. The risk 
increases for women with two or more affected first degree relatives to 12% but 
with very wide 95% CI (Stratton et al, 1998). 
Even though family studies provide information about the familial 
incidence of ovarian cancer, they fail to establish whether the observed 
increased risk is due to genetic factors. Twin studies, however, provide valuable 
information on whether familial risk is due to shared genetic factors rather than 
shared environmental factors. Twin studies, compare monozygotic twins that 
arise from a single fertilised egg and have 100% identical genotypes and 
dizygotic twins that share only 50% of their genotypes. Both groups share the 
shame environmental similarities and comparing the similarities of monozygotic 
(MT) with dizygotic twins (DT) can provide valuable observations on the 
influence of genetics in inherited risk of cancer. The principle behind this is that 
in order to establish whether familial aggregations of cancer are hereditary or 
due to shared environmental factors one needs to examine whether the 
observed cancer phenotype is concordant with the observed genetic similarities 
and in that case MT will more frequently have a cancer in the same anatomical 
site than DT (Neale et al, 1992). 
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An extensive comparison of MT and DT cancer concordance in large 
twin cohorts has been performed by Lichtenstein et al in 2000. This study 
reported a higher concordance of the same cancer in MT than DT in stomach, 
colorectal, lung, breast, prostate and ovarian cancer indicating that genetic 
factors have a more important role in cancer predisposition than non genetic 
factors shared within families in a dominant genetic effect manner. The 
cumulative risk for EOC development was calculated as 22% which is 6 fold 
higher than the risk shared between non-twin siblings (Lichtenstein et al, 2000).  
Following the realisation that familial aggregates of cancer are 
characterised by similar genetic contributions and after the generation of the 
human genome reference sequence enabled to distinguish genetic variation in 
distinct populations (The International HapMap, 2005) many probable genetic 
contributions to ovarian cancer susceptibility were discovered. Familial ovarian 
cancer has been categorised into two distinct familial cancer syndromes which 
are inherited in an autosomal dominant manner, hereditary breast/ovarian 
cancer syndrome and Lynch syndrome or hereditary non-polyposis colorectal 
cancer. 
 
1.5.1.1 High susceptibility/penetrance genes for ovarian cancer 
In hereditary cancer highly penetrant tumour suppressor genes like 
BRCA1/2, MSH are dominantly 'acting' as the inheritance of only one faulty 
gene copy is sufficient to predispose an individual to cancer, thus these genes 
are referred to as dominantly inherited. However, they 'act' recessively at the 
cellular level, so mutation or alteration of the normal copy is required for cancer 
to occur. This is better explained by the proposed genetic model of cancer 
development by the inactivation of tumour suppressor genes by Knudson et al 
in 1971 which is known as the two hit hypothesis. The first hit is the passing of a 
mutated copy of a gene to the offspring and the second hit is a random somatic 
mutation or deletion or loss of heterozygosity leading to loss of the normal 
second copy of the gene (Huang et al, 1997). In sporadic cancer cases, which 
will be later discussed, mutation in both copies of the gene have to randomly 
occur, thus families carrying an already defective copy of the gene have a 
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higher predisposition as only one random event needs to occur for the gene to 
be completely defective (Figure 1.9, A) 
 
1.5.1.2 Breast/Ovarian Cancer Syndrome associated genes 
The fact that ovarian cancer has a high prevalence in certain families led to 
the investigation of inheritance of predisposing mutations in cancer 
susceptibility genes within the familial ovarian cancer cases and the first tool 
used to link a gene to the disease was genetic linkage studies. 
Genetic linkage can be determined in humans using pedigree analysis. The 
first convincing evidence of a breast/ovarian cancer associated gene and its 
localisation was reported in the early 1990s with 40% of the families tested 
linked to a marker in chromosome 17q (Hall et al, 1990, Narod et al, 1991). 
These initial observations were confirmed by a larger study on 214 families, 
which provided evidence for linkage of breast and ovarian cancer of the majority 
of the families to a marker in the same chromosomal location (Easton et al, 
1993). The BRCA1 gene was later identified and described by positional 
cloning. It’s exact location is on chromosome 17q12-21 and is composed of 22 
coding exons spanning over 100 Kb of genomic DNA and coding for a protein of 
1863 aa and 208 kDa in size. Germline mutations of BRCA1 were detected in 
five out of eight families (Miki et al, 1994). A year after the discovery of BRCA1 
as a breast/ovarian cancer high susceptibility gene, BRCA2 was localised in 
chromosome 13q12-13 and was linked with 74% of the families studied 
(Wooster et al,1994).  
Several studies have since reported germline mutations in the BRCA1 
and BRCA2 genes with prevalence estimates varying considerably. Reports 
vary for BRCA1 from as high as 82% (Narod et al, 1995), to 57% (Ford et al, 
1995) and 43% (Gayther et al, 1999). The most comprehensive analysis of 
BRCA1 and BRCA2 mutations in ovarian cancer to date evaluated 283 families 
with 2 or more first degree relatives with ovarian cancer and reported a 37% 
prevalence for BRCA1 and 9% prevalence for BRCA2 (Ramus et al, 2007). 
Interestingly, prevalence of BRCA1 and BRCΑ2 mutations is strongly 
associated with the extent of ovarian cancer family history with the risk 
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increasing in multicase families as reviewed in (Gayther and Pharoah, 2010, 
Pharoah and Ponder, 2002, Ramus and Gayther, 2009).  
The variance in the estimates for penetrance for BRCA1 and BRCA2 in 
familial studies can be attributed to an extent to allelic heterogeneity but the 
magnitude of the differences reported is also suggesting that other factors could 
be modifying the risk between carriers. These could be lifestyle and 
environmental factors such as low parity increasing the risk, and oral 
contraceptive use reducing the risk. Additionally, genetic alterations in genes 
such as the androgen receptor gene and HRASI proto-oncogene have been 
shown to have an effect in modifying the risk for ovarian cancer (reviewed in 
Pharoah and Ponder 2002). 
A meta-analysis of 10 studies reported a cumulative risk for ovarian 
cancer to the age of 70 years of 40% and 18% for BRCA1 and BRCA2 
respectively (Chen et al, 2006). Another study combined data from 22 different 
studies and has reported the cumulative risk for BRCA1 mutation carriers from 
population based studies to be 39% and 11% for BRCA2 mutation carriers 
(Antoniou et al, 2003).  
The spectrum of BRCA1 and BRCA2 mutations has been reviewed by 
Pharoah and Ponder in 2002. More than 250 different germline BRCA1 
mutations had been discovered with the most frequents being 185delAG and 
5382insC both founder mutations in the Ashkenazi Jewish population. The most 
frequent of the germline alteration for BRCA2 is 6174delT, common in 
Ashkenazi Jews, and 999del5.  Most germline BRCA1 and BRCA2 mutations 
are predicted to result in protein truncation caused by frameshift, nonsense, 
splice-site and regulatory mutations and large genomic deletions, all distributed 
along the length of the genes. In-frame deletions and missense mutations are 
more uncommon in BRCA1 but found in BRCA2.  
The association of ovarian cancer risk with the BRCA genes has made 
critical the investigation of their function. In the last years significant progress 
has been made regarding the elucidation of BRCA1 and BRCA2 function at the 
cellular level. It is now widely established that BRCA genes act as tumour 
suppressor genes and have a role in maintaining genomic stability/integrity. 
Profound chromosomal translocations, duplications and aberrant fusion events 
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between non-homologous chromosomes have been observed in BRCA1/2 
deficient cells (Moynahan et al, Feb 2001, Moynahan et al, June 2001). 
Findings that BRCA1 and BRCA2 nuclear foci formed after treatment with DNA-
damaging agents interact with RAD51, an essential protein for the repair of 
double-strand DNA breaks, are suggesting that both genes are important for 
genomic integrity through a direct role in DNA repair (Chen et al, 1998, Scully et 
al, 2007).   
The clinical features and outcome of ovarian cancer patients with and 
without BRCA1/2 mutations has been investigated but results of such studies 
have been controversial. Significantly prolonged survival for patients and higher 
proportion of serous adenocarcinomas was reported for BRCA1 mutation 
carriers compared to non-carriers in some early studies (Rubin et al, 1996, Aida 
et al, 1998).  These studies were methodologically criticised for bias (Cannistra, 
1997 (letter)) but were supported with subsequent studies (Boyd et al, 2000, 
Ben et al, 2002). A Swedish study has reported higher proportion of serous 
adenocarcinoma in BRCA1 mutation carriers but found their survival similar or 
worse compared to non-carriers (Johansson et al, 1998). Pharoah et al reported 
no survival difference in mutation carrier families and Ramus et al reported 
slightly improved survival in Ashkenazi ovarian cancer patients with founder 
BRCA1 and BRCA2 mutations but not statistically significant (Pharoah et al, 
1999, Ramus et al, 2001). A recent larger and conclusive study has shown that 
BRCA1 and BRCA2 mutation carriers have improved prognosis with BRCA2 
mutation carriers showing the most improved prognosis (Bolton et al, 2012).   
The mechanism that underlies the reported improved survival for BRCA 
mutation carriers could potentially be a better response to the chemotherapeutic 
drugs that act by inducing DNA damage. The proposed role of BRCA genes in 
DNA repair mechanisms could explain why their loss is triggering a more 
efficient death of the treated cells due to the induced DNA damage, but this will 
be further discussed later. 
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1.5.1.3 Lynch Syndrome or HNPCC associated genes 
Hereditary non-polyposis colorectal cancer (HNPCC) is caused by germline 
mutations in genes involved in the DNA mismatch repair pathway, including 
MLH1, MSH2, MSH6 and PMS2. HNPCC is associated with tumours that 
exhibit microsatellite instability (MSI). The genes of the mismatch repair 
pathway (MMR) have the role of spotting and repairing any mismatches of 
single nucleotides as well as insertion or deletion loops. Defects in those genes 
can lead to accumulation of somatic mutations in a cell and cause 
tumourigenesis.  Microsatellite markers are sequences of DNA containing 
repetitive nucleotides and they are very susceptible in gaining errors if there is a 
defect in the MMR mechanism. Thus, in Lynch Syndrome where MMR genes 
are defective the number of microsatellite repeats observed in tumour is not 
consistent with normal tissue, and this condition is called microsatellite 
instability (MSI) (Gruber and Kohlmann, 2003, Manceau et al, 2011). 
The life-time risk for ovarian cancer development is 12% within families with 
Lynch syndrome (Aarnio et al, 1999). The majority of Lynch syndrome is 
attributed to mutations of MLH1 and MSH2 genes with 50% and 40% 
prevalence respectively. MSH6, MSH3, PMS1 and PMS2 mutations account for 
the rest 10% of the cases (Wheeler et al, 2000). The cumulative risk for 
developing ovarian cancer for Lynch syndrome mutation carriers has been 
estimated with the genotype restricted likelihood, which accounts for 
ascertainment bias in 537 families. The cumulative risk by the age of 70 for 
MLH1 mutation carriers was reported to be 20%, for MSH2 24% and for MSH6 
1% (Bonadona et al, 2011).   
 
1.5.2 Moderate/Low susceptibility genes for ovarian cancer  
With less than 60% of the familial ovarian cancer risk due to mutations in 
the high penetrance genes BRCA1, BRCA2 and MMR genes, this provided 
evidence of the existence of other genes which confer moderate or low risk in 
the development of ovarian cancer, indicating that ovarian cancer is a polygenic 
disease influenced by many genes.  The remaining susceptibility genes could 
be of moderate or low penetrance with a combined risk of 50% and could 
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account for the remaining excess familial risk and also attribute the risks for 
sporadic ovarian cancer in the population. This polygenic model of ovarian 
cancer is supported by evidence that was reported by the twin studies which 
showed that genetic factors are more important than environmental factors 
shared by the twins in ovarian cancer development. The tool used by 
geneticists to identify moderate/low risk susceptibility alleles is genetic 
association studies. 
1.5.2.1 Genetic association studies  
The aim of genetic association studies is to find associations between 
genetic polymorphisms and a disease or other quantitative characteristics by 
studying unrelated subjects in search of common variants that would elucidate 
cancer incidence in the general population. We have seen that linkage studies 
were used to identify the BRCA1 and BRCA2 genes in ovarian cancer families. 
Association studies are fundamentally different from linkage studies in the 
sense that in association studies the same allele is associated with the disease 
across the whole population whereas linkage studies present the association of 
different alleles with the disease across different families.  Since the realisation 
that ovarian cancer is a complex disease that involves many genes with a small 
effect, termed as low/moderate susceptibility genes, the shift of genetic 
epidemiology to association studies was evident. Association studies have a 
greater power to detect small effects than linkage studies do, but require many 
markers/polymorphisms to be analysed in large number of presumably 
unrelated individuals (Risch et al, 1996). The importance of genetic association 
studies in genetic epidemiology is explained by the need to identify more 
low/moderate penetrance alleles, the identification of large numbers of single 
nucleotide polymorphisms (SNPs) within the human genome, and the advances 
in genotyping techniques .   
Another form of association studies are survival association studies 
where genetic variants are screened and compared between alive and 
deceased patients in order to identify whether they may have an effect on the 
patients’ survival time and also the response to the treatment, which can lead 
into more personalised treatment.  
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1.5.2.2 Single nucleotide Polymorphism (SNP)  
Genetic association studies try to identify an association between 
polymorphisms and susceptibility in cancer or other diseases, by typing single 
nucleotide polymorphisms (SNP) in a population. A SNP represents DNA 
sequence variation in a single nucleotide with a >1% population frequency. 
Across the human genome the number of SNPs represents the majority of the 
polymorphisms. The International SNP Map working Group had provided a map 
of 1.4 million candidate SNPs and observed that two haploid genomes have a 
difference of 1 nucleotide per 1.331 bp, which is turn infers to the existence of 
11 million SNPs in a genome of 3.2 billion bp that vary in at least 1% of the 
entire population (Wang et al, 1998, Kruglyak and Nickerson, 2001, The 
International SNP Map Working Group, 2001). However, with the release of the 
1000 genomes project the number of mapped SNPs reached around 15 million 
(The 1000 genomes project consortium, 2011). SNPs are predominantly 
biallelic, meaning they are two different copies of a SNP in the human 
chromosome. One of the alleles of a SNP is maternally and one paternally 
derived as seen at Figure 1.5. 
 
 
 
 
 
 
 
 
                   
 
 
Figure 1.5: Possible variations of a SNP in population. 
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SNPs can have a functional role in influencing human phenotype and 
can be divided into two categories; the coding and noncoding SNPs. Coding 
SNPs are located in an exon of a gene and are termed synonymous if they do 
not modify the polypeptide sequence of the gene product due to the redundancy 
of the genetic code; for example a TC SNP can result to codons TTT or TTC 
and both code for the amino acid phenylalanine. Functional roles by 
synonymous SNPs have been regularly reported, with some examples being 
reports of synonymous SNPs having a role in changing the specificity of the 
resulted protein of the Multidrug Resistance 1 (MDR1) gene (Kimchi-Safati et al, 
2007) and affecting gene expression and mRNA folding and processing  (Wang 
and Sadée, 2006). Synonymous variations have also been associated with 
reducing the amount of the resulting protein by altering the stem loop secondary 
structures of the mRNA of Catechol-O-methyltransferase gene (Nackley et al, 
2006) and numerous other reports have assigned similar functions in altering 
the availability of the protein by changing the structure of the protein or by 
alternate splicing due to synonymous SNPs. A recent study has reported the 
implication of synonymous SNPs in altering binding capacity of (micro RNAs) 
miRNAs in a way that the protective allele was down regulated by this miRNA 
and the risk allele was not allowing the binding of the miRNA (Brest et al, 2011).  
Coding SNPs are termed non-synonymous when they do change the 
amino acid sequence of the protein and thus having the obvious functional role 
in protein production. A non-synonymous SNP can either be missense, which 
results in an alternative amino-acid, or nonsense which results in a production 
of a truncated protein by introducing a premature stop codon. About 60000 
SNPs exists in the coding regions of approximately 30,000 genes (The 
International SNP Map Working Group). 
Non-coding SNPs may be located in the gene’s introns, untranslated 
regions, or other regulatory regions but may be functional in influencing the 
availability of a protein by altering sites for transcription factors or disrupting 
splice sites on the translational level (Reumers et al, 2008). SNPs can also be 
found inbetween genes and in gene deserts which are large genomic segments 
with no genes and limited sequence conservation. However, gene deserts 
Chapter 1: Literature review 
 
53 
 
rarely have conserved regions which could harbour transcriptional regulatory 
elements and influenced by the non- coding SNPs located there.  
When a disease-associated SNP is identified it is important to estimate 
the degree on which the amino-acid substitution is damaging in cases of non-
synonymous SNPs and also the predicted function of synonymous or non-
coding SNPs if based in a regulatory region of the gene. There is a lot of 
progress recently in building functional prediction databases for SNPs. 
Databases, such as PupaSuite, can be used to evaluate known or predicted 
functional information about all the categories of SNPs (Barrett et al, 2005). 
Non-synonymous SNP functional prediction databases also include SIFT, 
PMUT, SNPeffect, LS-SNP, SNAP, PolyPhen, TopoSNP (reviewed by NG. and 
Henikoff, 2006). A recently published database for non-synonymous SNPs’ 
functional predictions is providing the most comprehensive integrated database 
of functional predictions from multiple algorithms (Liu et al, 2011).   
 
1.5.2.3 Linkage disequilibrium  
A genotyped SNP might be either the putative causal variant (direct 
association) or can be correlated with the SNP that is the actual causal variant 
of the studied phenotype (indirect association). It is now well established that 
SNPs within a chromosomal locus can be in correlation with each other. This 
non-random correlation between SNPs is called linkage disequilibrium (LD). 
Pairwise LD between two SNPs is measured by Lewontin’s D, known as 
association probability, but more commonly LD is expressed by the index r2 
which is related to the allele frequencies and is the square of the conventional 
correlation coefficient between the allele at the typed locus and the allele at the 
causal locus. LD is also relevant to haplotype blocks (haplotype is the allelic 
configuration along a single chromosome), by characterising the haplotype 
diversity within these blocks (Cordell and Clayton, 2005). The process of 
tagging SNPs relies on LD since the causal variant does not need to be studied 
directly but information can be provided by a SNP that is in LD with it. This will 
be discussed in more detail later in the description of genetic association 
studies designs. 
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1.5.2.4 The International HapMap project and the 1000 genomes project 
Of the >10million SNPs identified more than 5 million have been 
validated by HapMap. The International HapMap Consortium used DNA 
samples from Africa, Asia and Europe in order to investigate the common 
genetic variation in the human genome. The International HapMap project has 
genotyped millions of SNPs across the human genome and reported their 
frequencies in the population as well as the degree of LD between variants (The 
International HapMap, 2005).  
More recently, the 1000 genomes project has provided a deeper 
characterisation of human sequence variation in the purpose of aiming 
association and functional studies. Recently published data have revealed the 
location, allele frequency and local haplotype structure of approximately 15 
million SNPs. The vast majority of the variants were already present in dbSNP 
but a lot of newly discovered variants were identified mostly in relation to 
specific population groups with the African ancestry population providing the 
highest fraction of novel variants identified (The 1000 Genomes Project 
Consortium, 2011). 
 
1.5.2.5 Candidate gene and pathway approach to identify low penetrance 
susceptibility genes for ovarian cancer  
The first form of genetic association studies was to investigate the 
association of potentially functional SNPs, causing an amino acid change, with 
ovarian cancer development. In the design of these studies, SNPs within genes 
that have been predicted to have a functional role in the development of the 
disease for example from tumour expression studies are genotyped. Also SNPs 
within genes that are part of functional pathways that have been implicated in 
carcinogenesis, such as cell cycle control, DNA repair, steroid hormone 
metabolism, inflammation pathways.  Direct association is then investigated for 
these SNPs with pathways by having them genotyped in a number of ovarian 
cancer cases and their genotypic frequencies are then compared with healthy 
individuals to identify possible direct association of the typed polymorphisms 
with the development of the disease.   
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Small number case-control studies (not exceeding 200 cases or controls) 
have reported weak ovarian cancer associations of SNPs within candidate 
genes or genes involved in candidate pathways with a role in ovarian cancer 
development. One SNP of the cell cycle regulator gene TP53, which is a 
prevalent gene alteration in ovarian tumours, was found to be associated with 
the risk of developing various neoplasias including ovarian cancer (Agorastos et 
al, 2004). Another association reported is between a SNP in SOD2, a gene 
involved in inflammation and oxidative stress which are processes associated 
with ovulation (Olson et al, 2004). Ovarian cancer is a hormone-associated 
cancer and genes involved in hormonal regulation have also been investigated. 
The functional variant A2 was typed in CYP17, a gene involved in steroid 
hormone biosynthesis and was associated with increased risk in ovarian cancer 
development (Goodman et al, 2001, Garner et al, 2002) whereas another study 
did not report such evidence (Spurdle et al, 2000). Additionally, strong 
association was found between two variants in the FSHR gene, which codes for 
a follicle stimulating hormone receptor in the ovaries (Yang et al, 2006).  
Functional SNPs within genes involved in homologous recombination of double 
strand DNA breaks have been genotyped in relatively larger number of samples 
(>1000 cases and >2000 controls) with the most relevant positive associations 
of SNPs N372H, R188H and rs1799796 within BRCA2, XRCC2 and XRCC3 
respectively (Auranen et al, 2005).  Most of the results of those studies have not 
been validated in larger sample sizes however. 
Over time association with coding variants yielded only a handful of 
conclusive associations, mainly in bladder cancer, but not in other cancers 
including ovarian cancer. Very few coding variants were confirmed suggesting 
that the majority of common alleles contribute through alterations in regulation 
or expression of genes and pathways. So the putative causal SNP associated 
with risk in the development of a disease may possibly be a non-coding SNP 
and this realisation triggered the design of a second form of association studies 
where the polymorphism typed is a surrogate for the real causal SNP around 
the candidate locus and this is performed by using tagging SNPs (tSNPs).  
In order to identify genetic variation without genotyping every SNP in a 
chromosomal loci, a representative SNP called the tagging SNP is used, which 
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provides genotype information about all the SNPs that are found in LD (r2=1 is a 
marker of complete LD between 2 SNPs) with the selected SNP (Goldstein, 
2001). The combination of the alleles in multiple loci is called the haplotype. 
HapMap provides extensive genotype data and this resource was used to select 
tSNPs. SNP tagging is then performed using the Tager component of 
Haploview that is a software that provides information about haplotype blocks 
and LD between SNPs (Barrett et al, 2005).  
The indirect association approach using tagging SNPs was used by 
several studies that reported association of tSNPs with ovarian cancer risk in 
genes such as SHMT1, coding for an enzyme involved in one-carbon 
metabolism implicated with methylation patterns and DNA synthesis (Keleman 
et al, 2008), tumour suppressor gene RB1 and genes in the mismatch repair 
pathway such as PMS2 (Song et al, Nov 2006, Song et al, Oct 2006) and MLH1 
(Harley et al, 2008). 
However, these studies produced only marginally significant results that 
could be false positives, even when the statistical power was strengthened by 
following consortium approaches. Consortium approaches are study designs 
within multicentre collaborations which perform genotyping of SNPs in a staged 
way and the positive associations that are found in early stages are then 
validated in a larger number of samples, which gives the results a greater 
statistical power and minimises the errors. There are several consortium 
approach studies that have reported ovarian cancer associations with putative 
causal SNPs within candidate genes such as cell cycle regulators CDKN2A, 
CDKN1B (Gayther et al, 2007), TP53 (Schildkraut et al, 2009), tumour 
suppressor RB1, progesterone receptor PGR and cell cycle kinase AURKA 
(Ramus et al, 2008), MSL1 which is a gene implicated in histone and chromatin 
activation (Peedicayil et al, 2010) and several others.  
 
1.5.2.6 Ovarian Cancer Association Consortium  
The initial reports of all association studies failed to establish strong 
association of markers with ovarian cancer risk. The main issues for the 
difficulty in conducting statistically and methodologically rigorous ovarian cancer 
association studies are the following:  
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i) Because of the rarity of ovarian cancer the number of subjects used in most 
studies is hundreds rather than the thousands needed. 
ii) Because of the vast number of SNPs in the human genome the false positive 
associations using the significance level of 0.05.  
iii) Epithelial ovarian cancer is a heterogeneous disease and the small number 
of cases in each histological group makes it difficult to stratify for subtype in 
order to establish whether a candidate polymorphism affect more the risk for 
development of one subtype or the other.  
iv) Stratification of association data according to other epidemiological risk 
factors such as ovulation and endometriosis is difficult because of small number 
of cases.                                                                                                                  
v) Possible false positive associations in some studies arose from failure to 
perform stratification of population as the allele frequencies are different 
between ethnic groups and this may bias the results. 
The demand for addressing all these challenges and for making progress 
into understanding the contribution of genetic polymorphisms to susceptibility in 
ovarian cancer has led to the establishment of an Ovarian Cancer Association 
Consortium (OCAC) in 2005. This collaboration brought together more than 20 
groups around the world which together pooled more than 10,000 cases and 
15,000 controls. The ultimate goal of the OCAC was to identify as many 
possible low/moderate susceptibility alleles to EOC and stratify ovarian cancer 
risk using the genetic variation associations in combination with known 
epidemiological risk factors such as family history, ovulation and parity, oral 
contraceptive use. Better screening and prevention will be the outcome of such 
a focused effort with the goal of minimising EOC incidence and mortality. The  
initial efforts of the OCAC was to validate initial associations between SNPs in 
candidate genes and ovarian cancer reported by individual groups using the 
indirect SNP tagging approach and analysing the results in order to be in line 
with the issues for a robust association study design mentioned above (Ramus 
et al, 2008).  
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1.5.2.7 Genome Wide Association Studies: An agnostic but powerful 
approach  
Identifying a small number of SNPs that will together elucidate the risk for 
developing a disease in an estimated number of >15million SNPs in the human 
genome can be quite a challenge and taking into account that many of those 
SNPs may be non-coding, candidate pathway studies have a very limited power 
into achieving this goal.  Genome Wide Association Studies (GWAS) have thus 
emerged as an important and powerful tool for evaluating the frequency of 
thousands of SNPs in the human genome without any selection based on 
function. This agnostic approach is using tSNPs (r2>0.8) to discover regions that 
harbour genetic variants that are associated with the trait in question. It was 
predicted that a GWAS would require ~500,000 SNPs to be genotyped because 
of the low level of LD in the human genome (Kruglyak, 1999).  
GWAS are now widely used to identify low/moderate risk susceptibility 
alleles in several types of diseases including cancer in order to establish 
associations of loci with the disease. The tSNPs are genotyped using high-
throughput genotyping platforms in consortium collaborations. Some examples 
are loci associated with risk in breast (Hunter et al, 2007), colon (Tomlinson et 
al 2008), lung cancer (Amos et al, 2008, Hung et al, 2008) and prostate cancer 
(Thomas et al, 2008). An extremely significant result of GWAS was reported by 
the breast cancer-association consortium that identified an association of a SNP 
in FGFR2, a gene coding for fibroblast growth factor receptor, with increased 
risk for breast cancer with a P value of 2×10-76 (Easton et al, 2007) 
GWAS are often performed using a staged study design where 
significant associations of each stage are taken to the next stage to be 
genotyped in larger numbers to test replication and ultimately identify SNPs that 
reach genome-wide levels of statistical significance (p value<10-7). The results 
that are analysed in each stage are then combined in order to strengthen the 
power of the study and exclude false positives (Gayther and Pharoah, 2010). 
The ovarian cancer GWAS designed and carried out by our group and 
collaborators is shown in Figure 1.6.  
The first results from this study reported an association of SNP 
rs3814113 in locus 9p22 (Song et al, 2009). Further analysis of the GWAS data 
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also stratifying by subtype identified five additional susceptibility loci at 8q24, 
2q31, 3q25, 17q21 (Goode et al, 2010) and 19p13 (Bolton et al, 2010).  EOC is 
a heterogeneous disease consisting of serous, endometrioid, clear cell and 
mucinous subtypes and the genetic alterations involved in each subtype are 
also distinct as discussed before. GWAS multicentre collaborations, due to the 
collective numbers of samples, allow the stratification of association analysis 
according to distinct subtypes. Such analysis revealed that EOC heterogeneity 
is also influenced by common low-penetrance genetic variation, with the 
strength of association stronger in serous-only ovarian cancer cases in five out 
of six loci, the difference being more profound in loci 8q24 and 19p13. Common 
genetic susceptibility loci identified by our group’s and collaborators’ ovarian 
cancer GWAS and their association with histological heterogeneity are 
presented in Table 1.1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.1: SNPs found in association with epithelial ovarian cancer susceptibility. OR 
(95% CI): per allele odds ratio (95% confidence interval). The P values presented for all 
the samples and serous only samples are from the combined 3 stages of the GWAS 
*(Song et al, 2009), ** (Goode et al, 2010), *** (Bolton et al, 2010).  
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Figure 1.6: Schematic representation of GWAS design. a) The design of GWAS in the 
3 stage approach. In the first stage a large number of SNPs is genotyped in a small 
number of samples, The SNPs that have a statistical significant value are then 
genotyped ion a larger number of samples/ And finally the few SNPs that have a 
P>0.001 after combined analysis of stage 1 and 2 are taken forward to be genotyped in 
the whole sample set. b) The ovarian cancer GWAS designed by the Ovarian Cancer 
Association Consortium is shown. C) A Manhattan plot is showing the combined stage 
1 and 2 significant SNPs. Red highlights the SNPs found to have significant association 
with ovarian cancer with P values<10-5. (Figure obtained from Gayther and Pharaoh, 
2010, Permission to reproduce this image has been granted by Elsevier using 
Copyright Clearance Center's RightsLink service). 
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 Post GWAS characterisation: Functional follow up of 1.6
susceptibility loci  
Functional studies are often necessary to elucidate the biological 
mechanisms by which an associated region confers disease susceptibility.  The 
challenge in order to translate the implication of a susceptibility locus found to 
be associated with risk in EOC is to identify how the candidate associated SNPs 
affect risk modification and also identify the causal susceptibility gene related to 
this genetic variant. 
1.6.1 Functional follow up of candidate SNPs  
 
Even when association results point to a single variant, the true causal 
SNP is not always easy to identify as the associated SNP can just be serving as 
a surrogate for the causal one. The association observed with a marker can be 
a result of an underlying causal allele that is in LD (high r2 ) with the associated 
variant, and is possible that multiple functional alleles are causing the 
association. The associated SNP can be a common allele meaning that it has 
high population frequency >1%, or a rare allele meaning with a <1% minor allele 
frequency. 
When a locus with an associated SNP is identified, dense genotyping of 
markers in that region and performing fine mapping can identify a group of 
potential causal alleles and the key to this process in order to avoid missing the 
true causal variant, in case it was not initially genotyped, is to include all known 
markers in the associated locus. There are two different tests that can be used 
to analyse the results of fine mapping. One is to apply conditional regression 
and adjust for the lead candidate causal SNPs in order to remove any other 
association observed for variants in that region and thus identify the true causal 
SNP. The second statistical tool, used to identity multiple causal variants is to 
perform conditional haplotype analysis, where several haplotypes are defined in 
the hope of finding the haplotype that better explains the risk in that locus. 
Multiple alleles within HLA-B (major histocompatibility complex, class I B) 
associated with long term viral load control in HIV-infected patients were 
identified after fine mapping following a GWAS study (Pereyra et al, 2010). It is 
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important to mention at this stage that when the associated variant is common 
then fine-mapping is employed to identify the causal SNP, but in cases of a rare 
SNP, identification is performed using burden testing. This test aims into 
identifying whether the rare variants interspersed in a locus are distributed in a 
non-random way suggesting a functional role for them (Bansal et al, 2010).  
In the absence of genetic mapping, another method that can be used is 
to try and translate the SNP’s association into possible functional role. If a SNP 
is a non-synonymous SNP and they induce an amino acid substitution in a 
protein they might disrupt the function of the protein as previously discussed. A 
non synonymous SNP that is located in a highly conserved region might be 
deleterious and several software can be used to predict the function of coding 
variants (reviewed in Cooper and Shendure, 2011), such as PolyPhen 2 
(Polymorphisms phenotypic 2) that predicts the functional importance of an 
amino acid substitution (Adzhubei et al, 2010).   
Assessing the functional role of non-coding variants though is somewhat 
more challenging. The genome comprises of 99% noncoding sequence and it is 
not greatly annotated. However, it has been shown that almost 8% of the 
noncoding genome is under evolutionary constraint, meaning some genome 
sequences of several species when aligned maintain similarity through 
evolution, suggesting they are potentially functional sequences (Davydov et al, 
2010). These reports are indicating that the noncoding SNPs may have an 
impact to the functional sequences of the noncoding genome. Some of the 
approaches used to evaluate the functional role of noncoding sequences are 
looking at gene expression, sequence conservation mostly used for assessment 
of rare variants only, chromatin modifications, methylation of CpG islands in 
gene promoters, or allele specific loss of heterozygosity (Raychaudhuri, 2011). 
It should be noted here that coding SNPs’ functionality may also be investigated 
by these processes. 
Genetic variants can correlate with the transcript level of a gene and are 
often referred to as expression quantitative trait loci (eQTLs). Most such effects 
investigated are showing the cis-effects of the SNPs that are modulating the 
activity of a nearby gene’s promoter or enhancer or the mRNA stability (SNPs 
within 1000kb of the relevant gene). Trans-effects are SNPs affecting elsewhere 
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in the genome and have not been largely investigated to date (Freedman et al, 
2011). A recent study has identified transcripts whose expression is regulated 
by SNP-SNP interaction and reported that cis acting variants are involved in 
two-locus gene regulation (Becker et al, 2011).  One example of a study that 
reported both cis and trans effects of genetic variants on gene expression 
revealed that differences between ancestral population can be explained by the 
variation in ancestry affecting the genotype and in turn gene expression (Price 
et al, 2008). Another genome wide association approach has investigated cis 
effects of SNPs on levels of clinically relevant proteins in human serum and 
plasma correlating with gene expression (Melzer et al, 2008). A variant 
upstream of the KFL14 transcription factor involved in type 2 diabetes has been 
reported to act in cis influencing KFL14 expression levels and in trans 
influencing many genes regulated by KFL14 (Small et al, 2011). The 
investigation of the genetic variants’ effect on gene expression should be 
carefully assessed in the right cell models as it is tissue specific. The study that 
reported tissue specific genotype effect on gene expression has also revealed 
that common patterns observed across tissues are mainly due to cis regulation 
(Price et al, 2011).  Although initially, lymphoblastoid cell lines were used in 
eQTL studies, more studies have been recently performed in primary human 
tissues related with the disease studied (reviewed in Freedman et al, 2011). 
The investigation of such effects of SNPs associated with EOC risk on 
gene expression may thus help understand the process of EOC carcinogenesis, 
by providing hints about the mechanisms for common variants and identifying 
the likely causal gene. If the gene’s transcript is affected by genotype then it 
might be the causal gene. Increase of that gene’s expression with the risk allele 
may further suggest that the gene increases the risk in EOC development by 
gain of function, indicating an oncogene. If on the other hand the variant is 
correlated with decreased gene expression the gene may be involved by loss of 
function, possibly indicating a tumour suppressor gene (TSG). 
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1.6.2 Functional follow up of candidate genes  
Candidate genes emerging from association studies are genes that are 
located within associated disease risk loci and could be the target susceptibility 
genes. These genes could be involved in EOC development, progression and 
survival. Human in vitro models of the cells of origin for the disease could be 
used as a first line approach to evaluate the function of candidate genes at 
susceptibility loci identified by GWAS as it is proposed by the aim of this study. 
When a suitable in vitro model is established the role of the candidate gene can 
be evaluated firstly by evaluating any differential expression between the 
normal and cancerous primary cells and secondly by further assessing its effect 
on proliferation, apoptosis, cell cycle progression, anchorage independent 
growth, migration and chemosensitivity on selected cell lines. 
Culturing primary cell lines and establishing the suitable in vitro models 
has proven very challenging. Some examples of these difficulties include the 
isolation of prostate and colon normal epithelial primary cell lines and the 
isolation of fallopian tube epithelial cells to study ovarian cancer. One example 
of a successful in vitro model established is 3D cultures of MCF10A normal 
breast cell lines that closely reflect the architecture of the breast ascini in vivo. 
This model was used for evaluation of EOC susceptibility gene BRCA1 and loss 
of its function was correlated with dysfunctional differentiation in the lumen of 
breast epithelium (Furuta et al, 2005, Proja et al, 2010). In EOC, a study 
completed in our group has used an IOSE-MYC, IOSE-MYC/KRAS as an EOC 
transformation model to evaluate the expression of candidate genes that 
emerged from the ovarian cancer GWAS association study (Song et al, 2009, 
Goode et al, 2010, Bolton et al, 2010, Lawrenson et al, 2011).  
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 Somatic genetics of EOC  1.7
Ovarian cancer familial cases account for only one in ten ovarian cancer 
incidences and the rest fall under the category of sporadic cases (no family 
history). Somatic changes are all the collective differences in the DNA 
sequence of a cancer cell compared to the germ-line DNA sequence. These 
alterations can be mutations, insertions or deletions of small or large fragments 
of DNA, rearrangements, copy number variations where the normal diploid 
karyotype is increased known as gene amplification and gain or decreased 
known as copy number reduction resulting in complete absence of a DNA 
sequence. Somatic changes in turn can lead to altered expression of the genes 
and deregulation of pathways that lead to carcinogenesis. 
Understanding the molecular pathogenesis of EOC’s subtypes is 
important and identification of the genes implicated in its development and 
progression is crucial for improving its treatment and survival outcome. Initially, 
it was anticipated that the development of sporadic ovarian cancer would be 
attributed to a large extent to somatic mutations in BRCA1, BRCA2 and 
members of the MMR pathway. However, only a small proportion of the 
sporadic cases have been reported to harbour BRCA1, BRCA2 and MMR gene 
mutations, indicating a difference between hereditary and sporadic ovarian 
cancer, and ongoing research (Stratton et al, 1997) and constant improvement 
of the genetic technologies has led to identification of several somatic changes 
in EOC (The TCGA Study, 2011). 
Somatic alterations can lead to the abnormal function of two gene 
categories and lead to development of cancer including EOC; either by 
disrupting the activity of tumour suppressor genes or by activating oncogenes. 
Tumour suppressor genes normally function as inhibitors of cell proliferation. 
Tumour suppressor genes (TSGs) in cancer act recessively as both copies of 
the genes have to be inactivated in order for cell proliferation to become 
excessive. The normal counterparts of oncogenes are the proto-oncogenes and 
are responsible for the regulation of cell cycle progression, apoptosis, and 
movement of cells. Oncogenes act in a dominant manner as their activation can 
be caused by the alteration of a single allele. 
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A very comprehensive catalogue of the somatic alterations in EOC has 
been recently published by ‘The Cancer Genome Atlas Research Network’ 
(TCGA). TCGA was created as a pilot project in 2006 and was committed to 
creating a publicly available atlas of the genomic aberrations found in many 
forms of cancer. The goal of this project was to accelerate the understanding of 
the molecular basis of cancer and improve diagnosis, treatment and prevention 
of cancer (The TCGA Study, 2011). An overview of some of the most important 
mutations identified in ovarian cancer and their clinical implications will be 
presented. 
 
1.7.1 Common mutations in epithelial ovarian cancer disrupting the 
normal function of genes 
Mutations can be located in the coding regions of genes and cause 
amino acid changes and can be either activating (in the case of oncogenes) or 
inactivating (in the case of TSGs). 
1.7.1.1 Mutations in tumour suppressor genes and their clinical 
implications  
Inactivating mutations have been found in TP53, BRCA1, BRCA2, PTEN, 
CDKN2A TSGs and some of them have been implicated with the prognosis for 
EOC patients. 
The most common mutation in EOC is found in TP53 gene which is a 
TSG frequently found mutated in nearly half of all forms of cancer. p53 has 
multiple functions including acting as sequence specific transcription factor 
regulating the activation of other genes involved in a variety of cellular 
processes and acting as a cellular gatekeeper by monitoring cellular stress and 
inducing cell cycle arrest and apoptosis to prevent cell growth (reviewed in Bai 
and Zhu, 2006, Figure 1.7).   
Advanced ovarian cancers were reported in early studies to display TP53 
mutations in 40-50% of all cases which are mostly a result of transitions 
whereas the mutation rate in early stages was only 15% (Berchuck et al, 1994).  
Later studies that have sequenced the full coding sequence of TP53 in ovarian 
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cancers have demonstrated that the prevalence of TP53 mutation is similar (60-
70%) in all stages of serous cases whereas it is significantly lower in 
endometrioid, clear cell and mucinous cases that are the most common 
histological subtypes of early stage EOC (Leitao et al, 2004). A recent study has 
reported the TP53 mutation signatures to be even slightly higher in early stages, 
77% versus 63% in late stages, but yet still comparable. Interestingly, more 
specific analysis on the type of the mutation (null versus missense) showed 
significantly higher null (premature chain terminating) mutations in early than 
late stage of EOC (Bernardini et al, 2010). TSGA has reported TP53 mutations 
in 96% of high-grade serous ovarian cancer tumours (The TCGA Study, 2011). 
Recent research has reported that immunohistochemical analysis of p53 
expressing cells in ovarian tumours is a robust method to identify the presence 
of a TP53 mutation in ovarian carcinomas (Yemelyanova et al, 2011). 
There is controversial data regarding the association between TP53 
mutations and survival. Patients with TP53 mutations demonstrate 8-fold higher 
incidence of distant metastasis (Shahin et al, 2000) and significantly worse 
prognosis (Sood et al, 1999). Others have not found a correlation of null TP53 
mutation occurrence and patient survival but report higher than 2.5 fold 
presence of missense mutations in short term survivors than long term survivors 
of EOC (Bernardini et al, 2010). Additionally, EOC patients with TP53 mutations 
and/or p53 over-expression have been shown to have worse survival outcome 
which indicates that loss of functional p53 might confer a chemoresistant 
phenotype because p53 plays a role in chemotherapy-induced apoptosis (Hall 
et al, 2004). Again, p53 related prognosis has shown contradicting results 
favouring the survival and chemosensitivity of patients harbouring TP53 
mutations as reported by other equally valid studies (Lavarino et al, 2000, 
Havrilesky et al, 2003). 
It is possible, that studying and distinguishing between the different types 
of TP53 mutations might be a key into understanding the controversial role of 
p53 in ovarian cancer development. It is conceivable that women with distinct 
TP53 mutations which incapacitate p53 in DNA repair are having a more 
favourable prognosis as a result of their tumour cells inability to repair 
chemotherapy induced damage. On the other hand, women with other types of 
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mutations might be less responsive to treatment if their tumour cells are unable 
to undergo p53-mediated apoptosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7: Schematic representation of the role of p53 in various stress response 
pathways. P53 activation from several extracellular and intracellular signal leads to 
activation of downstream signalling pathways that trigger cell cycle arrest, apoptosis, 
DNA repair and senescence. (Figure taken from Bai and Zu, 2006). 
 
 
BRCA1 and BRCA2 mutations in germline DNA sequence account for 
<10% of ovarian cancer cases as previously discussed. These are the familial 
cases and are progressing quicker to late stages but are more responsive to 
platinum chemotherapy and have a better outcome (Pavelka et al, 2007). 
BRCA1  somatic mutations have been documented in 5% or sporadic cases 
(Stratton et al, 1997) whereas BRCA2 mutations are relatively uncommon in 
sporadic ovarian cancer (Foster et al, 1996), but later reports show BRCA1 and 
BRCA2 mutations in nearly 10% of sporadic cases (Jazaeri et al, 2002). TCGA 
analysis of 316 HGSCs has identified a 3.5% and 3.2% somatic mutation rate 
for BRCA1 and BRCA2 respectively (The TCGA Study, 2011). 
The existence of BRCA1 and BRCA2 mutations in familial and sporadic 
ovarian cancer, though in different prevalence, is something that suggests a link 
between the germline and somatic alteration in EOC carcinogenesis. 
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Complementary cDNA microarrays were used to investigate the role of BRCA 
mutations in ovarian carcinogenesis by comparing the gene expression patterns 
in cancers associated with germline BRCA1 and BRCA2 mutation and in 
sporadic ovarian cancers. The findings showed that there is a distinct 
expression profile difference between tumours with BRCA1 and BRCA2 
mutations indicating that BRCA1 and BRCA2 associated carcinogenesis may 
arise from distinct molecular pathways. These findings support that there are 
functional differences between the BRCA proteins, possibly in transcriptional 
control (Jazaeri et al, 2002). 
BRCA proteins are thought to be involved in the DNA double strand 
break repair pathway (Figure 1.8). Inactivating mutations in these genes confer 
reduced ability of the cells to repair the DNA damage caused by platinum 
compounds and lead to death of the cancerous cell. Interestingly, cancerous 
cells with a defective DNA repair show sensitivity to PARP inhibitors (Drew et al, 
2008). In this context somatic BRCA mutations might be an important biomarker 
to personalise treatment and select patient for PARP targeted therapy. Women 
with high grade serous ovarian cancer harbouring BRCA mutations but not 
BRCA1 deficiency have reported to exhibit improved survival and chemotherapy 
response (Yang et al, 2011).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8: Schematic Illustration of DNA DSB-induced activation of checkpoint and 
repair pathways. Figure from Bolderson E et al., 2009.   
Access Restricted in the 
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PTEN (Phosphatase and tensin homolog) codes for a protein that acts a 
cell cycle regulator by inhibiting the survival/growth promoting activity of the 
phosphoinisitide 3-kinase (PI3K)-Akt   signalling pathway and is mapped to 
chromosome 10q23.3. PTEN blocks Akt activation and indirectly blocks Mdm2 
release in the cytoplasm which in turn leads to p53 activation leading to cell 
cycle arrest and apoptosis.  
Somatic PTEN mutations are frequently found in endometrioid but not 
mucinous or serous ovarian cancer and typically more frequently occur in early 
stage disease indicating that PTEN mutations are an early event in ovarian 
carcinogenesis (Obata et al, 1998), although some studies have identified 
mutations of PTEN in subsets of low grade serous and mucinous tumours 
(Saito et al, 2000). TCGA analysis of 316 HGSCs has identified a 0.6% somatic 
mutation rate for PTEN (The TCGA Study, 2011). 
A reverse association between PTEN and TP53 mutations has been 
reported in a study that revealed 5% PTEN mutations in all subtypes of EOC 
and 20% in endometrioid alone (Kolasa et al, 2006). Somatic mutations of the 
PTEN gene result in protein inactivation and recurrent somatic mutations are 
found in CpG dinucleotides (Bonneau et al, 2000).  
Finally, CDKN2A (Cyclin-dependent Kinase 2A) is involved in cell cycle 
checkpoint control and was found mutated in approximately 10% of epithelial 
ovarian cancer (reviewed by Despierre et al, 2010) and TCGA reported that 
2.5% of the HGSCs studied harbour somatic mutations (The TCGA Study, 
2011). 
 
1.7.1.2 Mutations in Oncogenes and their Clinical implications  
Activating mutations have been reported in EGFR, KRAS, BRAF, 
PIK3CA, APC, CTNNB1, KIT and SMAD4 oncogenes in epithelial ovarian 
tumours, and the clinical implications of some of these mutations have been 
studied. 
Epidermal growth factor receptor (EGRF) phosphorylation induces 
activation of the PI3K-Akt and External signal Regulated Kinase (ERK) 
signalling pathways. EGFR over-expression has been linked with poor outcome 
in ovarian cancer (Skirnisdóttir et al, 2001). Early studies have identified four 
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EGFR types of mutations reported in ovarian tumours worldwide in exons 19 
and 20, but recent mutational analysis in all the exons revealed 27 additional 
nucleotide substitutions in exons 18, 19 and 20 in Japanese patients which 
might indicate an ethnic variation in EGFR mutations with the mutations present 
in all subtypes but endometrioid ovarian carcinomas (Tanaka et al, 2011). 
TCGA analysis of 316 HGSCs revealed a 0.6% somatic mutation rate for PTEN 
(The TCGA Study, 2011).  
Data from Non-Small Lung Cancer research have shown that patients 
with EGFR mutations have a better response to the EGFR selective inhibitor 
Gefitinib but such association was not found in ovarian cancer patients (Schilder 
et al, 2005). Tanaka et al have demonstrated that the EGFR mutational status 
of those patients did not correlate with EGFR expression, Akt activation or 
patient survival outcome, however showed that Akt inactivation is correlating 
with increased sensitivity to platinum based chemotherapy (Tanaka et al, 2011).  
The PI3K-Akt pathway is activated by activating hot spot mutations in 
PIK3CA (PI3K catalytic subunit-α) found in a small subset of endometrioid and 
clear-cell ovarian cancers (Campbell et al, 2004) as well as by somatic Akt 
activating mutations but the latter are a very rare event in ovarian cancer. TCGA 
analysis of 316 HGSCs has identified a 0.6% somatic mutation rate for PIK3CA 
(The TCGA Study, 2011) but a recent study of 30 ovarian tumours of several 
subtypes has reported 17% somatic mutation rate for PIK3CA (Janku et al, 
2011). 
Several mutations of members of the RAS-RAF-MEK-ERK-MAP kinase 
pathway have also been documented in ovarian cancer. The RAS proteins are 
small GTPases downstream of EGFR and are key components involved in 
pathways that couple growth factor receptors to mitogenic effectors and 
influence cell proliferation and differentiation. Several studies have reported 
KRAS activating mutations and collectively the published data support that they 
are more common in mucinous lesions (45%) than serous (15%) and more 
prevalent in borderline than invasive tumours with the 10 most common 
mutations located in codons 12 and 13 of KRAS (Fabjani et al, 2005, Auner et 
al, 2009). These data suggest that KRAS is involved in mucinous differentiation.  
In serous lesions, mutations of KRAS and also BRAF are typically found in 
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borderline and low-grade carcinomas. BRAF mutations are found in low grade 
serous ovarian tumours (12%) (Sieben at el, 2004). Consistent with previous 
reports TCGA analysis has found KRAS or BRAF somatic mutations in only 
0.6% of the 316 HGSCs studied (The TCGA Study, 2011). 
Mutational status of KRAS was not correlated with patients’ prognosis 
(Auner et al, 2009), however bearing in mind that KRAS and BRAF mutations 
are indicative of patients response to anti-EGFR treatments in colorectal cancer 
and are associated with poor survival in colorectal and lung cancer, further work 
is needed to elucidate their prognostic role in ovarian cancer. In a small study of 
30 ovarian tumours 35% were found to have simultaneous KRAS or BRAF and 
PIK3CA mutations. Patients harbouring simultaneous PIK3CA and KRAS or 
BRAF mutations were found to respond well to PI3K/AKT/mTOR inhibitors 
(Janku et al, 2011).  
 
1.7.2 Copy number changes in EOC and their clinical implications  
Besides mutational activation of oncogenes and mutations that inactivate 
TSGs, other frequent events such as copy number variation through 
chromosomal amplification, gain or deletion can lead to their activation or 
inactivation respectively. Comparative genomic hybridisation (CGH) and the 
more high-throughput array CGH (aCGH) have replaced older cytogenetic 
techniques such as chromosome banding and fluorescence in situ hybridisation 
(FISH) to identify recurrent patterns of copy number gain, amplification, loss 
(deletion) or allelic imbalance in ovarian tumours. 
DNA amplification is a mechanism that allows cells to increase 
expression of genes that act as oncogenes by regulating cell growth and 
resistance to chemotherapy. The detection of gene amplification is important for 
patient disease management for diagnostic, prognostic or therapeutic reasons.  
Copy number changes have distinct patterns in the different histological 
subtypes.  
MYC amplification in chromosome 8q24 was one of the first copy number 
changes identified in ovarian cancer (Baker et al, 1990). The same study 
reported no apparent relationship between MYC amplification and response to 
chemotherapy, which was confirmed in recent studies (Darcy et al, 2009).  
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Gain of CCNE1 and FGF3/4 was found in all serous carcinomas, and 
80% of serous borderline tumours exhibited amplification of FGFR1 and MDM2 
and 75% showed gain of PIK3CA. Previous CGH data have shown gain of 
PIK3CA in 40% of all histological subtypes associated with increased PIK3CA 
transcription (Shayesteh et al, 1999). Endometrioid carcinomas frequently 
exhibit gain of KRAS2 (67%), MYCN (50%), CCND2 (50%), ESR and JUNB 
(83%, Mayr et al, 2006). AKT2 amplification has been reported to 12% of 
ovarian tumours, and it might be correlated with poor prognosis to paclitaxel as 
cell lines that exhibited AKT2 amplification were resistant to paclitaxel 
(Bellacosa et al, 1995, Page et al, 2000). Amplification of many other 
chromosomal regions or genes in ovarian cancer has been associated with poor 
treatment outcome such as MUC1 in chromosome 1q21, ERBB2 in 17q21, 
CCNE1, JUNB in 19q12 and several others (reviewed in Despierre et al, 2010). 
The TCGA Study has recently reported somatic copy number alterations 
in a study of ~500 HGSCs. The most common focal amplification identified 
included genes CCNE1 and MYC and each was amplified in more than 20% of 
the tumours. More tightly localised amplification peaks, showed amplification of 
a target gene for p53, and the embryonic development gene PAX8, and the 
catalytic subunit of telomerase TERT. In an attempt to investigate whether 
certain gene changes may be linked to response to therapy they identified 22 
genes that are therapeutic targets including KRAS, MAPK1 and CCNE1 that 
were amplified in 10% of the tested HGSCs (The TCGA study, 2011) 
Chromosomal deletions which can be caused by translocations 
crossovers, inversions or breaks are mechanisms that allow cells to inactivate 
genes that would normally act as tumour suppressor genes. A few deletions of 
genetic material in several regions have been reported in ovarian cancer 
including the 3p, 1p, 17q, 17p13, 4q, 5q, 16q, 17p, 17q, Xp and Xq with the 
most common abnormality reported in ovarian cancer being the deletion or 
translocation of chromosome 6q (reviewed in Despierre et al, 2010). 
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1.7.3 Loss of heterozygosity (LOH) in EOC  
Tumour suppressor genes act recessively, which means that the loss or 
inactivation of both copies of the gene is essential for the normal proliferation of 
the cells to be rendered uncontrolled. The main strategy to identify tumour 
suppressor genes has been investigation for LOH or allele loss studies in 
tumours. Loss of heterozygosity to identify TSGs is based on the two-hit 
hypothesis formed by Knudson in 1993. The first hit is a mutation in one of the 
alleles, (inherited in the familial cases, or random in the sporadic) and the 
second hit may occur by either a mutation or methylation or a deletion of the 
remaining normal allele.  In case of deletion of the normal allele if the patient is 
heterozygous for a polymorphic marker the tumour will be homozygous, termed 
loss of heterozygosity (Figure 1.9, B).  
Thus, the investigation of multiple polymorphic markers in the tumour 
DNA compared to germline (blood) DNA of the same individual is used to 
determine the frequency of LOH in that genomic region. The initial method used 
to detect LOH was Southern Blot analysis of restriction fragment length 
polymorphisms (RFLPs) by autoradiography. This was replaced by the 
amplification of polymorphic microsatellite repeat markers by PCR, initially using 
radiolabelling and then fluorescent detection. (Cooke et al, 1996, Canzian et al, 
1996). SNP arrays now provide high marker density to find regions of LOH. 
With these SNP arrays, it is possible to identify the absence of the 
heterozygous loci in a tumour using the hidden Markov model, instead of 
needing to compare the tumour with a paired normal (Beroukhim et al, 2006).  
There are several studies that have reported LOH in sporadic ovarian 
tumours but two studies have investigated the frequency of LOH on all the 
chromosome arms in the same panel of tumours, called allelotype studies. The 
first of the two studies used Southern blotting which is not as accurate and the 
second one that use microsatellite markers has identified >35% frequency of 
LOH in chromosomal arms 5q, 6q, 7p, 8p, 9p, 13q, 14q, 17p, 17q, 18q, 21q and 
22q (Sato et al, 1991, Cliby et al, 1993). Many chromosomal regions were found 
to have frequent LOH in malignant epithelial tumours in the last 2 decades, and 
potential tumour suppressor genes within these chromosomes have been 
investigated. Candidate TSGs mapped at the arms where the LOH was 
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detected were subjected to expression analysis in ovarian tumours and/or cells 
lines to identify a possible role for them in ovarian tumourigenesis.  
The events that might lead to LOH are mutation, homozygous gene 
deletion or epigenetic changes. A frequency of ~20% LOH has been reported in 
chromosome 1 with the candidate putative TSG ARHI identified by differential 
display PCR, a gene appearing to be involved in growth signal regulation (Peng 
et al, 2000) through inhibition of STAT3 and FAK-Rho signalling pathways 
(Badgwell et al, 2011). On chromosome 5q, 46% of allele loss directed to 
identification of a candidate TSG Dab2/DOC2 a gene involved in a mitogenic 
signal transduction pathway (Cliby et al, 1993, Fazili et al, 1999). LOH 
frequency of up to 65% in chromosome 6q led to identification of the putative 
TSG LOT1, a gene possibly regulating growth signals (Cooke et al, 1996, 
Abdollani et al, 1999, Niederacher et al, 1999). On chromosome 9, 34% LOH 
has been found in 9p later possible related with the cell cycle regulatory TSG 
CDKN2A and subsequent studies reported no mutations or deletions or 
methylation of CDKN2A (Shih et al, 1997) and not significant association of 
CDKN2A gene expression and LOH at its corresponding locus (Niederacher et 
al, 1999). In chromosome 10q frequency of LOH was reported to be 16% in 10q 
involving PTEN.  In chromosome 11p 35% of LOH lead to identification of 
deletions in the candidate TSG TSG101 highly expressed in ovarian cancer cell 
lines (Lu et al, 1997, Liu et al, 2002). High frequency of LOH was reported in 
chromosome arm 13q involving TSGs BRCA2 and retinoblastoma 1 (RB1), but 
the low mutation rate reported in BRCA2 in ovarian cancers indicates other 
TSG in chromosome 13 might be involved in ovarian tumourigenesis (Sato et al, 
1991). The high frequency of LOH (61%) in 17p can partially be represented by 
alterations found in TP53 as they are mostly found in advanced stages (Philips 
et al, 1996). Additionally, methylation analysis revealed HIC-1 (Hypermethylated 
in cancer 1 gene) and positional cloning revealed OVCA1 and OVCA2 (Ovarian 
cancer genes 1 and 2) as candidate TSGs implicated in EOC development 
(Wales et al, 1995, Schrock et al, 1996). Higher than 50% frequency of LOH 
reported for chromosome 17q is related to BRCA1 mostly caused by 
hypermethylation of its promoter region and more rarely by mutation (Wilcox et 
al, 2005, Despierre et al, 2010). Loss or deletion of chromosome 18q has been 
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reported to occur in 25 to 40% of ovarian carcinomas (Cliby et al, 1993, Arnold 
et al, 1996) 
 
1.7.3.1 Allele specific LOH 
LOH is non random in TSGs with loss of the normal allele. If LOH at a 
region was random there would be loss of either of the two alleles. At a 
population level, random LOH would result in equal loss of either of the two 
alleles in a large number of tumours. However it is possible that if a SNP has a 
functional role there may be preferential loss of one allele over the other, as 
reported in a breast cancer study for LOH in DAL-1/4.1B. In this study, a C/T 
intragenic SNP was analysed for LOH and it was reported that the C allele was 
preferentially retained, suggesting that allele-specific LOH is occurring 
(Kanokwan et al, 2004).  
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Figure 1.9: Two hit Knudson hypothesis and loss of heterozygosity in ovarian cancer. 
a) Representation of the two hit Knudson’s hypothesis for sporadic and hereditary 
ovarian cancer. The somatic event can be mutation, deletion, or methylation, b) 
Schematic illustration of loss of heterozygosity and the principle for detecting it using 
either RFLP analysis or microsatellite analysis. 
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 Epigenetics 1.8
 
The term "epigenetic" refers to a change in gene expression that is not 
due to a change in sequence of bases of DNA (Galm et al, 2006). Commonly 
occurring epigenetic changes are DNA methylation and chromatin remodelling 
by histone protein acetylation and methylation, as well as nucleosome 
positioning and non-coding RNAs, specifically miRNA expression. Aberrations 
in these epigenetic mechanisms have been associated with the development of 
cancerous lesions and their response to chemotherapy, thus affecting their 
clinical outcome (Ducasse and Brown, 2006). 
1.8.1 Methylation of DNA 
 
DNA methylation is the covalent addition of a methyl group to the 5’-
carbon of cytosine in CpG dinucleotide sequences to form the so called fifth 
base, 5-methylcytosine. The transfer of the methyl group to the cytosine ring 
from the donor molecule S-adenosyl-L methionine (SAM) is facilitated by DNA 
methyltransferases (Kumar et al, 1994). The human genome is not methylated 
on its whole but instead there are scattered methylated and unmethylated 
segments throughout the genome.   
The frequency of CpG dinucleotides in the human genome is 20% less 
than expected, due to spontaneous deamination of methylated cytosine and 
conversion to thymine through evolution. From existing CpG dinucleotides 
scattered around the human genome approximately 60-90% is methylated and 
the high frequency of their methylation provides a possible justification for the 
under-representation of CpGs in the human genome. CpG dinucleotide 
sequences that are found to be very highly concentrated in areas are called 
CpG islands and comprise 1-2% of the genome (Clark and Melki, 2002). CpG 
islands appear in lengths of 500-5000 base pairs (bp) and are mostly located at 
the 5’ region of genes and associated with the promoters of more than half of 
the human genes. In contrast to the bulk of DNA which is methylated and 
located in regions of gene inactivity, the CpG sites within CpG islands are 
always unmethylated and are located in regions of genes activity. Absence of 
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methylation in the CpG islands is a prerequisite for the gene under their control 
to be actively transcribed and is important for tissue specific genes to be 
activated (Yoder et al, 1997). 
There are two ways via which DNA methylation is believed to regulate 
gene expression, whether by blocking the binding of transcription factors to the 
promoter of the gene or by causing the formation of inactive chromatin state 
(Molloy and Watt, 1990, Bird and Wolffe, 1999).    
 
1.8.2 Methylation in normal development, cancer, EOC and its clinical 
relevance 
The patterns of methylation in the human genome are established in the 
embryo, initially with hypomethylation of the paternal DNA, following with de 
novo methylation of specific CpG sites just before blastocyst implantation. The 
methylation state of a CpG island is not always maintained in each cell division 
and a switch between de novo methylation and hypomethylation at each cell 
division creates a heterogeneous pattern of methylation for any molecule, for 
example for tissue differentiation where the activation of tissue specific genes is 
needed, known as epigenetic reprogramming (Reik et al, 2001). However, the 
general imprinting patterns of methylation occurring in the early embryo are 
shared and inherited/maintained independently of the heterogeneity that can be 
found in individual CpG sites. Disruption of these pre-set patterns during adult 
life has been linked to ageing and disease. The cancer epigenome is 
characterised by global changes in DNA methylation, which in turn result to 
altering gene expression profiles and play an important role in oncogenic 
transformation. 
Two types of abnormal methylation in cancer have been identified in 
cells: hypomethylation and hypermethylation. One possible consequence of 
hypomethylation of the genome is loss of transcriptional control in normal 
"silent" areas, which could lead to the expression of genes, such as oncogenes, 
which are normally disabled (Dunn et al,2003). The second change in DNA 
methylation observed in cancer is hypermethylation of CpG islands in areas of 
gene promoters associated with suppression of transcription and is, along with 
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mutations, a mechanism for inactivating tumour suppressor genes (Herman et 
al, 2003) and has been proposed as one of the two hits in Knudson’s 
hypothesis for oncogenic transformation. The growing list of hypermethylated 
and hypomethylated genes in EOC has been extensively reviewed in Barton et 
al, 2008.  
Some of the genes reported to show hypermethylation of the CpG 
islands within their promoters are genes involved in cell cycle such as RB1 
hypermethylation in glioblastomas (Nakamura et al, 2001). Transcription factors 
RAS homologue RASSF1A are also found hypermethylated in most cancers 
including lung, liver, ovarian and breast cancer (Burbee et al, 2001, Yoon et al, 
2001). Genes involved in the repair have been found to be hypermethylated 
such as BRCA1 in ovarian cancer (Ibanez et al, 2004). Finally, also genes 
involved in apoptosis, for example in TMS1 gene in ovarian cancer have been 
reported to show hypermethylation (Terasawa et al, 2004).  
Epigenetic regulation of BRCA1 has been extensively studied in ovarian 
cancer and hypermethylation of its promoter has been found in up to 20% of 
EOCs, associated with LOH in the BRCA1 locus and loss of BRCA1 
expression. These reports indicate that the second hit for BRCA1 inactivation 
may very well be silencing of BRCA1 expression by hypermethylation (Chan et 
al, 2002, Ibanez et al, 2004, Teodoridis et al, 2005). Other tumour suppressor 
genes with reported LOH that have been reported to be down-regulated in 
ovarian cancer partially as a result of hypermethylation are ARHI, CDKN2A, 
RASSF1A, MLH1, SFRP1 (a wnt antagonist) and Trail receptor DR4. Gene 
methylation patterns of some genes are also relatively distinct for different 
histological subtypes or aggressiveness of tumour with examples of a cell cycle 
regulator inhibitor SFN and WT1 (Wilm’s tumour suppressor gene 1) exhibiting 
hypermethylation mostly in clear cell cancers. RASSF1 and APC (Adenomatous 
polyposis coli) hypermethylation is more often found in invasive ovarian 
carcinomas rather than in low malignant potential tumours (reviewed in Barton 
et al, 2008). Global DNA hypomethylation increases with malignancy in EOCs.  
There are much less genes reported to be hypomethylated than 
hypermethylated. These include metastasis-related gene synuclein-γ (SNCG) 
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and Sat2 gene that is involved in rearrangement of heterochromatin (reviewed 
in Barton et al, 2008). 
DNA methylation patterns have been also associated with the 
responsiveness to chemotherapy. Methylated genes implicated in drug 
resistance are those genes involved in processes known to influence 
chemosensitivity such as DNA repair and damage response pathways. For 
example methylation of BRCA1 has been associated with improved response to 
chemotherapy (Teodoridis et al, 2005). Silencing due to hypermethylation of the 
DNA mismatch repair gene MLH1 has been implicated with acquired resistance 
to platinum based drugs (Plumb et al, 2000). 
The identification of epigenetic changes that correlate with 
tumourigenesis or clinicopathological parameters and patient outcome may 
reveal new markers that will be used in assessment of risk, therapeutic 
approaches and individualised treatment. 
 
1.8.3 Genotype-dependent DNA methylation 
Evaluating genotype specific methylation could be an additional 
approach for characterising the potential functional role of SNPs that arise from 
GWAS. One of the most fascinating discoveries around DNA methylation is the 
fact that two homologous chromosomes can be differentially methylated. 
Gametic imprinting and X chromosome inactivation are factors that can cause 
differential methylation of homologous chromosomes.  DNA methylation can be 
influenced by the environment and chromosome’s parental origin and genome 
sequence. It is possible to investigate DNA methylation patterns in a population 
along with SNPs typing and see if allelic differences between the chromosomes 
influence DNA methylation. There are several studies that suggest that the 
majority of DNA methylation variation is explained by genotype and that genetic 
variants may have a much bigger impact in DNA methylation than gametic 
imprinting. A study has reported allele specific methylation of the human C-HA-
RAS-1 gene (Chandler et al, 1987). More recent studies are more powerful in 
detecting allele specific methylation patterns since recent advances in DNA 
sequencing technologies.  
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A family study has recently reported that the different levels between the 
homologous chromosomes were rarely completely reversed and proposed that 
DNA methylation is conserved in loci in an allele-specific manner (Gertz et al, 
2011). Another recent study linked a SNP in the 5’UTR of MLH1 with 
dominantly inherited constitutional epigenetic silencing by studying methylation 
patterns relatively to genotype in three generations of a family with increased 
risk in developing cancer (Hitchins et al, 2011). These observations support a 
model of evolution where genetic variants and not environment, shape 
epigenetics. Therefore, genetics may be the main regulatory system for 
oncogenic transformation and epigenetics just a mediator.    
 
 
 Cell cycle and its regulation  1.9
The reproduction of a cell is carried out in a coordinated process that 
involves four distinct phases comprising the cell cycle, known as G1, G2, S, and 
M. The basic events that occur during the cell cycle are the accurate duplication 
of the genetic material taking part during the S phase and the segregation of the 
replicated chromosomes and cellular organelles into the two identical daughter 
cells that occurs during mitosis (M phase) (Malumbres and Barbacid 2001). 
Undifferentiated embryonic cells rapidly perform repeated cycles of DNA 
replication (S phase) and nuclear and cellular division (M phase). In that case, 
the replication of the genetic material starts straight after the end of mitosis 
resulting in the completion of a cell division cycle skipping phases G1 and G2 
(Massaque et al, 2004). As embryogenesis further unfolds the needs of the 
adult cell, being now in a much more complex environment, are increased. As a 
result, two additional phases take part during the cell cycle, phase G1 and G2. 
G1 and G2 function as “gap” periods before entry to S or M phase respectively. 
These allow for the cell to grow and duplicate their organelles as well as 
providing time for the cell to ensure that the internal and external environmental 
conditions are optimal for the cell to successfully proceed and complete the S 
and M phases (Malumbres and Barbacid 2001). On the genomic level, the gap 
periods are making sure that throughout the cell cycle the genetic material that 
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is replicated and to be segregated between the daughter cells will be accurate 
and with no mistakes.  
One of the most important features of the cell cycle is its incredible 
precision, which is achieved by the activity of various checkpoints throughout 
the cell cycle. At these checkpoints the progress of the cell cycle is monitored, 
securing the integrity of the genetic material. There are three checkpoints during 
a cell cycle. One is controlling the transition between G1 and S phase, one is 
the intra-S phase checkpoint and finally a checkpoint is found between the S 
and M phase. Although distinct, these checkpoints all respond to DNA damage 
and share several of the same proteins that sense DNA damage, others that 
are signal transducers to effector proteins that start a cascade of events that 
causes DNA repair or in failure of accurate repair, trigger cell cycle arrests and 
apoptosis (Houtgraaf et al, 2006). Cell cycle checkpoint and chromosome 
segregation machinery interact with core components of the DNA damage 
response to ensure that the correct genetic material will be passed on to 
daughter cells. 
 
1.9.1 DNA damage and mechanisms for DNA repair  
The integrity of the genome of eukaryotic cells is constantly challenged 
throughout the cell cycle. A large amount of damage can be caused to the DNA 
by exogenous environmental factors such as cigarette smoke, industrial 
chemicals, UV, several forms of ionizing radiation, and various genotoxic 
chemical agents. In addition, DNA damage can be induced by endogenous 
processes such as errors in the DNA replication caused by nucleotide 
misincorporation and natural by-products created during the normal cell 
metabolism known as Reactive Oxygen Species (ROS) (Tuteja et al 2001, 
Houtgraaf et al 2006). There is a variety of DNA lesions that can be caused by 
these exogenous and endogenous agents including base deletions, 
mismatches, single-strand breaks (SSBs), double-strand breaks (DSBs), DNA 
crosslinks and chemical adducts. For example, ionising radiation can cause 
SSBs and DSBs in the DNA that if not accurately repaired they give rise to 
mutations and structural rearrangement of the genome (Houtgraaf et al, 2006).  
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All forms of DNA lesions can lead to DNA alterations and mutations that if not 
properly repaired are passed onto the progeny and accumulations of such 
alterations infer a substantial risk of developing uncontrolled cell growth leading 
to cancer development. 
The cell has evolved several complex and sophisticated mechanisms in 
order to counteract the numerous threats to its genomic integrity and each of 
those mechanisms is directed to the repair of a specific type of DNA lesion. 
These mechanisms are part of the cell’s DNA Damage Response (DDR) and 
are distinct pathways, often interlinked, consisting of numerous proteins that 
form a cascade of events starting from the recognition of the DNA lesion, 
recruitment of other components of the repair pathway to the site of damage 
and finally repairing the damage as accurately as possible. The four main DDR 
mechanisms in a eukaryotic cell are: 
Base Excision Repair (BER) pathway: This mechanism is responsible 
for the removal of destroyed DNA bases. BER is the cell’s predominant 
response to single strand DNA damages that are generated from the cell’s 
metabolism and ROS. Additionally, BER is often involved in the repair of subtle 
DNA lesions such as SSBs caused by ionising radiation, alkylation products, as 
well as lesions caused by some chemotherapeutic drugs such as adriamycin 
and mitomycin (Izumi et al, 2003, Christmann et al, 2003, Houtgraaf et al, 
2006). The first step is the detection and removal of the damaged base by 
recruitment of DNA glycosylases to the site of damage (Scharer et al, 2001). 
Following the excision of the damaged base the nucleotide gap is correctly filled 
in by polymerase β (Pol-β) and then ligated by the Ligase3/XRCC1 complex 
(Houtgraaf et al, 2006). Key enzymes to this process are PARP1 and PARP2 
which are acting as sensors and signal transducers for lesions such as SSBs 
(Lord and Ashworth, 2008). 
Nucleotide Excision Repair (NER) pathway: This mechanism is used by 
the cell for the repair of bulkier adducts on single strand DNA that distort the 
normal architecture of the DNA helix. Some of these lesions/adducts are 
pyrimidine dimers that can be caused by ultraviolet light, or adducts that are 
caused by genotoxic agents such as benzopyrene (Friedberg et al, 2001). NER 
can be carried out in two distinct pathways, the global genomic repair (GGR) 
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and the transcription coupled repair (TCR). TCR is taking place when the 
lesions formed are blocking the path of RNA polymerase during the 
transcription process and GGR occurs when the architecture of the DNA helix is 
distorted by incorrect base pairing (Balajee et al, 2000, Mullenders et al, 2001). 
For both pathways of NER although the detection of the lesion differs, the repair 
process is identical with the excision of the DNA around the lesion and the gap 
repaired by DNA polymerases and finally ligated with ligase I. Important 
enzymes involved in the NER pathway are XPA that confirms the existence of 
the DNA lesions after the DNA helix is unwound and ready to be excised and 
the Excision repair cross-complementing proteins 1  and 4 (ERCC1 & ERCC4) 
which are the key proteins during the DNA excision step (Houtgraaf et al, 2006). 
Mismatch Repair (MMR) pathway: This repair mechanism is responsible 
for the removal of non-complementary bases that occur either in the process of 
deamination, oxidation or methylation of bases or by transcriptional errors 
(Umar et al, 1996). The recognition of the modified bases is carried out by the 
MutSα complex, consisting of homologous proteins MSH2 and MSH6. MSH2 
can also be couple with the repair protein GMSH3 forming the complex MutSβ. 
Each complex has different substrates and thus plays a different role in the 
MRR process (Christmann et al, 2003). Once the MutSα complex recognises 
and binds to the mismatched base, it recruits MLH1 and PMS2 homologous 
repair proteins to the complex. The excision of the DNA sequence that contains 
the mismatched base is carried out by exonuclease I and the correct sequence 
is filled in by polymerase δ (Longley et al, 1997, Genschel et al, 2002). 
Double strand break (DSB) repair mechanism: DNA DSBs are the most 
threatening DNA damages triggered in response to genotoxic stress and can 
lead to chromosomal abnormalities such as fragmentations, deletions and 
translocations and further to cell death. Thus, the rapid repair of such DNA 
damages is one of extreme biological significance. There are two mechanisms 
for dealing with the repair of DNA DSBs: homologous recombination (HR) 
and non-homologous end joining (NHEJ). The choice of which mechanism to 
be used is largely dependent upon the cell cycle phase when the DSB occurs. 
HR mainly takes place during S or G2 phases. For HR to occur, necessary 
requirements that have to be fulfilled are the DNA replication and the two sister 
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chromatids formation. In contrast, NHEJ can take place throughout the cell 
cycle but mainly occurs during the G0/G1 phases (Takata et al, 1998). HR is a 
complex conservative mechanism restoring the exact DNA sequence that was 
damaged. NHEJ is simpler but is error prone with the result of loss of genetic 
information and mutagenesis. 
During non homologous end joining, the ends of the broken DNA strands 
are joined, without necessarily requiring DNA homology at the points of the 
joining. The first step in this process is the formation of a heterodimer complex, 
consisting of the proteins Ku78 and Ku80, which protects the damaged area 
from being cleaved by exonucleases. After binding to the DNA, the heterodimer 
interacts with the catalytic subunit of DNA-PK (XRCC7, DNAPKcs ) forming a 
holoenzyme. The DNAPKcs complex activates XRCC4 which binds to ligase IV, 
which is turn joins the broken ends. Before the joining of the broken ends, 
damaged DNA on the 3’ end is removed by the complex MRE11-Rad50-NBSg1 
which have an exonuclease, endonuclease and helicase role respectively and 
DNA is removed from the 5’ end by endonuclease FEN 1(Critchlow et al, 1998, 
Christmann et al, 2003). 
During homologous recombination, DNA homology is a requirement and 
the damaged chromosome is in direct contact with a homologous intact DNA 
sequence from the sister chromatid that is acting as a template for the synthesis 
of new DNA at the DSB site. The most important proteins involved in HR are 
BRCA1, BRCA2, PALB2, ATM, CHK1, CHK2, Rad51 and Rad52 (Houtgraaf et 
al, 2006). In the event of a DNA DSB, a complex formed of BRCA1-abraxas-
Rap80 binds to the ubiquitylated histones following phosphorylation of the 
histone gamma H2AX (γH2AX).  The damage sensor complex formed by 
MRE11-Rad50-NBS1 (MRN complex) is processing the ends of the two broken 
DNA chains in a 5’-3’ direction. The BRCA1-CtIP complex is in turn associated 
with the MRN complex and through ATM and CHK2 dependent phosphorylation 
of BRCA1 the BRCA1-PALB2-BRCA2 complex is formed to trigger the Rad51 
mediated HR (Roy et al, 2012). The protein Rad51 searches the genome for an 
intact copy of the damaged DNA on the sister chromatid. Each damaged 3’ 
DNA strand is joined with a heptamer complex that is formed by Rad52 
interacting proteins, which protects it from further cleavage by exonucleases.  
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The Rad52 complex interacts with the Rad51 complex (Rad51C, Rad51D, 
XRCC2 and XRCC3) activating the process of exchange of homologous parts 
of genetic material between the damaged and the intact sister chromatid.  
Another important protein that interacts with Rad51 is RPA, which acts to 
stabilise the Rad51 inducible exchange of homologous DNA parts.  After 
completion of the DNA synthesis, the final ligation and branch migration of the 
repaired strands follows. (Golub et al, 1998, Stasiak et al, 2000, Sonoda et al, 
2001, Christmann et al, 2003, Houtgraaf et al, 2006, Roy et al, 2012). 
 
1.9.2 Defects in DNA damage response in neoplastic development  
 
As previously discussed, tumours are often characterised with genomic 
and chromosomal instability, and DNA alterations such as nucleotide 
substitutions, insertions and deletions. Defects of the DDR have often been 
linked to neoplastic development by giving rise to those DNA abnormalities. 
One example is mutations in the mismatch repair genes MSH2 and MLH1 are 
linked to hereditary non-polyposis colorectal cancer. Another example are 
silencing mutations or epigenetic silencing of BRCA1 and BRCA2 genes 
causing defects in homologous recombination that is found defective to 50% of 
high-grade serous ovarian adenocarcinomas both in familial and sporadic 
ovarian cancer. 
There is substantial evidence that DDR is dysfunctional during neoplastic 
development. DNA DSBs marker, γH2AX nuclear foci formation, has been 
found to be markedly elevated in precancerous lesions. There is the hypothesis 
that activation of oncogenes such as MYC and RAS causes the formation of 
multiple replication forks that stall and collapse triggering the DDR and cell 
cycle checkpoint to repair DNA lesions before mitosis takes phase. Inactivation 
of ATM, ATR and p53 which play a critical role in DNA DSB repair and cell cycle 
checkpoint control can in turn cause the progression to mature tumours from 
those precancerous lesions. With important players of the DDR becoming 
inactivated the cells proceed through the cell cycle with unrepaired DNA lesions 
increasing the chance of oncogenesis (Martin et al, 2008).  
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A cancerous cell is using the normal mechanisms of the cell for further 
growth and survival. Thus, several cancer treatments are to date aiming in 
exploiting DDR defects in order to target and eliminate the cancer cells. For 
example, platinum agents that cause inter and intrastrand crosslinks in DNA are 
effectively used in the treatment of high grade serous ovarian cancer since it 
has been reported that HR is often defective in such cases due to inactivation of 
the BRCA1 and BRCA2 genes. Similarly, platinum therapy is effective in 
patients that have ERCC1 mutations and thus defective NER pathway 
responsible for removal of large DNA adducts. Recent evidence have shown 
that a promising approach is to target directly specific components of a DDR 
pathway such as topoisomerase inhibitors that cause DNA breaks across the 
genome to be unrepaired (Martin et al, 2008). 
Very successful specific inhibitors are PARP inhibitors (Lord and 
Ashworth, 2008). Members of the PARP family are involved in DNA repair 
through three different mechanisms and thus are a very attractive target for 
therapy. Firstly, though direct interaction of PARP1 with XRCC1, Polβ and 
PARP2 interacts with XRCC1, Polβ, DNA ligase III that are key proteins in the 
BER pathway (Masson et al, 1998, Schreiber et al, 2002). Secondly, PARP1 is 
modifying chromatin structure, after DNA damage occurs. PARP1 binds to the 
20S proteasome and increases its proteolytic activity. This leads to the 
degradation of oxidatively damaged histones and chromatin structure 
modulation with in turn facilitates the access of DNA repair enzymes to the site 
of DNA damage (Mayer-Kuckuk et al, 1999, Ullrich et al,1999). Finally, a 
specific binding site on members of the PARP family enables their interaction 
with a large number of repair enzymes and molecules involved in the 
checkpoints of the cell cycle, such as P53, P21, XPA, MSH6, DNA ligase II, 
XRCC1, DNAPKcs, Ku70, NF-kB. With their poly ADP ribosylation PARP 
proteins can regulate DNA repair, cell cycle regulation and apoptosis (Pleschke 
et al, 2000). 
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 Survival and Chemoresistance in EOC_An overview  1.10
The reported overall survival rates for stage II-IV diagnosed patients is 
19-30% (Pfeiderer, 1984, Gonzalez-Diego et al, 2000). For EOC treatment 
platinum therapy is the most widely used which includes cisplatin or carboplatin, 
often in combination with taxane therapy (paclitaxel) (Rustin et al, 1996). 
Although chemotherapy is widely used to treat EOC the survival rate hasn’t 
improved over the last decades due to disease recurrence, possibly caused by 
drug resistance that has a significant role in tumour progression (Bradshaw and 
Arceci, 1998, Haq and Zanke, 1998).  
Some of the known mechanisms for platinum resistance include reduced 
drug delivery to targeted DNA and also increased ability of cells to respond 
efficiently to DNA damage induced by platinum and defected genes in the DNA 
repair, apoptosis and cell cycle control pathways (Kelland et al, 2007). There 
are many studies that show that germline genetic variation has a role in survival 
and further in chemoresistance. One study has shown that polymorphisms in 
glutathione S-transferases (GSTs) can be a valuable marker to determine 
patient prognosis as they found significantly better survival in advanced EOC 
patients with the null GSTM1 genotype  (Medeiros et al, 2003). Polymorphisms 
in the epidermal growth factor (EGF) also have been reported to be associated 
with EOC survival (Heffler et al, 2007). Another study has shown that patients 
with amplifications in Cyclin E (CCNE1) gene had poor survival and short 
response time (Etemadmoghadam et al, 2009). Several studies have also 
shown that there is a significant survival difference between EOC patients with 
and without BRCA1 and BRCA2 mutations (Chetrit et al, 2008, Tan et al, 2008).  
Survival analyses have been performed in studies to identify molecular markers 
that affect survival and this could possibly be related to chemoresistance. This 
could lead to better understanding of the causes of chemoresistance in groups 
of patients and more efficient individualised treatment but also the development 
of valuable tools for accurate prognosis. Thus, a lot of research focuses on 
using in vitro cell models to provide information that will enable the development 
of treatment that can overcome drug resistance.  
Several studies have shown that p53 function is altered in drug resistant 
EOC cells and that when lost it confers resistance to cisplatin (Fajac et al, 1996) 
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whereas sensitivity to paclitaxel is retained regardless of TP53 status (Jones et 
al, 1998). Another study has reported a mechanism of resistance to paclitaxel 
by showing that the up-regulation of the transcription factor NAC-1 confers 
resistance to paclitaxel (Jinawath et al, 2009). DNA methylation has also been 
associated with chemoresistance when after treating EOC cell lines with the 
hypomethylation agent azacitidine, increased sensitivity to carboplatin was 
observed and this mechanism was further linked to the induction of apoptosis 
through the caspase 3 and caspase 8 pathways (Li et al, 2009). An increased 
efflux of cisplatin has been reported in some cisplatin resistant cell lines and it 
has been proposed that cisplatin might be exported from the cells using 
chaperones and transporters that mediate copper homeostasis (Katano et al, 
2002). Other studies have tried to silence genes in order to evaluate their 
involvement in drug resistance, for example a study reported that knocked down 
clusterin in cisplatin resistant cell lines can lead to increased resistance to 
cisplatin and inhibited proliferation, invasion and migration (Wei et al, 2009). 
These studies and numerous others have shown that differential gene 
expression, protein conformation and function, methylation patterns, impaired 
uptake of platinum compounds are some of the mechanisms that can lead to 
resistance to chemotherapy. There is now a growing list of proposed 
mechanisms and molecular markers of chemoresistance in hope of 
improvement of individualised therapy.  
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 Summary 1.11
Epithelial ovarian cancer (EOC) is a complex disease that is 
characterised with molecular and histological heterogeneity and thus should not 
be treated as a single disease. The heterogeneity of EOC serves as a major 
challenge for elucidating its initiation, development and progression and the 
appropriate in vitro models should be selected depending on the subtype to be 
studied. Both NOSE and FT in vitro models could be used; and recapitulating in 
the most appropriate way the tissue micro-environment could be achieved by 
establishing three-dimensional models of the appropriate cell of origin for the 
subtype to be studied.   
The different subtypes of EOC can be classified not only according to the 
proposed site of origin, but also distinct DNA alterations. EOC is a polygenic 
disease originating from different sites and can be familial or sporadic. Although 
the high susceptibility genes BRCA1, BRCA2, and gene members of the MMR 
pathway are responsible for approximately half of the familial incidence of EOC, 
a large proportion of familial cases as well as the reported sporadic cases 
accounting for 90% of EOC, are not attributed to defects in those genes. The 
remaining susceptibility genes could be of moderate or low penetrance and can 
be identified by genetic association studies which aim to discover associations 
between polymorphisms and cancer susceptibility by genotyping SNPs in a 
population. Genetic association studies initially investigated potentially 
functional SNPs, such as non-synonymous coding SNPs, or focused in 
polymorphisms tagged in candidate genes of pathways implicated with the 
disease. Genome wide association studies (GWAS) have emerged in the last 
decade as a powerful tool for evaluating the frequency of thousands of SNPs in 
a genome wide manner regardless of an existing proposed function for these 
variants. GWAS are performed using a staged study design where significant 
associations are taken to the next stage to be genotyped in larger sample 
numbers.  The most significant result of a GWAS to date has been the 
identification of an association of a SNP within FGFR2 with increased risk for 
breast cancer (P= 2×10-76). An ovarian cancer GWAS performed by our group 
and collaborators has reported significant associations of SNPs in loci 2q31, 
3q25, 8q2, 9p22, 17q21 and 19p13.  
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The main challenge emerging form the vast amount of data reported by 
GWAS has been to translate the implication of the risk (or survival) associated 
loci in disease development by investigating how the candidate risk associated 
alleles affect risk modification and which are the causal susceptibility genes 
related to these risk variants. Firstly, it should be noted that the initially 
genotyped risk associated SNP might be the putative causal variant but could 
be correlated with the actual causal variant(s) which can be determined by 
performing fine mapping of the associated loci.  
Several attempts have been made to assign functional relevance of risk 
associated SNPs emerging from GWAS. Bioinformatics in silico analyses can 
be performed to identify any predicted function for such SNPs which may be 
causing amino-acid substitutions in case of coding SNPs or in the case of non-
coding SNPs their potential impact on the functional sequences of regulatory 
elements for gene expression, promoter methylation and chromatin 
modifications. Some of the approaches that can be used to evaluate cis and/or 
trans effects of SNPs in transcriptional regulation include investigating gene 
expression, methylation of CpG islands in gene promoters, chromatin 
modifications, miRNA expression, gene splicing and loss of heterozygosity in 
respects with genotype using in vitro assays. Examples include the reported 
association of a risk allele with increased expression of the PVT1 oncogene in 
locus 8q24 (Meyer et al, 2011), and increase of FGFR2 expression in the rare 
homozygote samples of the risk associated SNP for breast cancer using 
microarray analysis (Meyer et al, 2008). However, no studies have proposed yet 
a systematic approach investigating several aspects of possible functional 
effects or GWAS derived risk associated alleles as well as the functional role of 
candidate genes within the identified loci. 
A systematic functional investigation of GWAS identified risk or survival 
associated loci using appropriate tissue specific in vitro models will elucidate the 
way in which low-moderate risk variants lead to the initiation of EOC 
pathogenesis and will be beneficial for the more effective screening prevention 
and individualised treatment of the disease.   
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 Aims of the thesis  1.12
The overall aim of this thesis was to employ appropriate models to 
investigate the functional role of genetic variants and candidate genes of low/ 
moderate effect that emerge from pathway based approaches and GWAS in 
epithelial ovarian cancer. 
Given the recent proposal for multiple cells of origin for EOC, it was 
hypothesised that it is necessary to study EOC tumorigenesis using both NOSE 
and FTE in vitro models. Chapter 3 describes the establishment and 
characterisation of FTE cell lines and tests the hypothesis of whether 3D 
models of FTE cultures more closely resemble the in vivo characteristics of the 
FTE than traditional 2D cultures. Additionally, the largest primary NOSE cell line 
repository was established and characterised as it was hypothesised that 
studying differential expression in NOSE & FTE compared to EOC cell lines 
would be a powerful tool to identify whether candidate genes are implicated in 
EOC development.  
The aim for the work described in chapter 4 was to test whether variants 
within candidate genes selected from a pathway based approach may be 
implicated in EOC development.  The potential functional role of candidate 
SNPs was evaluated by assaying allele specific LOH in primary tumours. 
Additionally, the clinical implication of the candidate genes was evaluated by 
testing whether LOH in these genes would affect the survival of EOC patients. 
In Chapter 5 the post-GWAS functional characterisation of EOC risk 
associated loci is described. Although the ovarian cancer GWAS allowed the 
discovery of genetic variants significantly associated with ovarian cancer 
susceptibility, it is not known whether candidate genes within the associated loci 
region are the susceptibility targets or if they have a somatic role in EOC. 
Additionally, is it is unknown whether the associated SNPs have a regulatory 
role in EOC development. The functional role of candidate genes within a 1Mb 
region of EOC susceptibility SNP was investigated in the established NOSE & 
FTE versus EOC cell lines expression model. Furthermore, in order to 
investigate the potential synergy between genetic variation and epigenetic or 
gene expression changes into the development of sporadic EOC, genotype 
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specific methylation and genotype specific gene expression in non-tumour 
samples were performed.  
Even if post-GWAS characterisation studies identify candidate genes that 
may have a role in EOC, further functional assays in appropriate in vitro models 
should be performed in order to elucidate the molecular mechanisms by which 
these genes are involved in EOC development. Therefore, in chapter 6, 
MERIT40, one of the GWAS candidate genes found to have differential 
expression between normal (NOSE & FTE) and EOC cell lines, and an 
intriguing function as a BRCA1 associated protein in DNA repair, was knocked 
down in EOC cell lines and reversal of neoplastic phenotype and re-
sensitisation to platinum drugs was assayed. 
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2 Materials and Methods  
 
 General cell culture  2.1
2.1.1 Plasticware and general cell culture equipment used  
Cell culturing was performed in a laminar-flow safety cabinet (Heraus), 
and cells were incubated in a Heracell incubator (Heraus) at 37oC, 5% CO2. The 
cells were grown in tissue culture treated disposable 60mm, 100mm and 
145mm dishes, 25cm2, 75cm2 and 175cm2 flasks, or 6, 24 and 96multiwell 
plates (Greiner, Corning or Appleton Woods Ltd). Falcon tubes of 15ml or 50ml 
(Greiner) were used to centrifuge cell suspensions. Cell culture pipette tips 1ml, 
5ml, 10ml, 25ml were purchased form Greiner or Appleton woods. All glassware 
was washed and autoclaved by heating to 121oC for 15 minutes at a pressure 
of 103kPa to sterilise. 
 
2.1.2 General tissue culture techniques and common reagents 
All tissue culture media were stored at 4oC. Antibiotic and growth factor 
solutions were stored at −20oC. Puromycin solutions (Sigma) were prepared in 
ethanol (Sigma). Gentamycin solutions were purchased form Sigma. 
Penicillin/Streptomycin 100× was provided by Gibco. Cells were washed with 
sterile 1X phosphate buffered saline (PBS) (VWR). A 10× PBS solution was 
diluted 1:10 with DDW and the 1× solution was sterilised by autoclaving. 
Foetal bovine serum (FBS) (Invitrogen or Lonza) was batch tested before 
use. For this normal ovarian fibroblasts were used that are sensitive to serum. 
Cells were mass cultured in the test serum for a minimum of 7 days before 
plating at clonal density (Three replicates of 100 cells per well in a 6 well plate). 
Cultures were re-fed every 2-3 days and stained with crystal violet. To stain 
cells, cultures were fixed in 100% methanol (VWR) for 10 minutes and then 
rinsed with DDW. Cultures were then stained with 0.5% crystal violet (Sigma) 
solution (in DDW). After 10 minutes plates were rinsed with DDW and left to air 
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dry. Colonies were then counted. Colony formation efficiency (CFE) was 
calculated using the following formula:     
Total Number of Colonies 
Initial Number of Cell Plated 
 
2.1.3 Passaging, counting and freezing cells 
To passage the cells, the cell monolayer was washed with sterile PBS, 
and 500μl-1ml of 1x Trypsin-EDTA (Invitrogen) was added to the flask and 
incubated at 37°C for 2-5 minutes for the cells to detach. Trypsin was then 
inactivated with 10x higher volume of media containing FBS. The cells were 
resuspended gently to break clumps and reseeded to the required dish or flask.   
To freeze cells, following cell detachment and inactivation of Trypsin, the cell 
suspension was collected and centrifuged at 1,500rpm for 5 minutes to pellet 
cells. The supernatant was then aspirated and the cell pellet resuspended in 
freezing solution for cryopreservation. Freezing solution was prepared using 
10% DMSO (Sigma) in FBS (Invitrogen). Resuspended cells in freezing solution 
were aliquotted into freezing vials (Nunc) and the vials were stored in a Mr 
Frosty container overnight at -80°C, to slowly cool at 1°C per minute before 
cells were transferred into liquid nitrogen for storage at −196°C. 
For cell counting, following cell detachment and inactivation of Trypsin, 
cells were resuspended gently to break cell clumps and counted under the light 
microscope using a haemocytometer (Neubauer). 
 
2.1.4 Mycoplasma testing  
All cell cultures were tested frequently for mycoplasma contamination. 
When cell cultures are infected with mycoplasma it is not visible like other 
contaminations as no turbidity is caused in the media and they are resistant to 
antibiotics routinely used in cell cultures. Mycoplasma infections if unnoticed 
can affect gene expression and morphology of cells.  Two methods were used 
to detect mycoplasma infections, Hoescht staining and polymerase chain 
reaction (PCR). Hoescht fluorescently stains mycoplasma DNA which makes it 
then visible under a fluorescent microscope. Hoescht staining has a sensitivity 
of detecting mycoplasma of a concentration of least 106cfu/ml. For this 
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technique cells had to be incubated for two weeks in antibiotic free media to 
prevent possible antibiotic suppression of mycoplasma so lower levels than 
could be detected. The cells were then split on dishes containing coverslips and 
when they reached 60% confluency they were fixed in freshly-made Carnoy’s 
fixative (3:1 methanol:acetic acid, Sigma). For this, 3ml of fixing solution was 
added to the cell culture media and incubated for 5 minutes in room 
temperature. Fixative was discarded and 5ml of fresh fixative was added for 5 
more minutes. The last step was repeated and the coverslips were then washed 
with DDW and air dried. 50μl Hoescht bisbenzimide solution (0.05μg/ml in 
DDW, Sigma) was then added to coverslips, and cells were observed under the 
fluorescent microscope. Mycoplasma positive cells were identified by bright 
spotty cytoplasmic staining (mycoplasma DNA). In cultures that are free of 
contaminating mycoplasma, only the cell nuclei should be detected. For 
analysis of staining, positive and negative controls were stained in parallel. 
For mycoplasma screening by PCR, 1ml medium was removed from the 
cell cultures. The aliquoted media was spun at 13,000rpm for 30 minutes, and 
the majority of the supernatant was then removed leaving approximately 20μl. 
Pellets (not visible) were then resuspended in 50μl of TE buffer (10mM Tris-HCl 
with 1mM EDTA) with added Proteinase K (200μg/ml final concentration, 
Sigma), and incubated for 1h at 55°C. Proteinase K was deactivated by 
incubating at 98 − 100°C for 10 minutes. PCR was performed using the 
following primers that detect all mycoplasmas targeting the 16S rRNA gene: 
Forward primer (MYCO-F): 5’-GGGAGCAAACAGGATTAGATACCCT-3’ 
Reverse primer (MYCO-R): 5’-TGCACCATCTGTCACTCTGTTAACCTC-3’ 
The PCR reactions were prepared as follows: 
Reagent Volume added (µl) 
dH2O 7.38 
10X PCR Buffer (Applied Biosystems) 1.5 
25mM MgCl  (Applied Biosystems) 1.5 
10mM dNTPs (Invitrogen) 1.5 
MYCO _F primer 1 
MYCO _R primer 1 
AmpliTaq Gold (Applied Biosystems) 0.12 
Sample 1 
Total volume 14 
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The PCR was performed using the 9700 PCR machine at 55oC 
annealing temperature, 40 cycles. Then the PCR product was subjected to 
electrophoresis on a 1.5% agarose gel. The 1.5% agarose (Sigma) gel was 
prepared in 1xTBE buffer with the addition of ethidium bromide. 5μl of 1Kb DNA 
Ladder (Promega) was added on the first lane of the gel. 2μl of 5x DNA loading 
dye was added in 8μl of PCR product and then loaded on the gel. The gel was 
then run at 90V for ~1hour 15 minutes. The gel was visualised under Ultraviolet 
(UV) light where PCR product was confirmed.  
 
2.1.5 Cell lines used in this study and their culturing conditions 
2.1.5.1 EOC cell lines 
All EOC cell lines of several subtypes were cultured in the following 
media listed in Table 2.1 and incubated at 37oC, 5% CO2. All the media and 
reagents were purchased form Sigma apart from L-Glutamine which was 
purchased from Invitrogen and FBS which was purchased from GIBCO. 
EOC cell line Subtype Culturing media 
A2780 Serous RPMI 1640 +10% FBS + L-Glutamine 
A2780CP Serous DMEM:F12, 10% FBS 
COV318 Serous DMEM +10% FBS+L-Glutamine+Lasparagine 
FUOV1 Serous DMEM/F12 + 10% FBS 
HEY Serous RPMI 1640 +10% FBS + L-Glutamine  
HEY A8 Serous RPMI 1640 +10% FBS 
MPSC1 Serous RPMI 1640 +10% FBS 
OAW 42 Serous 
DMEM + 10% FBS + Na Pyr + 20μg/ml Insulin + 
L-Glutamine 
OAW 42M Serous 
DMEM + 10% FBS + Na Pyr + 20μg/ml Insulin + 
L-Glutamine 
OVCA 429 Serous 
MEM EAGLE + 10% FBS + NEAA + L-Glutamine 
+ Na Pyr 
OVCA 433 Serous MEM EAGLE + 10% FBS 
OVCAR 5 Serous RPMI 1640 +10% FBS + L-Glutamine 
OVCAR-3 Serous RPMI 1640 +10% FBS 
OVM215 Serous RPMI 1640 +10% FBS 
PEO-14 Serous RPMI 1640 +10% FBS + L-Glutamine 
SKOV 3 Serous RPMI 1640 +10% FBS 
SKOV 3IP Serous RPMI 1640 +10% FBS 
UWB1.289 Serous RPMI 1640 +10% FBS 
UWB1.289+BRCA1 Serous RPMI 1640 +10% FBS 
1847 Unknown histology* RPMI 1640 +10% FBS + L-Glutamine 
1847 AD Unknown histology* RPMI 1640 +10% FBS + L-Glutamine 
CAOV3 Unknown histology* DMEM + 10% FBS + NEAA/glucose 
COV 413 Unknown histology* DMEM +10% FBS+L-Glutamine+Lasparagine 
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COV 624 Unknown histology* DMEM +10% FBS+L-Glutamine+Lasparagine 
DOV 13 Unknown histology* 
MEM, 10% FBS + NEAA (Non essential 
aminoacids) 
HOC 7 Unknown histology* DMEM + 10%FBS 
IGROV1 Unknown histology* DMEM + 10%FBS 
INTOV-2 Unknown histology* RPMI 1640+ 10% FBS+ L-Glutamine+ 50uL β 
Mercaptoethanol +1% Na Pyr 
JAMA-2 Unknown histology* RPMI 1640 +10% FBS + L-Glutamine 
LK1 Unknown histology* RPMI 1640 +10% FBS + L-Glutamine 
LK2 Unknown histology* RPMI 1640 +10% FBS + L-Glutamine 
OAW-41M Unknown histology* RPMI 1640 +10% FBS + L-Glutamine 
OC316 Unknown histology* RPMI+10%FBS+L-Glutamine 
OVCA X Unknown histology* RPMI 1640 +10% FBS 
OVCAR 8 Unknown histology* RPMI 1640 +10% FBS + L-Glutamine 
OVCAR-10 Unknown histology* RPMI 1640 +10% FBS 
OVP1 Unknown histology* RPMI 1640 +10% FBS + L-Glutamine 
PXN94 Unknown histology* RPMI 1640 +10% FBS + L-Glutamine 
COV 644 Mucinous DMEM +10% FBS+L-Glutamine+Lasparagine 
EFO 27 Mucinous 
RPMI 1640 + 20% FBS + L-Glutamine + NEAA + 
Na Pyr 
COV-434 Granulosa cell DMEM +10% FBS+L-Glutamine+Lasparagine 
C13 Endometrioid DMEM +10% FBS+L-Glutamine+Lasparagine 
OV2008 Endometrioid RPMI 1640 +10% FBS + L-Glutamine 
OV-TRL-90T Endometrioid M199:MCDB105 + 15% FBS+ L-Glutamine 
TOV 112D Endometrioid M199:MCDB105 + 15% FBS+ L-Glutamine 
ES-2 Clear cell McCoy's 5A + 10%FBS + L-Glutamine 
TOV 21G Clear cell M199:MCDB105 + 15% FBS+ L-Glutamine 
Table 2.1: Culturing media of EOC cell lines used in this study. * the collection of these 
cell lines spans over several years and the terminology of histopathological 
examination has varied. The term “unknown histology” is referring to cell lines that their 
subtypes is probably serous but collected long ago before the subtypes were well 
differentiated from pathologists.  
 
2.1.5.2 Normal ovarian fibroblast and non-ovarian cell lines 
HUVEC, T71 and INOF2 were used later as controls for 
immunofluorescence staining experiments and 293T was used to package 
lentiviruses. The culturing conditions of these cell lines are shown in Table 2.2. 
Cell line Type Culturing media 
HUVEC 
human endothelial from 
umbilical cord EBM media (Cambrex Cat No CC-3156) 
293T Cells 
human embryonic Kidney/ 
retroviral producing DMEM, 15% FCS, L-Glutamine 
INOF2 
a normal ovarian 
fibroblastic cell line  DMEM, 15% FCS, L-Glutamine 
T71 
endometrial cancer cell 
line 
MCDN105:Media199, 15% FCS, L-
Glutamine 
Table 2.2: Culturing media of normal ovarian fibroblast and non-ovarian cell lines used 
in this study.  
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 Establishing and characterising primary cell lines 2.2
2.2.1 Collection and culturing of Normal Ovarian Surface Epithelial 
(NOSE) and Fallopian Tube Epithelial (FTE) cell lines. 
NOSE cell lines: The dates of operations for eligible patients for 
collection were confirmed on the operating schedule list in University College 
London Hospital (UCLH). Patients that were suitable for NOSE cells collection 
were patients that were subjected to Total Abdominal/Laparoscopic 
Hysterectomy (TAH/LH) due to endometrial cancer or endometriosis and there 
were no suspicion of metastasis to the tubes or ovaries. Patients’ consents 
were collected by a trained nurse the day before surgery (Mrs Nyaladzi 
Balogun). All informed consents from donors were prepared according to a 
protocol approved by the Joint UCL/UCLH Committees on the Ethics of Human 
Research (Committee Alpha). During surgery, when the specimen was removed 
from the patient it was placed on a sterile kidney dish. Using sterile gloves the 
uterus was orientated so that the flat side was at the bottom. Each ovary was 
then gently brushed twice with a sterile Transwab brush swab (Medical Wire 
and Equipment Ltd) and the cells were placed in a tube containing NOSE 
culturing media (NOSE-CM). NOSE-CM was composed of MCDB 105 media 
pH 6.5 (containing L-Glutamine & 25mM Hepes), (SIGMA) and Media 199, 
(SIGMA) in a 1:1 ratio. and supplemented with 15% FBS, 10ng/ml Human 
recombinant Epidermal Growth Factor (hEGF) (Invitrogen), 0.5μg/ml 
Hydrocortisone (HC) (SIGMA), 5μl/ml Human recombinant insulin (GIBCO or 
SIGMA), 35μg/ml Bovine Pituitary Extract (BPE) (GIBCO) and 50μg/ml 
Gentamycin sulphate salt (SIGMA). The cells were placed in the tube containing 
NOSE-CM by shaking the cytobrush. NOSE cells were then cultured in a T25 
flask at 37°C, 5% CO2 until 50-70% confluent. The medium was replaced with 
fresh every 3 days. Cells were then trypsinised as described above, and split in 
a ratio of 1:3-1:7, depending on the growth characteristics of each individual cell 
line. No antibiotics were used after the second passage. A NOSE primary cell 
line collection database was created where the date of collection, left or right 
ovary collected, diagnosis and surgical procedure performed, patient number 
and date of birth were recorded. Samples were kept only when confirmed free 
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of tumour by the pathology report. A pathology report was generated stating the 
exact stage and form of endometrial cancer the patient had and confirming if the 
ovaries were normal and free of tumour (Dr Rupali, Dr Benjamin). 
FTE cell lines: A similar procedure than the one used for NOSE was 
adopted with the difference in the sample collection procedure during surgery. 
In summary, the ampullary region of the FT of women that underwent total 
abdominal hysterectomies but had normal tubes was dissected to expose the 
FT lumen and brushings were collected from the lumen epithelium. FTE cells 
were also cultured in NOSE-CM media. In parallel, during these procedures FT 
tissue was collected in formalin. 
 
2.2.2 Growth Curves for FTE primary cell lines and X-gal staining for 
senescence 
 Growth curves for FTE cell lines were performed to calculate the 
population doubling times and also to determine the lifespan of a cell line before 
it senesces. 100,000 cells were plated in 60mm culture dishes in triplicate. The 
cells were regularly split before they reached confluency at a ratio of 1:3 to 1:7 
and the number of cells was counted for each replicate at each passage. The 
population doublings (PD) were calculated using the formula: PD=log (total cell 
number/initial cell number)/log2. The cumulating population doublings were 
plotted and average population time was calculated based on the middle of the 
growth curve for each cell line. The lifespan of the cell lines was determined by 
the number of days in culture until they senesced.  
 When the cells stopped dividing and had vacuolated cytoplasms, 
senescence was confirmed by assaying for β-galactosidase expression using X-
gal. The culture medium was aspirated and 2ml of 0.05% glutaraldehyde in PBS 
was added. The plate was then incubated for 5 minutes at room temperature 
and glutaraldehyde was discarded. Cells were washed with PBS and 2ml of 
PBS was added and incubated for 10 minutes at room temperature. PBS was 
aspirated and cells washed again in PBS. Cells were then covered with the X-
Gal solution (1 mg/ml X-Gal in 5 mM K4Fe(CN)6·3H2O/5 mM K3Fe(CN)6/1 M 
MgCl2/PBS, Promega) and incubated at 37°C, 5% CO2 for 2-48 hours until the 
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cells developed a visible blue culture. The stained cells were visualized and 
photographed under a light microscope. 
 
2.2.3 Karyotyping of FTE cell lines  
FTE cells were plated at 40-60% confluency in a 25cm2 flask. The 
karyotypic analysis was performed at The Doctors Laboratory (TDL). The 
cytogenetic profiles were analysed and commented by a senior Cytogeneticist 
(Mr. Terry Ballard). 
 
2.2.4 Immunofluorescence cytochemistry of cultured cells  
NOSE, FTE and control cell lines were grown on coverslips. When they 
reached ~80% confluency cell monolayers were washed with ice cold PBSAg 
(PBS with 0.3% fish skin gelatin, Sigma). Cells were then fixed for 10 minutes in 
cold 3% formaldehyde (VWR) prepared in PBS. The fixative was aspirated and 
fixed cells were washed with ice cold PBSAg. The cells were permeabilised by 
incubating for 5 minutes at room temperature in 0.3%v/v Triton X-100 (Sigma) 
in PBSAg and rinsed twice with PBSAg. In order to block unspecific binding of 
the antibodies each cell monolayer was incubated with 50μl 1% v/v non-immune 
goat serum (Invitrogen) for 10 minutes at room temperature. After aspiration of 
the blocking serum 50μl of optimally diluted primary antibody in PBSAg was 
applied to the coverslips. A summary of all the primary antibodies and their 
dilutions used for cell line characterisation by immunofluorescence staining is 
shown at table 2.3. The cells were incubated with primary antibody at room 
temperature for 1 hour. After rinsing the primary antibody with PBSAg, the 
appropriate Alexa Fluor-488 (1:2500 dilution, Invitrogen) secondary antibody 
(Table2.3) was applied and incubated for 20 minutes in the dark. After rinsing 
thoroughly with PBSAg, Evans Blue (Sigma) solution (Prepared with 1μl of the 
stock in 10ml of PBS) was applied to the coverslip for 10 minutes in order to 
stain the cytoplasm of the cells. The coverslips were then rinsed with PBS and 
transferred to labelled slides to add 5μl of DAPI (Vector Laboratories Inc) used 
for nuclear staining. Mounting medium (Sigma) was quickly added and the cells 
were covered with a coverslip. The slides were incubated for 30 minutes in 
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room temperature in the dark before visualising under an Olympus BX64 
fluorescence microscope. If not observed immediately slides were kept at -4°C 
protected from light for maximum of one week. 
Antibody Dilution Source 
Anti-Ck7 (clone LP5K) 1:1000  CRUK 
Anti-pan cytokeratin (clone AE1/AE3) 1:1000  Dako 
Anti-BerEP4 1:1000  Dako 
Anti-CA125 1:1000  Dako 
Anti-E-Cadherin 1:2500  Cell Signalling 
Anti-FSP 1:1000  Sigma 
Anti-Factor VIII Related Antigen 1:1000  Neomarkers 
Anti- PAX8 1:1000  Proteintech 
Anti-Laminin 1:1000  Sigma 
Anti-Vimentin 1:1000  Abcam 
Secondary Anti-mouse IgG  1:2500 Invitrogen 
Secondary Anti-rabbit IgG 1:2500 Invitrogen 
Secondary Anti-mouse IgG 1:2500 Invitrogen 
 
Table 2.3: Antibodies used to characterise NOSE, FTE and control cell lines 
 
2.2.5 Immunohistochemistry of cultured cells  
Cells cultured in 100mm dishes in the appropriate culture medium were 
trypsinised and counted as previously prescribed. Cells were seeded on 16 
chamber slides (NUNC) at a 2×103 density and incubated at 37oC, 5% CO2 for 
24-48 hours until they reached 60-80% confluency. The cell culture medium 
was then removed and replaced with neutral-buffered formalin (VWR). The 
samples were then processed into paraffin for immunohistochemistry at the 
University College Hospital Histology Services. Immunohistochemistry was 
performed at University College Hospital Advanced Diagnostic Laboratory.  
Due to the high cost of the 16 chamber slides some cell lines were 
prepared in two dimensional agarose gel cell pellets for paraffin processing. 
Cells were cultured in 100mm dishes under normal culturing conditions until 
they reached 90% confluency. For the preparation of the pellets 2% agarose 
(Sigma) was dissolved in distilled water. Agarose was allowed to cool down 
enough to not kill the cells when added to the pellets. Cells were trypsinised, 
pelleted and the media removed. The pellet was then thoroughly flicked and 
one drop of 2% agarose was added with a Pasteur pipette directly on the pellet 
with constant agitation so that the cells were mixed and diluted in the gel. The 
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pellet was allowed to cool for 15min at room temperature, removed from the 
tube and fixed in formalin. The agarose pellet was then processed in paraffin 
and stained with appropriate markers as before.  
2.2.6 Three-dimensional (3D) culturing of FTE cells and processing for 
immunohistochemistry 
In order to generate 3D cultures, 1×106 FTE cells were cultured in 
100mm tissue culture dishes previously coated with 2.5% Poly-
hydroxymethylacrylate (polyHEMA) solution (Sigma) to prevent cells’ 
attachment to the surface of the vessel. 2.5% polyHEMA solution was made in 
95% ethanol. The solution was then heated at ~65ºC until fully dissolved (1-2 
hours). Under sterile conditions the plates were coated with the PolyHEMA 
solution and allowed to evaporate. A second coat was then applied to ensure 
complete covering of the surface. Before use the plates were washed with PBS 
twice. The cell line to be cultured in 3D was first cultured in 2D at <90% 
confluency. Cells were trypsinised and counted. The cells were thoroughly 
resuspended to ensure single cell suspension and between 1x106 cells were 
cultured in 100mm double coated dishes. The cells were then incubated for 15, 
26 or 40 days at 37oC, 5% CO2. The media was carefully replaced every 3-4 
days by tilting the plate, letting the spheroids settle and carefully removing up to 
80% of the culturing media before slowly replenishing with fresh.  
The 3D cultures were then fixed and processed for 
immunohistochemistry as follows. The 3D cultures were removed from the 
incubator and culture medium containing the spheroids was poured into 50ml v-
bottomed tube. Spheroids were left at room temperature to settle for 20 
minutes. The cell culture medium was then removed and replaced with neutral-
buffered formalin (VWR). The samples were then processed into paraffin for 
immunohistochemistry at the University College Hospital Histology Services 
similarly to FT tissue previously collected. Immunohistochemistry of the FTE 3D 
cultures and FT tissue was performed at University College Hospital Advanced 
Diagnostic Laboratory. Representative slides for each cell line were also stained 
with Heamatoxylin and Eosin (H&E) to visualise the architecture of the 3D 
cultured spheroids. 
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 Investigating loss of heterozygosity (LOH) & allele 2.3
specific LOH  
2.3.1 Microcell-mediated chromosome transfer of chromosome 18  
The experimental procedure of microcell-mediated chromosome  transfer 
of chromosome  18 (MMCT-18) was performed by Dimitra Dafou and is 
extensively described in Dafou et al, 2008. Briefly, human monochromosome  
hybrids were generated in mouse A9 cells. The A9:monochromosome  donor 
hybrids were exposed to colcemid for 48 hours to induce micronucleation. The 
hybrid donor cell lines, tagged with Hytk selectable marker, were fused with 
EEOC cell lines TOV112D and TOV21G (American Tissue Culture Collection). 
TOV21G and TOV112D hybrid clones were selected with hygromycin B 
(Sigma). The tumourogenicity of the resulting hybrid clones was assessed with 
anchorage independent growth in soft agar and matrigel invasion assays.  
The parental cell lines and two clones of each cell lines that showed 
reduction of neoplastic phenotype were used in gene expression microarray 
analysis, microsatellite genotyping, cytogenetic analysis to confirm uptake of 
complete or partial chromosome 18 in MMCT hybrids. 29,098 genes were 
screened by 32,878 probes in the microarray analysis. An Anova test was used 
to generate P values for differential gene expression between the hybrids and 
parental. These were further adjusted for multiple testing. The results were 
ranked to finally lead to generation of a list of candidate genes significantly up 
or down regulated in the hybrids.  Nine candidate genes were selected to be 
used for genotyping tagging SNPs within them and genotyped in the iPLEX 
genotyping platform. 
 
2.3.2 Malova collection of samples  
MALOVA (Malignant Ovarian Cancer prediction) is a Danish collection of 
samples and it consists of 446 women of 30-80 years of age that have been 
diagnosed with EOC between 1994 and 1999. All the cases were recruited into 
the study at surgery before diagnosis of the disease, therefore they are said to 
be incident cases. Follow-up has been done of the patients to collect survival 
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information and until now 201 deaths have been confirmed. Tumour samples of 
all cases were paraffin embedded and made in tissue array slides.  Genomic 
DNA from the cases was extracted from pre-operative blood samples by 
Whatman International Ltd with chloroform protocol (Ely, UK). 301 tumours and 
their matching germline DNA were used for the LOH study. 
 
2.3.3 DNA extraction from Malova tissue array slides 
Methylene green solution (Sigma) was prepared by adding 1-1.5ml of 
methyl green in 200ml of distilled water. The Malova tissue array slides were 
then used for methyl green staining. Methyl green staining of each slide was 
then performed as follows: Xylene (Sigma) for 5 minutes, then again in Xylene 
for 5 minutes, then in 100% ethanol for 5 minutes, then in 85% ethanol for 5 
minutes, then in 75% ethanol for 5 minutes, then rinsed in distilled water, then in 
methyl green solution for 30sec to 1minute until tissue was slightly green, then 
in distilled water for 5 minutes twice. The slides were then left to air dry for 15-
30 minutes until completely dry. 
Extraction Buffer (EB) was prepared for all extractions to be made in the 
same batch. 30µl EB was prepared for each sample of the tissue array slides to 
be micro-dissected. The EB was prepared on ice and kept on ice while being 
used. EB buffer recipe is shown below. Some of the reagents used for the EB 
(MgCl2 and 10×Buffer) were from the Amplitaq Gold kit (Applied Biosystems).  
Reagent Volume (µl) 
dH2O (distilled 
water) 
25.54 
10xBuffer 3 
MgCl2  1.8  
Proteinase 
(SIGMA) 
K(SIGMA) 
 
0.48 
 
Tween-20 
(SIGMA) 
0.15 
 
 
The methyl green slide was then placed on the microscope. The marked 
area to be dissected was located, and a sterile 21G 11/2" needle, 0.8 × 40 mm, 
(BD Microlance) was dipped into EB and the tissue scraped (one 10x field is 
required) trying to avoid any stroma or necrotic tissue. For best results the 
needle was held with the curve facing against the direction of scraping. The 
flakes of tissue were rinsed in the EB, until the whole area was extracted. Each 
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sample was vortexed for 5-10sec and then spun down. The samples were then 
incubated at 55oC for 24 hours. After this incubation the samples were spun 
down, and 1µl Proteinase K (Promega) was added in each sample and then 
vortexed, spun down and incubated for further 24 hours at 55oC. Samples were 
then vortexed and spun down again. Proteinase K was inactivated by heating 
the paraffin samples at 99°C for 15 minutes. Then the samples were placed on 
ice for 10 min and were either used straight away or stored at -20oC. 
 
2.3.4 Testing the efficiency of DNA extraction from Malova tissue array 
slides  
The efficiency of the DNA extraction following micro-dissection of the 
tissue array slides was assayed by performing a PCR against BRCA1 exon 17. 
The following primers were used: 
Forward 1.17F  agctgtgtgctagaggtaactc  
Reverse 1.17R  gtggttttatgcagcagatg 
The following PCR mix was prepared and 2µl of DNA was added for each 
reaction. 
 
Reagent Volume (µl) 
dH2O 6.38 
10X PCR Buffer (Applied Biosystems) 1.5 
25mM MgCl  (Applied Biosystems) 1.5 
10mM dNTPs (Invitrogen) 1.5 
BRCA1.17 _F primer 1 
BRCA1.17 _R primer 1 
AmpliTaq Gold (Applied Biosystems) 0.12 
Total volume before DNA addition 13 
 
The PCR program was then performed at 55oC, 40 cycles. Then the PCR 
product was subjected to electrophoresis on a 1.5% agarose gel.  
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2.3.5 iPLEX Genotyping assay (Sequenom) for tSNPs from MMCT-18 
genes 
Haploview software was used to generate tagging SNPs (tSNPs) across 
the nine candidate genes by Lydia Quaye in context with an association study 
she was performing at the time. The Sequenom MassARAY iPLEX multiplex 
genotyping platform was used to genotype the genomic and matching tumour 
Malova extracted DNA samples for the MMCT-18 LOH study. A list of the 
primers used for this experiment is shown in Table 2.4. 120μl of 500nM of the 
forward and reverse primers of all the SNPs were combined in a primer mix for 
a final concentration of 100nM in each reaction of 5μl. Additionally a dNTP mix 
was prepared with 100nM of each of the dATP, dCTP, dGTP and dTTP. Then a 
PCR mastermix was prepared for each sample: (1.85μl distilled Milli-Q water, 
0.625μl of PCR buffer with 10X magnesium chloride [MgCl2], 0.325μl of 25mM 
MgCl2, 0.1μl of 25mM dNTP mix, 1μl of primer mix [500nM of each primer], and 
0.1μl of 5U/μl Hotstar Taq® DNA polymerase enzyme), and added to 10ng of 
germline DNA or dried 2μl of the tissue array extracted tumour DNA. The PCR 
program used was the following: 94oC for 15 minutes, cycled 45 times (at 94oC 
for 20 seconds, 56oC for 30 seconds, 72oC for 60 seconds), and inactivated at 
72oC for 60 seconds.   
The product of this PCR pre-amplification mixture was then treated with a 
shrimp alkaline phosphatase step (SAP) to dephosphorylate the unicorporated 
dNTPs in order to prevent them from being incorporated in following primer 
extension reactions that would lead in having results with contamination peaks. 
This cleaning step was performed by incubating the PCR products with 
2μl of SAP mix (1.53μl distilled Milli-Q water, 0.17μl of 10x SAP buffer and 0.3μl 
of 1U/μl SAP enzyme for each sample). The incubation steps were 37oC for 20 
minutes and 85oC for 5 minutes. The dephosphorylated mixture was then 
cooled to 4oC.   
The extend primers were then pooled into four groups according the 
mass of the extend primers. The signal-to-noise ratios of the extend primers 
decrease with increasing extend primer mass, therefore these adjustments in 
extend primer concentrations were required in order to equilibrate the signal-to-
noise ratios of the extend primers of different masses. The extend primers were 
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arranged into increasing masses, and the primers were split into 4 groups. 
Therefore, lower mass primers were grouped with other low mass primers and 
high mass primers were grouped with other high mass primers. The final 
concentration of the lowest mass primers was half of those in the highest mass 
group. Thus an extend primer mix was prepared whereby the final 
concentrations of the group 1 extend primers (lowest mass) was 0.625μM, 
group 2 was 0.833μM, group 3 was 1.042μM, and group 4 (highest mass) was 
1.25μM. 
An iPLEX reaction mix was prepared (for each sample): 0.755μl distilled 
water, 0.2μl of 10X iPLEX buffer, 0.2μl of iPLEX termination mix, 0.804μl of the 
extend primer mix and 0.041μl of the iPLEX enzyme. 2μl of this cocktail was 
added to each sample.  The mixture was mixed and covered with adhesive 
seal. This was subsequently cycled for the following PCR conditions: 
HOLD 
40 CYCLES 
HOLD HOLD 
Hold 5 cycles 
94oC 
30 seconds 
94oC 
5 seconds 
52oC 
5 seconds 
80oC 
5 seconds 
72oC 
3 mins 
4oC 
15 mins 
 
The iPLEX reaction products were desalted by adding 25μl of water and 
6mg of Clean resin (using a dimple plate). A nano-dispenser was used to 
dispense the iPLEX reaction products onto a 384-element SpectroCHIP 
bioarray. The SpectroCHIPs were read on Autoplex. The genotypes were called 
using the Typeranalyzer software and the peak heights exported to excel for 
further analysis. The peak heights were used to analyse LOH and allele specific 
LOH. 
 
2.3.6 Analysis for Loss of Heterozygosity (LOH) 
The ratio of the allele peak heights between the tumour and the germline 
DNA for heterozygous (informative) individuals was used to determine LOH 
(Canzian et al, 1996). The formula L= (at2 x an1)/(at1 x an2) was used, where 
at1,at2 and an1,an2 are the peak heights of the 2 alleles of the tumour and the 
germline DNA respectively. A value of L<0.6 and L>1.67, would indicate that 
one of the alleles has decreased more than 40% resulting in LOH (Canzian et 
al, 1996). The calculated frequency of overall LOH for a specific gene was 
based on the combined analysis of multiple tSNPs within the gene. LOH was 
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recorded if any informative SNP in a gene showed LOH, even if other 
informative tSNPs did not show LOH. Allele specific LOH (AS LOH) was 
assayed based on the deviation from the expected 1:1 random ratio of loss of 
one allele compared to the other allele. Evidence of AS LOH would be shown 
by preferential loss of one allele compared to the other. The P value was 
calculated using a two-sided Fisher’s test. An example of an output form the 
iPLEX genotyping result where the peak heights for the two alleles are 
demonstrating LOH between the tumour and germline DNA of a sample for 
SNP rs144848 in BRCA1 is presented in Figure 2.1. 
 
 
 
 
 
 
 
 
 
Figure 2.1: Example of LOH based on allele peak heights generated by the iPLEX 
genotyping platform. Presented is an iPLEX histogram where rs144848 of BRCA2 was 
genotyped in the same patient’s tumour and germline DNA/ The peak heights of the 2 
alleles are used in the formula to determine whether there is loss of heterozygosity.
  
 
 
  
Chapter 2: Materials and methods 
 
111 
 
2.3.7 Survival analysis  
Survival analysis was performed to establish whether LOH status was 
associated with Malova patients’ survival. Similarly to the analysis of overall 
LOH across genes, LOH was recorded if any informative (heterozygous) tSNP 
in a gene showed LOH, even if other informative tSNPs showed no LOH. 
Univariate analysis: Survival analysis relatively to LOH was performed 
in STATA statistical software using Cox proportional hazards regression model 
to measure the effect of LOH over the time death takes to occur within the 
specified 10 year period and Kaplan Maier curves were generated. The STATA 
commands I used for survival analysis were: i) set mem 290m, ii) stset 
yearoutcome, failure(outcome) enter(yearenter) exit(time 10), iii) stsgraph, 
by(lohstatus), iv) xi:stcox lohcode 
Multivariate analysis: Cox regression analysis in STATA was also used 
to estimate the effects of age at diagnosis, histological subtype, stage and 
grade of the tumour on the 286 samples used for the analysis, using the <40 
age group, serous histology, grade 1 and localised/early stage as 
calibrators/references to compare the rest with for each prognostic factor 
respectively. The analysis was performed in STATA using the command xi: 
stcox i.histology i.agegroup i.grade i.stagegroup. The results of all genes 
were adjusted for the prognostic factors age at diagnosis >60 and advanced 
stage that were both significantly associated with worse survival. This kind of 
analysis is termed as multivariate analysis. Cox regression multivariate analysis 
was performed to assess the effect of LOH of each gene on survival in all 
subtypes, serous only and non-serous only subtypes adjusted for prognostic 
factors where appropriate. The commands used in STATA software where: i) 
rename _Iagegroup_4 age4 and/or rename _Istagegro~2 stage2, ii) xi: stcox 
GENElohstatus age4 stage2. 
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Plex SNP Forward primer Reverse primer Extend primer
28plex rs2280201-PCR1 ACGTTGGATGTCTGCATTATCTTAGGAAC ACGTTGGATGCACACTCCCAGTTTATGTGA TCTGCCCTGAGCAAA
28plex rs11655966-PCR1 ACGTTGGATGTCCCTCCTAATCAGTGTGCC ACGTTGGATGCTTTACCTGCAATTGAGGGG GAGCAGGGAGCAAAA
28plex rs2394655-PCR1 ACGTTGGATGCCCACACGTAGGTCCTTCTA ACGTTGGATGAGCGAGGTGGGAATCCCAGT AATCCCAGTGTGTGAG
28plex rs7239066-PCR1 ACGTTGGATGAGAGAAGGGGATGGATTTAC ACGTTGGATGCATCCCTAACTTCCATATCC CCATATCCAAGCCATCA
28plex rs11082221-PCR1 ACGTTGGATGCCTTCCCTCAATTCTGATGC ACGTTGGATGGGGAACCCCAATTTAGAGTC AGAGTCTGTCCAAAGCA
28plex rs3750772-PCR1 ACGTTGGATGCCAGGTTCTAGTGCCATCC ACGTTGGATGTCTAGGCACCCGAGGCAGC TCCACCACCACACTGGTT
28plex rs2246713-PCR1 ACGTTGGATGGGTGGGTGGATAGAGATGTG ACGTTGGATGGAGGTAGAACCAAAAGCCTG AAAAGCCTGAAGGGGCTA
28plex rs7189819-PCR1 ACGTTGGATGATTCCTTTACATCACCCAGC ACGTTGGATGCTAGTTTTAGCTCTGCCACG GCCCCGCACTGTCATTCGC
28plex rs4541111-PCR1 ACGTTGGATGAGGCACGTTCAGCAGGCTA ACGTTGGATGATGGGTTTGCGGTGCACAG CCATTGCACAGCGCCTGGT
28plex rs975590-PCR1 ACGTTGGATGACAGGGAAGGTGCCATGAGT ACGTTGGATGTGAGGACTCGTTTCCTTGTG AGGTATGAGGCTGTCCTGG
28plex rs3923086-PCR1 ACGTTGGATGCCAAAAAAGCCAAAACAGCC ACGTTGGATGTACCACCAAGATAGCAGGAC GCATGGAAGAAAGAGTGTT
28plex rs9821568-PCR1 ACGTTGGATGGCTATGGATCCTTTCTCTGG ACGTTGGATGGCCCAAATACCTCTTGAAGT TACCTCTTGAAGTTGGGAAC
28plex rs2894111-PCR1 ACGTTGGATGTGGCATCAGCAACCTTGCCT ACGTTGGATGCACCCTCCCACCTAATGTAT GGCCACCTAATGTATTCCCCC
28plex rs9931702-PCR1 ACGTTGGATGCAACTTATGAAATGGCTAAC ACGTTGGATGGTATGTAATGAGCAGTCTCC TGAGCAGTCTCCAAATGAAGA
28plex rs793477-PCR1 ACGTTGGATGCTGTGTCTCTTTGAGCAAAC ACGTTGGATGCAATCCCCAGATGAAGATTAC CAGAGGAAACTGAGGTTTACA
28plex rs3181328-PCR1 ACGTTGGATGGCTGAACATCTAACAGTTTTG ACGTTGGATGGGTCTAACATTGTTTCCCCT AACCAAACATCACAATCCTCTG
28plex rs2394656-PCR1 ACGTTGGATGTGGAGAGCAAGGAGGCACAG ACGTTGGATGAGATCAACAGCTCCGCCTAC GCATCTCCGCCTACCGCAAAGC
28plex rs7650365-PCR1 ACGTTGGATGGGGTGTGTTGGTAACTTTTG ACGTTGGATGCCAACTAGCCTATGACCTTG GATCCTATGACCTTGATCATCTA
28plex rs6788750-PCR1 ACGTTGGATGACTCTTCCACAATATGAAGG ACGTTGGATGGATAATCTTTGGACTCCTTG CTTGGGACTCCTTGAAGGTAGTT
28plex rs10999152-PCR1 ACGTTGGATGTGTCTTTTCCCAGACTGTCG ACGTTGGATGTAGGCGTTGGAGGGATAACT GAGGGATAACTTGGAGAGAAAAC
28plex rs17446518-PCR1 ACGTTGGATGCATGGATTGAATGAGCACTG ACGTTGGATGAGATGCTTTCAGCAGGCAAG GCTGTCAGCAGGCAAGGGTTCATA
28plex rs13063604-PCR1 ACGTTGGATGAATCCAGGCTTTCTGATCCG ACGTTGGATGAGAGATTTCTAGCAGGAGGG GGGCGGAGGGAAGCTGGGTGGCAC
28plex rs9651713-PCR1 ACGTTGGATGCCTCCTAGTTCACACCACAT ACGTTGGATGACCAGGATGGTACAGGATTC GTACAGGATTCAATATTCTATCAAA
28plex rs7908957-PCR1 ACGTTGGATGTCCTCTGGGATGTGCATGTG ACGTTGGATGCCCTGCTCTGAGAGCTCTAA TTTCGCTGAGAGCTCTAAATGGCAC
28plex rs11868547-PCR1 ACGTTGGATGGGAGCTCTGATGCCTTGAAC ACGTTGGATGGGTATGAACCCCCATTCCAG GGGCGGGCACAGCACCTGCATGGTTA
28plex rs144848-PCR1 ACGTTGGATGATCTGAAGTGGAACCAAATG ACGTTGGATGGTCACTTCCACTCTCAAAGG CCCTTCCACTCTCAAAGGGCTTCTGAT
28plex rs799917-PCR1 ACGTTGGATGAAGGTTTCAAAGCGCCAGTC ACGTTGGATGAGAGTGGGCAGAGAATGTTG CCGGCTGCATTTCCTGGATTTGAAAAC
28plex rs17801966-PCR1 ACGTTGGATGGGTTCTACGGTTAGAACAGC ACGTTGGATGATTAGTGCCCCTCAAGTCTG CAAGTCTGATTTAATGATATTAGACTAG
33plex rs9864437-PCR1 ACGTTGGATGAGCTGGTGTCCTTTCTGCG ACGTTGGATGTTCCCTTCTCTCATCCACCC CCCTTCCCCAGTGAC
33plex rs4295944-PCR1 ACGTTGGATGAGCTCATCTGGGACCCTCA ACGTTGGATGAAGGGGTTGTGCCCCAGAC CCAGACCCGCAAAGA
33plex rs2271695-PCR1 ACGTTGGATGCGCTGCTTCACAGAGTTGAC ACGTTGGATGCAAGATGGCCTATCTTGCCG CCCTCCACGCCAACAT
33plex rs10999147-PCR1 ACGTTGGATGATGCCTTCAGTGCACAGCTC ACGTTGGATGTAATGAGGTTTCCAGCCAGC CAGGCCTATGAGGACA
33plex rs1637001-PCR1 ACGTTGGATGAGAGTTTTGGTACCAGAGGC ACGTTGGATGTTTAGAAAATCCTGTCTCCC CCTGTCTCCCATTTTCC
33plex rs11762932-PCR1 ACGTTGGATGCTCTGCATGTGGTTATTCGG ACGTTGGATGAGTGCAATAAAGCGAGATAC AAGCGAGATACACCTGT
33plex rs4857836-PCR1 ACGTTGGATGTTTTGCCCTTGCAGGGGACT ACGTTGGATGATGCCAGTAGCACCCCCAA TCTCACCCCCAACCAAGT
33plex rs7591-PCR1 ACGTTGGATGACCTTTCCTCCACACACCTT ACGTTGGATGATGGCAAACAGAATGTACAG TAACACAAAAACCCGAAC
33plex rs3743772-PCR1 ACGTTGGATGTTGTTTGTCTCTGCCCCATC ACGTTGGATGTTACGTAACAGCGCCTGGGA TGTCAGTCATGGAAGTAT
33plex rs1053495-PCR1 ACGTTGGATGCCCACATAGAAGCCACTGAT ACGTTGGATGTTGCAGGTGCACTGACGTTC GGCCATGGGGAGAAATGA
33plex rs17338680-PCR1 ACGTTGGATGCCTTTTAACTACTCTCCATC ACGTTGGATGCCTATTCTATGGGTGAAGGC GAAGGCTGCTAGGGTATTG
33plex rs11079571-PCR1 ACGTTGGATGTGGAGGGGTTGTGACTCAG ACGTTGGATGAGGGACCAGAAGTCAGAGGC CCTTCTTGGCTGCAGTGCTC
33plex rs11618371-PCR1 ACGTTGGATGGCCGATATTGTAAGGCCCTC ACGTTGGATGCGAAGGACCTAGAACAGTGA CTCGAATTTGGGGAACCCTG
33plex rs7210356-PCR1 ACGTTGGATGGTTCACACCTGGGAATAGAC ACGTTGGATGCAAGACAGAGTTCCAACTCC TCCCCCTCCTCAGCTGTGTGC
33plex rs2282657-PCR1 ACGTTGGATGGGAGTTGAATATATTCTGG ACGTTGGATGCCAAAAGATCACCAGTGTAA TCACCAGTGTAAAACGTAAGG
33plex rs793446-PCR1 ACGTTGGATGGCAAGGCACTGTACTTGCTA ACGTTGGATGATGATCAGACTGATCTGTGC AGGTTTTGGGGAAAAAAGAAC
33plex rs3783194-PCR1 ACGTTGGATGATTTTCTCCCTAATAGCAC ACGTTGGATGGGGTGATGAGTGGGATTTAG CTAGTGGGATTTAGTTTCTCTA
33plex rs523104-PCR1 ACGTTGGATGGTCAGAGACTCTCCAGCATC ACGTTGGATGTCTTGCAAACAGAATCTGCC GGGGATGACTGTGAAGAGATGA
33plex rs3783197-PCR1 ACGTTGGATGGGAAGACTTTTGGCTTGTTG ACGTTGGATGTGATGGCCTGTCAGGCTTTT CTCAATGAACTGATTAACCACAA
33plex rs2394644-PCR1 ACGTTGGATGGTGTATGTGTGTTGTGGCAG ACGTTGGATGTAAGAGAGCGGAACAAACCC GGGCGCGGAACAAACCCTGATTG
33plex rs13091198-PCR1 ACGTTGGATGCTTTCACTTAGCATGATGCTG ACGTTGGATGTAGAATACTATTCAGCTGG GCTGGAAAAAGAAATAAGTACTA
33plex rs12494994-PCR1 ACGTTGGATGGCATTGCACTGTATTAGAAGC ACGTTGGATGTCTTGTTTGAATTTCCCAGG CCCTTGCAGTTTGTAATAGCTGCT
33plex rs3181174-PCR1 ACGTTGGATGCGATCATGAACATAAAGCAAC ACGTTGGATGAACTTTCCCCACAGAGAAGG AGGAGGGGAGTTTATTTTGTATAG
33plex rs3732402-PCR1 ACGTTGGATGGGTCACCAAAAGGCTATCAC ACGTTGGATGGATGATAGCCATTAGGGAGG CTCTCGCCATTAGGGAGGCTACCAG
33plex rs3181175-PCR1 ACGTTGGATGACAAGATTTCTTTTCATG ACGTTGGATGTATGTCTTGGTTGGGTCACG GTCACGTAACCAAACATAAAAGTAT
33plex rs9860614-PCR1 ACGTTGGATGCCGTAAGTCCATTCTGATAC ACGTTGGATGTGCTCACCTCTAGAGAACTG GAGAACTGAGTATTTACCAAAATTAT
33plex rs4791171-PCR1 ACGTTGGATGAGCCACCACAACCTGCCAAA ACGTTGGATGCAGTGCTGCAAGGATTTTGG GTGATGCAAGGATTTTGGTGGGAGTC
33plex rs9304261-PCR1 ACGTTGGATGGCTCTTCTCTAGGTCATATC ACGTTGGATGCTATGAAAATACAGTCTTTCT TTTGTTTTTTTAAAAAAAGACTTAAAT
33plex rs6480440-PCR1 ACGTTGGATGACGGCTGGCACTCATAAGAG ACGTTGGATGCTGTTTCCCAAGAAGTTCTC GGCGCAGAAAAGCTGTTTAATGGAAGA
33plex rs518604-PCR1 ACGTTGGATGATCCCAGTACTGGCTGTCTT ACGTTGGATGCTCTTTGTAGGATCAAGTGG CATGGAGAAGAGGGCTTGAAGTTGATC
33plex rs995845-PCR1 ACGTTGGATGGATAACCAACAATTTGTCTTC ACGTTGGATGTGCCTGGCTGTTTTCTTTAC CCTTACTGGCTGTTTTCTTTACTATAGA
33plex rs796977-PCR1 ACGTTGGATGTGGCAATCACGGTGTAGTAG ACGTTGGATGTTCTCTGGCAATCTCATGGC GGATATTAATTTGGGACACTACTCTTGT
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.4: Summary of the primer sequences used for iPLEX genotyping of the tSNPS 
in the MMCT-18 candidate genes.  
 
  
Chapter 2: Materials and methods 
 
113 
 
 Evaluating Gene expression 2.4
2.4.1 Cell line RNA extraction  
The RNeasy Mini Kit was used for RNA extraction of EOC, NOSE and 
FTE cell lines according to the manufacturer’s instructions. A NanoDrop® 
Spectrophotometer was used to determine the concentration of the extracted 
RNA by reading the absorbance at 260nm. The ratio of absorbance at 260nm 
and absorbance at 280nm was used for purity estimation. 
2.4.2 Reverse transcription of cell line RNA into cDNA 
Quantified RNA samples were normalised to 100ng/µl in RNase free H2O 
in 0.5ml eppendorf tubes. 1μg of RNA was used for the reverse transcription 
reaction. 1μg of random primers (Promega) and 15Units (0.35ul) of RNasin 
(Promega) were added and the total volume of the reaction brought to 14µl with 
RNase free H2O. This step introduces first strand synthesis. The samples were 
then heated at 75oC for 5 minutes in order for secondary structures to melt and 
immediately cooled to prevent reformation of the secondary structures. The 
samples were then briefly spun down. 5µl of M-MLV Reverse Transcriptase 
reaction buffer (Promega), 1μl of M-MLV Reverse Transcriptase enzyme and 
5µl of 2.5mM dNTPs (Promega) were added to the sample which were then be 
incubated for 10 min at room temperature. The reactions were incubated at 
45oC for 50 minutes. The cDNA was then diluted down to 5ng/µl by addition of 
175µl RNase free H2O (Promega). The efficiency of the reverse transcription 
(RT) reaction was then assayed by β-actin PCR. Human female DNA, 
(Promega) was used as a positive control for the PCR reaction. The primers 
used for β-actin used were the following: 
 
Forward β-actin_F: GTCCTCTCCCAAGTCCACAC 
Reverse β-actin_R: GGGAGACCAAAAGCCTTCAT 
 
10ng of cDNA was added in a 96 well PCR plate (2µl of the 5ng/µl stocks) 
containing the following reaction mix.  The following recipe was used to prepare 
the PCR reactions: 
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Reagent Volume (µl) 
H2O 7.38 
10X PCR Buffer 1.5 
25mM MgCl   1.5 
10mM dNTPs (Promega) 1.5 
β-actin_F  0.5 
β-actin_R  0.5 
AmpliTaq Gold (Applied Biosystems) 0.12 
Total volume before DNA addition 13 
 
 
A standard PCR program was performed for 60oC annealing temperature, 40 
cycles. Finally, 8µl PCR product +2ul loading dye is run on a 1.5% agarose gel 
to confirmed production of cDNA during reverse transcription reaction. 
 
2.4.3 Optimisation of Taqman® Real time PCR expression assay to 
evaluate differential expression of candidate genes  
It is known that different endogenous controls are more appropriate to 
use for the normalisation of expression assays in different tissues, therefore a 
panel of 4 endogenous controls (housekeeping genes) were initially tested in 
NOSE and EOC cDNA samples. These were β-actin, GAPDH, TBP (TATA 
binding protein) and 18S (18S ribosomal RNA). GAPDH and β-actin were 
chosen as the more reliable for these samples as they exhibited no significant 
variation between samples. The expression of the candidate genes was 
normalized against those two endogenous controls.  
The next step in the optimisation was to check whether multiplexing of 
the endogenous controls with the target probes would provide reliable results. 
The standard curves were more reliable when the probes were not multiplexed 
therefore I decided to perform downstream experiments using “2 tube reactions” 
where the endogenous and the target probe were assayed in separate tubes.  
Other optimisation experiments were also performed. A Real time experiment 
using cDNA produced with oligodTs versus random hexamers was tested. No 
difference was found between the two different cDNA preparations. Assays 
were also optimised with respect to the minimum amount of probe needed. The 
optimised reactions recommended by Applied Biosystems were 20μl reactions. 
For the purpose of my experiments I initially scaled down the reaction to 10μl 
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and subsequently to 5µl reactions after drying the cDNA. Two probes were used 
to test that drying the cDNA would provide reliable relative expression data. The 
curves produced suggested reliable consistent data. 
 
2.4.4 Evaluating gene expression by performing Real time PCR in 
ABI7900 Taqman® Sequence detection system  
4ng of EOC and NOSE cDNA (4ng) were plated in 384 well PCR plates 
(VWR) and then dried. All samples were run in triplicates. Housekeeping genes 
were used as loading controls. Additionally, 8 serial dilutions of a mix of the 
cDNAs used starting from 5x more concentrated cDNA than the samples to be 
run was prepared in order to be used to create a standard curve that would 
confirm the quantity of cDNA versus expression linear relationship.  
Taqman® Real time PCR probes and Taqman® Real time PCR Master 
Mix (Applied Biosystems) were used for the reactions. Taqman® gene 
expression probes were obtained from Applied Biosystems for SKAP1 
(hs00175372_m1), TIPARP (hs00604498_m1), HOXD3 (hs00232506_m1), 
BNC2 (hs00417700_m1) ,HOXD1 (hs00707081_s1), MYC (hs00153408_m1), 
MERIT40 (hs01572961_m1), ANKRD41 (hs00401326_m1), STAG3 
(hs00429370_m1). All assays had a FAMTM reported dye at the 5’ end of the 
probe and a non-fluorescent quencher at the 3’ end of the probe. The 
mastermix used contained buffer, dNTPs, passive reference dye, thermostable 
hot-start DNA polymerase, and other components formulated for reliable 
TaqMan® Assay-based real-time PCR. The assays were carefully chosen to 
make sure that they would detect the maximum number of transcripts. 
The following reaction mix was prepared: 
Reagents 
Volume 
(µl) 
dH2O 2.25 
Taqman® probe (20×) 0.25 
Taqman® Universal PCR Mastermix 
(2x) 2.5 
 
The Real time PCR expression assays were performed using the Applied  
Biosystems7900 Taqman® Sequence Detection System and the following 
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program ([50oC (2min), 95oC (10 minutes), 50 cycles: 95oC (15sec) & 60oC 
(1min)].  
 
2.4.5 Evaluating gene expression by performing Real time PCR in a 
Fluidigm 96.96 Dynamic array. 
A large number of gene expression assays was multiplexed using 
Taqman® Real time PCR probes in the Fluidigm 96.96 Dynamic array platform. 
A comprehensive list of all the Taqman® Real time PCR probes used for my 
study in this array is shown in Table 2.5. The selected assays were multiplexed 
in 7 different sets (Fluidigm chips). The experimental procedure involved one 
pre-amplification step and before the Real time PCR step. This experiment was 
run by Miss Eva Wozniak, the research assistant in our laboratory, and it 
included assays and samples provided from several different projects within our 
group including the ones for my study. 
Protocol for pre-amplification 
The extracted cDNA from the NOSE, FTE and EOC cell lines was used 
to perform a pre-amplification step, which is a technique that causes 
amplification of just the target genes to be measured quantitatively. The step of 
pre-amplification included a small dilution of primers for each gene and only 
performed 10 PCR cycles so that entering the plateau phase is avoided. 
However, pre-amplified cDNA provided with a sample containing increased 
number of desired transcripts in the range of 500 fold. 
Protocol for Fluidigm 96.96 Real-Time PCR 
The first step involved priming 
of the Dynamic Array IFC. The control 
line fluid was injected into each 
accumulator on the chip (picture of the 
chip is shown on the right). The chip 
was then placed into the Integrated 
Fluidic Circuit (IFC) controller and then 
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the Prime (136x) script was run to prime the control line fluid into the 
chip. The second step involved preparing 10x assays using the volumes 
indicated below: 
 
Reagent Volume per Inlet (µl) 
20x Taqman® Gene Expression Assay 
(AB) 
2.5 
2x Assay Loading Reagent (Fluodigm) 2.5 
Total Volume 5 
Final Concentration (at 10x) Primers: 9µM;  Probe:2µM 
 
The third step involved the preparation of the Sample Pre-Mix and Samples 
combing the reagents as follows: 
Reagent Volume per Inlet (µl) 
Taqman®Universal PCR Mastermix 2x (AB) 2.5 
20x GE Sample Loading Reagent (Fluodigm) 0.25 
cDNA 2.25 
Total Volume 5 
  
  
 The Taqman® Universal PCR Master Mix was then combined with the 
GE Sample Loading Reagent in a 1.5ml sterile tube-enough volume to fill an 
entire chip. A volume of 2.75µl of this Pre-Sample Mix was then aliquoted for 
each sample. In each of those aliquots 2.25µl (4ng) of cDNA was added making 
a total volume of 5µl. The fourth step of the assay was to load the chip. When 
the Prime (136x) script described at the first step was finished, the primed chip 
was removed from the IFC controller and 5µl of each assay and each samples 
was pipetted into their respective inlets on the chip. The chip was then returned 
to the IFC controller and the Load Mix (136x) script was run for the samples and 
the assays to be loaded into the chip. When this was completed the loaded chip 
was removed from the IFC controller and the blue protective film was peeled 
from the underside of the chip and the chip was ready to be run immediately 
according the Fluodigm Data collection Software instructions. 
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Gene Study Taqman® assay (AB) 
KIAA1715 Post GWAS analysis Hs00327995_m1 
EVX2 Post GWAS analysis Hs01372231_m1 
HOXD13 Post GWAS analysis Hs00968515_m1 
HOXD12 Post GWAS analysis Hs00706957_s1 
HOXD11 Post GWAS analysis Hs00360798_m1 
HOXD10 Post GWAS analysis Hs00157974_m1 
HOXD9 Post GWAS analysis Hs00610725_g1 
HOXD8 Post GWAS analysis Hs00251905_m1 
HOXD4 Post GWAS analysis Hs00429605_m1 
HOXD3 Post GWAS analysis Hs00232506_m1 
HOXD1 Post GWAS analysis Hs00707081_s1 
MTX2 Post GWAS analysis Hs00198047_m1 
KCNAB1 Post GWAS analysis Hs00963155_m1 
SSR3 Post GWAS analysis Hs00606481_m1 
TIPARP Post GWAS analysis Hs00296054_m1 
LOC730091 Post GWAS analysis Hs00327629_m1 
PA2G4P4 Post GWAS analysis Hs01689228_gH 
LEKR1 Post GWAS analysis Hs00416272_m1 
MYC Post GWAS analysis Hs00905030_m1 
PVT1 Post GWAS analysis Hs01069044_m1 
BNC2 Post GWAS analysis Hs00417700_m1 
CNTLN Post GWAS analysis Hs01124982_m1 
SP6 Post GWAS analysis Hs01941471_s1 
SP2 Post GWAS analysis Hs00370726_m1 
PNPO Post GWAS analysis Hs00216680_m1 
ATAD4 Post GWAS analysis Hs00256987_m1 
CDK5RAP3 Post GWAS analysis Hs00602528_g1 
COPZ2 Post GWAS analysis Hs00212698_m1 
NFE2L1 Post GWAS analysis Hs00231457_m1 
CBX1 Post GWAS analysis Hs01080635_g1 
SNX11 Post GWAS analysis Hs00203367_m1 
SKAP1 Post GWAS analysis Hs00175372_m1 
HOXB1 Post GWAS analysis Hs00157973_m1 
HOXB2 Post GWAS analysis Hs00609873_g1 
HOXB3 Post GWAS analysis Hs00231127_m1 
HOXB4 Post GWAS analysis Hs00256884_m1 
HOXB5 Post GWAS analysis Hs00357820_m1 
HOXB6 Post GWAS analysis Hs00980016_m1 
LOC404266 Post GWAS analysis Hs00420340_m1 
HOXB7 Post GWAS analysis Hs00270131_m1 
HOXB8 Post GWAS analysis Hs00256885_m1 
HOXB9 Post GWAS analysis Hs00256886_m1 
PRAC Post GWAS analysis Hs00741542_g1 
HOXB13 Post GWAS analysis Hs00197189_m1 
TTLL6 Post GWAS analysis Hs00403596_m1 
SIN3B Post GWAS analysis Hs00391562_m1 
CPAMD8 Post GWAS analysis Hs00610855_m1 
HAUS8 Post GWAS analysis Hs00928622_m1 
MYO9B Post GWAS analysis Hs00188109_m1 
USE1 Post GWAS analysis Hs00218426_m1 
OCEL1 Post GWAS analysis Hs00226198_m1 
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NR2F6 Post GWAS analysis Hs00172870_m1 
USHBP1 Post GWAS analysis Hs00230579_m1 
MERIT40 Post GWAS analysis Hs00204343_m1 
ANKRD41 Post GWAS analysis Hs00401326_m1 
ABHD8 Post GWAS analysis Hs00225984_m1 
DDA1 Post GWAS analysis Hs00911895_g1 
MRPL34 Post GWAS analysis Hs04194538_sH 
TMEM16H Post GWAS analysis Hs00394261_m1 
GTPBP3 Post GWAS analysis Hs00378443_m1 
CCNE1 MERIT40 functional analysis Hs01026536_m1 
CDKN1A MERIT40 functional analysis Hs00355782_m1 
CDKN2A MERIT40 functional analysis Hs00923894_m1 
PTEN MERIT40 functional analysis Hs02621230_s1 
RB1 MERIT40 functional analysis Hs01078066_m1 
BUBR1 MERIT40 functional analysis Hs01084828_m1 
MAD1 MERIT40 functional analysis Hs00231137_m1 
MAD2L1 MERIT40 functional analysis Hs01554513_g1 
MAD2L2 MERIT40 functional analysis Hs01057448_m1 
CHK1 MERIT40 functional analysis Hs00967506_m1 
CHK2 MERIT40 functional analysis Hs00200485_m1 
BUB1 MERIT40 functional analysis Hs00177821_m1 
BUB3 MERIT40 functional analysis Hs00190920_m1 
ATM MERIT40 functional analysis Hs01112307_m1 
FANCD2 MERIT40 functional analysis Hs00276992_m1 
PARP1 MERIT40 functional analysis Hs00242302_m1 
RAD51 MERIT40 functional analysis Hs00153418_m1 
RAD51C MERIT40 functional analysis Hs00427442_m1 
RAD51D  MERIT40 functional analysis Hs00172529_m1 
BARD1 MERIT40 functional analysis Hs00184427_m1 
BRCA1 MERIT40 functional analysis Hs01556193_m1 
BRCA2 MERIT40 functional analysis Hs00609073_m1 
MERIT40 MERIT40 functional analysis Hs00204343_m1 
BRE MERIT40 functional analysis Hs01046283_m1 
CCDC98 MERIT40 functional analysis Hs01128826_m1 
RAP80 MERIT40 functional analysis Hs00212459_m1 
BRCC3 MERIT40 functional analysis Hs00827974_m1 
ERCC1 MERIT40 functional analysis Hs01012158_m1 
ERCC2 MERIT40 functional analysis Hs00361161_m1 
XPA MERIT40 functional analysis Hs00166045_m1 
XRCC5 MERIT40 functional analysis Hs00221707_m1 
XRCC6 MERIT40 functional analysis Hs00995282_g1 
POLB MERIT40 functional analysis Hs00160263_m1 
MLH1 MERIT40 functional analysis Hs00179866_m1 
MSH2 MERIT40 functional analysis Hs00953523_m1 
PMS1 MERIT40 functional analysis Hs00922262_m1 
PIK3CA MERIT40 functional analysis Hs00907966_m1 
KRAS MERIT40 functional analysis Hs00364284_g1 
BRAF MERIT40 functional analysis Hs00269944_m1 
HOXA10 MERIT40 functional analysis Hs00172012_m1 
CDK12 MERIT40 functional analysis Hs00212914_m1 
BAD MERIT40 functional analysis Hs00188930_m1 
TP53 MERIT40 functional analysis Hs01034249_m1 
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ABHD8 MERIT40 functional analysis Hs00225984_m1 
CPAMD8 MERIT40 functional analysis Hs00610855_m1 
DDA1 MERIT40 functional analysis Hs00911895_g1 
GTPBP3 MERIT40 functional analysis Hs00378443_m1 
MRPL34 MERIT40 functional analysis Hs04194538_sH 
MYO9B MERIT40 functional analysis Hs00188109_m1 
NR2F6 MERIT40 functional analysis Hs00172870_m1 
OCEL1 MERIT40 functional analysis Hs00226198_m1 
USHBP1 MERIT40 functional analysis Hs00230579_m1 
ANKRD41 MERIT40 functional analysis Hs00401326_m1 
TMEM16H MERIT40 functional analysis Hs00394261_m1 
USE1 MERIT40 functional analysis Hs00218426_m1 
PAX8 FTE project Hs00247586_m1 
Table 2.5: List of all the Taqman® Real time PCR expression assays used for the 
Fluidigm 96.96 Dynamic array. 
 
2.4.6 Analysis of Real time PCR gene expression data  
The expression data obtained from Real time PCR using the ABI7900 
Taqman® Sequence detection system or the Fluidigm 96.06 Dynamic array 
were analysed in a similar manner as follows. Initially, to confirm the linear 
relationship of expression versus RNA quantity for each target probe and 
endogenous control probes a standard curve was created using the expression 
data generated by the serial dilutions of a mix of the cDNAs used. Data were 
assumed reliable if an excellent fit (Correlation coefficient R2 between 0.95 and 
1) of the standard curve data to a straight line was observed or at least being 
able to create a suboptimal curve (R2>0.8). Additionally, quality control analysis 
regarding the pass rates for the assays and samples tested was performed to 
ensure the reliability of the data as will be described in more detail in Chapter 5. 
The Real time expression data were analysed using the comparative 
ΔΔCt method according to Applied Biosystems provided and the expression 
values of all cell lines were generated relative to either the lowest or highest 
expression of a NOSE cell line for each cell line normalized against GAPDH 
and β-actin. To validate the Comparative Ct method of analysis, the data were 
also analysed using the standard curve method and the relative expressions of 
each sample were compared between the two analyses to confirm that the 
relationship would remain the same. Differences in the relative expression of 
each candidate gene between EOC cell lines and normal cell lines were 
assessed using the nonparametric two sided Wilcoxon Rank sum test using R 
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software (R Foundation for Statistical Computing, Vienna, Austria) and P values 
and representative boxplots using the median of the expression for each group 
were generated. The following commands were used in R:  
To generate P values:  
wilcox.test(Relative_gene_expression~Cell_group,alternative="two.sided"
,paired=FALSE,conf.int=TRUE) 
To generate boxplots: 
Cell_group[Cell_group==2] <- "EOC cell lines (number of samples)" 
Cell_group [Cell_group ==1] <- "NOSE & FT cell lines (number of 
samples)" 
those.cell.lines <-as.factor(Cell_group) 
levels(those.cell.lines) 
pdf(file="NOSE&FTvsEOC_gene.pdf",paper="a4",family="Helvetica")  
boxplot(Relative_gene_expression~Cell_group,xlab="Cell lines", 
ylab="Relative gene expression",cex.main=0.8, main="Gene expression in 
NOSE & FT vs EOC cell lines normalised to GAPDH") 
Statistically significant values were considered if P<0.05. In experiments 
with multiple test multiple testing correction was performed by correcting the P 
value cut off relative to the statistical tests performed [P= 0.05/(number of 
statistical tests performed]. 
 
2.4.7 Genotype Specific gene expression analysis  
The DNAeasy Blood and tissue Kit (Qiagen) was used for DNA 
extraction of NOSE and FTE cell lines respectively according to the 
manufacturer’s instructions. Extracted DNA was quantified using a NanoDrop® 
reading the absorbance at 260nm. The ratio of absorbance at 260nm and 
absorbance at 280nm was used for purity estimation. 250ng of 36 NOSE DNA 
samples were included in the genotyping performed for the Stage II ovarian 
cancer GWAS performed by our group and collaborators using a custom 
Illumina Infinium iSelect BeadChip for a total of 22,790 SNPs including the 
SNPs of my interest. The genotyping of the 36 NOSE samples was repeated 
and additional 16 NOSE and 4 FTE cell lines DNA were included in genotyping 
performed in the context of an association study performed within our laboratory 
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and collaborators. Briefly, the latter study was (Collaborative Oncological Gene-
Environment Study (COGS) where 211,155 SNPs, including the SNPs of my 
interest, were genotyped in McGill University and Genome Quebec Innovation 
Centre using a custom Illumina Infinium iSelect assay.  
To ensure reliability of the genotyping the minor allele frequency (MAF) 
of the genotyped SNPs of interest was calculated from the NOSE &FTE 
samples genotypes and compared to the HapMap-CEU reported MAF. The 
following formula was used to calculate MAF: 
 
MAF= (2×RH+H/(2×(RH+H+CH))   where 
RH: Rare homozygotes, H: Heterozygotes, CH: Common homozygotes.  
   
Genotype specific expression was calculated using expression data 
previously generated using the comparative ΔΔCt method. The expression of 
each genotype group was evaluated relative to the average expression of the 
common homozygotes for each candidate SNP normalised against the 
expression of the endogenous control genes. To analyse gene specific gene 
expression, linear regression analysis was initially used to assess the difference 
in expression between common homozygotes, heterozygotes and rare 
homozygotes. However the sample size was very small and to avoid the result 
of regression being skewed from a rare homozygote that is an outlier, the rare 
homozygotes were combined with the heterozygotes. Wilcoxon Rank sum test 
was applied to test if the rare allele had a role in the expression of the candidate 
genes. The statistical analysis and generation of comparative boxplots was 
performed in R statistical software using the commands previously described. 
 
2.4.8 Genotype specific methylation analysis  
One of the studies included in the ovarian cancer GWAS was the 
UKOPS (United Kingdom Ovarian Population Study) with participants recruited 
form the UK. There were 691 cases and 1,051 controls included in this study. 
The UKOPS controls were aged 50-76 years and were healthy postmenopausal 
females. Germline DNA was extracted at Tepnel, using a chloroform based 
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extraction method and 800ng (2×400) for each sample. Genotyping data for 
those samples were available for the SNPs of my interest from the ovarian 
cancer GWAS. Additionally, methylation data were made available to me by 
Prof Martin Widschwendter within our group. The methylation analysis was 
performed on germline DNA of 148 healthy UKOPS individuals using the 
Illumina Infinium Human Methylation27 BeadChip  for approximately 27,000 
CpGs mapping to promoters of 14,000 genes in (Teschendorff et al, 2009) and 
later on additional 108  UKOPS samples (Teschendorff et al, 2010). The 
methylation status (β-value) of each CpG island associated with the genes of 
my interest was analysed relative to the genotype of the related SNP. 
Methylation differences were assessed in two ways. Firstly, methylation status 
was compared between the common homozygotes and the rare 
homozygotes/heterozygotes combined using the Wilcoxon rank sum test as 
previously described to evaluate the effect of the rare allele on methylation. 
Secondly, linear regression analysis was performed comparing the methylation 
status of the three genotype groups separately to evaluate the extent of the rare 
homozygote genotype affecting methylation compared to the other two 
genotype groups.  
Finally, previous reports have shown that methylation status can be 
affected by age, so the set was divided into three age groups and linear 
regression analysis was performed in R to determine if methylation of any of the 
selected CpG islands was affected by age. If no association was detected 
between the age distribution and the methylation status any positive 
associations found between methylation and genotype were assumed reliable 
and non-age biased.  
An example of the commands used in R to perform linear regression analysis 
and representative boxplots were as follows: 
To generate P values:  
lm(UKOPS_group_ SNP.genotype~Relative_gene_CpG_methylation) 
summary(lm(UKOPS_group_ SNP.genotype~Relative_gene_CpG_methylation)) 
To generate boxplots: 
UKOPS _group_ SNP.genotype [UKOPS _group_SNP.genotype ==3] <- "Rare (#)" 
UKOPS _group_ SNP.genotype [UKOPS _group_ SNP.genotype ==2] <-"Rare and 
hets (#)" 
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UKOPS _group_ SNP.genotype [UKOPS _group_ SNP.genotype ==1] <- 
"Common (#)" 
those.UKOPS.SNP.genotypes <-as.factor(UKOPS _group_SNP.genotype) 
levels(those.UKOPS.genotypes) 
pdf(file=" UKOPS_genotype_CpG.pdf",paper="a4",family="Helvetica") 
boxplot(Relative_gene_CpG_methylation ~ 
UKOPS_group_SNP.genotype,xlab=" SNP genotype ", ylab=" 
Relative_gene_CpG_methylation ",cex.main=0.8, main="Gene CpG 
methylation relative to SNP genotype") 
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 In vitro assays to investigate functional role of a 2.5
candidate gene emerging from the GWAS 
2.5.1 GIPZ lentiviral shRNA system for gene silencing 
The functional role of MERIT40 was investigated using in vitro assays 
described later on in this section. For this purpose, MERIT40 was knocked 
down in EOC cell lines using the lentiviral GIPZ small hairpin RNA (shRNAmir) 
system purchased from Open Biosystems. This system was chosen to achieve 
stable knockdown of the gene which is facilitated by the lentiviral delivered 
shRNA in the infected cell line through the endogenous miRNA pathway. Using 
lentiviral delivery systems is advantageous compared to retroviruses because 
they have the ability to infect non-diving cells. The desired shRNAs are cloned 
into a GIPZ plasmid shown in Figure 2.2. 
 
 
 
 
 
Plasmid Element Description 
CMV Promoter RNA Polymerase II promoter 
cPPT 
  
Central Polypurine tract 
helps translocation into the nucleus of non-dividing cells  
WRE Enhances the stability and translation of transcripts 
turbo GFP Marker to track shRNA expression 
Puro
r
 Mammalian selectable marker 
AMP
r
 Ampicillin bacterial selectable marker 
5'LTR 5' long terminal repeat 
pUC ori High copy replication and maintenance in e.coli 
SIN-LTR 3' Self inactivating long terminal repeat 
RRE Rev response element 
ZEO
r
 Bacterial selectable marker 
 
Figure 2.2: Lentiviral GIPZ plasmid containing the shRNAmir sequences 
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2.5.2 Human GIPZ plasmids containing shRNAmir  
Three different MERIT40 targeting shRNAmir clones were available in 
the Open Biosystems (OB) library with the distinct sequences shown below. 
 
MERIT40 shRNAmir 1 (shRNA_M1) (5’-3’) (OB, V2LHS_213618) 
TCCGAGGCAGTAGGCACTCCTAGTTTGTCATGGATAATTACATCTGTGGCTTCAC
TAATTATCCATGACAAACTAGGATCGCTCACTGTCAACAGCA 
 
MERIT40 shRNA mir 2 (shRNA_M2_) (5’-3’) (OB, V2LHS_252352) 
TCCGAGGCAGTAGGCACCCTCAATGTCTCCCAGAAGATTACATCTGTGGCTTCA
CTAATCTTCTGGGAGACATTGAGG TCGCTCACTGTCAACAGCA 
 
MERIT40 shRNAmir 3 (shRNA_M3) M3 (5’-3’) (OB, V2LHS_214050) 
TCCGAGGCAGTAGGCACACCTTCAATCTGGAAGGACTTTACATCTGTGGCTTCA
CTAAAGTCCTTCCAGATTGAAGGTTCGCTCACTGTCAACAGCA 
 
Additionally, three GIPZ plasmids were used as controls. The first one 
contained a shRNA of non-targeting sequence that would serve as a negative 
control (OB, RHS4346). Another negative control included was an empty GIPZ 
plasmid containing no shRNA (OB, RHS4349). As a positive control a GIPZ-
shRNA_GAPDH was used (OB, RHS4371).  
Finally, for lentivirus packaging, two plasmids were used that contain the 
genetic information needed for production of the lentiviral particles that will 
encase and deliver the GIPZ-shRNAs to the EOC cell lines used as well as a 
gene providing resistance to ampicillin for selection of bacterial colonies. The 
packaging vectors used were pMDG and p8.91. 
 
2.5.3 Preparation of GIPZ-shRNA and packaging plasmid DNA 
All plasmids were provided in DH5α bacterial glycerol stocks. The GIPZ 
and packaging plasmid containing bacteria were streaked on LB-agar plates 
containing 100µg/ml ampicillin (Sigma). LB agar plates were prepared using the 
following recipe: 5g Tryptone 2.5g NaCl, 2.5g Yeast Extract 1.5 % Agar (All 
Sigma), distilled H2O to 500ml. The solution was then sterilised by autoclaving 
and allowed to cool to below 60oC before adding ampicillin (dissolved in 70% 
ethanol). The LB-agar with antibiotic was then poured into sterile 100mm petri 
dishes within a laminar flow hood, and allowed to cool and set before replacing 
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the lid. Once the LB-plates were set the bacterial swabs were spread onto them 
using the quadrant streaking technique to achieve well-spaced bacterial 
colonies. Plates were incubated inverted overnight at 37oC. Single colonies 
were picked from each plate with sterile forceps and inoculated in 3ml of LB 
medium with 100µg/ml ampicillin depending on the plasmid contained. The 
medium was then incubated overnight in a shaking incubator with shaking at 
225rpm at 37oC. The following day 200µl of the bacterial culture solution was 
further inoculated in 100ml of LB medium with ampicillin and incubated 
overnight in a shaking incubator with shaking at 225rpm at 37oC. The following 
day the bacterial cultures were split in 12ml aliquots and pelleted by 
centrifugation at 5,200 rpm. The supernatant was then removed and plasmid 
DNA was prepared using the QIAprep Spin Miniprep Plasmid DNA Isolation kit 
according to the protocol provided by the manufacturer. The resulting DNA 
pellets were resuspended in 60µl 10mM Tris-Cl pH 8.5 buffer included in the kit. 
Plasmid DNA concentration and purity was determined using a NanoDrop® 
Spectrophotometer. 
 
2.5.4 Sequencing of GIPZ-shRNA plasmid DNA 
Following preparation of plasmid DNA all GIPZ plasmids were 
sequenced to verify the shRNA sequences were correct and contained no 
mutations acquired during the preparation process (sequencing was performed 
by Open Biosystems). The sequence for all plasmids was confirmed as 
expected apart from shRNA_M2 which had a base substitution in which may 
affect the efficiency of the MERIT40 knockdown for this shRNA. 
 
2.5.5 Lentivirus GIPZ-shRNA production 
The GIPZ-shRNA lentiviruses were produced in 293T packaging cell 
lines. The procedure was performed as follows. Day one: 293T cells were 
seeded 24 hours before transfection into a 100mm plate with 8ml complete 
media (DMEM, 15% FCS, L-Glutamine) and incubated at 37°C, 5% CO2. 293T 
cells had to be sub-confluent in the day of transfection. Day 2: The cells were 
co-transfected with GIPZ-shRNA (or GIPZ_control) plasmid and the lentiviral 
Chapter 2: Materials and methods 
 
128 
 
packaging vectors pMDG and p8.91. Plasmid DNA was diluted in 1.5ml tubes to 
a total volume of 15µl with TE pH8.0 as follows: 1μg p8.91 (gag-pol expressor), 
1μg pMDG (VSV-G expressor) and1.5μg pGIPz DNA and finally sterile TE 
added to a final volume of 15μl. For each transfection mix, 200μl of Optimem 
(Gibco) was added to a second micro-tube and 10µl of Fugene® transfection 
reagent (Promega) was added to the center of the tube caring not to touch the 
sides. The mixture was mixed gently by inversion and not vortexed. DNA was 
then added to the Optimem-Fugene mix and once again mixed by inversion. 
The mix was centrifuged for 2 seconds to remove the mix from the sides of the 
tube and incubated at room temperature for 15 minutes. During this incubation, 
the media on the cells was replaced with fresh pre-warmed complete media. 
After the 15 minute incubation, the Optimem/DNA/Fugene mix was added to the 
cells drop wise and the plates were swirled to mix well. The cultures were 
incubated at 37°C, 5% CO2 for 24hours. Day 3: The medium containing the 
transfection mix was replaced with 8ml of fresh complete medium and the cells 
were returned to 37°C, 5% CO2. Days 4 to 6: The cells were visualised under a 
fluorescent microscope to confirm GFP expression The supernatants-containing 
lentivirus were harvested 24, 48 and 72 hours after the media change that was 
performed at day 3. The medium of each virus was collected into a 50ml syringe 
and filtered through a 0.45μm filter (Millipore) into a centrifuge tube. Fresh 
complete media (8ml) was added to the cells for supernatant to be collected the 
following day if needed. The viral supernatant was stored at -80oC in 1-3ml 
aliquots. The transfection procedure and collection of the virus is shown at 
Figure 2.3. 
 
 
 
 
 
Figure 2.3: Lentivirus GIPZ-shRNA production procedure 
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2.5.6 Lentivirus GIPZ-shRNA titration 
To ensure that the lentiviral stock produced was viable and to test what 
fraction of target cells could be transduced a titration was performed. This 
enables the number of copies of viral construct per target cell to be controlled. 
The titration of a virus was performed by placing dilutions of the virus onto a 
chosen cell line. Several different cells can be used to determine the virus titre 
but titres may vary to several orders of magnitude thus I decided it was 
appropriate to use an EOC cell line since the cell lines to be transduced were all 
EOC cell lines. Fluorescence activated cell sorting (FACS) was used to 
measure GFP expression of cells and quantifying the amount of lentiviral 
particles in order to calculate the lentivirus transducing units (TU) per ml.  
The day before titration, 100,000 C13 EOC cells were seeded into all 
wells of a 6-well tissue culture plate, ensuring a uniform spread of cells on the 
bottom of the wells. One 6-well plate was prepared for each lentiviral stock to be 
titrated. One control plate of uninfected cells was plated as a negative. The cells 
were incubated at 37°C, 5% CO2 for a couple of hours until attached. 1:3 serial 
dilutions of the viral supernatant containing 8μg/ml polybrene were prepared 
and added to 6 wells as shown at Figure 2.4. Polybrene (Sigma) is a cationic 
polymer which is used to enhance the efficiency of lentiviral infection of cells. 
The infected cells were incubated for 48-72 hours at 37°C, 5% CO2. 
 
 
 
 
 
 
 
Figure 2.4: Lentivirus GIPZ-shRNA titration procedure. 
 
Before fluorescence-activated cell sorting (FACS) analysis, the culture 
medium of the infected and uninfected control was removed and the cells 
washed with PBS and trypsinised. The cells were resuspended thoroughly to 
disrupt clumps and then transferred to a FACS tube (ELKAY) containing 500μl 
PBS. If the FACS analysis was not performed within 1 hour, cells were fixed in 
4% (w/v) paraformaldehyde solution for 30 minutes and kept for maximum one 
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week at 4°C. The FACS analysis was performed in a CyAn ADP flow cytometer 
(Dako Cytomation).The percentage of GFP-positive cells was then determined 
by FACS analysis. The titre was then calculated using the dilutions that had 10-
20% GFP positive cells. The titre of the virus is calculated in transducing units 
(TU)/ml, according to the formula: 
  (1×105 seeded cells× % GFP-positive cells) 
                                    µl of vector 
 
2.5.7 Stable infection of EOC cell lines with lentivirus GIPZ-shRNA 
The EOC cell cultures to be infected were trypsinised and counted as 
previously described. 1×105 cells were plated in their corresponding complete 
media in a 100mm plate and incubated at 37°C, 5% CO2
 for 2-4 hours until they 
attached. The media was then removed and replaced with 10ml of complete 
media containing 8µg/ml polybrene and the appropriate amount of virus 
supernatant. The amount (µl) of virus supernatant to be added was calculated 
based on the TU established for each virus at the titration using the following 
formula:    
(1×105 seeded cells× 1 MOI) 
               TU/ml 
MOI stands for the multiplicity of infection which determines the amount of 
transducing units per cell. 1TU/cell was used. The TU/ml calculated for each 
virus and the amount of supernatant used based on the desired MOI of 1 was 
as follows: 
 
Lentivirus GIPZ-
shRNA 
TU/ml MOI Cells to infect 
Virus supernatant 
to infect with (µl) 
GAPDH 3.56×105 1 1×105 281 
Empty 4.40×105 1 1×105 228 
Non-Silencing 3.93×105 1 1×105 255 
MERIT40 (M1) 9.37×105 1 1×105 1067 
MERIT40 (M2) 1.89×105 1 1×105 5284 
MERIT40 (M3) 1.56×105 1 1×105 639 
 
The infected cells were incubated for 72 hours and subjected to 
puromycin selection. Infected cells were selected with 0.5-1.5 µg/ml puromycin, 
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depending on the cell line, to avoid any contamination of the stably infected cell 
lines with non-infected cells. Alongside, control uninfected cell lines were 
seeded and treated with puromycin. The control cell lines were 100% killed in 3-
7 days. 
 
2.5.8 Confirmation of MERIT40 knockdown  
2.5.8.1 Confirmation of MERIT40 knockdown at the mRNA level 
  RNA was extracted from the stably infected and the relative control EOC 
cell lines and transcribed into cDNA as previously described. Gene expression 
was determined by Taqman® Real time PCR probes in ABI7900 Taqman® 
Sequence detection system and analysed with the comparative ΔΔCt method 
as previously described. The samples used as calibrators were the control EOC 
cell line for each set of infected cell lines. 
 
2.5.8.2 Confirmation of MERIT40 knockdown at the protein level  
Cell line protein extraction: The transduced cell lines were cultured in 
145mm plates until they reached 70% confluence. The cells were then starved 
for 24 hours using serum free culture media in order to reach basal levels of 
protein. The plates were then placed on ice and washed twice with ice cold 
PBS. 500µl of lysis buffer (0.02% NP40, 6mM Hepes pH 7.4, 30mM NaCl, 
0.2mM EDTA, 17µg/ml aprotinin,1µg/ml pepstatin, 1µg/ml leupeptin, 100µg/ml 
AEBSF and phosphatase inhibitors cocktail) (all Sigma) was added on plate and 
the cells were scraped with a cell scraper while on ice. The cell lysate was then 
quantified or stored at -20oC until used. Before quantification cell debris were 
cleared by centrifugation at 13,000 rpm for 20min at 4oC. The supernatant was 
then transferred to a fresh tube and the pelleted cell debris discarded. The 
protein lysates were then quantified diluted to 1.25µg/ml and 5X Laemli buffer 
(50mM Tris pH 6.8, 10% v/v glycerol, 2% SDS (w/v), 0.1% bromophenol blue 
(w/v), 2% beta-mercaptoethanol) (all Sigma) was added to give a final protein 
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concentration of 1µg/ml. Before use, protein samples were denatured at 100oC 
for 3min. 
Bradford assay for protein quantification: Protein samples were 
quantified using Bradford assay and the Commassie protein assay kit (Pierce). 
The Bovine Serum albumin (BSA) standards were prepared as described in the 
manufacturer’s protocol and the proteins were quantified according to the 
standard microplate protocol provided by the manufacturer. 2µl of each 
standard or unknown was used instead of the 5μl mentioned in manufacturer’s 
instructions. 1:2 dilutions of the unknown concentration proteins were used. 
After spectrophotometric measurement at 595nm, a standard curve was 
generated and the concentrations of the unknown protein samples were 
extrapolated from the standard curve’s equation, accounting for the dilution 
factor as appropriate. 
Western Blot: The protein lysates of the control and infected cell lines 
were shipped to University of Southern California, Keck School of Medicine, 
Department of Preventive Medicine where Dr Kate Lawrenson performed a 
western blot with a custom made antibody that was provided by Chen J.’s 
laboratory, Department of Therapeutic Radiology, Yale University School of 
Medicine (Feng et al, 2009). Ponceau staining was used as loading control. 
 
2.5.9 Measuring cell viability using MTT 
The viability of cell lines following inducible stress and also their ability to 
proliferate in culture was evaluated by performing an MTT assay (3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a yellow tetrazole) 
colorimetric assay. MTT is reduced by the mitochondria of living cells to a 
purple formazan product. 
MTT assay optimization: The cell number that should be plated for 
assays that would be followed by MTT end point readouts and MTT reduction is 
cell type dependent and was optimised to avoid surpassing the limit of 
detection. The optimal MTT incubation time was also determined for the 
different cell lines. I have tested the intensity of the absorbance reading after 
plating 2000-12000 cells and have created graphs for the number of cells 
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versus the absorbance’s intensity for the EOC cell lines tested. All the cell lines 
showed a linear relationship of cell number versus intensity. According to the 
MTT optimization performed 6000-10000 cells were plated in the subsequent 
MTT assays for cell lines SCOV3IP, EFO27, HOC7, TOV112D, MPSC1, 
OAW42. The MTT incubation times were found to be optimal between 2.5 and 
3.5 hours. Plating 6000-10000 cells and incubated MTT between 2.5-3.5 hours 
was also acceptable for OVCAR3, A2780/A2780CP, OV2008/C13 cell lines, 
according to previous optimisation experiments performed for these cell lines 
within our group (Miss Sheetal Dyal, personal communication). 
MTT assay for viability or proliferation: The appropriate amount of 
cells was seeded in 96 well tissue culture plates and incubated at 37°C, 5% 
CO2 for 72 hours. The assays were performed in 96 well plates and all samples 
were run in 8 replicates. A 1mg/ml MTT (Sigma) solution was used. The culture 
medium was aspirated from the cells and 100μl of MTT was added per well. 
After 2.5-3.5 hours incubation 37°C, 5% CO2 the MTT was removed and 100μl 
of dimethyl sulfoxide (DMSO) (Sigma) was added to solubilize the MTT reduced 
by the mitochondria of the cells producing a purple colour. The absorbance that 
was indicative of cell viability/proliferation was then read at 562nm using the 
Tecan Spectrafluor Plus plate reader.  
 
2.5.10 Cisplatin and carboplatin dose response assays 
6000 to 10000 cells were plated with 100µl of the appropriate medium in 
each well of a 96 well plate 16 hours before dosing with cisplatin (UCLH 
pharmacy) or carboplatin (UCLH pharmacy) leaving 4 wells empty for 
background control. The seeded cells were incubated 37°C, 5% CO2. After 16 
hours incubation the culture medium was removed and replaced with fresh 
complete medium. The assay was performed in quadruplicate for each cisplatin 
concentration. The cisplatin and carboplatin concentrations that were used for 
the dosing are shown at Table 2.6. The cisplatin and carboplatin dilutions were 
then prepared to yield final concentrations in 200µl. The cells were then 
incubated for 48hours. The medium containing cisplatin was then removed and 
an MTT assay was performed as described previously to assess cell viability. 
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The dose response curves and IC50 (amount of drug needed to kill 50% of the 
cells) of the cell lines to cisplatin and carboplatin were generated by PRISM 
software, after performing a nonlinear regression analysis for the production of 
a variable slope of cisplatin concentration versus cell viability and the 95% 
Confidence Intervals (CI) were also calculated.  
2.5.11 Gamma H2AX immunofluorescence staining  
Gamma H2AX staining was performed in cells cultured in normal 
conditions in order to assay the ability to repair spontaneous endogenous DNA 
damage. Round coverslips were placed on a 6 well plate. Cells to be assayed 
were trypsinised, pelleted and counted. 2×105 cells were seeded per well and 
incubated at 37oC, 5% CO2 for 48 hours. After incubation cells were fixed on the 
coverslips with 4% paraformaldehyde (Sigma). Fixed cells were incubated 
overnight at 4oC in PBS. Cells were stained as previously described in the 
immunofluorescence cytochemistry section using a 1:1000 dilution of the 
primary γH2AX antibody (Abcam). Pictures of the stained cells were obtained 
under the 40x objective of an Olympus BX64 fluorescence microscope. 50 cells 
per condition were monitored for expression and intensity of γH2AX which 
indicated active DNA repair following spontaneous DNA damage and the results 
were plotted in histograms. 
2.5.12 Irradiation of cells to assay DNA repair for exogenous DNA 
damage 
X-Ray irradiation of cells was performed to account for the ability of cells 
to repair the DNA damage induced. 8×104 cells were plated in complete media 
in a 96-well tissue culture plate leaving 4 empty wells to be used as background 
control. The cells were incubated at 37oC, 5% CO2 overnight. The following day, 
the cells were subjected to increasing doses (1, 10 and 100 Grays) of ionising 
radiation (X-Ray). Following irradiation the cells were incubated for 72 hours at 
37oC, 5% CO2. The ability of cells to repair damage and survive was assayed 
by performing an MTT assay and generating dose response curves and the 
IC50 of the cells to irradiation dosing as previously described.  
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Table 2.6: Cisplatin and Carboplatin concentrations used for dosing EOC cells to 
generate dose response curves. 
 
2.5.13 Cell cycle analysis using flow cytometry  
Cultured cells of no more than 80% confluency were trypsinised, 
centrifuged, washed in PBS and resuspended in 1ml of 70% ethanol in serum 
free media. The cells were left overnight at 4oC to be fixed. The cells were then 
centrifuged at 4,000rpm in a microcentrifuge for 2 minutes. The cell pellet was 
resuspended in 0.5-1ml PBS containing 50µg/ml propidium iodide (PI) (Sigma) 
which stains the cell’s DNA and 40µg/ml RNase A to get rid of any RNA traces 
that can bind PI. The samples were left for 30 minutes in the dark at room 
temperature. The cell cycle profiles were generated using a CyAn ADP flow 
cytometer (Dako Cytomation) using the FL3 channel (>580nm). Cell cycle 
profile analysis was performed in Summit.v4.3 software (Beckman Coulter) 
Carboplatin Concentrations ( M) Cisplatin Concentrations ( M) 
0 0 
0.3 0.3 
0.5 0.5 
1 1 
3 3 
5 5 
7.5 10 
10 15 
12 20 
14 30 
16 40 
18 50 
20 60 
25 70 
30 80 
40 90 
50 100 
70 120 
90 140 
110 160 
130 180 
150 200 
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2.5.14 Proliferation analysis with BrDU labelling using flow cytometry 
Cultured cells were allowed to reach 80% confluency. The cells were 
removed from the incubator and BrDU was added to each plate to a final 
concentration of 10µM. One plate for each cell line to be tested was left with no 
added BrDU to serve as a negative control. The plates were incubated for 1 
hour at 37oC, 5% CO2. The media was then aspirated and the cells trypsinised, 
washed twice with PBS and fixed with 0.5-1ml cold ethanol at 4oC overnight. 
The following day the cell pellet was washed twice with PBS and then 
resuspended in 2M HCL/5%Triton X-100 (Sigma) adding dropwise while 
vortexing. The cells were then incubated for 30 minutes at room temperature. 
The acid was spun off and the pellet washed twice PBS and once with PBS-T 
(PBS, 0.1% BSA, 0.2% Tween 20, pH 7.4) (all Sigma). 2µl of primary anti-BrDU 
antibody (Becton Dikinson) was added directly to the cell pellet and incubated 
for 20minutes at room temperature in the dark. Following incubation the pellet 
was washed twice with PBS-T and incubated with 50µl FITC-conjugated rabbit 
anti-mouse (Fab’) 2 fragments (DAKO) secondary antibody in a 1:10 dilution for 
20 minutes at room temperature in the dark. Finally, the cells were washed with 
PBS, resuspended in 300-600µl of PBS containing 50µg/ml propidium iodide 
(PI) (Sigma) and 40µg/ml RNase A and incubated at room temperature in the 
dark for 20 minutes. The analysis was performed by flow cytometry using a 
CyAn ADP flow cytometer using the FL3 channel for PI (>580nm) and the FL1 
channel for FITC (515-545nm). FACS profile analysis was performed in 
Summit.v4.3 software.  
 
2.5.15 Preparation of metaphase spreads  
Slide cleaning: Microscope slides (Chance Propper, gold star washed) 
were washed in slide racks in a solution of 3% conc. HCl in 70% methanol 
(Analar): and 30% distilled water for a minimum of 1 hour but not more than 24 
hours. They were then rinsed with 10 changes of distilled water (2 litres per 
wash).  
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Preparation of solutions: The following solutions were prepared:  
Hypotonic solution 0.075M KCl (pre warmed at 37 C) and Carnoy’s Fixative 
consisting of 3:1 Methanol and Acetic acid (Sigma). Carnoy’s fixative was used 
only freshly prepared. 
Arresting cells in metaphase and preparing metaphase spreads: 
Cells were cultured in 100mm plates to 85% confluence.  Colcemid (Sigma) 
was added to cell cultures to a final concentration of 0.1µg/ml. The cell cultures 
were then incubated for 2 hours and 15 minutes at 37°C, 5% CO2. Culture 
media containing colcemid was removed and cells washed with PBS, 
trypsinised and centrifuged for 5 minutes at 1500rpm. The supernatant was 
removed and pellet flicked loose.1.5 ml of pre-warmed hypotonic solution was 
then added slowly against the side of the tube while gently vortexing and the 
volume was then brought up to 6ml. The cells were incubated at 37°C for 
20min. Following incubation the tube was inverted to mix. The reaction was 
stopped by adding 10 drops of fixative while gently vortexing. Cells were spun 
down and supernatant discarded. The pellet was flicked and 1.5ml of freshly 
prepared fixative was added slowly against the side of the tube while gently 
vortexing. The volume was brought to 6ml and tube was inverted to mix before 
incubation at room temperature for 10min. The tube was again inverted to mix, 
cells pelleted and the supernatant removed. The pellet was flicked and 1.5ml of 
freshly prepared fixative was slowly added against the side of the tube while 
gently vortexing and the volume brought to 6ml, tube inverted to mix and 
incubated at room temperature for 30 minutes. Cells were centrifuged, 
supernatant discarded and 2ml of freshly prepared fixative was added dropwise 
while vortexing.. 
Cell dropping procedure and metaphase spreads visualisation 
under the fluorescent microscope: Cells were dropped using a Pasteur 
pipette onto the pre-cleaned slides from approximately 3-5 cm height. The 
slides were allowed to dry before 10ul of 10mg/ml DAPI was added on the slide 
and a coverslip placed and positioned on top. The metaphase spreads were 
then visualised under an Olympus BX64 fluorescence microscope under the 
100× oil objective and chromosomes of 4-10 cells per sample were counted. 
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2.5.16 Migration assays 
Each condition was run in triplicate. Cells were cultured in a 100mm plate 
to not more than 80% confluency. Cells were then trypsinised, pelleted and 
washed in PBS to remove traces of serum. Cells were then resuspended in 
20ml serum free media (SFM) and counted. A cell suspension was then 
prepared in SFM to a final concentration of 6x104 cells/ml. 750µl of culture 
media supplemented with 10% FBS, used as chemoattractant, was added in 
the wells of a 24 well plate. 24-well inserts (ThinCert 8µm, Greiner) were 
transferred with sterile forceps on top of the wells containing the 
chemoattractant taking care not to trap bubble beneath the membranes. 
Immediately after placing the insert on the chemoattractant, 0.5ml of the cell 
suspension prepared (3x104 cells per well) was added to the inserts. The plates 
were then incubated for 20 hours at 37oC, 5% CO2. Non migrating cells were 
removed from the upper surface of the membrane by insertion of a cotton swab 
into the insert and applying gentle pressure while moving the tip over the 
membrane surface. To stain the migrated cells 1.5ml of 1% Crystal Violet 
(Sigma) was added in the wells of a clean 24 well plate. The inserts were 
dipped in the stain for 15min then  washed in the PBS for 15 min. Excess liquid 
and stain was removed from the inside of the inserts using a cotton swab. The 
inserts were placed upside down and the membranes allowed to dry overnight. 
The membranes were then carefully removed from the inserts using a scalpel 
and placed bottom side down on microscope slides containing a drop of 
immersion oil. A second drop of oil was then placed on top of the membrane 
and a coverslip was placed on top of the membrane and gentle pressure 
applied to remove any air bubbles.  
The migrating cells were observed and photographed under 40x 
magnification of a light microscope. The number of migrated cells were counted 
using cell counter plug-in in Image J software (Schneider et al, 2012). Ideally 
cells in 4 central fields of triplicate membranes were counted. Histograms of 
mean number of migrating cells were plotted for the controls and treated cell 
lines with error bars indicating the variation between replicates. 
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2.5.17 Assay for Anchorage Independent Growth 
This assay was performed in 6-well plates. 6.0% agar containing bacto-
peptone (all Sigma) at 10mg/ml was melted at 65°C and added to pre-warmed 
complete medium in a 1:10 ratio. The solution was immediately thoroughly 
mixed and 1.6 ml was quickly dispensed into each well of a 12 well tissue 
culture plate. Agar was allowed to set and used on the same day. The cells to 
be tested for anchorage independent growth were trypsinised and resuspended 
thoroughly in complete media to obtain a single-cell suspension and counted. 
Complete medium was then warmed to 37oC and appropriate number of cells 
added to the medium. Each cell line was plated in triplicate in numbers ranging 
from 500 to 10000 cells depending on the experiment. A positive control EOC 
cell line, TOV112D, was used to test that the gel heat did not kill the cells within 
the suspension when plated. One tenth volume of 3.3% melted agar (containing 
10mg/ml bacto-peptone) was added immediately to the cell suspension, mixed 
well and 1.2ml was gently overlayed on the base layer. Agar was allowed to set 
at room temperature and incubated at 37oC, 5% CO2 for 2-4 weeks depending 
on the cell line’s doubling times. After 2-4 weeks, the agars were fixed and 
colonies stained in red/purple with 0.5ml p-iodotertazolium violet (1mg/ml), 
prepared in absolute methanol 24 hours at 37oC. Pictures of the soft agar plates 
were obtained on a Box gel documentation system using the GeneSnap image 
acquisition software (Syngene) and the colonies were counted using the cell 
counter plug-in in Image J software. 
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3 Establishing in vitro models of primary normal 
ovarian surface epithelial and fallopian tube 
epithelial cell lines. 
 
 Introduction 3.1
EOC is a disease characterised by heterogeneity and one of the major 
challenges for studying and elucidating the molecular events that leads to the 
development of the distinct EOC subtypes has been the identification of the site 
of origin for each of those subtypes. Although the ovarian surface epithelium 
(OSE) has been conventionally thought to be the site of origin for all EOCs, 
there is emerging evidence that a big proportion of high grade serous 
carcinomas emerge from FTE cells (Piek et al, 2003, Medeiros et al, 2006, 
Tone et al, 2008, Callahan et al, 2007). More recent evidence support that the 
secretory cells of the fallopian tube (FTSEC) are the sole cell of origin for both 
low grade and high grade serous carcinomas (Kurman et al, 2011). FTE cells 
have also been proposed as potential precursor cells of poorly differentiated 
mucinous adenocarcinoma (Shan et al, 2012, in print). 
There are growing data to support an FTE & FTSEC origin for a 
proportion of high-grade serous EOCs, however there are no studies to date 
that have been able to provide evidence to exclude the OSE as an origin for this 
subtype. In contrast, there is plenty molecular evidence that supports the OSE 
origin of several EOC subtypes as previously discussed. This evidence include 
reports of p53 signatures in OSE lined inclusion cysts of BRCA1 and BRCA2 
mutation carriers and reports showing that expression of distinct HOX genes in 
OSE are giving rise to distinct EOC subtypes (Naora, 2007, Pothuri et al, 2010). 
Our group proposes a model supporting a multiplicity of sites of origin for EOC 
and suggesting that different subtypes emerge mainly either from the normal 
ovarian surface epithelium or from the distal end of the fallopian tube 
(Kindelberger et al, 2007). Thus, it is essential to study the pathogenesis of 
EOC using both NOSE and FTE in vitro models. 
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Normal ovarian surface epithelial (NOSE) cells isolation (Auersperg et al, 
1984), culturing conditions (Li et al, 2004) and immortalisation (Maeda et al, 
2005) have been well established and optimised over the past decades. NOSE 
cells have successfully been immortalised and used in models to study 
transformation monitoring their phenotype after induction of genes such as 
TNFα, MYC, BRAF, KRAS (Maeda et al, 2005, Kwong et al, 2009, Lawrenson 
et al, 2011) 
The research in order to isolate FTE cells has increased over the last few 
years since their proposed role of being the precursors of certain types of EOC. 
Earlier studies have tried to isolate epithelial cells of the fallopian mucosa using 
methods such as enzymatic treatment with trypsin and/or pancreatin. The 
epithelial status of the isolated cells was confirmed with anti-cytokeratin 
antibodies of CK7, CK8, CK18, CK19 and PKK1. The lifespan of the isolated 
cells was reported to be extremely short and all studies have failed to 
successfully subculture FT isolated cells (Henriksen et al, 1990, Comer et al, 
1998). More recent advances have isolated FTSEC cells and cultured them ex 
vivo on collagen matrix (Levanon et al, 2010) but did not sub-culture them or 
compared their phenotypic characteristics with FT tissue in vivo.  
The classical techniques for isolating and culturing epithelial cells involve 
culturing of cell monolayers on plastic surfaces. These traditional two-
dimensional (2D) in vitro techniques are causing the loss of the normal 
architecture, geometrical features and cell-cell interactions and interactions of 
cells with extracellular matrix that characterise tissues in vivo.  Seminal work in 
three-dimensional (3D) modelling by Bissell and colleagues has shown that 3D 
culturing of normal breast epithelial cells can induce gland formation, restore 
cellular polarity and induce up-regulated expression of biologically active 
molecules expressed in vivo (Aggeler et al, 1991, Jones et al, 1993, Streuli et 
al, 1995). Recent work within our group has generated 3D models of NOSE 
cells in order to better model the microenvironment of the ovary in vivo. The 
morphological and biological characteristics have been compared between 
NOSE 3D and 2D models and OSE in vivo to confirm that 3D cultures more 
closely resemble the tissue in vivo than the 2D cultures. In this study two 
different techniques for establishing 3D cultures were tested, the polyHEMA 
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coated vessels and the rotary cell culture system (RCCS). The 3D structures 
grown in the RCCs had a chaotic internal structure and exhibited higher levels 
of apoptosis compared to the polyHEMA grown 3D cultures. Thus, use of the 
polyHEMA coated vessels to culture 3D cultures was proposed to be a more 
appropriate 2D modelling approach (Lawrenson et al, 2009). 
 
Aims of this chapter: 
1. The first large scale NOSE cell line repository (n>50) will be collected 
and characterised to be further used to study the expression of candidate 
genes involved in EOC development in following chapters. 
2. Collect, establish and sub-culture primary FTE cell lines (n>3). 
3. Establish 3D cultures of FTE cell lines. Investigate the morphological and 
growth and lineage characteristics of the primary FTE cell cultures in 2D 
and further compare with 3D FTE cultures and FT tissue. 
4. The differential expression of genes that are known to have an 
implication in ovarian cancer development will be assayed between of 
the established NOSE & FTE cell lines and EOC cell lines using real time 
expression assays. 
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 Establishing and characterising a primary NOSE cell line 3.2
repository 
NOSE cell lines were isolated from brushings of normal ovaries during 
surgical procedures that took place in University College London Hospital 
(UCLH). The women were identified as suitable for participation in this study 
when their diagnosis did not involve malignancy or disease of the ovaries and 
they were not carriers of a familial mutation in any of the high risk genes 
identified for ovarian cancer subjected to prophylactic salpingo-oophorectomies. 
The patients were consented the day before or on the day of surgery. 
When the surgical procedure was open body surgery, the brushings were 
collected in surgery after the specimen was removed from the patient by 
brushing the surface of both the left and the right ovary when possible as 
described in more detail in the methods section of this project. In the case of 
laparoscopic surgery, brushings were either collected after excision of the 
specimen or by the surgeon while the ovaries were still in the patient. 
All the specimens that were suitable for this study would have to have no 
malignancy and this was confirmed in three stages. Firstly, ovaries were 
confirmed to be normal on the day of the surgery based on the morphology of 
the ovaries by the surgeon in charge. Secondly, a report was drawn by a 
pathologist (Dr Rupali, Dr Benjamin, The Rockfeller Building, UCLH) after 
histopathological examination of cross sections of the samples. Finally, 
malignancy was tested by fluorescent immunocytochemical staining of the 
established cell lines for the ovarian cancer marker CA125.  
The NOSE brushings collected were immediately transferred to NOSE 
culturing media (NOSE-CM). This is a culture medium that contains insulin, 
epidermal growth factor (EGF), bovine pituitary extract (BPE), hydrocortisone 
(HC) and foetal bovine serum (FBS) (Li et al, 2004). 
Growth of epithelial colonies was observed under the microscope within 
5-12 days following initial seeding. The morphology of the colonies in the initial 
seeding flask was cuboidal, and as soon as they were further passaged 
became more elongated, fibroblast like resembling normal epithelial-
mesenchymal transition (EMT). Studies have previously shown that epithelial 
cells can undergo EMT in vitro coupled with over-expression of FSP and over-
Chapter 3: NOSE & FTE in vitro models 
 
144 
 
expression of several cytokines can contribute to this, one of the most important 
being the EGF (Okada et al, 1997). The optimal culturing medium for extending 
the in vitro lifespan of NOSE cell lines contains EGF which likely contributes to 
the observed EMT. 
A total number of 72 patients were consented and subjected to isolation 
of brushings, with brushings from the left and right ovary collected from 53 
patients, brushings solely from the right from 10 and brushings solely from the 
left from 8 patients. A total of 124 brushings were collected from those 71 
patients. The success rate for NOSE collection with this protocol is as high as 
88% as 6 brushings (from 3 patients) were lost due to bacterial contamination, 
and 9 (from 5 patients) did not grow. Of the 63 remaining patients, 3 of them 
were reported to have ovarian malignancies after histopathological examination 
of the cross sections and were also excluded from this study. 60 NOSE cell 
lines were isolated and established as suitable to use in this study (six of them 
were contributed by Dr Kate Lawrenson that isolated and established them as 
part of her PhD). Patient information as well as the histopathological report for 
each is presented on Appendix 1, Table 1. Previous work in our group in four of 
the NOSE cell lines has established that their life span ranges between 12- 15 
passages. Therefore all the work with the NOSE cell lines has been done whilst 
they would be up to their 8th passage to ensure that their population doubling 
times would remain in a linear scale. 
The 60 suitable for this study NOSE primary cell lines were cultured and 
frozen for subsequent passages. The established primary NOSE cell lines were 
additionally genotyped for 7 SNPs, in order to allow for their positive genetic 
identification in the future. A table summarising the NOSE genotyping 
information is shown in Appendix 1, Table 4. 
The NOSE cell lines were further characterised by immunofluorescence 
cytochemistry for the following markers: 
 
AE1:AE3  :Pancytokeratin.  Keratins are proteins insoluble to water that form 
the filaments composing part of the cellular cytoskeleton in epithelial tissues. 
Nineteen human epithelial keratins have been found and can be acidic (Type I) 
or basic (Type II) (Moll et al., 1982). Acidic and basic keratins are found 
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together in pairs the composition of those pairs depending in the type of the 
epithelial cell, its growth environment and stage of differentiation. AE1:AE3 is a 
pooled pan-cytokeratin antibody with the AE1 part recognising parts of the 
acidic subfamily and the AE3 part recognising members of the basic subfamily 
and is a very good general stain for cells with epithelial origin.  This marker was 
used in order to confirm the epithelial status of the NOSE cell lines. 
CK7  :Cytokeratin 7. Ck7 is a basic (type II) keratin and has been found 
to be expressed in various tissues including the epithelial duct of the 
genitourinary tract. This marker was also used in order to assay for the 
epithelial status of the NOSE cell lines. 
CA125 :Cancer antigen 125. It is a membrane associated mucin found in 
epithelial cells of the female reproductive track. The main biological function of 
this protein is to provide a barrier which prevents the attachment of infectious 
agents and foreign particles on the epithelial cell surface. CA125 levels have 
been found to be elevated in the patients with invasive ovarian cancer (Osman 
et al, 2008). This marker was used in order to confirm that the collected cell 
lines were not malignant. 
FSP  :Fibroblast specific protein. It is a member of the calmodulin S100 
troponin C superfamily.  FSP is a protein expressed in cells of mesenchymal 
origin such as fibroblasts and is found in the cytoplasm of fibroblasts but not 
cells of epithelial origin. However several studies have shown that epithelial 
cells in early development or even later in adults can undergo a morphological 
conversion from cuboidal to more elongated fibroblast –like appearance and 
decreased expression of cytokeratin, a process that is known as EMT. This 
process has been linked to the over-expression of FSP (Okada et al, 1997). 
NOSE cell lines have been shown to undergo EMT in vitro (Lawrenson et al, 
2009). This marker was used in order to confirm that the NOSE cell lines did not 
have fibroblast contamination from the stromal cells in the ovary. However due 
to expected EMT low levels of FSP expression present in the established cell 
lines is acceptable. 
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FVIII  :Factor VIII. It is a blood clotting factor and is a glycoprotein which 
is expressed by endothelial cells. This marker was used to confirm that there 
was no blood cell contamination within the NOSE cell lines due to the nature of 
the surgical procedures prior collection. 
 Each immunofluorescence staining experiment was performed with 
positive and negative controls. Secondary antibody negative controls were 
NOSE cell lines that were incubated with only the FITC (Fluorescein 
isothiocyanate) conjugated secondary antibody without prior incubation with a 
primary antibody. Positive and negative controls for marker expression were cell 
lines that from literature are known to express or not a specific marker. As 
positive control for FVII Human Umbilical Vein Endothelial Cells (HUVEC) were 
used. None of the NOSE cell lines exhibited any endothelial cell contamination 
as none of them stained positive for FVIII. T71, an endometrial cancer cell line, 
was used as a positive control for markers AE1:AE3, CK7 and CA125.  
All 60 primary NOSE cell lines that were established stained positive for 
epithelial markers. The positive expression of epithelial markers was scored as 
low, moderate and strong depending on the % of cells staining positive (Table 
3.1). Based on the large number of the primary cultures established and 
characterised I propose that the expression of marker AE1: AE3 is a stronger 
indicator for NOSE epithelial status than CK7. 51 of the characterised cell lines 
demonstrated strong or moderate expression of AE1:AE3 whereas only 34 cell 
lines demonstrated strong or moderate expression of CK7. None of the cell 
lines stained for the cancer antigen CA125 consistent with the reports of the 
histopathologist for the selected cell lines reporting them as non-malignant. 
Finally, INOF2 which is a normal ovarian fibroblastic cell line was used as 
positive control for the FSP marker (Lawrenson et al, 2010). INOF2 had a very 
strong expression of FSP (Figure 3.2), an indication that the low expression of 
FSP observed in several NOSE cell lines was due to EMT and not due to 
stromal contamination. Only one cell line, NOSE 217 L, exhibited a very strong 
expression of FSP and this cell line was excluded from any further studies. An 
example of the expression of these markers in three NOSE cell lines and the 
control cell lines is shown in Figure 3.2 and a summary for the staining of all 61 
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NOSE cell lines is shown in Table 3.1. The images for the characterisation of all 
60 NOSE cell lines are presented in Appendix 1, Figure 1.  
An additional observation made was that the expression levels of 
epithelial markers differed between the patients. In an attempt to investigate 
how and if pan-cytokeratin expression would modify depending on the age of 
the patient  the mean age of the patients that their OSE brushings stained 
strong, moderate or low for AE1:AE3 was calculated  and is presented in Figure 
3.1. I found that there was a slight trend indicating that expression of 
cytokeratins may decrease as the age of patients increase. However after linear 
regression analysis in R the result was not statistically significant as the 
deviations of each group were significantly overlapping. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Correlation of patient age with expression of AE1:AE3 marker for 
pancytokeratin for isolated NOSE cells.  
 
  
 
P= 0.566 
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Table 3.1: Summary of fluorescent immunocytochemistry results for the established 
NOSE primary cell lines. Table presents the scoring of immunostaining for the selected 
markers AE1:AE3, CK7, CA125, FSP and FVII. The control cell lines used to assay 
positive and negative control staining for the markers are shown at the bottom of the 
table. Highlighted in red are cell lines that exhibited a strong positive staining for FSP 
and were excluded from this study. (n/a= not applicable, where staining was not 
necessary and was not performed.   
NOSE cell line Passage AE1:AE3 CK7 CA125 FSP FVIII
3 7  ++++  ++  -  +/-  -
9 8  ++  +  -  +/-  -
11 5  +++  ++  -  -  -
13 5  ++  +  -  -  -
18 L 7  ++  +++  -  -  -
24 R 5  ++++  +++  -  -  -
175 L 4  +  -  -  -  -
176 R 6  +++  ++  -  +/-  -
179 R 5  +++  +  -  -  -
181 L 5  ++  +  -  -  -
185 R 4  +  ++  -  +  -
189 L 6  +++  ++  -  -  -
191 L 5  +  +  -  -  -
192 L 4  ++  ++  -  -  -
197 L 4  ++++  +++  -  +/-  -
198 L 5  ++  +++  -  +/-  -
200 L 6  +++  +  -  +  -
206 L 6  +++  +++  -  +/-  -
211 L 4  +++  +  -  +/-  -
216 L 4  +++  -  -  -  -
217 L 8  +++  +/-  -  ++++  -
218 L 6  +++  +++  -  -  -
224 L 4  ++++  +++  -  -  -
228 R 3  +++  ++  -  -  -
229 L 5  ++  ++  -  -  -
230 R 5  +++  +  -  +/-  -
231 L 4  +  ++++  -  -  -
232 L 5  +++  +++  -  +/-  -
236 L 7  +++  ++  -  +/-  -
238 L 5  ++  ++  -  -  -
239 L 6  ++  +  -  -  -
241 L 6  ++  +/-  -  +/-  -
243 R 3  +++  +++  -  +/-  -
245 L 4  +++  +++  -  +  -
246 L 5  ++  ++  -  +/-  -
250 L 4  ++  ++  -  +/-  -
252 L 4  ++  +  -  -  -
253 L 4  +++  ++  -  +  -
254 ? 7  +++  ++  -  -  -
255 L 4  ++  +  -  -  -
257 L 4  ++  +  -  -  -
261 L 4  +++  ++  -  -  -
265 L 4  ++  ++  -  +/-  -
266 R 4  +  ++  -  +/-  -
267 R 4  ++  +  -  +/-  -
268 L 5  ++  +  -  -  -
270 L 5  ++  ++  -  +/-  -
273 L 5  ++  +  -  +/-  -
274 L 6  ++  +/-  -  -  -
277 L 4  +  +  -  -  -
278 R 4  +  +  -  +/-  -
279 R 4  +++  +++  -  +/-  -
280 R 4  ++  +++  -  +/-  -
283 L 4  ++  +++  -  -  -
284 L 8  ++++  +++  -  -  -
286 L 6  +  +  -  -  -
NOSEFT02 R 7  +  +  -  +/-  -
NOSEFT05 L 4  +++  +  -  +/-  -
1M R 4  ++  ++  -  -  -
2M R 3  ++  +++  -  +/-  -
Controls Passage AE1:AE3 CK7 CA125 FSP F8
T71 23  ++++  +++  ++ n/a  -
INOF2 5  -  -  -  ++++ n/a
HUVEC 3  -  - n/a  +/-  +++
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Figure 3.2: Examples of fluorescent immunocytochemistry of NOSE cell lines. NOSE 
cell line expression of AE1:AE3, CK7, CA125, FSP, FVII was captured under a 
fluorescent microscope (Images at 200×). The blue stain is DAPI that binds to A-T 
regions of DNA enabling visualisation of the nuclei. The red stain is Evans Blue that is 
staining the cytoplasm. Finally, the green stain is indicating the expression of the 
marker of interest. None of the cell lines was found to express FVIII or CA125 with the 
positive control cell lines HUVEC and T71 respectively showing strong expression. 
Very low expression of FSP is shown for NOSE 241 L.  One example each for strong, 
mild and low AE1:AE3 epithelial staining is shown for NOSE 224 L, NOSE 241 L and 
NOSE 277 L respectively.     
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 Establishing and characterising primary fallopian tube 3.3
epithelial cell lines 
3.3.1 Collection and culturing of primary Fallopian tube epithelial cell 
lines 
Histological and molecular analyses suggest that a proportion of ovarian 
cancers may be originating from FTE cells. Therefore, it is essential to include 
FTE cells in any study that investigates EOC. Thus, I aimed to develop primary 
cultures of FTE cells both in 2D and 3D. 
Patients who were due to undergo surgical procedures such as fibroids 
and polyps resection and total abdominal hysterectomies (TAH) for endometrial 
cancer were consented for participation on the day of the surgery. The fallopian 
tubes were initially inspected in surgery by the surgeon in charge as normal and 
identification of the distal region was made. The fallopian tubes were also later 
inspected by a histopathologist and confirmed as free of malignancy. This 
region of the fallopian tube (FT) was dissected and brushings were taken from 
the lumen of the sub-fimbrial, ampullary region.  
The FTE brushings were successfully grown in NOSE-CM media and 
reached confluency within 10-14 days. In total 8 samples were collected, from 
patients of ages from 38-65. From these patients, 6 primary cell cultures have 
been maintained and successfully sub-cultured (Table 3.2), and out of the 
remaining 2 one senesced very early and one did not grow. In, addition FT 
tissue was collected from 2 patients and embeded into paraffin as control tissue 
with wich to compare 2D and 3D cultures. 
The morphology of the primary FTE cells in vitro was quite 
heterogeneous containing: a) swirly (endometrial –like cells) b) epithelial cells 
(small and cuboidal), c) mesenchymal looking cells (larger and elongated) 
(Figure 3.3). In an attempt to characterise separately the different morphologies 
observed distinct colonies were initially picked from the different 3 morphologies 
of the cells. After one passage though they all looked morphologically the same 
resembling more the mesenchymal morphology initially observed. FTE cells 
possibly undergo EMT very quickly, but still possessing more epithelial 
morphology than NOSE, as FTE cells are smaller, with a regular polygonal 
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morphology and dense cytoplasm.  Of the six cell lines obtained the morphology 
of FT283 and FT284 cell lines resembled more the morphology of the NOSE 
cell lines being more mesenchymal-like and elongated. The morphology of 
FT05 was also distinct from the rest with cuboidal and smaller cells that 
proliferated very aggressively in a similar manner to cancerous cell lines. 
 
Table 3.2: Information regarding the established primary FTE cell lines. Tabulated are 
patient age and diagnosis, menopausal status and histopathological reports for the 
specimens. 
 
 
Using the protocol described for collection and culture of FTE cells, I 
have successfully sub-cultured primary FTE cells for over 13 passages. The 
growth curves for FTE cell lines FT01, FT02, FT03, FT05, FT283 and FT284 
are shown on Figure 3.5. The growth curves were started at passage 3 to 
passage 5 for each cell line and were performed in triplicate. After 11-13 
passages 100% of the cells underwent senescence, as assayed by 
senescence-associated -galactosidase expression (Figure 3.4). The lifespan of 
FTE cells has been <60 days similarly to previous studies reporting the lifespan 
of NOSE cell lines (Lawrenson et al, 2009). The average population doubling 
was calculated for each of the cell lines and ranged from 16 to 21. The mean 
time for a population doubling to occur ranged from 21 to 42 hours (Table 3.3). 
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The FTE cell line FT05 was behaving differently than the other 5 in culture as it 
was sub-cultured for more than 18 passages in contrast with the rest of the cell 
lines that possessed a similar lifespan to the NOSE cell lines of maximum 12 to 
13 passages. 
 
 
Figure 3.3: Different morphologies of primary FTE cultures. A) epithelial-like B) 
mesenchymal like, C) endometrial-like. 
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FT01 PD FT02 PD FT03 PD FT05 PD FT283 PD FT284 PD
0 0.0 0.0 0.0 0.0 0.0 0.0
3 3.1 2.0
4 4.0 3.9 2.0
5 6.1 3.4
7 7.7
8 5.4 6.8
9 11.0 6.8 10.1
10 5.7
11 12.2
12 14.1 7.4 9.6
13 9.4 7.4
14 11.9
15 16.7 16.6
18 19.3 9.8 10.2
19 11.6 19.1 14.5
22 17.8
23 22.4 13.9 22.7 12.5
27 13.2
28 24.4 16.0 21.2 14.3
29 26.0
33 15.2 26.9
34 16.6 24.2 15.3
36 30.1
39 31.8
40 26.3 19.7 15.9
41 26.6
44 22.4
46 32.8
49 29.2
51 23.2
55 32.4
60 35.4
Average PD 15.9 13.6 9.6 10.8 18.0 21.2
Mean PD time (hrs) 27.4 29.2 37.2 38.2 21.6 42.1
St Dev of PD time (hrs) 1.4 0.3 1 2 0.5 0.8
Population Doublings (PD)
Days in culture
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.3: Population doublings of the established primary FTE cell lines. The average 
population doublings time (hours) was calculated based on the median population 
doubling for each cell line. 
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Figure 3.4: Growth curves and -galactosidase staining for senescence of FTE cell 
lines. a) FT01, b) FT02, c) FT03, d) FT05, e) FT283, f) FT284.  The lifespan of the cells 
did not exceed 60 days after which point all the cell lines reached senescence as 
shown by staining for -galactosidase expression (blue colour). 
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Cell line Passage
Total number 
of cells 
analysed
Karyotype Karyotype description
FT01 p4 20 46, XX
Model Karyotype showed a normal female chromosome 
complement and banding pattern.
FT02 p5 17
46, XX, [17]/47, XX, +2 
[2]/46,XX, DER,(11) t (11; 
acro p arm) (p15; p11.2) 
[1]
Model karyotype showed a normal female chromosome 
complement and banding pattern.  However 2 cells were found 
with trisomy 2 and 1 cell seemed to have a structurally 
abnormal chromosome 11 with the satelite region of an 
acrocentric chromosome attached to its short arm at break 
point p15.
FT03 p3 20 46, XX
Karyotype of 20 cells showed a normal female chromosome 
complement and banding pattern
FT05 p3 20
46,XX,t(6;6)(p21;q21) [11]/ 
47,XX, t (6;6) (p21;21), 
+mar [2]/46,XX, t (2;3) 
(p21; q13) [1]
No karyotypically normal cells were found
FT283 p7 10 46, XX
Model Karyotype showed a normal female chromosome 
complement and banding pattern. A single cell with structurally 
abnormal karyotype was seen.
FT284 p4 6 46, XX
A model Karyotype showed a normal female chromosome 
complement and banding pattern.
3.3.2 Karyotyping of established FTE cell lines 
Cells of normal origin, that are not transformed should possess a normal 
karyotype, therefore the karyotype of the 6 established FTE cell lines was 
analysed. Cells of low passage number were sparsely seeded in a 25cm2 flask 
a day before they were collected and chromosomal spreads were prepared. 
The karyotypes were then examined by a qualified clinical cytogenetistist under 
a light microscope (TDL genetics, London). The number of chromosomes as 
well as their length, the position of the centromeres, banding pattern and any 
other physical characteristics was commented on to give a detailed description 
of any abnormalities. Five out of 6 cell lines had a normal model karyotype of 
46, XX with two of them having a small proportion of cells (3/20 and 1/20) 
carrying a structural abnormality, possibly a harvesting artefact as commented 
by the cytogenetisist. One out of the six cell lines was found to have 
karyotypically abnormal cells in 20/20 cells that were analysed. This cell line 
was FT05, and its abnormal karyotype could explain the aggressive proliferative 
phenotype this cell line shows since it is clearly a transformed cell line. The 
karyotypes of the FTE cell lines are shown in Figure 3.17 and a summary of the 
karyotype descriptions is provided in Table 3.4. 
 
 
 
 
 
 
 
 
 
Table 3.4: Karyotype description of the established primary FTE cell lines. Karyotyping 
analysis revealed a normal model karyotype for 5 of the 6 cell lines collected.    
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Figure 3.5: Karyotypes of the established FTE cell lines. The karyotyping revealed a 
normal model karyotype for 5 of the 6 cell lines collected. Cell lines FT01, FT02, FT03, 
FT283 and FT284 have a karyotype of a normal female chromosome complement and 
banding pattern (46, XX). Cell line FT05 however, revealed a female karyotype with a 
complement of 46 chromosomes and an apparently balanced reciprocal translocation 
between one chromosome 6 at breakpoint p21 and its homologue at breakpoint q21 as 
indicated by the arrows in the figure above.   
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3.3.3 Immunofluorescent staining of FTE cell lines  
I chose to characterise the fallopian tube cell lines established by 
staining with a panel of markers to establish their epithelial origin and identify 
which epithelial markers they mostly express and to confirm that they are not 
contaminated with other cell types during collection. 
AE1:AE3  : Pan-cytokeratin.  This marker was used in order to confirm the 
epithelial status of the FTE cell lines. 
CK7  : Cytokeratin-7. This marker was also used in order to confirm the 
epithelial status of the FTE cell lines. 
BerEP4 :  Ep-Cam. Ep-Cam is an epithelial specific antigen. It is a 
glycoprotein located on the cell surface of epithelial cells and has been linked to 
epithelial differentiation (Latza et al, 1990) and found to be expressed in many 
epithelial carcinomas. It is also used a marker for cells of epithelial origin but 
expression in high levels may indicate neoplastic transformation. 
CA125 : Cancer antigen 125.  Although this is a marker that indicates 
malignancy in NOSE cell lines, it is also a lineage marker that is expressed by 
Mullerian epithelium during Mullerian development and its expression is 
retained in FT tissues (Auersperg, 2001). This marker was used to investigate 
whether the FTE cell lines would retain Mullerian lineage specific markers when 
isolated and cultured. 
FSP  : Fibroblast specific protein. This marker was used in order to 
confirm that the FTE cell lines did not have fibroblast contamination from the 
stromal cells underlying the mucosa of the tubes. Having seen morphological 
signs of EMT in vitro while sub-culturing the FTE cell lines, low levels of FSP 
expression were expected to be observed. 
Laminin :  Laminins are glycoproteins that are forming the extracellular 
matrix. They are structural support proteins in the microenvironment of epithelial 
tissue holding the cells together. Laminin has been shown to play a role in the 
development of some types of cancer such as colon cancer (Kitayama et al, 
1999) and breast cancer (Beliveau et al, 2010) and even ovarian cancer (Poon 
et al, 2011) 
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Vimentin :  Vimentin is a type II intermediate filament protein. Vimentin is 
part of the cytoskeleton of cells together with actin and tubulin and is strongly 
expressed by mesothelial cells, and in cells that undergo epithelial-to-
mesenchymal transition. Vimentin has been shown to be highly expressed in 
different types of carcinomas such a colon and breast (McInroy and Maatta, 
2007). It has also been shown that Vimentin expression is inversely associated 
with keratin expression in breast cancer (Thomas et al, 1999). The same study 
showed that relative keratin and Vimentin expression can better indicate the 
prognosis and tumour phenotype than investigating the two markers 
independently. 
E-Cadherin :  E-Cadherin is a transmembrane protein with a role in cell 
adhesion and is very important for the architectural organisation of tissues. E-
cadherin is not expressed in ovarian surface epithelium (OSE) but it is 
expressed in the epithelium of the inclusion cysts and it is also expressed in 
epithelial ovarian carcinomas. Screening FTE primary cell cultures for 
expression of this marker will provide an insight for their proposed role as cell of 
origin for EOC. 
FVIII  :  Factor VIII antibody. This marker was used to confirm that there 
was no blood cell contamination in the FTE cell lines.  
Each immunofluorescence staining experiment for characterisation of the 
FTE cell lines was performed with positive and negative controls (Figure 3.6) 
similarly to the NOSE cell line characterisation for markers, AE1: AE3, CK7, 
CA125, FSP and FVIII. T71was also used as a positive control for marker 
BerEP4. INOF2 was also used as positive control for Vimentin and laminin 
expression. FTE cell lines FT01, FT02, FT03, FT05, FT283 and FT284 were 
characterised for the markers described between passages 5-7 and pictures 
were obtained under the 200x of a fluorescent microscope (Figures 3.7, 3.8 and 
3.9). A summary of the staining is shown on Table 3.5. 
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Table 3.5: Summary of i fluorescent immunocytochemistry results for the established 
FTE cell lines. The intensity of the staining is presented with a range from (-) to (++++) 
similarly to Table 3.2 for the NOSE cell line staining. Interestingly, only one of the FTE 
cell lines is expressing the marker CA125 and none of them are expressing E-
Cadherin. Vimentin is also moderately to strongly expressed in all the cell lines which is 
an indication of the EMT they are undergoing noticeable morphologically as the 
passage number increased while culturing them. 
 
All the cell lines were free of cell contaminants such as stromal cells and 
endothelial cells since they stained negative for the markers FSP and FVIII 
respectively. Low FSP expression was observed in FT05 but this could be 
attributed to EMT the cells undergo rather than stromal contamination, 
especially after comparing with the high expression of FSP by the stromal line 
INOF2 shown in Figure 3.6. 
Most of the cell lines had in common the fact that they were negatively 
stained for marker CA125 apart from cell line FT02. None of the FTE cell lines 
were found to express E-Cadherin or BerEP4 which are found expressed in 
EOCs. Previous work in the lab with the NOSE cells has shown that they do not 
express BerEP4 either in similar in vitro cultures (Kate Lawrenson, personal 
communication). Additionally, all of the cells lines were found to stain positive 
for Vimentin and laminin. 
A striking observation regarding cell line FT01 was the absence of 
AE1:AE3 and strong positive expression of CK7. This was in contrast with the 
NOSE cell lines and also primary FTE cell lines FT01, FT02, FT283 and FT284 
in which AE1:AE3 was the epithelial marker found to be expressed in higher 
levels than CK7. FT05 stained negative for both AE1:AE3 and CK7 epithelial 
markers. The abnormal staining results may be related to the chromosomal 
abnormality detected in this cell line. These data may suggest that FT05 has 
undergone some degree of neoplastic transformation. More work would be 
needed to fully characterize the malignant phenotype of this cell line.   
Cell line Passage AE1:AE3 CK7 BerEP40 FSP CA125 Laminin Vimentin E-Cadherin FVIII
FT01 7  -  ++++  -  -  -  +++  ++  -  -
FT02 7  +++  +  -  -  +++  +++  ++++  -  -
FT03 7  ++  +/-  -  -  -  ++++  ++++  -  -
FT05 5  -  -  -  +/-  -  +++  +++  -  -
FT283 7  ++  +  -  -  -  ++  ++  -  -
FT284 5  +++  ++  +/-  -  -  +++   ++++  -  -
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Figure 3.6: Fluorescent immunocytochemistry of positive and negative control cell lines 
for nine markers. Images were captured under a fluorescent microscope (Images at 
200×). The blue stain is DAPI enabling visualisation of the nuclei. The red stain is 
staining the cytoplasm. Finally, the green stain is indicating expression of the marker of 
interest. 
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Figure 3.7: Fluorescent immunocytochemistry of FT01 and FT02 primary cell lines for 
nine markers (Images at 200×). The blue stain is DAPI. The red stain is Evans Blue. 
The green stain is indicating expression of the marker of interest. The positive and 
negative controls for these markers are shown in figure 3.6.   
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Figure 3.8: Fluorescent immunocytochemistry of FT03 and FT05 primary cell line for 
nine markers (Images at 200×). The blue stain is DAPI corresponding to nuclei. The 
red stain is staining the cytoplasm. Finally, the green stain is indicating expression of 
the marker of interest. The positive and negative controls for these markers are shown 
in figure 3.6.   
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Figure 3.9: Fluorescent immunocytochemistry of FT283 and FT284 primary cell lines 
for nine markers (Images at 200×). The blue stain is DAPI corresponding to nuclei. The 
red stain is staining the cytoplasm. Finally, the green stain is indicating expression of 
the marker of interest. The positive and negative controls for these markers are shown 
in figure 3.6. 
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3.3.4 Isolated FTE cultures are rich in secretory cells confirmed by 
lineage marker PAX-8 
In order to establish an in vitro model for studying EOC carcinogenesis 
from FTE cell lines it was important to ensure that they recapitulate the 
histology of the FT tissue and will express lineage specific markers. Fallopian 
tube epithelial mucosa cells in vivo are separated into secretory and ciliated 
cells. When the FTE cells were cultured the cilia were lost either due to culturing 
or possibly revertion of the cells to a secretory type phenotype.  The proposed 
cell of origin for many serous EOC is the secretory cell of FT epithelium 
(FTSEC) (Levanon et al, 2008, Kurman et al, 2011). Previous work performed in 
an ex-vivo FT system has established that an FT secretory cell lineage marker 
is PAX8 (Levanon et al, 2010). PAX8 is a paired box nuclear protein with a role 
as a transcription factor that triggers expression of genes involved in thyroid and 
reproductive tract development. Staining of the FTE cultures with PAX8 aimed 
to elucidate whether they express this lineage specific marker and the 
percentage of the expression would show whether the secretory cells 
predominantly maintained their characteristic in these cultures. In Figure 3.11 it 
is shown that all the FTE cell lines established expressed PAX8 localised as 
expected in the nucleus. The expression of PAX8 by 100% of FTE cells 
indicates that the ciliated FTE cells when cultured may be reverting to a 
secretory phenotype. Each PAX8 immunofluorescence staining experiment for 
characterisation of the FTE cell lines was backed by positive and negative 
controls (Figure 3.10). T71, an endometrial cancer cell line, was used as a 
positive control which demonstrates 100% strong expression of Pax-8. 
  
 
 
 
 
 
 
Figure 3.10: Fluorescent immunocytochemistry of positive and negative control cell 
lines for PAX8 marker. Images were captured under a fluorescent microscope (Images 
at 200×).  
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Figure 3.11: Fluorescent immunocytochemistry of FTE cell lines for lineage marker PAX-8 (Images at 200×).The 
blue stain is DAPI, enabling the visualisation of the nuclei. The red stain stains the cytoplasm. Finally, the green 
stain is indicating expression of PAX8 which is expressed by 90-100% of the cells in culture. (*) Nuclear localisation  
in a punctate pattern is observed as shown at the 1000× magnification image. The positive and negative controls for 
for PAX8 are shown in figure 3.10. 
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3.3.5 Investigating the efficiency of FTE cell lines to grow in an 
anchorage independent manner 
Transformed cell lines have the ability to grow in an anchorage 
independent manner in soft agar. However, non-malignant cells should not have 
the capacity to grow colonies in soft agar. The efficiency of FTE cell lines to 
grow in an anchorage independent manner was assayed by performing soft 
agar assays with different number of initially plated cells (20000, 10000 and 
5000 cells) for 4 weeks. All assays were performed in triplicate and results were 
confirmed in independent experiments. Interestingly and unexpectedly, all the 
FTE cell lines that were subjected to anchorage independent growth assays 
formed colonies even when seeded in low density (5000 cells/well). The colony 
forming efficiency (CFE) was calculated for all the cell lines and is shown on 
Figure 3.12. A detailed table with the colony counts for each replicate is shown 
in Appendix 1, Table 2. The CFE of FT05 which was a chromosomally 
abnormal, possibly transformed, cell line was more aggressive closely 
resembling the efficiency of TOV112D EOC cell line to grow in an anchorage 
independent manner. However, the colonies formed were more similar in size to 
the colonies of the other FTE cell lines. 
The morphologies of the FTE colonies in soft agar were closely 
inspected and did not resemble the morphology observed in the cancer cell line 
TOV112D with the exception of FT05 which was more compact and dense than 
the rest (Figure 3.13). TOV112D colonies formed in soft agar were much larger 
and compact but for the FTE cell lines the colonies formed were much smaller 
and possessed a ring, looking like cells migrating to or from the colony.  
In order to achieve a better visualisation of the structure of the FTE 
colonies formed in soft agar, the colonies were embedded in paraffin, cross 
sectioned and stained with Heamatoxylin and Eosin (H&E) (Figure 3.14). 
Observation of the stained cross sections clarified that the ring observed on the 
outside of the colony was not formed by cells migrating from or towards the 
colony but rather debris from cells as they were under sub- optimal growing 
conditions showing karyorexis and producing cellular debris. The soft agar FTE 
colonies were very small ranging between 20-100μm in size compared to the 
>500μm colonies of EOC cell line TOV112D. Cross sections of various sizes of 
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these colonies revealed that instead of increased proliferating ability and 
efficiency to grow in soft agar in the aggressive way observed in cancer cell 
lines, the FTE colonies resembled more closely cell aggregates. Most colonies 
and particularly slightly bigger colonies such as the ones formed by FT03 were 
seen to produce a hyline type material typically observed in 3D cultures (Figure 
3.14).  
 
 
 
 
 
 
 
 
 
 
Figure 3.12: Anchorage independent growth efficiency for FTE cell lines. The colonies 
were counted after seeding 5000, 10000 and 20000 cells and cultured for four weeks. 
All FTE cell lines apart from FT05, which demonstrated a very high CFE, had a CFE 
between 6-13%. TOVTOV112D EOC cell line was used as a positive control for 
anchorage independent growth. The Table is showing the averaged CFE in soft agars 
for each of the FTE cell lines. The histogram represents the averaged CFE for each of 
the tested cell lines.  
  
Number of cells 
seeded FT01, p8 FT02, p8 FT03, p5 FT05, p5 FT283, p8 FT284, p8 112D 
1000 59
5000 11 7 13 35 8 12
10000 10 7 14 37 6 11
20000 11 6 12 34 4 11
CFE average (%) 11 7 13 36 6 12 59
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Figure 3.13: Colony morphology of FTE cell lines growing in soft agar after seeding 
20000 cells and cultured for four weeks. Visibly is the ring of single cells extending form 
the colonies of the FTE cell lines compared to the TOV112D cell line colonies that 
appear more compact and with a defined perimeter. Closer investigation shown in 
figure 3.14 revealed that the rings are most possibly cell debris rather than single cells 
migrating towards the colonies. 
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Figure 3.14: Representative H&E staining of FTE colonies grown in soft agar. The 
outer ring seems to be formed by debris produced by the cells during karyorexis. 
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 Establishing primary FTE cell lines as three-dimensional 3.4
(3D) spheroid cultures  
Studying cells using two-dimensional (2D) in vitro models can provide 
information about the markers they express and the cell line’s proliferating 
abilities but it is limiting as the cell-cell interactions and cell-extracellular matrix 
contacts that are characterising the in vivo tissue are not represented. Creating 
three-dimensional in vitro models offers insight into the microenvironment of the 
cells more closely resembling the complex tissue architecture. I have 
established FTE 3D cultures on polyHEMA coated tissue culture plates in an 
attempt to create a model that recapitulates FT tissue morphology and function 
in regards with architecture, marker expression and proliferating abilities. FTE 
cells successfully formed spheroids within 24 hours after seeding and were 
incubated for 15 days. During this period the 3D structures increased in size 
and became more compact (Figure 3.15). The spheroids were embedded into 
paraffin blocks and sections were cut and stained with H&E to enable the study 
of the internal architecture and histology of the spheroids (Figure 3.16). 
Cross sections of the 3D spheroids revealed a similar architecture for 3D 
cultures of cell lines FT01, FT02, FT03, FT283, and FT284 (Figure 3.16). The 
spheroids were of varying size and shape. For most of the spheroids a single 
layer of epithelial like flattened cells was present in most, however multiple 
layers of peripheral cells were observed in some of them. These circumferential 
layers of cells in the periphery of the spheroids were mostly consisting of 
spindle shaped cells. The spheroids had a crescentic cap which was more 
prominent in cell lines FT01, FT02, FT283 and FT284. The central portion of the 
spheroids had hyline material with some cellularity which resembles the 
extracellular matrix material present in the in vivo tissue. Some spheroids 
showed more than one hyline cores (foci) surrounded by spindles of rounded 
cells with prominent nucleoli. The hyline produced contained a number of viable 
cells mixed with abundant karyorectic debri (nuclear dust). The viable cells in 
the inner core of the matrix of the structures exhibited cellular pleiomorphism as 
some cells had significantly larger nuclei and abundant cytoplasm and some 
had indistinct cytoplasmic borders. Nuclei pleiomorphism was also obvious with 
most of cells possessing round nuclei with prominent nucleoli. A few cells 
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appeared to have spindle shaped nuclei and were more elongated. Within the 
hyline material there were residual cells that often showed apoptosis and 
degenerative changes such a karyorexis and cytoplasmic vacuolation 
responsible for the nuclear dust mixed with the hyline material. Maybe cells 
produce matrix and then undergo degeneration changes which is why 
karyorexis was observed throughout the structures. Interestingly, the 
appearance of hyaline material was sometimes enveloped in cell cytoplasm. 
This is observed in tumours sometimes. The 3D structures of cell line FT05 had 
a very different architecture than the rest. Nuclei were more proliferative with 
oval or round shapes. Spheroids were multi-layered and more cellular with 
smaller amounts of hyline matrix. Cap structures were not as prominent as in 
the other cell lines. Spheroids were very cellular in central matrix with a lot of 
karyorexis probably corresponding to increased cellularity. Some spheroids had 
small hyline bodies and hyline material seemed to form where cellular growth 
was smaller. 
3D cultures were created for 15, 26 and 40 day incubation periods 
(Figure 3.15) in order to see whether increased apoptosis within the spheroids 
was an attempt of the 3D structure to recapitulate the FT architecture in vivo 
and a lumen would be formed. 3D cultures incubated for longer than 15 days 
displayed an increased proportion of apoptotic cells. The increased rate in 
apoptosis and karyorexis was subtle and may have been related to the limited 
availability of nutrients for the inner core of the spheroids as the structures 
increased in size. 
Overall, comparing the 3D cultures of FTE and NOSE I found that FTE 
spheroids also presented crescentic caps similarly to the NOSE however less 
prominent that the NOSE. The presence of hyline material was found in both 
NOSE and FTE 3D structures but FTE spheroids appeared to have more 
cellularity within the cores (Figure 3.16). Similar to NOSE, the architecture 
observed in FTE 3D structures more closely resembles the in vivo FT 
architecture of cell interaction and interaction of cell with extracellular matrix 
than the 2D FTE cultures.  
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Figure 3.15: Formation of FTE 3D cultures in polyHEMA coated plates in 1-15 day time points. Day 0 and top row images were captured under 
the 50× magnification and bottom row images were captured under the 200× magnification of a light microscope. Visualisation of how the 
spheroids begin to form as early as in 24 hours after seeding by forming loose aggregates to later proliferate to form larger and more compact 
spheroids. 
.  
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Figure 3.16: Representative H&E staining of FTE 3D cultures. 3D cultures of FTE cell lines for 15, 16 and 40 days. H&E stained cross sections 
of FTE 3D cultures show morphological characteristics and comparison with NOSE 3D cultures. FTE spheroids also present crescentic caps 
similarly to the NOSE (red arrows), however less prominent that the NOSE. The presence of hyline material is seen in both NOSE and FTE 3D 
structures (blue circles) but FT spheroids appear to have more cellularity within the cores. (*): NOSE 4 image was contributed by Dr Kate 
Lawrenson. 
Chapter 3: NOSE & FTE in vitro models 
 
174 
 
In vivo
MARKER FT02 FT03 FT283 FT284 FT02 FT03 FT283 FT284 FT03
AE1:AE3 (MCK)  ++  +++  +++  ++++  +/-  +  ++++  ++  ++++
CA125  +  +  +/-  ++  -  +/-  ++  -  +++
PAX8  +  +  ++  +  +/-  +/-  +++  +/-  +++
E-CAD no data no data no data no data  -  +/-  +  -  +
VIMENTIN  +++  ++++  ++++  ++++  ++ 
(*) 
 +++  +++  +++  ++++
LAMININ  ++++  ++++  ++++  ++++  ++++  ++++  ++++  ++++  ++
ER  -  -  ++  +  -  -  +  -  +++
MUC-1  ++  +  +  ++  +/-  -  +++  -  ++++
MIB-1 (%) 70% 70% 70% 50% <5% <5% <5% <5% <5%
p53Do7  +++  +++  ++  +++  +/-  +  +  +/-  +
2D monolayer 3D spheroid 
 Comparison of FT tissue with 3D FTE and 2D FTE 3.5
modelling systems. 
With the architecture of the 3D FTE modelling system more closely 
resembling the in vivo FT architecture and cell interaction, it was important to 
compare the expression of key markers between the FT tissue in vivo, the 3D 
FTE cultures and the 2D FTE cultures. FT tissue was collected from the 
ampullary region of the tube and then embedded into paraffin. 2D cultures 
cultured on glass chamber slides were also fixed in the same process and 
stained for several markers to compare with the sections of 3D cultures stained 
for the same markers. 
Four cell lines were taken forward to be stained for several markers: 
FT02, FT03, FT283, FT284. FT01 was not used to limit the cost of the 
experiments and because it was the only of the FTE cell lines that had stronger 
expression of CK7 than AE1:AE3 in contrast with the rest of the cell lines taken 
forward. FT05 was excluded as it was found to not express any epithelial 
markers, had abnormal karyotype and aggressive proliferation observed both in 
the 2D growth curves as well as the differential architecture of the 3D spheroids 
in exhibited. A summary of the staining for all the selected markers is presented 
in Table 3.6.  
 
 
 
 
 
 
 
 
 
Table 3.6: Summary of immunohistochemical staining comparison between 2D, 3D 
FTE cell lines and FT tissue. Intensity scoring was performed as previously described 
for the NOSE immunofluorescence cytochemistry staining. The best model has been 
the 3D FT283 cell line as it has strong expression of lineage markers that resemble the 
in vivo tissue compared to the 2D culture of this cell line.    
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3.5.1 Proliferation of FT in vivo compared to the 3D and 2D FTE 
modelling systems 
I stained FT tissue and 2D and 3D FTE models with Ki-67 which is an 
antibody that recognises a nuclear protein coded by MIB1 gene that is 
associated with cellular proliferation. It is known that tubal mucosal epithelial 
proliferation is not evident is normal fallopian tubes. Consistent with this, I found 
that epithelial cells of the FT mucosa do not have proliferating ability (Figure 
3.17). One of the main characteristics of FTE 2D cultures was that they 
underwent proliferation rapidly in culture which is not a true resemblance of the 
proliferative abilities of the epithelial cells in the FT in vivo. I found that 3D 
models have significantly reduced expression of Ki-67 which more closely 
resembles the FT activity in vivo.  
3.5.2 Epithelial and lineage markers expressed in FT in vivo compared to 
the 3D and 2D FT modelling systems 
The epithelial mucosa of the FT in vivo expressed the pancytokeratin 
marker AE1:AE3, and its expression remained strong in the 2D FTE cell lines 
established. The expression of this marker within the 3D FT spheroids was 
seemingly lower but was mainly positioned at the outer epithelial layers as seen 
on Figure 3.18, with the exception of cell line FT283 where a more widespread 
expression of the marker was observed in the core of the spheroid too. Thus, 
the outer layer epithelial staining of the 3D cultures resembled more closely the 
architecture of the FT tissue. 
CA125 is developmentally expressed in the Mullerian epithelia including 
the FT epithelial mucosa (Sharl et al, 1989). However, only weak staining for 
CA125 was observed in the 2D and 3D FTE cultures (Figure 3.19).  
PAX8 is a marker that is expressed by the secretory cells of the FT 
mucosa and I compared the expression of PAX8 in the 2D and 3D FTE cultures 
(Figure 3.20). The staining of PAX8 in FT02, FT03, FT283 and FT284 2D 
cultures was located in the nucleus as expected in 100% of the cells (Figure 
3.21). Low levels of PAX-8 staining were also observed in 100% of the cells in 
the 3D cultures of FT02, FT03 and FT284. 3D culture of FT283 demonstrated a 
stronger than the 2D nuclear PAX8 staining in ~80% of the cells (Figure 3.21). 
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E-Cadherin is another Mullerian development key marker expressed in 
the derived epithelia including the FT epithelium. It is not expressed in OSE due 
to their uncommitted phenotype but is expressed in the OSE lining of the 
epithelial inclusion cysts. Immunohistochemical staining for the FT 3D and 2D 
cultures for this marker was performed. Previously, I showed by 
immunofluorescent staining that the 2D FTE cultures did not express this 
marker (Figures 3.7-3.9). E-Cadherin was found very weakly to negatively (+/-) 
expressed in a small amount of scattered cells within the spheroids, with the 
FT283 3D culture exhibiting the stronger staining, but still not resembling the 
strong expression of the tissue in vivo (Figure 3.22). This observation might be 
connected with EMT observed in the morphology of the FT when cultured in 
vitro. Regaining some of the E-Cadherin expression in the 3D cultures 
demonstrated an ability of the FTE cells to resemble a more epithelial 
morphology through MET and could possibly indicate a role in the secondary 
tumour formation from the TIC where MET is important as shown in other 
cancers as well. 
Muc-1 is a glycosylated glycoprotein that is expressed in a variety of 
epithelial cells in vivo including endometrial epithelium and the fallopian tube 
mucosa. It is up-regulated in the secretory phase of the menstrual cycle and 
positive staining for Muc-1 is indicative of the perseverance of the secretory cell 
phenotype and function in culture. Expression of Muc-1 was moderately 
observed in the 2D FTE cultures and increased Muc-1 expression was only 
found in the 3D culture of the FT283 cell line (Figure 3.23). 
3.5.3 Extracellular matrix markers expressed in FT in vivo compared to 
the 3D and 2D FT modelling systems 
Previous work within our group with NOSE 3D cell lines has shown that 
the expression of extracellular matrix proteins was different between 2D and 3D 
cultures as cells cultured in 3D tend to form different cell-cell interactions and 
produce more extracellular matrix proteins (Lawrenson et al, 2009). To test 
whether the same applied between FTE 2D and 3D cultures I investigated 
expression for Vimentin and laminin. In contrast to the NOSE 2D vs 3D model, 
FTE cell lines produce extracellular matrix proteins Vimentin and laminin when 
cultured in 2D and 3D (Figure 3.24 and 3.25) 
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Figure 3.17: Immunohistochemical staining for proliferation of FT in vivo compared to 2D and 3D FTE cultures. Samples were stained with Ki-
67. The in vivo section is showing tubal fimbria where papillary processes are covered by tubal epithelium with a core of fibrovascular tissue 
and vessels. At the tubal epithelium normal architecture is observed with the elongated ciliated cells with the more rounded interspersed 
secretory cells. The tubal epithelium is multi-layered with cellular stratification similarly to the multilayered 3D spheroids of the FTE cultures. 
The arrows show the some of the cells that express Ki-67 in the tubal mucosa and the 3D cultures. It is evidence that the expression of Ki-67 
is abundant in the 2D FTE cultures, especially for cell lines FT02, FT03 and FT283 and significantly reduced in the 3D cultures. 
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Figure 3.18: Immunohistochemical staining for AE1:AE3 epithelial marker compared between FTE cell lines in 2D, 3D and FT tissue. Universal 
staining observed in the cytoplasm of all the 2D cultures and outer layer staining for 3D structured for FT02, FT03 and FT284.  
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Figure 3.19: Immunohistochemical staining for CA125 lineage marker compared between FTE cell lines in 2D, 3D and FT tissue. The red 
arrows show representative areas of positive cytoplasmic staining. Increased expression of CA125 was found for FT283 when cultured in 3D. 
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Figure 3.20: Immunohistochemical staining for PAX8 lineage marker compared between FTE cell lines in 2D, 3D and FT tissue. Striking 
difference between the staining of FT283 3D and the rest. FT283 seems to be a complex structure comprising of a mixture of secretory cells 
strongly expressing PAX8 and presumably ciliated cells that are not expressing PAX-8. The brown cytoplasmic staining is unspecific staining 
due to staining conditions. 
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Figure 3.21: Immunohistochemical staining showing a punctate nuclear PAX8 staining 
in a 2D FTE culture. In the majority of the FT 2D cultures a faint nuclear staining for 
PAX8 was observed in 100% of the cells in culture. 
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Figure 3.22: Immunohistochemical staining for E-Cadherin marker compared between FTE cell lines in 3D and FT tissue. The arrows show 
examples of positive staining. 
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Figure 3.23: Immunohistochemical staining for MUC-1 marker compared between FTE cell lines in 2D, 3D and FT tissue. Increased 
expression of MUC-1 was found for FT283 when cultured in 3D. 
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Figure 3.24: Immunohistochemical staining for Vimentin ECM marker compared between FTE cell lines in 2D, 3D and FT tissue. The red 
arrows show the localisation of Vimentin expression in the basement membranes between the FT mucosa cells in vivo and a similar 
localisation observed in the matrix produced by the FTE cells in the 3D cultures. 
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Figure 3.25: Immunohistochemical staining for laminin marker compared between FTE cell lines in 2D and 3D and FT tissue. Laminin is 
expressed by FTE cells equally in 2D and 3D. 
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 Evidence supporting a dual cell of origin for EOC 3.6
development 
3.6.1 PAX8 evidence supporting a dual origin of EOC 
As previously mentioned it is proposed that EOC may have a dual origin 
from FTE and NOSE cells. To investigate the dual cell origin hypothesis for 
EOC I have investigated the differential expression of PAX8 between NOSE, 
FTE and EOC cell lines and evaluate the expression for this lineage marker. 
Briefly, NOSE and FTE cell lines that have been confirmed to be normal after 
histopathology examination and that have been confirmed to have an epithelial 
status (n=60 and n=5 respectively) were cultured and RNA was extracted from 
cell lines of passage 3 to passage 8. RNA was also extracted from 47 
commercially available EOC cell lines shown in Appendix 1, Table 3. The 
extracted RNA’s quality was confirmed with spectrophotometry and agarose gel 
electrophoresis and subsequently transcribed into cDNA as described in the 
methods section. The differential expression was assayed performing a 
Fluidigm gene expression assay. The study design and the quality control 
analysis will be described in more detail in Chapter 5. 
Linear regression analysis was performed to observe if there was a 
significant difference in the expression of PAX8 between the 3 types of cells. I 
found that PAX8 was over-expressed in EOC cell lines compared to NOSE and 
FT and that there was a trend of increasing PAX8  expression from NOSE to FT 
to EOC cell lines ( P=4.5×10-6, Figure 3.26 A). This result should be taken with 
caution as only one FTE cell line has been in included in the analysis, the rest 
of the samples failed to amplify. It is worth mentioning that this cell line is the 
FT283 which has been shown to have the highest levels of PAX8 in the 
immunohistochemistry staining experiments. 
I have also investigated the expression of PAX8 between Serous 
Ovarian Carcinomas (SOC) and normal FT using mRNA expression data 
publicly available from the TCGA (www.cbioportal.org.uk) and found consistent 
with my observations that PAX8 was significantly over-expressed in SOC 
compared to normal FT (P=0.002, Figure 3.26 B). PAX8 has also been found 
amplified in high grade EOCs (TCGA, 2010).  
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Figure 3.26: Boxplots representing PAX8 differential expression. A) Differential 
expression of PAX8 between EOC, FT and NOSE cell lines. B) Differential expression 
of PAX8 between SOC and Normal FT according to TCGA 
 
To date PAX8 has been shown to be expressed in thyroid follicular cells 
and other cells of the reproductive system. It was intriguing to investigate 
whether this reproductive lineage marker was expressed in NOSE cell lines and 
if so to what extent. I stained cell lines NOSE 231 L, NOSE 228 R and NOSE 
270 L and found that the expression of PAX8 varied in those cell lines with one 
of them expressing strong PAX8 in about 20% of the cell population and the 
other 2 expressing low PAX8 in 10% of the cell population (Figure 3.27). 
I found that 50% of the patients (n=6) exhibited expression of PAX8 in 
the OSE in vivo. My study also confirmed previously reported expression of 
PAX8 in inclusion cysts and identified expression of PAX8 in other ovarian 
structures such as in rete ovarii and mesoneprhic tubules and ducts (Table 3.7, 
Figure 3.28).   
P= 4.5E×10
-6
  
 
A) P = 0.002 B) 
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Figure 3.27: Fluorescent immunocytochemistry of NOSE cell lines for FT and 
reproductive tract lineage marker PAX-8 (Images at 200×). The blue stain is DAPI 
enabling the visualisation of the nuclei. The red stain is staining the cytoplasm. Finally, 
the green stain is indicating expression of PAX8 which is expressed by 10-20% of the 
cells in culture, showing strong expression in only 1 of the 3 cell lines. The positive and 
negative controls for PAX8 are shown in figure 3.10. 
 
Patient 
number 
Age at 
surgery 
OSE 
staining 
Other PAX8 +ve 
structures 
N1 56  - Not present 
N2 65  ++ 
Inclusion cysts        
Rete ovarii 
N3 67  +++ 
Inclusion cysts        
Rete ovarii  
Mesonephric tubules 
N4 75 Not present 
Paraovarian cyst 
Inclusion cyst 
N5 62  ++ Mesonephric duct 
N6 74  - Inclusion cysts 
N7 57  - Not present 
 
Table 3.7: Summary of immunohistochemical staining for PAX8 expression in the OSE 
and cortical inclusion cysts in normal ovaries.   
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Figure 3.28: Immunohistochemical staining showing expression of PAX8 in inclusion 
cysts and ovarian surface epithelium. A) OSE staining negative for PAX8: i) N7 OSE, ii) 
N1 OSE, iii) N6 OSE. B) OSE staining positive for PAX8: i) N2 OSE, ii) N3 OSE, iii) N5 
OSE. C) Ovarian inclusion cysts staining positive for PAX8: i) N2 inclusion cyst, ii) N3 
early inclusion cyst, iii) N6 inclusion cyst. D) Other ovarian structures staining positive 
for PAX8: i) N2 rete ovarii, ii) N3 mesonephric tubules, iii) N4 paraovarian cyst.  
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3.6.2 Assaying differential expression of genes implicated with EOC 
development in NOSE, FTE and EOC cell lines. 
An important aim of this thesis was to create a large repository of NOSE 
cells and assay their differential expression to EOC cell lines in order to identify 
candidate genes involved with EOC development emerging from large 
screening studies. Given the dual origin hypothesis for EOC development a 
small panel of FTE cell lines will be included to form together with the NOSE 
cell lines the normal cell lines that the expression of candidate genes will be 
compared to the expression in EOC cell lines in the following chapters.  
In order to validate the NOSE& FTE versus EOC differential expression 
as an appropriate model to identify or validate genes emerging form large 
screening studies, the expression of genes that have a well-established in EOC 
development was investigated. Six genes were investigated due to their 
prominent role in propagating EOC development using Taqman gene 
expression assays in the Fluidigm 96.96 Dynamic array. The design of this 
assay will be discussed in more detail in chapter 5 of this thesis. The mRNA 
expression data from NOSE & FTE versus EOC cell lines were compared with 
publicly available microarray data from the TCGA. The TCGA database now 
includes publicly available expression data for several of the common human 
cancers. mRNA expression data from 489 serous ovarian carcinomas (SOC)  
and 8 normal fallopian tube (FT) tissues were downloaded from CBIO portal 
(http://www.cbioportal.org). It should be noted that the normal FT samples in 
TCGA are samples coming from whole normal fallopian tubes. Thus, some 
stromal contamination could be present. The analysis was performed in 2 
groups of datasets. The first dataset contained mRNA expression data for all 
genes coming from median values from all three mRNA expression platforms 
used. The second dataset contained merged and scaled mRNA expression 
values of genes represented by all three expression platforms. In the present 
study I will present only the analysis using the first dataset as it was the more 
comprehensive and provided data for the highest number of samples. I have 
assessed any possible differences in the expression of the candidate genes in 
SOC and normal samples from TCGA using the non-parametric Wilcoxon rank 
sum test in R software. 
Chapter 3: NOSE & FTE in vitro models 
 
191 
 
Three genes that are well established oncogenes in EOC development 
are BRAF, KRAS and MYC. Linear regression analysis was performed to assay 
the differential expression in NOSE, FTE and EOC cell lines. I found that BRAF 
and KRAS were over-expressed in EOC cell lines compared to NOSE and FTE 
cell lines and that there was a trend of increasing expression for both genes 
from FT to NOSE to EOC cell lines (P= 4.22×10-5 and P= 0.019 respectively, 
Figure 3.29  A & C). KRAS and BRAF were also found over-expressed in SOC 
compared to normal FT tissue according to TCGA (P= 2.09×10-5 and P= 
2.53×10-4, Figure 3.29 B &D). A small trend of increasing MYC expression was 
also observed. MYC expression was found to increase from NOSE to FT to 
EOC cell lines (P= 0.021). The expression of the gene was not differential 
between SOC and normal FT according to TCGA (Figure 3.29 E & F). 
Three tumour suppressor genes implicated in EOC development have 
also been investigated, BRCA1, BRCA2 and TP53. The results were not as 
expected, interestingly not confirming the loss of function role these genes have 
in EOC development. All three genes were found to be significantly over-
expressed in EOC compared to both NOSE and FTE cell lines (Figure 3.30 A, C 
& E). Consistent with this observation a trend of over-expression for BRCA1 
was found in SOC compared to normal FT according to the TCGA mRNA data, 
although not statistically significant. The same trend of over-expression in SOC 
compared to normal FT was found for BRCA2 and that was statistically 
significant (P= 1.38×10-6, Figure 3.30 D). The observed and unexpected over-
expression of EOC implicated tumour suppressor genes in EOC compared to 
NOSE & FT also observed for some of them in the SOC versus normal FT 
model will be further discussed. 
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Figure 3.29: Differential expression of A) KRAS, C) BRAF and E) MYC between 
NOSE, FTE and EOC cell lines. Increased expression of these genes was observed in 
EOC cell lines, which is in line with the role that they have in EOC development. B) 
KRAS and D) BRAF over-expression was also observed in SOC compared to normal 
FT but no differential expression was found for F) MYC in SOC and normal FT 
according to TCGA mRNA expression data analysed.  
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Figure 3.30: Differential expression of A) BRCA1, C) BRCA2 and E) TP53 between 
NOSE, FTE and EOC cell lines. Increased expression of these genes was observed in 
EOC cell lines. In line with this observation, B) a trend for over-expression of BRCA1 in 
SOC compared to normal FT was observed and D) BRCA2 was significantly over-
expressed in SOC compared to the normal samples according to TCGA.   
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 Discussion 3.7
3.7.1 Establishing a NOSE cell line repository  
Understanding the biology of EOC development is closely interlinked with 
improving the design of experimental approaches used to evaluate and validate 
biomarkers associated with EOC development. Several studies have assayed 
the differential expression of genes between EOC and normal ovaries in order 
to identify genes associated with early stage disease and development. Several 
of those studies have used microarray analysis using RNA from EOC tumour 
samples and bulk normal ovaries. Over the years several genes have been 
reported to be differentially expressed in serous ovarian carcinomas and normal 
ovaries using microarray analyses (Ono et al, 2000, Welsh et al, 2001, Grisaru 
et al 2007). These studies used RNA from EOC tissue and whole normal 
ovaries to compare mRNA levels and then proposed to have identified several 
candidate molecular markers for EOC development. Whole normal ovaries, 
however, have a mixture of epithelial, stromal, endothelial and other types of 
cells. Therefore it is possible that the differential expression found between bulk 
extracted normal ovary and ovarian cancer samples might partially reflect the 
expression differences between the cell populations rather than a real 
implication of the genes in neoplastic development. Therefore, it would be more 
appropriate to compare the mRNA levels in EOC samples with the mRNA levels 
of the proposed precursor cells of epithelial origin NOSE and FTE cells. In 
realisation of the need to evaluate differential expression between EOCs and 
the specialised precursor cells rather than whole ovaries several small scale 
studies have used small numbers of NOSE or IOSE cell line RNA or ovarian 
surface epithelial scrapings instead of normal ovaries to assay differential gene 
expression (Mok et al, 2001, Tonin et al, 2001, Zorn et al, 2003, Huddleston et 
al, 2005). 
Although NOSE cells have been previously isolated, cultured and 
characterised (Auersperg et al, 1999, Lawrenson et al, 2009), the value of this 
study lies with it being the first study that has established a large repository of 
NOSE cell lines in order to be used for assaying the differential expression of 
candidate genes with a potential role in EOC development compared to EOC 
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cell lines. All of the collected cell lines expressed the epithelial markers CK7 
and/or AE1/AE3 and only one was excluded due to a possible stromal 
contamination. Some of the established primary NOSE cell lines showed small 
levels of FSP expression but was much lower than the expression of the marker 
by the control stromal cell lie INOF2 used. Additionally, It is well established that 
OSE cells have an uncommitted phenotype in vivo, expressing both epithelial 
and mesenchymal markers (Auersperg et al, 2001) and that they show this 
phenotypic plasticity in vitro, where they undergo epithelial to mesenchymal 
transition and take up a more fibroblastic like morphology (Salamanca et al, 
2004, Zavadil and Böttinger, 2005, Ahmed et al, 2006).  
Alongside the characterisation of NOSE cell lines for epithelial status I 
made an observation that the expression of pan-cytokeratin was decreased as 
the age of the patients increased but was not statistically significant. However, 
the trend observed could further be investigated in a real time expression 
analysis where expression of specific cytokeratins correlated with age of the 
individuals could be assayed. To my knowledge there are no reports that have 
shown an association between cytokeratin expression and the age of the 
patient in any epithelial cell type. One previous study has investigated in the 
expression of cytokeratins relative to the age of the patients in seminoma cases 
of the human testis and found no association (Cheville et al, 2000).  
 
3.7.2 Establishing primary FTE cell lines in 2D and 3D and comparing to 
FT tissue  
Given the recent proposal for multiple cells of origin for EOC, it was 
hypothesised that it is necessary to study EOC tumorigenesis using both NOSE 
and FTE in vitro models. Thus, I aimed to establish and characterise primary 
FTE cell lines and also create a 3D model of these cultures hypothesising that it 
would better reflect the architecture and biological activity of FTE cells in vivo. 
Successful isolation and sub-culturing of 6 FTE cell lines was achieved. One of 
them was found to have an abnormal karyotype possibly indicating that it may 
be a transformed cell line and that could explain the differences observed in its 
morphology and staining patterns compared to the rest. This cell line was FT05, 
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and its abnormal karyotype could be related to the aggressive proliferative 
phenotype this cell line showed and the absence of epithelial marker 
expression. 
An interesting finding was the observation that FTE cell lines formed 
colonies in soft agar even when seeded in low densities (5000 cells/well). This 
observation was initially surprising as ability for anchorage independent growth 
is mainly attributed to transformed cell lines. One speculation would be that the 
FTE colonies on soft agar were aggregates of cells formed due to their ability to 
migrate. However, previous work has demonstrated that the ability of FTE cells 
in ex vivo cultures for healing in wound assays was due to detainment of their 
proliferative ability rather than migration (Levanon et al, 2010. The colony like 
structures I observed were not very cellular and produced a hyline type material 
typically observed in 3D cultures. This may suggest that in soft agar FTE cells 
form colonies not due to being transformed but more due to an ability to form 
3D structures that recapitulate the microenvironment of the tissue accompanied 
with the production of extracellular matrix. The FTE cells look polarised in some 
of the larger structures, arranged on the outer layer of the colony like 
formations. Further work to investigate the polarity of those cells in those 
structures would be interesting to follow. 
The FTE cell lines expressed epithelial markers CK7 and AE1:AE3 with 
one being more expressed than the other in certain cell lines. It is conceivable 
that the tubal epithelial mucosa is diverse across the tube regarding the 
expression of epithelial markers. The procedure collection was kept as constant 
as possible but depending on the part of the tube that was given by the surgeon 
in surgery the brushing of the mucosa could be closer to the fimbrial end or the 
ampullary region. 
It has been previously shown that ex vivo FTE cultures expressed 
BeREP4 and E-Cadherin (Levanon et al, 2008) which was not the case with the 
in vitro 2D cell cultures I maintained. It is possible that different collection 
methods in ex vivo and in vitro systems can lead to expression and 
maintenance of different markers.  
An interesting observation was the absence of CA125 expression in all 
the cell lines apart from FT02. CA125 would be expected to be expressed in 
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FTE cells given the Mullerian developmental origin of FTE cells. Clinically, the 
only difference between FT02 cell lines and the rest was that it was derived 
from a patient had some evidence of chronic salpingitis although the cell line 
was found to be karyotypically normal and was included in subsequent 
analyses. Previous work has shown that patients with acute chronic salpingitis 
have elevated blood levels for CA125 (Moore et al, 1998) although this may not 
necessarily relate to the FT02 cell line specific levels of CA125. All the FTE cell 
lines were found to stain positive for Vimentin which could be explained as 
these cells have phenotypic plasticity in vitro and their morphology is rapidly 
changing to more epithelial-mesenchymal as they are sub-cultured further, a 
process known as EMT.  
Previous work performed in an ex-vivo FT system has established that 
an FT secretory cell lineage marker is PAX8 (Levanon et al, 2010). I found that 
90-100% of the cells in all the primary FTE cultures I established expressed 
PAX8 indicating that they are rich in FT secretory (FTSEC) cells. This is an 
indication that secretory cells’ lineage characteristics are maintained in these in 
vitro cultures with the ciliated cells reverting to a phenotype of the secretory 
cells or that culturing conditions are not optimal for ciliated cell growth.  
FTE cells were further cultured in 3D in vitro models. Previous work 
within our group has established that the architectural organisation and certain 
molecular features of the OSE in vivo are better represented by NOSE 3D 
cultures compared to the 2D counterparts (Lawrenson et al, 2009). The most 
striking observation was the restoration of the FT in vivo architecture and cell 
interaction with extracellular matrix in the 3D cultures with the production of the 
hyline material. I also found that the FTE 3D cultures are better representing the 
true biological activity of the FT epithelial mucosa in vivo mainly due to the 
universal reduction in the expression of proliferative marker Ki-67 and cell cycle 
regulator p53 in the 3D cultures compared to the 2D cultures. FT epithelial 
mucosa proliferation is not normally found in normal FT tissue in vivo and if 
found it is mild. It has been reported that elevated tubal proliferation does not 
exceed 4% of the 72 normal tubes tested (Yanai-Inbar et al, 2000). Since tubal 
epithelial proliferation in the literature is associated with the presence of 
malignant lesions (Yanai-Inbar et al, 2000) an FTE model that recapitulates the 
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tissues proliferative activity such as the 3D cultures I generated will be more 
appropriate for future studies of EOC carcinogenesis for subtypes originating 
from FTE epithelial cells. Additional work within our group has investigated 
using gene microarrays gene expression differences between the 2D and 3D 
FTE cultures. Interestingly, it was found that the less proliferative phenotype of 
3D FTE cultures was reflected in global gene expression changes that occurred 
when FTE cells were transferred from a 2D to a 3D microenvironment. Genes 
associated with cell cycle regulation, DNA replication and DNA repair were 
found to be down-regulated in the 3D FTE cultures possibly responsible for the 
observed reduction in proliferation observed (Lawrenson et al, submitted and 
under review). 
The expression of PAX8 and CA125 was increased in 3D cultures 
compared to the 2D FTE cultures and better representing their expression 
found in vivo only for cell line FT283 so that was not a universal observation. It 
was surprising that the 3D models seemed to generally express more 
moderately the lineage marker PAX8. Similarly, MUC-1 which is a marker that 
represents the secretory phase of FTE cells was strongly expressed in the 3D 
culture of FT283 cell line compared to the 2D but this not a consistent 
observation for all the cell lines. A possible explanation could be that when the 
cells were cultured in 3D, a proportion can reverse back to the ciliated 
phenotype that was lost in the 2D cultures. Assuming that is true, I propose that 
the FTE 3D models I established would still be an appropriate model to study 
EOC development because even if some serous EOCs are mainly proposed to 
originate from FTSEC, interaction of ciliated and secretory cells together with 
the influence from the tissue microenvironment might be important for 
neoplastic development.  
3D cultures seemed to produce a matrix where laminin and Vimentin are 
major components but the expression of both markers was not increased 
notably compared to the 2D cultures. However, the organisation of the 
extracellular matrix in the 3D cultures resembled more closely the in vivo 
expression and localisation than 2D cultures. Vimentin staining at the 3D 
spheroids was observed only in between cells, indicating the importance for it to 
maintain the structure of these spheroids and recapitulating the in vivo 
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organisation. Finally, the organisation of the epithelial marker AE1:AE3 
expression in the outer layer of the FTE 3D cultures resembled more closely the 
in vivo localisation that the expression in the 2D cultures. 
3.7.3 Investigating EOC using combined in vitro models of NOSE and 
FTE  
This study was based on the hypothesis that EOC has a dual if not 
multiple cell of origin. Previous work has shown that the expression of the 
Mullerian lineage marker CA125 is present in FTE tissue, OSE lining of ovarian 
inclusion cysts and EOC tumours but not in the OSE in vivo (Auersperg et al, 
2001). Thus, I investigated the expression of PAX8, another lineage marker, 
between FTE, NOSE and EOC cell lines using mRNA from the established 
primary NOSE and FTE cell lines and commercially available EOC cell lines. 
Expression of PAX8 was found to be higher in FTE than NOSE and higher in 
EOC than both NOSE and FT, but that was based only in one FTE sample. 
Assuming this would be validated, based on that observation, it is conceivable 
that ectopic relocation of FTE cells to the ovary could be responsible for the 
development of high grade serous EOC. Alternatively, tumours may develop in 
the tube and involve the ovary later on since most EOC are diagnosed at a late 
stage. This is in line with reports that CA125 that is the stronger EOC marker is 
not expressed in NOSE cell lines but is in FTE. Supporting this model, a recent 
study has found that PAX8 is expressed in mucinous EOC tumours created 
from FTE cells that were subjected to ectopic expression of human HRAS 
(Shan et al, 2012).  PAX8 was also reported to be amplified in high grade 
serous ovarian carcinomas according to the TCGA (The Australian Ovarian 
Cancer Study Group/Australian Cancer, Study, 2011). 
Interestingly, I found that PAX8 was expressed in low levels in the NOSE 
cell lines too (10-20%) of the cultured cells. I have also found that PAX8 was 
expressed in OSE, the OSE lining of ovarian inclusion cysts and other ovarian 
structures in vivo. There are previous reports that have indicated that PAX8 
expression is present in the epithelia of the ovarian inclusion cysts but not in the 
OSE (Bowen et al, 2007). My observation is consistent with a more recent study 
reporting focal expression of PAX8 by the OSE (Ozcan et al, 2011). I propose 
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that the role of PAX8 in developmental differentiation of coelomic epithelia to 
endosalpingeal epithelia may by accompanied with a role in EOC development 
either by indicating the ectopic transport of secretory fallopian tube cells to the 
ovary or by being switched on in the OSE and facilitating their differentiation to 
Mullerian morphology as they form the inclusion cysts. The fact that some of the 
ovaries studied did not express PAX8 in the OSE but in the inclusion cysts may 
suggest that the change may be happening at the inclusion after the OSE is 
differentiated. The other structures that were found to express PAX8 do not 
originate from Mullerian or coelomic differentiation but are mesonephric type 
epithelia like observed in samples from the male testis and might be indicating 
another role for PAX8 at the developmental process where the Wolfian duct is 
deactivated for Mullerian development to take place. Collectively these results 
support that both NOSE and FTE cells should be used in models for studying 
EOC development. 
To establish that a NOSE & FTE versus EOC mRNA differential 
expression assay was a good model for studying the potential significance of 
candidate genes in EOC development, I evaluated the expression of a handful 
of genes with a well-established role in EOC development. I have used the 
established NOSE and FTE cell lines in order to compare their expression of 
well-established oncogenes in EOC development with EOC cell lines. I found 
that the oncogenes KRAS, BRAF and MYC were all significantly over-
expressed in EOC cell lines compared to both NOSE and FTE cell lines. A 
slight trend revealed that BRAF and KRAS are slightly more expressed in 
NOSE than FTE cell lines. This is in line with reports that the main precursor 
cell of low/borderline grade serous and mucinous EOC, where KRAS and BRAF 
mutations are mainly found, is the OSE (Cheng et al, 2005, reviewed in Naora, 
2007) 
An interesting observation was made regarding the differential 
expression of well-established tumour suppressor genes between NOSE & FTE 
and EOC cell lines. BRCA1, BRCA2 and TP53 although known to be implicated 
in EOC development as tumour suppressor genes, were found based on the 
NOSE, FTE and EOC expression model to have a gain of function role. This 
observation was supported by a similar trend of BRCA1 and BRCA2 being over-
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expressed in SOC compared to normal FT after analysis of TCGA available 
mRNA data. Emerging evidence may suggest that tumour suppressor genes 
may function as being “oncogene-like” if exploited and activated by the cancer 
cell in order to surpass the stress caused by cytotoxic drugs for instance (Zheng 
et al, 2012). Additionally previous studies have shown that cisplatin resistant 
tumours have found to harbour secondary activating mutations in BRCA1 
(Swisher et al, 2008) and BRCA1 over-expression promoted cisplatin resistance 
in ovarian cancer cells (Chock et al, 2010). Thus, it is conceivable since 
BRCA1, BRCA2 and p53 are all involved in DNA repair and survival pathways 
they could be rewired and used by the cancer cell to repair DNA breaks caused 
by cytotoxic drugs such as platinum drugs or DNA damage from endogenous 
replication. Another recent study has proposed a novel function of BRCA1 
positively regulating the secretion levels of follistatin which is a protein found 
elevated in ovarian carcinoma. Knocking down BRCA1 in an immortalised 
NOSE (IOSE) cell line and SKOV3, a cancer cell line that possesses wild type 
BRCA1, caused a significant decrease in the proliferation and migrating ability 
of the cell lines (Karve et al, 2012). 
Based on the latter indication of tumour suppressor genes acting in a 
tumour supporting role, it may be possible that there is a limitation of using a 
model studying differential expression of candidate genes between NOSE & 
FTE and EOC lines, or even SOC and normal FT. The limitation applies to not 
being able to study early events in oncogenesis which would involve the loss of 
function for tumour suppressor genes that later are re-activated in the cancer 
cells to overcome stress. However, that may be not true for certain tumour 
suppressor genes that maintain their function in early and late stages. Specific 
in vitro transformation models where defined genetic modification will be 
imposed to NOSE and FTE cell lines, preferably in 3D, could better elucidate 
the events of early oncogenesis in EOC. Such studies have been previously 
performed with oncogenes such as overexpressing KRAS and BRAF in 3D 
IOSE cell lines (Lawrenson et al, 2011) and HRAS in 2D FTE cells (Shan et al, 
2012, in print). 
The difference in the expression of the investigated genes observed 
between the EOC and NOSE & FTE compared to SOC versus normal FT could 
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be explained by the differences both in the cancer and normal samples of the 
two models. This also reflects the well-established fact that EOC cannot be 
treated as a single disease since all the histological subtypes are distinct in the 
risk factors and molecular pathways implicated in their development. The EOC 
cell lines used were cell lines representing several types of EOC and the SOC 
in TCGA were high grade serous carcinomas. NOSE and FTE cells are both 
proposed to be the cell of origin for different proportions of serous and other 
subtypes of EOCs but each may contribute to the development of certain 
subtypes to a different extend. Additionally, the normal FT tissue used to 
generate mRNA expression data by TCGA mainly consists of stromal cells. 
Such high proportion of stromal cells in these samples means high proportion of 
genetic material of many fibroblastic and connective tissue cells which is not 
ideal and may bias the result of expression analyses of genes that are naturally 
differentially expressed in epithelial and stromal cells. For those reasons, 
differences in the expression patterns of candidate genes between the different 
models are not surprising if not indeed expected.  
The EOC cell lines are originating from different subtypes of EOC and 
thus in following chapters I will combine the FTE and NOSE cells which to 
compare their expression of candidate genes with the diverse set of EOC cell 
lines. Another limitation of this model is that ideally I would like to investigate the 
expression of candidate genes between certain subtypes of EOC and specific 
cells of origin for each. The number of samples available and the uncertainty of 
histological characterisation of the EOC cell lines does not make this possible.  
Additionally, further work elucidating the exact cell of origin for particular types 
of EOC is needed so that the functional role of candidate genes can be assayed 
in the most appropriate model. 
3.7.4 Conclusion 
To conclude, this is the first study that reports establishing a large scale 
bank of primary NOSE cell lines and sub-culturing of primary FTE cells, rich in 
secretory cells to further create FTE 3D models which better reflect the in vivo 
FTE activity and architecture. I propose that studying the differential expression 
of genes between large numbers of NOSE & FTE and EOC cell lines is an 
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appropriate model for identifying candidate oncogenes involved in EOC 
development. The potential identification of a gain of function gene using this 
model however should be taken with the knowledge that the molecular events 
represented may not be reflecting early events of oncogenesis initiation and 
could very well be a tumour suppressor gene being reactivated in late stages of 
the disease thus found over-expressed in EOC cell lines. In following chapters I 
will present on how this model is used as a first line evaluation of the functional 
role in of candidate genes that are arising from pathway approaches and 
Genome Wide Association Studies (GWAS) in EOC.  
Additionally, I propose that the 3D in vitro models of FTE cells 
established more closely represent the normal architecture and molecular 
features of the FT tissue in vivo. In the future, 3D models of FTE cells can be 
employed in the study for the early events of tumour initiation which is of critical 
importance given the proposal that a proportion of several subtypes of EOC 
arise from the epithelial mucosa of the FT. It is of critical importance to 
understand the molecular events that take place in the fallopian tube mucosa to 
make it more prone to neoplastic transformation. One hypothesis could be that 
the phenotype of FTE cells is influenced by the mitogenic environment of the 
ovarian stroma. Alternatively, the region on transition between FTE cells and 
ovarian mesothelial-type epithelial cells is inherently more prone to neoplastic 
transformation. Both FTE and NOSE 3D models could be used to impose 
defined genetic modifications that are characteristic for different subtypes of 
EOC in order to elucidate the molecular events that take place for EOC initiation 
and development to occur. Finally, the 3D in vitro models of the FTE cells can 
be of great value for studying developmental molecular processes during 
embryogenesis and also benign fallopian tube diseases such as salpingitis and 
pelvic inflammatory disease. Ultimately, it is hoped that such the FTE 3D in vitro 
models can give much needed insight into the biology of fallopian secretory 
epithelial cells and the pathogenesis of diseases associated with them. This 
knowledge will be invaluable in increasing our ability to diagnose and treat 
benign and malignant disease arising in the fallopian tubes.   
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4 Investigating the role of common alleles in 
candidate susceptibility genes associated with 
risk and development of epithelial ovarian 
cancer 
 
 Introduction  4.1
Familial EOC comprises only 10% of all EOC cases and mutations in the 
high risk susceptibility genes BRCA1, BRCA2 and members of the MMR 
pathway account only for 37%, 9% and 5% respectively of all hereditary ovarian 
cancer cases (Aarnio et al, 1999, Ramus et al, 2007, Bonadona et al, 2011). 
The remaining unattributed risk for EOC familial cases could be accounted for 
by other genes of low/moderate penetrance in the population which could also 
contribute to the risks for sporadic ovarian cancer in the population. The 
approach used for identification of low penetrance genes for EOC is genetic 
association studies.  
Genetic association studies are aiming in identifying genetic variants 
(SNPs) that are associated with EOC by comparing the frequencies of the 
genotypes of selected SNPs in unrelated subjects with EOC compared to 
healthy individuals. The most common approaches used are either a candidate 
gene or a pathway approach by genotyping SNPs within genes with a predicted 
function in EOC development even though now they have been superseded by 
the GWAS approach where SNPs are genotyped throughout the human 
genome. Initial candidate gene approaches have not been very successful in 
identifying strong associations with risk in EOC because the candidate genes 
were selected based on their predicted and not known role in ovarian 
carcinogenesis, or because the genotyped SNPs were initially only non-
synonymous SNPs in the hope of identifying the causal genetic variation within 
amino-acid changing polymorphisms.  
Additionally, the power of individual studies has been limited due to small 
number of samples, a problem tackled by the collaboration of several groups 
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into consortium approaches. The putative causal SNP associated with risk in 
the development of EOC may possibly be a non-coding SNP. Association 
studies can identify the putative causal SNP associated with the risk, and that 
SNP might be a non-coding SNP (regulatory SNP). In association studies the 
polymorphisms typed serve as surrogates for the real causal SNP around the 
candidate locus and this is achieved by using tagging SNPs (tSNPs) which 
provide genotype information about all the SNPs that are found in LD with it.  
Chromosomes that are implicated in EOC development can be identified 
by array CGH (aCGH) and LOH studies, and tumour suppressor genes within 
some of the identified loci have been identified (reviewed by Despierre et al, 
2010). BRCA1 and BRCA2 high risk ovarian cancer genes were recorded with 
LOH in ovarian cancer of ~60% and 40% respectively (Sato et al, 1991, Futreal 
et al, 1994) with a larger more recent study reporting higher BRCA1 and 
BRCA2 LOH frequencies of 82% and 69% respectively both in hereditary and 
sporadic ovarian tumours (Brozek et al, 2009). The exact genetic events leading 
to the somatic alterations identified by LOH or CGH studies are complicated to 
translate without further research. Traditional mechanisms leading to LOH (or 
allelic imbalances) are loss of whole chromosomes or chromosomal regions. 
Many are random passenger changes such as translocations and then loss of a 
rearranged chromosome. Selection of clones with these changes could be due 
to mutations or epigenetic changes being the second hit and knocking out an 
important gene. Allelic imbalances can occur where the LOH is linked to 
preferential loss of a specific allele, suggesting that this SNP is functionally 
important in pathogenesis in the sense that is implicated in a mechanism that is 
responsible for loss of the encoded protein in tumours. As the copy number of 
genes of interest is unknown, what is recorded as LOH could be any form of 
allelic imbalance. Previous studies have reported LOH in genes where the 
second hit was not attributed to mutations, and allele specific LOH has been 
previously proposed as an alternative mechanism functionally contributing to 
disease development (Kittinyom et al, 2004). Furthermore, identifying significant 
LOH frequency in a chromosomal locus specifically involves particular genes in 
this locus. Many methods have been used to identify candidate genes such as 
mutational analysis and positional cloning approaches. 
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A popular approach used to identify the functional importance of LOH 
and chromosomal deletions is microcell-mediated chromosome transfer 
(MMCT) and is a reliable strategy to identify candidate genes with functional 
relevance to EOC. Briefly, ovarian cancer cells with the aberrated chromosome 
are fused with microcells generated from a donor normal cell line that contains 
single copies of the human normal chromosomes tagged with a selectable 
marker. MMCT allows for genetic mapping through a process of functional 
complementation of the tumourigenic phenotype where the resulting hybrid cell 
lines containing the wild-type chromosome can be tested for phenotypic 
changes with assays that can suggest a reversal of transformed phenotype 
such as anchorage independent growth assays, growth rates, tumourigenicity in 
nude mice, and expression of specific genes (Schulz et al, 1987, Kruzelock et 
al, 2000, Doherty and Fisher, 2003, Dafou et al, 2009). The genes identified by 
MMCT can be used in pathway approach association studies where SNPs 
within the candidate genes can be investigated. 
Previous CGH analysis within our group has identified several 
chromosomes that were completely or partially deleted in chromosomes 4-6, 
13-15 and 18 (Ramus et al, 2003). These chromosomes were transferred using 
MMCT in two EOC cell lines TOV112D and TOV21G and the donor-recipient 
hybrids were tested for their neoplastic phenotype in vitro. TOV112D+18 and 
TOV21G+18 hybrids exhibited neoplastic suppression in anchorage independent 
growth assays and invasion assays as well as reduced tumourigenicity in 
immunosuppressed mice compared to parental TOV112D and TOV21G, 
suggesting that chromosome 18 may harbour important tumour suppressor 
genes with functional importance in EOC development (Dafou et al, 2009). 
Microarray gene expression analysis was used to identify differentially 
expressed genes between the hybrid and the parental cell lines for 
chromosome 18. More than 500 genes were identified to be up or down-
regulated in the hybrid cell lines and the genes were ranked according to the P-
value (cut-off: 0.05) and the fold-change difference in expression (>1.5 fold). 
The top 190 genes were selected and evaluated for their known predicted 
function, the number of common SNPs and how efficiently they could be tagged 
according to their sizes. Nine genes whose differential expression between 
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hybrid and parental cell lines was consistent between the different hybrid clones 
were selected based on their possible role in the development of EOC and how 
efficiently they could be tagged. 
We hypothesized that SNPs within those genes may have an association 
with ovarian cancer and this was tested within our group. The candidate gene 
selection and SNP tagging was performed in the context of studying genetic 
susceptibility and survival of candidate genes in chromosome 18 and 16 (Quaye 
et al, 2009, Notaridou et al, 2010). Nine genes were selected from the MMCT-
18 study: AIFM2, AKTIP, AXIN2, CASP5, FILIP1L, RBBP8, RGC32, RUVBL1 
and STAG3. These genes met the selection criteria of having a known function, 
exhibiting consistent fold change data between the different hybrid and parental 
cell lines, having between 3 and 20 tSNPs and at least one common variant 
(MAF>0.05) per 2kb of gene. The function of the genes was obtained from 
Genecards (http://genecards.org/) and their predicted role in ovarian cancer and 
other cancers was researched in Oncomine (http://www.oncomine.org/). 
Haploview software was used to sufficiently identify the tSNPs within the 
selected genes with SNP selection criteria MAF≥0.05 and HWE ≥0.01 using 
HapMap Data Release 22. The tSNPs of the selected genes were separated in 
multiplex panels using iPLEX Gold Assay Design software after testing several 
different gene combinations to create the most efficient multiplexes. 
I further chose to test the functional importance of the selected SNPs by 
performing allele specific LOH analysis in ovarian tumour samples. My 
hypothesis was that associated SNPs identified may be implicated in EOC 
development by having a functional role in somatic alterations. 
 
Aims of this chapter: 
1. Evaluate the potential of allele specific LOH (AS LOH) for SNPs in 
candidate genes emerging from the MMCT-18 functional 
complementation study in primary ovarian tumours. 
2. Evaluate overall LOH in candidate genes of the MMCT-18 study and 
determine the effect of LOH in patients’ overall survival.  
3. Evaluate differential expression of some candidate genes between 
NOSE and EOC cell lines  
Chapter 4: Functional analysis of MMCT-18 genes and tSNPs 
 
209 
 
 Allele specific loss of heterozygosity analysis of MMCT-4.2
18 candidate ovarian cancer moderate susceptibility 
alleles  
The function of the selected candidate genes from the MMCT project and 
the number of tSNPs that were genotyped and used for AS LOH analysis is 
shown at Table 4.1. A total of 58 tSNPs of the 9 MMCT-18 candidate genes 
was selected to be genotyped in 2 iPLEX multiplex assays, a 33plex and a 
27plex assay. Additionally to the tSNPs of the candidate genes, one SNP from 
BRCA1 and one from BRCA2 were included in the assays, in order to serve as 
controls for assaying LOH.  
DNA extraction with needle microdissection of 301 ovarian tumour 
samples from formalin fixed paraffin embedded samples of the Malova 
collection of samples was performed as described in the methods section. The 
efficiency of the DNA extraction was checked by PCR amplification of a control 
fragment (BRCA1 exon 17). Germline matching DNA was also available, 
extracted from the blood of the selected 301 patients. 
Analysis for LOH was performed in 301 and 239 tumour DNA samples 
and their matching genomic DNA in a 33plex and a 27plex SNP reaction 
respectively. In an initial run 181 tumour DNA and their matching genomic DNA 
samples were genotyped for the total of 60 tSNPs. In a subsequent run 120 
extra samples were genotyped for the 33plex and only 58 additional samples 
were genotyped for the 27plex. The reason for the difference in the amount of 
samples run for each set of SNP plexes was merely because of the cost and 
the limited availability of reagents at the time. 
The ratio of the allele peak heights between the tumour and the germline 
DNA for heterozygous (informative) individuals was used to determine LOH as 
previously described in the methods section. AS LOH was assayed based on 
the deviation from the expected 1:1 random ratio of loss of one allele compared 
to the other allele. Evidence of AS LOH would be shown by preferential loss of 
one allele compared to the other. The P value was calculated using a two-sided 
Fisher’s test. 
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Quality control criteria were applied to the data. Deviation from Hardy 
Weinberg Equilibrium (HWE) was assessed using the χ2 test which measures 
the deviation from the expected frequencies. SNPs deviating from HWE may 
confound trait-allele association as they are thought to reflect genotyping error. 
Studies that deviated for HWE at P<10-4 were excluded from the analysis. SNPs 
where the call rate of the genomic DNAs was <90% were excluded. Moreover, 
based on 13 duplicates of genomic DNA, SNPs with less than 98% genotype 
concordance between the duplicate samples were excluded from the analysis. 
Additional secondary QC for concordance of recording LOH was performed. 
Genotyping of 95 paraffin samples was repeated for the 33Plex in order to 
confirm that the peak heights ratios were reproducible, thus in order to validate 
the LOH data. Due to limited reagent availability only 13 duplicate samples were 
repeated for the 27plex. If SNPs were recorded as having LOH for a specific 
allele in the initial run and the peak height of the same allele was found to be 
reduced in the validation run with peak height ratios similar to the LOH values 
(L<0.8 or >1.4), they were classed as concordant. If the concordance of LOH 
between the duplicate samples was <85% the assay was excluded from the 
analysis. For duplicate samples that were concordant the log average of the L 
value was used in the analysis. A summary of the LOH concordance analysis 
for the selected SNPs is shown in Appendix 2, Table1. 
Following all the steps of QC, out of the 60 SNPs genotyped 1 was 
excluded from the analysis because it was not polymorphic, 1 assay failed 
(failed PCR), 7 were excluded because they failed on genomic call rate. 5 were 
excluded because of discordances in the genotypes of genomic duplicates and 
9 were excluded because of LOH discordances. A summary of the quality 
control analysis for the selected SNPs is shown in Appendix 1, Table 1. 
Quality control analysis was also performed for the samples. Genomic 
and paraffin samples that failed in >20% of the assays were excluded. 9 and 10 
genomic samples were removed from the 33plex and 27plex respectively at this 
stage. 6 and 1 paraffin samples were also removed from the 33plex and 27plex 
respectively. The remaining number of samples after these first steps of sample 
QC was 286 and 228 tumour DNA samples and their matching genomic DNA 
for the 33plex and a 27plex respectively. Additionally, genomic DNA plates that 
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demonstrated <90% call rate were excluded from the analysis. A different 
number of samples was removed from each SNP at this stage (Table 4.2, 
column “Number of samples after QC”). The final amount of samples analysed 
per SNP reflected the number of samples that remained after all the QC 
analysis as well as samples that failed for individual assays even though they 
had passed the overall pass rate. Additionally, samples that were discordant for 
LOH were removed from the analysis (Table 4.2, column (“Final number of 
samples analysed”). 
One SNP for each of the BRCA1 and BRCA2 genes were included as 
controls for detecting LOH. These SNPs showed that LOH can be detected 
using the iPLEX genotyping assay, and the L value was a non-subjective 
measure of the difference in the allele peak height ratios. LOH for rs799917 in 
BRCA1 was 56% and 28% for rs144848 in BRCA2. This was in consistent with 
the high rates of LOH already published for these genes. However BRCA1 
rs799917 and BRCA2 rs144848 SNPs had low LOH concordance ratios, 75% 
and 67% respectively. One needs to bear in mind that only 4 and 3 duplicates 
that were informative were included for those assays respectively (part of the 
27plex). One discordant result in each assay caused the concordance 
percentage to drop to 75% and 67% for BRCA1 and BRCA2 respectively 
(Appendix 2, Table 1). 
The remaining 37 tSNPs after QC analysis were analysed for allele 
specific LOH. The results of analysis for allele specific LOH for all genotyped 
SNPs are summarised in Table 4.2. I found STAG3 rs1637001 [A/G] SNP 
demonstrating allele specific LOH. Out of 190 tumours that were informative 
(heterozygous) for this SNP, 16 showed evidence of LOH and there was 
preferential loss of allele A in 94% of the cases (P=0.015, Figure 4.1). Analysis 
of 25 informative duplicate samples for this SNP revealed a 99% concordance 
for recording LOH and for all 3 duplicate samples that exhibited LOH 100% 
preferential loss of allele A was confirmed.    
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Array comparative genomic hybridisation (aCGH) analysis of ovarian 
tumours had been performed for the Malova set in the context of another project 
within our group (Dr Christopher Jones). Therefore, I investigated whether the 
preferential loss of allele A for rs1637001 in STAG3 was the result of deletion of 
the common A allele or amplification of the rare G allele using these data. 
aCGH was performed for 12 of the ovarian tumours that showed allelic 
imbalance for rs1637001. Eight of these tumours, corresponding to cases 278, 
1628, 1455, 1078, 262, 439, 3778, 1149 showed copy number gain for STAG3 
and four tumours (cases 629, 1618, 977, 1661) were copy number neutral 
(Figure 4.2); none of the tumours showed deletion of STAG3. These data 
suggested that, for the majority of tumours, there was amplification of the rare G 
allele rather than deletion of the common A allele. For tumours that were copy 
number neutral for STAG3, it is possible that the somatic alterations that were 
revealed by LOH analysis were not detected by aCGH due to subsequent 
amplification of the remaining allele. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.1: Candidate genes selected from the MMCT-18 project. The predicted 
functions for these genes and tSNPs within them genotyped by iPLEX are presented. A 
number of SNPs was excluded from the analysis after quality control analysis.  
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Gene SNP
Number of 
samples 
after QC
Final number 
of samples 
analysed NI Hets
Samples 
with 
LOH LOH %
LOH 
allele 1 
LOH 
allele 2 
Ratio of 
allele loss P value
AIFM2 rs1053495 228 228 199 29 12 41 7 5 1.4 1.000
AIFM2 rs2394656  228 227 168 59 14 24 7 7 1.00 1.000
AIFM2 rs6480440 286 270 187 83 21 25 10 11 1.1 1.000
AIFM2 rs2280201  228 228 185 43 12 28 6 6 1.00 1.000
AIFM2 rs10999147 286 286 242 44 9 20 3 6 2.0 0.637
AIFM2 rs3750772  228 228 194 34 5 15 3 2 1.50 1.000
AIFM2 rs10999152  179 172 118 54 23 43 9 14 1.56 0.554
AKTIP rs9931702 228 224 125 99 48 48 27 21 1.29 0.683
AKTIP rs17801966  179 176 139 37 15 41 10 5 2.00 0.462
AKTIP rs7189819  227 224 139 85 23 27 10 13 1.30 0.768
AKTIP rs3743772 286 259 238 21 10 48 7 3 2.3 0.650
AXIN2 rs11868547  228 225 115 110 58 53 27 31 1.15 0.853
AXIN2 rs7591 286 284 155 129 74 57 30 44 1.5 0.322
AXIN2 rs7210356 286 284 224 60 36 60 20 16 1.3 0.814
AXIN2 rs4791171 221 215 133 82 42 51 22 20 1.1 1.000
AXIN2 rs3923086  228 228 123 105 52 50 26 26 1.00 1.000
CASP5 rs518604 286 281 141 140 29 21 14 15 1.1 1.000
CASP5 rs3181328  228 228 188 40 10 25 3 7 2.33 0.650
CASP5 rs9651713  228 222 185 37 12 32 3 9 3.00 0.400
CASP5 rs3181175 173 172 119 53 13 25 8 5 1.6 0.695
CASP5 rs2282657 228 147 70 77 24 31 13 11 1.2 1.000
FILIP1L rs796977 286 280 164 116 18 16 8 10 1.3 1.000
FILIP1L rs793477  179 177 146 31 7 23 5 2 2.50 0.576
FILIP1L rs9864437 286 285 193 92 24 26 9 15 1.7 0.561
FILIP1L rs6788750  228 223 118 105 23 22 7 16 2.29 0.231
FILIP1L rs12494994 286 266 193 73 24 33 14 10 1.4 0.772
RBBP8 rs7239066  228 228 182 46 13 28 7 6 1.17 1.000
RBBP8 rs11082221  228 228 212 16 6 38 2 4 2.00 1.000
RBBP8 rs9304261 138 137 88 49 20 41 11 9 1.2 1.000
RGC32 rs11618371 286 286 228 58 25 43 17 8 2.1 0.252
RGC32 rs995845 286 273 167 106 36 34 13 23 1.8 0.341
RGC32 rs975590  228 226 145 81 23 28 12 11 1.09 1.000
RUVBL1 rs3732402 286 283 143 140 33 24 14 19 1.4 0.554
RUVBL1 rs4857836 286 286 173 113 21 19 17 4 4.3 0.052
RUVBL1 rs9821568 228 223 166 57 10 18 7 3 2.33 0.650
STAG3 rs11762932 286 283 195 88 13 15 6 7 0.9 0.523
STAG3 rs1637001 286 282 190 92 16 17 15 1 15.0 0.015
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.2: LOH and allele specific LOH in tumours for 37 tSNPs across the MMCT-18 
candidate genes. NI: Non informative (homozygous), Hets: heterozygotes.  
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Figure 4.1: P values against ratio of allele loss of MMCT-18 tSNPs genotyped by 
iPLEX. SNP rs1627001 [A/G] of STAG3 demonstrated 94% preferential loss of the 
common allele A and is highlighted on the graph in red. 
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Figure 4.2: aCGH profiles of 12 of the 16 tumours that exhibited LOH for rs1637001 of 
STAG3. Regions around the zero baseline are highlighted in yellow and indicate no 
change in chromosomal copy number, regions significantly below the baseline are 
highlighted in red and indicate loss. Gain or amplification is indicated by green in 
regions that are found significantly above the baseline. The probability of having gain or 
loss was calculated by a log2 ratio number and the cut-off indicating loss or gain was 
distinct for each aCGH experiment. The figures presented are a magnification of the 
aCGH profiles specifically for chromosome 7 and STAG3 is mapped on each figure. A) 
Tumours that showed neutral copy number, B) tumours that showed copy number gain.     
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 Evaluating LOH frequency across the MMCT-18 4.3
candidate genes  
LOH of all tSNPs within the genes is demonstrated in Figure 4.3 and 
individual LOH per SNP shown in Table 4.2. The role of the candidate genes in 
ovarian cancer was evaluated by assaying for overall LOH within the gene. 
Every patient sample was genotyped for tSNPs within a gene, and if a patient 
demonstrated LOH in at least one of the tSNPs within a gene, it was counted as 
LOH observed for this sample for the candidate gene. The results of the 
analysis for overall LOH across the candidate genes are shown on Table 4.4. 
The highest LOH was observed in AXIN2 which demonstrated 64% LOH, 
AKTIP with 46% LOH and RGC32 with 36% LOH.  
I also looked at LOH across the candidate genes stratified by subtype. 
The number of samples available was small so I grouped the subtypes and 
compared the serous with the ECs, MCs, CCCs and OthCs combined. LOH 
was significantly higher in serous samples compared to the rest subtypes in 
RBBP8 gene with a P<10-4. No significant differences were seen for the LOH in 
other genes between the different subtypes.  
 
 
Table 4.3: LOH % across MMCT-18 candidate genes in ovarian tumours stratified by 
histological subtype. SC: Serous carcinoma, MC: Mucinous Carcinoma, OthC: Other 
Carcinoma, CCC: Clear Cell Carcinoma, EC: Endometrioid Carcinoma. The P value is 
indicating statistical significance of difference of LOH occurrence between different 
histological subtypes and is calculated using Fisher’s exact test. 
 
 
  
All 
samples
AIFM2 
LOH
AKTIP      
LOH
AXIN2     
LOH 
CASP5       
LOH 
FILIP1      
LOH
RBBP8     
LOH 
RGC32    
LOH
RUVBL1    
LOH
STAG3      
LOH 
151 36 38 89 43 36 28 37 27 14
135 19 25 61 27 27 6 26 24 16
1 0.122 0.329 0.224 0.229 0.5781 0.0009 0.4062 1 0.5679
CCC, EC, MC, OthC
P value 
Histology
SC
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Figure 4.3: Histogram demonstrating LOH for all tSNPs within the MMCT-18 candidate 
genes. 
 
 
Gene 
Number of 
SNPs 
genotyped 
Heterozygotes 
Samples 
with 
LOH 
% LOH 
AXIN2 5 235 150 64 
AKTIP 4 137 63 46 
RGC32 3 185 63 34 
CASP5 5 214 70 33 
FILIP1L 5 196 63 32 
RUVBL1 3 167 51 31 
AIFM2 7 202 55 27 
RBBP8 3 148 34 23 
STAG3 2 162 30 19 
BRCA1 1 97 54 56 
BRCA2 1 89 25 28 
 
Table 4.4: Summary of the LOH% identified for the MMCT-18 candidate genes. A 
sample was considered to have LOH within a gene if at least one of the tSNPs was 
exhibiting LOH.   
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 Finally, I decided to examine whether LOH in the candidate genes 
correlated with loss found by aCGH analysis. Based on the genomic positions 
of the candidate genes indicated by Build 36, the middle of each gene was 
mapped on the aCGH profiles of the samples used to investigate LOH in order 
to find whether the corresponding region had loss, copy number neutral or 
gain/amplification. No chromosome segmenting was detected within the 
positions of the genes of interest indicating that mapping the middle of the gene 
was a reliable representation of the copy number status of the region. Only 95 
of the 286 samples in this study had aCGH data available. Therefore only a 
small number of samples with LOH had available aCGH data. The aCGH result 
was compared with the LOH recorded for each candidate gene (Table 4.5). 
 I compared the percentage of samples with LOH with the percentage of 
samples with loss found by aCGH. I found that LOH in genes AKTIP, CASP5 
and RGC32 was consistent with the percentage of tumours that were found to 
have loss in aCGH analysis. LOH in genes AXIN2 and FILIP1L did not correlate 
with copy number variation found by aCGH which revealed copy number neutral 
in the mapped regions for the majority of the samples. This could be the result 
of deletion being masked by a subsequent amplification and therefore not 
detected as loss. Another explanation could be because LOH is caused by 
microdeletions that cannot be detected by aCGH which is reproducible in 
detecting changes in regions >0.5 million basepairs.  
AIFM2, RUVBL1, RBBP8 and STAG3 exhibited higher percentage of 
samples with gain and the number of samples with loss did not correlate with 
the percentage of LOH found for these genes. Comparison of the number of 
samples that exhibited LOH per gene with the aCGH profile revealed similar 
conclusions, with several of the samples with LOH showing not only loss but 
also no changes or gain in the copy number by aCGH (Table 4.6). LOH across 
genes and individual samples could likely be due to amplification of the 
remaining allele rather than deletion of the lost one.    
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Table 4.5: aCGH analysis indicating the % of tumours found to have copy number 
changes for the MMCT-18 candidate genes. Copy number was evaluated after 
mapping in the middle of each candidate gene. Percentage of LOH across candidate 
genes is also shown to compare. Highlighted in green are genes that LOH correlates 
with loss, in blue are genes where LOH does not correlate with loss and the majority of 
the samples have no CN change, and in orange genes where LOH does not correlate 
with loss as the majority of samples are showing gain in the aCGH analysis. 
 
 
 
Table 4.6: Number of tumours exhibiting copy number changes for the MMCT-18 
candidate genes. Tabulated is the number of samples found to have copy number 
neutral, loss or gain evaluated by aCGH analysis mapped at the middle of each 
candidate gene.  
 
  
Gene Position (Build 37)
% of samples 
with loss 
% of samples 
with no 
change 
% of samples 
with gain 
%  LOH 
across gene
AIFM2 chr10:71872030-71892690 2.9 69.1 27.9 27.2
AKTIP chr16:53525192-53537170 29.4 63.2 7.4 46.0
AXIN2 chr17:63524681-63557740 7.4 85.3 7.4 63.8
CASP5 chr11:104864967-104893895 21.2 68.2 10.6 32.7
FILIP1L chr3:99551988-99833349 3.0 89.4 7.6 32.1
RBBP8 chr18:20513295-20606449 6.0 76.1 17.9 23.0
RGC32 chr13:42031542-42045013 29.4 67.6 2.9 34.0
RUVBL1 chr3:127799800-127842671 3.2 65.1 31.7 30.5
STAG3 chr7:99775538-99812010 1.5 42.4 56.1 18.5
Gene
Number of samples 
with LOH 
Number of samples 
with loss
Number of samples 
with no change
Number of samples 
with gain
AIFM2 20 3 15 2
AKTIP 23 9 13 1
AXIN2 57 8 45 4
CASP5 28 3 22 3
FILIP1L 19 0 17 2
RBBP8 13 1 11 1
RGC32 32 5 23 4
RUVBL1 23 1 13 9
STAG3 17 0 5 12
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 The association between LOH status and ovarian cancer 4.4
survival 
I decided to investigate if the candidate genes had any involvement in 
patient survival from ovarian cancer and thus I evaluated survival of the Malova 
cases showing LOH in the primary tumours for the 9 candidate genes.  
The patients from the MALOVA tumour set used for the LOH analysis 
have been recruited in a study over a 10 year period and follow up data were 
taken to assess the number of survivors and those who die over that period of 
time. The start of the survival period was defined at the date blood was taken 
from each patient and the end was either death or end of the 10 year follow up 
period for the study. Survival was measured by the hazard ratio (HR) which is 
the conditional probability of death. Similarly with survival analyses that use 
genetic polymorphisms or gene mutations as variables that can affect survival, 
in the current study LOH and no-LOH were used as the variables that could 
affect survival. If LOH in a particular gene was significantly associated with 
survival then a statistically significant difference of the HR would be observed 
between the patients with LOH and patients with no-LOH in that gene.   
Similar to the analysis of overall LOH across genes, LOH for a case was 
recorded if at least one informative (heterozygous) tSNP in a gene showed 
LOH. The survival analysis was performed in STATA statistical software using 
Cox proportional hazards regression model to measure the effect of LOH of the 
MMCT-18 candidate genes over the time death takes to occur within the 
specified 10 year period (survival). This model determined the estimates of 
hazard ratios (HR) for the LOH versus no-LOH groups. To illustrate the survival 
of the LOH versus the no-LOH groups, over a period of time, Kaplan-Meir 
survival curves were generated. These are graphs of time versus survival 
probability and are a series of horizontal steps of declining magnitude which for 
large enough samples sizes are representative of the true survival function for 
that population. The Kaplan-Meir survival curves would be statistically different 
from one another if the variables had a significantly differential effect on the 
outcome of a patient. If the time of the blood draw is different than the time of 
diagnosis then left truncation should be taken into account. Thus, left truncation 
is accounted when there is a proportion of patients with delayed entry in the 
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study possibly biasing the outcome in the end of the 10 year follow up. All the 
patients in this study entered the study at the time of diagnosis thus left 
truncation did not apply.  
 
4.4.1 Univariate survival analysis 
A summary of the results is shown on Table 4.7. Kaplan-Meier Curves of 
the significant results were also constructed (Figure 4.4). Four genes showed 
association of LOH with patient survival. I found that patients with LOH in the 
genes CASP5 and AIFM2 had significantly worse survival than cases without 
LOH in all subtypes of EOC HR=1.47 (1.04-2.08), P=0.031 and HR=1.59 (1.09-
2.30), P=0.015 respectively. Cox regression analysis by histological subtype, 
serous versus non-serous, did not reveal an association of poor survival in LOH 
patients linked with a distinct subtype. Significantly worse survival was also 
found in cases with LOH compared with the ones with no LOH in the genes 
AXIN2 and RBBP8 when all subtypes were analysed, with HR=2.18 (1.52-3.12), 
P<0.0001 and HR=2.48 (1.60-3.84), P<0.0001 respectively. Analysis for 
survival in serous and non-serous disease revealed that the association was 
driven by LOH association with survival from non-serous disease in AXIN2 and 
serous disease for RBBP8. Interestingly, LOH in BRCA1 was not associated 
with worse survival when all subtypes were analysed, however, after subtype 
specific analysis, LOH in BRCA1 was associated with worse survival in non-SC 
patients [HR=3.40 (1.38-8.48), P=0.008] but had no effect in the survival of in 
SC patients.  
Multiple testing for the univariate analysis was performed using 
Bonferroni’s correction (n=33, PB<0.002: significant cut-off). The association of 
AXIN2 LOH with worse survival in non-SCs remained significant. The 
associations of AXIN2 and RBBP8 LOH with worse survival in all EOC subtypes 
also remained significant after Bonferroni correction. However, it is puzzling why 
they are stronger associations than the ones observed in the distinct subtypes 
since they are driven only by non-serous and serous for the AXIN2 and RBBP8 
respectively.  
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4.4.2 Assessing the effect of clinical factors on the survival of EOC 
patients 
Clinical factors such as age at diagnosis, histological subtype, stage and 
grade of the tumour are known to affect the survival for EOC patients. These 
factors are known as prognostic factors as they can be used to estimate the 
patient’s outcome and chances for survival. The survival analysis initially 
performed is termed as univariate as it did not take into account any effects of 
the clinical prognostic factors on the survival of the patients studied. Therefore, 
any positive associations may have been falsely created and also real 
associations may have been hidden due to the effect of the clinical prognostic 
factors.  
On that note, cox regression analysis was used to estimate the effects of 
these factors on the 286 samples used for the analysis, using the <40 age 
group, serous histology, grade1 and localised/early stage as 
calibrators/references to compare the rest, for each prognostic factor 
respectively. The analysis was performed in STATA. The results of the effect of 
the clinical prognostic factors on EOC survival analysis in the dataset of the 286 
patients are summarised in Table 4.8 and Kaplan-Meier curves of the significant 
results are shown in Figure 4.5. This analysis revealed that the survival of 
patients that were over 60 years old was significantly worse compared with the 
patients under 40 years old (HR=3.66 [1.15 -11.7], P=0.28). Patients within the 
age group between 40 and 60 years old did not show any significant survival 
difference to the calibrator group. Additionally, tumours of advanced/late stage 
(Stage III&IV) had a dramatically statistically significant increased mortality 
when compared with the localised tumours (Stage I &II, HR= 6.76 [4.32-10.59], 
P<0.0001). The histological subtype and grade of the tumour was not 
significantly associated with survival of the 286 patients.  
 
4.4.3 Multivariate survival analysis 
The results of all genes were adjusted for the prognostic factors age at 
diagnosis >60 and advanced stage, which were both significantly associated 
with worse survival. This kind of analysis is termed as multivariate analysis. Cox 
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regression multivariate analysis was performed in STATA to assess the effect of 
LOH of each gene on survival in all subtypes, serous only and non-serous only 
subtypes adjusted for prognostic factors where appropriate. The results of the 
multivariate survival analyses for all the genes are summarized in Table 4.7 
(Multivariate analysis *). Following multivariate analysis only LOH in RBBP8 
remained associated with worse survival in all EOC subtype patients after 
adjusting for age and stage (HR=1.73 (1.11-2.70), P=0.015). However, following 
multiple testing correction the result did not remain significant.  
The sample set used for this study was not a very large one and the 
adjustments for prognostic factors were based on their association to survival 
from EOC in the 286 samples alone. Dr Chris Jones, in the context of drawing a 
survival model for another study within our group, combining only serous cases 
from >400 cases of the Malova and other tumour study cohorts has approached 
the analysis in a different way. In this analysis Cox proportional data were 
generated by extracting the survival probability for a median age and then 
adjusted each patient’s survival outcome for age and stage and residual 
disease. This multivariate analysis adjustment based on large numbers of 
tumours is a more accurate adjustment (Chris Jones, personal communication). 
Additionally to the multivariate analysis described before, I have also used 
these adjusted survival probabilities as an alternative to the previously 
performed multivariate survival analysis of the serous cases for LOH in each of 
the candidate genes. I subsequently compared the HR and P values of the two 
multivariate analysis for the serous tumours and found LOH in none of the 
selected genes LOH was significantly associated with survival outcome (Table 
4.7, Multivariate analysis**). 
Multivariate survival analysis when adjusting with the appropriate 
prognostic factors removed most significant associations found between LOH 
and survival with the univariate analysis, especially after identifying a very 
significant association of EOC stage and worse survival. I decided to look at the 
association of LOH with the different variables: age, stage and grade in an 
attempt to clarify whether LOH was associated with any of them. A Pearson chi-
squared nonparametric test was performed using STATA statistical analysis 
software. I found that LOH in AXIN2, RGC32 and BRCA1 was significantly 
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associated with more advanced EOC stage (P<0.0001, P=0.016 and P=0.011 
respectively) and higher grade (P=0.001, P=0.001 and P=0.01 respectively) 
(Table 4.9). Additionally, LOH in RBBP8 was significantly associated with higher 
stage (P<0.0001), LOH in AKTIP with higher grade (P=0.002) (Table 4.9). 
Therefore, LOH in both AXIN2 and RBBP8 were the most significantly 
associated with increased EOC stage. Interestingly, LOH in AXIN2 and RBBP8 
were extremely significantly associated with survival in all EOC subtypes in the 
univariate analysis before adjusting for stage. The association of LOH with 
stage might be responsible either for driving the positive association in the 
univariate analysis or by masking a positive result in the multivariate analysis. 
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Gene Histology
Informative 
Cases
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
All subtybes 202 1.59 (1.09-2.30) 0.015 1.37 (0.95-1.99) 0.095 N/A N/A
SC 105 1.46 (0.93-2.31) 0.101 1.41 (0.90-2.23) 0.134 2.49 ( 0.90-6.86) 0.079
ECC, MC, CCC, OthC 97 1.46(0.74 -2.86) 0.271 1.29 (0.66-2.53) 0.463 N/A N/A
All subtybes 137 1.21 (0.81-1.8) 0.352 1.15 (0.77-1.72) 0.494 N/A N/A
SC 83 1.15 (0.72-1.85) 0.563 1.17 (0.73-1.87) 0.524 0.45 (0.09-2.34) 0.345
ECC, MC, CCC, OthC 54 1.42 (0.67-3.02) 0.366 1.15 (0.54-2.45) 0.727 N/A N/A
All subtybes 235 2.18 (1.52-3.12) <0.0001 1.28 (0.88-1.88) 0.19 N/A N/A
SC 125 1.57 (0.99-2.48) 0.056 1.32 (0.83-2.10) 0.246 2.02 (0.58-7.02) 0.27
ECC, MC, CCC, OthC 110 2.75 (1.54-4.93) 0.001 1.48 (0.80-2.72) 0.21 N/A N/A
All subtybes 185 1.31 (0.91-1.89) 0.149 0.91 (0.63-1.31) 0.614 N/A N/A
SC 95 1.14 (0.72-1.81) 0.58 1.15 (0.73-1.83) 0.551 0.97 (0.37-2.54) 0.944
ECC, MC, CCC, OthC 90 1.42 (0.79-2.59) 0.239 0.63 (0.34-1.19) 0.157 N/A N/A
All subtybes 214 1.47 (1.04-2.08) 0.031 1.71 (0.82-1.67) 0.378 N/A N/A
SC 116 1.28 (0.04-1.95) 0.251 1.18 (0.78-1.80) 0.43 2.38 (0.94-6.03) 0.068
ECC, MC, CCC, OthC 98 1.52 (0.82-2.81) 0.187 1.43 (0.77-2.65) 0.261 N/A N/A
All subtybes 196 1.27 (0.88-1.82) 0.203 1.16 (0.80-1.67) 0.436 N/A N/A
SC 104 1.16 (0.74-1.84) 0.522 1.01 (0.64-1.60) 0.969 6.3 (0.27-2.20) 0.77
ECC, MC, CCC, OthC 92 1.41 (0.77-2.58) 0.26 1.84 (0.99-3.43) 0.053 N/A N/A
All subtybes 167 0.97 (0.65-1.46) 0.886 1.13 (0.76-1.72) 0.525 N/A N/A
SC 94 0.88 (0.52-1.46) 0.611 0.90 (0.54-1.51) 0.697 1.40 (0.41-4.80) 0.588
ECC, MC, CCC, OthC 73 1.2 (0.62-2.40) 0.561 1.72 (0.87-3.41) 0.122 N/A N/A
All subtybes 148 2.48 (1.60-3.84) <0.0001 1.73 (1.11-2.70) 0.015 N/A N/A
SC 84 2.09 (1.25-3.50) 0.005 1.56 (0.93-2.61) 0.091 1.78 (0.60-5.29) 0.301
ECC, MC, CCC, OthC 64 2.53 (0.97-6.60) 0.059 2.47 (0.93-6.55) 0.07 N/A N/A
All subtybes 162 0.76 (0.46-1.27) 0.294 0.79 (0.48-1.32) 0.386 N/A N/A
SC 85 0.78 (0.40-1.54) 0.477 0.80 (0.41-1.56) 0.507 1.69E-16 1
ECC, MC, CCC, OthC 77 0.79 (0.37-1.71) 0.552 0.81 (0.37-1.76) 0.593 N/A N/A
All subtybes 95 1.60 (0.98-2.60) 0.062 0.87 (0.52-1.44) 0.581 N/A N/A
SC 58 0.65 (0.36-1.19) 0.16 0.62 (0.34-1.15) 0.132 0.94 (0.24-3.77) 0.935
ECC, MC, CCC, OthC 37 3.40 (1.38-8.48) 0.008 0.85 (0.33-2.18) 0.731
All subtybes 87 1.58 (0.77-3.22) 0.21 0.96 (0.45-2.04) 0.919
SC 57 1.34 (0.64-2.79) 0.441 1.32 (0.63-2.77) 0.459 0.48 (0.06-3.76) 0.482
ECC, MC, CCC, OthC 30
BRCA2
No cases showed LOH No cases showed LOH
Multivariate **
CASP5
FILIP1L
RUVBL1
RBBP8
STAG3
BRCA1
Univariate Multivariate *
AIFM2
AKTIP
AXIN2
RGC32
 
 
 
 
 
 
 
          
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.7: Results of univariate and multivariate survival analysis relative to LOH of the 
MMCT-18 candidate genes. P values indicate the statistical significance of difference in 
survival of two groups, one exhibiting LOH across the candidate gene and the other not 
(*adjusted for age and/or stage where appropriate, ** analysis performed with adjusted 
according to median age probability adjusted for age, stage and residual disease). HR: 
Hazard rate is indicating the conditional probability of the death providing the patient 
has survived up to a period.  SC: Serous Carcinomas, MC: Mucinous Carcinomas, EC: 
Endometrioid Carcinomas, CCC: Clear Cell Carcinomas, OthC: Other Carcinomas. 
N/A: No data available as this analysis was performed only in combined serous cases. 
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Figure 4.4: Kaplan Meier plots generated for the genes where LOH was significantly 
associated with survival of patients (Univariate analysis). The y axis shows the survival 
probability and the x axis the analysis time in years. The association of LOH in CASP5 
and AIFM2 with worse survival was found in all subtypes. The association of LOH in 
AXIN2 and BRCA1 with worse survival was linked to non-serous subtypes. The 
association of LOH in RBBP8 with worse survival was driven by serous subtypes.   
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Prognostic Factor Cases HR (95% CI) P value
< 40 8
40-49 48 2.32 (0.7 -7.67) 0.169
50-59 85 2.70 (0.84 -8.73) 0.097
≥ 60  145 3.66 (1.15 -11.7) 0.028
Serous 151
Mucinous 37 1.15 (0.69-1.91) 0.591
Endometriod 42 0.61 (0.37-1.02) 0.057
Clear Cell 29 0.90 (0.47-1.72) 0.745
Other 27 1.22 (0.75-1.98) 0.414
1 64
2 104 1.07 (0.7-1.63) 0.768
3 118 1.35 (0.9-2.03) 0.146
Localised 103
Advanced 183 6.76 (4.32-10.59) <0.0001
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Callibrator
Callibrator
Callibrator
LOH- Stage LOH- Age LOH- Grade
AIFM2 chi2 2.309 1.049 2.701
P value 0.129 0.789 0.259
AKTIP chi2 1.31 4.87 12.11
P value 0.252 0.182 0.002
AXIN2 chi2 23.198 2.716 13.984
P value <0.0001 0.438 0.001
RGC32 chi2 5.838 2.144 14.174
P value 0.016 0.543 0.001
CASP5 chi2 2.1365 3.938 6.807
P value 0.144 0.14 0.078
FILIP1L chi2 2.956 5.519 3.01
P value 0.086 0.138 0.222
RUVBL1 chi2 1.064 2.251 4.625
P value 0.302 0.522 0.099
RBBP8 chi2 12.844 0.49 8.095
P value <0.0001 0.921 0.017
STAG3 chi2 0.374 3.227 5.169
P value 0.541 0.358 0.075
BRCA1 chi2 6.501 1.604 9.201
P value 0.011 0.659 0.01
BRCA2 chi2 2.132 3.8339 6.151
P value 0.144 0.28 0.046
Gene
 
 
 
 
 
 
 
 
Table 4.8:  Summary of Cox regression survival analysis evaluating the effect of clinical 
prognostic factors on EOC survival. The results are based on survival data from 286 
patients. Grade 1, 2 and 3 indicate well differentiated, moderately differentiated and 
poorly differentiated tumours respectively.  
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.9: Pearson Chi squared non parametric test revealing the association of LOH 
in candidate genes with stage, age and grade for the MMCT-18 candidate genes. 
Stage (1 degree of freedom), age (3 degrees of freedom) and grade (2 degrees of 
freedom).  
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Figure 4.5: Kaplan Meier curves illustrating the effect of age and tumour stage on the 
survival of 286 EOC patients. 
  
Chapter 4: Functional analysis of MMCT-18 genes and tSNPs 
 
229 
 
 Evaluating differential expression of two MMCT-18 4.5
candidate genes between NOSE and EOC cell lines 
I evaluated the differential expression of RBBP8 and STAG3 in a panel 
of 45 NOSE compared to 24 EOC cell lines normalised to two endogenous 
genes, GAPDH and β-actin using Taqman Real Time PCR. I chose to evaluate 
the expression of STAG3 to investigate whether the allele specific LOH 
observed in SNP rs1637001 is functionally important in a regulatory manner 
affecting the expression of the gene. RBBP8 was chosen because LOH across 
the gene was significantly associated with worse survival from EOC even after 
multivariate analysis. The reason for not investigating the differential expression 
for all 9 candidate genes was due to limited reagent availability and cost at the 
time and attention to only the most interest results was decided.  
The mRNA expression data were analysed using the comparative ΔΔt 
method and the expression values of all cell lines were generated relative to 
either the lowest or highest expression of a NOSE cell line for each cell line 
normalized against GAPDH and β-actin. Differences in the relative expression 
of each candidate gene between EOC cell lines and NOSE cell lines were 
assessed using the nonparametric two sided Wilcoxon Rank sum test using R 
software and P values were generated. Statistically significant values were 
considered if P<0.05.  
I have also investigated the expression of all the MMCT-19 candidate 
genes between high grade serous ovarian carcinomas (SOC) and normal 
samples (from whole FT tissue) using mRNA expression data publicly available 
from the TCGA. Additionally, I have investigated whether there is a correlation 
of expression of these genes with copy number variation found in the SOC 
(www.cbioportal.org.uk). 
I found that expression of RBPP8 was significantly higher in the NOSE 
cell lines compared to the EOC cell lines (P=0.044, Figure 4.7 A), which 
indicates a loss of function role for RBBP8 in EOC development consistent with 
the increased expression of RBBP8 in the hybrid cell lines of the MMCT-18 
project. According to TCGA data there was no difference in the expression of 
RBBP8 between SOC and normal samples (Figure 4.7 B) and no significant 
copy number change was associated with the expression of the gene (Figure 
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4.7 C). Comparison of STAG3 expression between EOC and normal cell lines 
showed no differential expression (Figure 4.7 D) whereas TCGA data revealed 
that SOC had significantly reduced expression compared to normal tissue (P= 
7.1×10-6, Figure 4.7 E). An interesting observation is that the over-expression of 
the gene in SOC was characterized by copy number variation compared to 
normal. All the SOC samples had copy number loss, gain or amplification 
leading to STAG3 over-expression indicating different mechanisms that may 
lead to STAG3 under-expression in SOC compared to normal (Figure 4.7 F). 
I have also looked at the differential expression of the remaining 7 
candidate genes between SOC and normal FT samples and found that AIFM2 
was significantly over-expressed in SOC compared to normal (P=0.009, Figure 
4.6 A). The over-expression of AIFM2 in SOC was observed in the SOC that 
exhibit higher copy number that the normal (Figure 4.6 B). None of the other 6 
genes were differentially expressed between SOC and normal according to 
TCGA.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6: Differential expression of AIFM2 MMCT-18 gene between SOC and normal 
FT tissue. A) Differential expression between SOC and normal FT for AIFM2. 
Differential expression relative to copy number variation between SOC and normal FT 
for AIFM2. 
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Figure 4.7: Differential expression of selected MMCT-18 genes between EOC and 
NOSE cell lines and between SOC and normal FT tissue. Differential expression 
between EOC and NOSE cell lines for: A) RBBP8 , D) STAG3. Differential expression 
between SOC and normal FT for: B) RBBP8, E) STAG3. Differential expression relative 
to copy number variation between SOC and normal FT for: C) RBBP8, F) STAG3.    
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 Discussion 4.6
 
Previous studies have demonstrated LOH in the chromosomal location 
18q using microsatellite analysis (Cliby et al, 1993, Chenevix et al, 1992) and 
loss in chromosome 18q using CGH analysis (Arnold et al, 1996). Subsequent 
research has revealed tumour suppressor genes implicated with ovarian cancer 
development located in chromosome 18 and reported loss of their expression, 
including SMAD4, SMAD2 and DCC and Cables (Dong et al, 2003). Previous 
CGH performed within our group has also reported loss of chromosome 18q in 
55% of tumours analysed  (Ramus et al, 2003) and microcell mediated 
chromosome transfer of chromosome 18 (MMCT-18) and subsequent 
microarray analysis had been performed in order to identify potential genes 
implicated in EOC development (Dafou et al, 2009). My project focused on nine 
candidate genes from several chromosomes that showed altered expression in 
the MMCT-18 project and aimed to identify any potential functional role of SNPs 
within these candidate genes in the EOC development and survival from 
ovarian cancer.  
In the present study I evaluated LOH across genes AIFM2, AKTIP, 
AXIN2, CASP5, FILIP1L, RBBP8, RGC32, RUVBL1 and STAG3 in ovarian 
cancer. I have chosen to investigate LOH across the candidate genes using 
tSNPs across the genes to investigate whether genetic variants have a 
functional role in ovarian carcinogenesis by leading to LOH. Such functional role 
would be evidence for an alternative mechanism for selection of cells with 
growth advantage once they have lost one allele, rather than the traditional 
mechanisms such as mutations and epigenetic changes. To date numerous 
common genetic variants have been shown to be associated with the risks of 
several cancer types, but rarely has any functional rationale been established 
for their risk association. Therefore, I investigated whether tSNPs within all nine 
genes were somatically altered in primary ovarian cancers alongside an 
association study performed for the same tSNPs within these genes by Lydia 
Quaye within our group. Furthermore, I was interested to establish if there were 
any associations of LOH across the candidate genes with survival from ovarian 
cancer. I have also correlated the LOH frequencies I found with aCGH data 
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available within our group and I have examined the expression of all MMCT-18 
candidate genes using expression data from TCGA for SOC and normal FT 
tissue or by assaying the differential expression of two selected genes in EOC 
versus NOSE cell lines. As previously discussed the results from these two 
expression models may show different roles for candidate genes in EOC 
development and is explained by differences both in the cancer and normal 
samples of the two models. Similarly that expression results may vary between 
the MMCT-18 microarray analysis results coming from only one of the hybrid 
cell lines used and the expression of a particular gene in EOC cell lines that 
represent several different histologies of ovarian cancer or SOC that are only 
high grade serous adenocarcinomas. Ideally, in the future, the number of EOC 
cell lines used in similar expression assays will be large enough to separate the 
analysis according to the subtypes of EOC the cell lines have originated from. A 
summary of the LOH and expression results and TCGA information for each 
gene is shown in Table 4.10. 
The highest LOH frequency was found for gene AXIN2, and was 64%. 
This observation may suggest a loss of function role for AXIN2 in ovarian 
cancer development. The mechanism for the high observed LOH for AXIN2 did 
not rely on preferential loss of a specific allele of any of the genotyped SNPs (5 
genotyped SNPs in tumour and matching germline DNA, with ratios of allele 
loss ranging between 1-1.5). However, it should be noted that preferential loss 
of an allele of another AXIN2 SNP could be a possibility, because tSNPs do not 
provide LOH information for SNPs in LD with them but only genotype 
information. 
AXIN2 is located in chromosome 17 and codes for a protein that controls 
axin formation during embryonic development. AXIN2 has been shown to be 
implicated in major pathways including the Wnt signalling, stress activated 
protein kinase (SAPK) and transforming growth factor β (TGFβ) pathways 
(Polakis, 2000, Salahshor et al, 2005). AXIN2 negatively regulates the Wnt 
signalling pathway by inducing the formation of a β-catenin destruction complex 
and is also involved in mitosis by influencing chromosome segregation. AXIN2 
aberrations including LOH, mutations and deletions have been identified in 
many forms of cancer including medulloblastoma, breast cancer, hepatocellular 
Chapter 4: Functional analysis of MMCT-18 genes and tSNPs 
 
234 
 
carcinomas and oesophageal squamous cell carcinomas (Salahshor et al, 
2005). The deregulation of β-catenin is a reported feature in ovarian 
endometrioid carcinomas and mutations in AXIN2 have been shown to 
contribute to that, indicating a tumour suppressor role for AXIN2 (Wu et al, 
2001).  In agreement with an AXIN2 tumour suppressor role specifically in ECs 
is the fact that it was up-regulated only in hybrid TOV112D (endometrioid 
carcinoma cell line) of the MMCT-18 project and not in the TOV21G (clear cell 
line) hybrid. Interestingly, the univariate survival analysis I performed showed 
that the LOH found in AXIN2 was strongly associated with worse survival of the 
non-SC tumour group containing ECs (HR=1.59 (1.09-2.30), P=0.001), which is 
a result that remained significant after Bonferroni correction. The fact that the 
association did not remain significant after prognostic factor adjustment is a 
result of the strong association of LOH in AXIN2 with the stage on ovarian 
cancer and should be taken into account that adjustments in that case might be 
masking real association of LOH with survival. If anything, the fact that LOH in 
AXIN2 is such an important indicative marker of EOC stage is an interesting 
finding of this study as loss of chromosome 17 has been previously associated 
with stage in EOC. Previous studies have shown that LOH in chromosome 17 in 
ECs may indicate transition to a more aggressive tumour (Shenson et al, 1995). 
Additionally, another study has reported that high frequencies of chromosome 
17 loss were associated with high grade tumours and when stage was used as 
the outcome variable in multiple logistic regression analysis, chromosome loss 
was significantly associated with worse survival (Pieretti et al, 2002). 
High LOH was also found in gene AKTIP with overall LOH of 46%. 
AKTIP, also known as FT1, is widely distributed in adult tissues and has been 
shown to induce apoptosis regulating the function of Protein Kinase B (PKB)/Akt 
activity (Remy et al, 2004). The high observed LOH was consistent with a 29% 
loss observed by aCGH in 68 of the ovarian tumours used for the LOH analysis 
in cytoband 16q12.2 where AKTIP gene was located suggesting a loss of 
function role for AKTIP in EOC development consistent with the up-regulation of 
the gene in the MMCT-18 hybrids. To my knowledge this is the first report 
showing high frequency if LOH in AKTIP in ovarian cancer and there is no 
further literature suggesting any AKTIP aberrations found in ovarian cancer. 
Chapter 4: Functional analysis of MMCT-18 genes and tSNPs 
 
235 
 
Mutational analysis by Sanger Institute revealed no mutations of this gene in 
breast carcinomas (http://www.sanger.ac.uk/perl/ genetics/CGP/ cosmic) and 
only 0.2% of SOC studied revealed AKTIP somatic mutations according to 
TCGA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.10: Summary of results for the nine MMCT-18 candidate genes. UV: 
Univariate, MV: Multivariate, (*): did not remain significant after Bonferroni correction.  
 
The observed allelic imbalance, recorded as LOH for AIFM2 gene was 
27%. AIFM2 is a gene coding for a mitochondria associated protein implicated 
in caspase-independent apoptosis. Previous work has suggested that AIFM2 
has a promoter that is activated by p53 and has been found down-regulated in a 
majority of human tumours of several tissues including kidneys, colon, cervix 
and ovary (Wu et al, 2004). Interestingly, we found that the region containing 
AIFM2 had a 28% copy number gain contradicting the observed LOH and up-
regulation on the hybrids that indicate a tumour suppressor role for this gene. 
Also contradicting the loss of function role proposed by the LOH and up-
regulation in the hybrids was the over-expression of AIFM2 I found in SOC 
compared to normal FT tissue (P=0.009) after analysis of TCGA mRNA 
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expression data. It is interesting that the increased expression of AIFM2 in SOC 
was attributed mainly to copy number gains found in the SOC samples that 
were over-expressed compared to normal according to TCGA. The different 
roles for the genes proposed by the different models studies can have various 
explanations. The gain detected by CGH in contrast with the loss detected by 
LOH analysis, may indicate that the LOH observed is due to amplification of the 
remaining allele rather than deletion of the lost one. SOC are high grade serous 
ovarian carcinomas and the hybrid cell lines are non-serous cell lines. Thus the 
difference in the expression of the gene in the two models may indicate that 
AIFM2 may have a distinct role in EOC development for serous and another for 
non-serous subtypes. Another plausible explanation for the contradiction may 
be based on previous observations that show that some cancer cells have up-
regulated expression of a mutated protein and dominant-negative protein as is 
the case for p53 for many tumours (Lutzker et al, 1996). It would be interesting 
to perform mutational analysis for AIFM2 in the samples where gain was 
identified by aCGH to test such a hypothesis. However, there are no reported 
mutations in AIFM2 in a panel of 489 SOC analysed by TCGA.  
CASP5, an up-regulated gene in the TOV21G hybrids, was found to 
exhibit 33% LOH. The region of CASP5 also demonstrated a 21% loss by 
aCGH further supporting its tumour suppressor role in ovarian cancer. CASP5 
is a member of the cysteine aspartic acid protease family and acts as an 
apoptosis regulator. I did not identify any AS LOH for the CASP5 tSNPs I 
genotyped. CASP5 has been reported to be occasionally mutated in human 
cancers that demonstrate microsatellite instability including gastric, colon, lung 
(Soung et al, 2008), leukaemia (Takeuchi et al, 2003) and endometrial cancer 
(Schwarz et al, 1999). According to TCGA only 0.6% of the SOC studied were 
found to have a somatic mutation. CASP5 expression is down-regulated in non-
small cell lung cancer and has been proposed to be a tumour suppressor gene 
that when inactivated contributes in lung carcinogenesis and promotes the 
highly metastatic phenotype (Gemma et al, 2001). I found that LOH in CASP5 
was associated with worse survival for ovarian cancer (HR=1.47 (1.04-2.08), 
P=0.031) in the univariate analysis. Even though the association did not remain 
significant after multiple testing correction. The fact that no association was 
Chapter 4: Functional analysis of MMCT-18 genes and tSNPs 
 
237 
 
found in none of the subgroups when the subtypes were stratified in serous and 
non-serous samples indicates that as the sample size of the study increases the 
association becomes apparent. Additionally, the association did not remain after 
adjusting for prognostic factors. The association of CASP5 LOH with survival 
from EOC, if strengthened by larger sample size studies, could be explained 
with CASP5 being implicated in chemotherapy response. CASP5 has recently 
been reported to be implicated with the outcome of combination chemotherapy 
in a study that showed that by using a PI3-Kinase inhibitor in combination with 
Adriamycin, a leukaemia chemotherapeutic drug, the levels of CASP5 
significantly increased leading to a major increase in the chemosensitivity of 
cancer cells (Suvasini et al, 2010). 
FILIP1L with 32% LOH identified, was shown to be up-regulated in the 
hybrids, thus a candidate tumour suppressor gene for ovarian cancer. The 
region corresponding to the gene did not demonstrate significant copy number 
changes by aCGH, similarly to the genes AXIN2 and RBBP8, which although 
they exhibited high frequency of LOH they did not show similar changes by 
aCGH. The reason why frequent LOH in these candidate genes did not 
correlate with the aCGH may be because of the different sensitivities of the two 
methods for detecting allelic loss. More probable is that LOH analysis may have 
detected allelic deletions that were accompanied by the conversion or 
duplication of the remaining allele, resulting in allelic imbalance without a 
change in copy number. 
FILIP1L is coding for filamin A interacting protein and is involved in cell 
proliferation and migration. I have not identified any allele specific loss in any of 
the tSNPs genotyped within this gene, thus other mechanisms may be 
responsible for the observed LOH. Recent research reports decreased 
expression of FILIP1L in ovarian cancer cell lines compared to normal ovarian 
epithelial cell lines. This study provides evidence supporting that the observed 
down-regulation is due to hypermethylation of a promoter which is related to the 
invasive phenotype in ovarian cancer (Burton et al, 2011). The therapeutic 
potential of this gene was pursued by a group that recently proposed a gene 
therapy treatment for ovarian cancer after using polymeric nanoparticles to 
deliver functional FILIP1L in ovarian cancer cell lines in vitro and then to in vivo 
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models and successfully achieving an effective growth inhibition of the tumour 
and reversed neoplastic phenotype (Xie et al, 2011). 
RBBP8 is coding for a retinoblastoma binding protein which regulates 
cell proliferation. RBBP8 has been shown to control double strand break 
resection leading to homologous recombination (Huertas et al, 2009). Its 
expression is regulated post transcriptionally possibly by differential efficiency of 
its RNA translation at different stages of the cell cycle. RBBP8 expression 
varies with the cell cycle progression in a manner identical to BRCA1, peaking 
at the G1/S checkpoint control. RBBP8 interacts with BRCA1, CTBP1 (C-
terminal binding protein 1) and RB1 and it is conceivable that it serves as a 
regulatory link between these three distinct pathways of tumour suppression 
(Yu et al, 2000, Chinnadurai, 2006). The association of RBBP8 with ovarian 
cancer risk is inconclusive. Whereas one recent study has shown association of 
RBBP8 haplotypes and breast cancer risk in a cohort of 2,825 BRCA1 mutation 
carriers (Rebbeck et al, 2011), no such association with ovarian cancer risk in 
BRCA1/2 mutation carriers was reported (Rebbeck et al, 2009). We have found 
associations of tSNPs in RBBP8 with risk in developing EOC in a cohort of 
sporadic ovarian tumours when the analysis was restricted to serous ovarian 
cancer cases in a study of 829 SCs and 2895 controls [HetOR = 0.83 (0.70–
0.98), HomOR = 0.80 (0.63–1.03), p-trend = 0.032] (Notaridou et al, 2011). I 
found 23% overall LOH in RBBP8 in accordance with MMCT-18 hybrid up-
regulation indicating RBBP8 has a tumour suppressor role in ovarian cancer. In 
the univariate survival analysis I found an association of RBBP8 LOH with 
worse survival of serous ovarian cancer patients [HR=2.09 (1.23-3.50), 
P=0.005] although the result did not remain significant after Bonferroni 
correction. The association of RBBP8 LOH with worse survival of all EOC 
subtypes patients was significant after Bonferroni correction (HR=2.48 (1.60-
3.84), P<0.00001). Both recorded associations were not significant after 
Bonferroni in the multivariate analysis after adjusting for clinical factors. Similar 
to AXIN2, it is conceivable that the multivariate negative results for RBBP8 
revealing no such association could be positive results masked by the fact that 
stage and LOH in those genes are so closely associated. In parallel, an 
association study by Lydia Quaye has reported two tSNPs in RBBP8 being 
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associated with ovarian cancer survival (Quaye et al, 2009). Taking into account 
these observations and the biological function of RBBP8 it is intriguing to 
hypothesise that the association of RBBP8’s LOH with worse survival of ovarian 
cancer patients might be a true observation and could be related to absence of 
the gene product conferring resistance to chemotherapy. This hypothesis is 
strengthened by research that has reported significant down-regulation of 
RBBP8 in tamoxifen resistant breast cancer cells and further showed that 
silencing RBBP8 was associated with acquired tamoxifen resistance in breast 
cancer (Wu et al, 2007). I have evaluated the expression of RBBP8 in EOC and 
NOSE cell lines and found that it was under-expressed in EOC cell lines. 
Expression data from the TCGA revealed no difference in the expression of 
RBBP8 between ovarian tumour and normal FT tissue. This indicates that 
RBBP8 under-expression in EOC cell lines may be implicated in 
chemoresistance for particular subtypes of EOC and depending on the cell type 
they originate from. Additionally, lower expression of RBBP8 by stromal cells 
within the FT tissue used for the TCGA expression data may mask a possible 
higher expression in FT epithelial cells. Future work to evaluate the expression 
differences between chemotherapy resistant and sensitive EOC cell lines of 
different subtypes could elucidate RBBP8’s possible role in chemosensitivity for 
ovarian cancer patients.  
RUVBL1 was down-regulated in the hybrids and aCGH showed a 31% 
gain at the region where the gene is mapped. Interestingly, LOH analysis 
showed a frequency of 30% LOH for RUVBL1. However, as LOH could just be 
allelic imbalance the observed LOH might be due to amplification of the 
remaining allele. We have also shown that two SNPs in RUVBL1, rs13063604 
and rs7650365, were associated with increased risk of serous ovarian cancer in 
a parallel association study performed by Lydia Quaye (Notaridou et al, 2011). 
RUVBL1 is involved in chromatin remodelling. It is essential for transcriptional 
regulation of proto-oncogenes and cell proliferation and plays an essential role 
in oncogenic transformation by MYC (Wood et al, 2000). This biological feature 
fits tightly with the observation of RUVBL1 being down-regulated in the hybrids 
indicating a gain of function role in ovarian cancer development. However, the 
precise functions of this protein are not fully understood and it is possible that in 
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different tissues or even different subtypes of tumour cells it might acquire 
distinct functions. For example, recent work has shown that RUVBL1 is 
modulating the foci formation by RAD51 following DNA damage by double-
strand DNA breaks and crosslinks (Gospodiniv et al, 2009). Thus, it is 
conceivable that RUVBL1 may be influencing the response of tumour cells to 
DNA crosslinking drugs such as cisplatin. I am unable to draw a more 
substantial hypothesis on the role of RUVBL1 in EOC using the data from this 
project and information in the literature. More research is needed to elucidate 
the oncogenic molecular pathways RUVBL1 is implicated in to fully understand 
its role in EOC development.  
I also made conflicting observations for the gene RGC32 in cytoband 
13q14.11 for which aCGH data showed 30% loss and LOH analysis showed 
34% LOH, but it was down-regulated in TOV112D hybrids. RGC32 is involved 
in cell cycle regulation and it is induced by p53 in response to DNA damage but 
its role in carcinogenesis is still controversial. RGC32 has been reported to be 
over co-expressed with mitotic marker Ki-67 in colon, breast and prostate 
cancer indicating that is required for growth in tumour cells by deregulating the 
cell cycle (Fosbring et al, 2005). A recent study has reported that RGC32 was 
down-regulated via promoter methylation in non-small lung cancer and the 
methylation status of the tumours was associated with worse survival in patients 
with functional p53 and favourable survival in cases with TP53 mutations (Kim 
et al, 2010). The latter finding suggests that it may be interesting to conduct a 
study in the future that will look into the LOH frequency and expression of 
RGC32 in ovarian tumours and EOC cell lines respectively stratifying them 
according to their TP53 mutational status. RGC32 was not found to be 
differentially expressed between SOC and normal FT according to the mRNA 
data from TCGA or between EOC and NOSE cell lines. 
STAG3, on chromosome 7q22.1, encodes a component of the meiosis 
specific cohesion complex (Pezzi et al, 2000, Prieto et al, 2001). STAG3 is not 
expressed in embryonic stem cells that form follicle like ovarian structures and 
is thought to contribute to the inability of those cells to progress through meiosis 
(Ivana Novak et al, 2006). STAG3 has also been shown to be activated in 
lymphoma cells with TP53 mutations induced by irradiation (Martins Kalejs et al, 
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2006). Other studies have implicated mutations within STAG3 with 
chromosomal instability observed in colorectal cancers (Thomas et al, 2007), 
and the gene is associated with chromosome segregation and down regulation 
in testicular cancer (Skotheim et al, 2005). STAG3 was up-regulated in 
TOV21G hybrids. In agreement to this, I found that there was 19% LOH in 
STAG3 in ovarian tumours. Interestingly, I did not find any differential 
expression of STAG3 between NOSE and EOC cell lines. The latter result did 
not correlate with the up-regulation found in the hybrids or with the expression 
data from TCGA showing higher expression of STAG3 in normal FT tissue 
compared to SOC. Whether this difference was due to expression of stromal 
cells in the FT tissue driving the observed increased expression in normal 
compared to SOC or was a very strong indication that STAG3 may be 
implicated only in the development of high grade serous EOCs originating from 
FT cells remains to be investigated. However, I am inclined to propose the 
latter. A subtype specific role of STAG3 in EOC development was also 
suggested by the increased expression of STAG3 found only for the hybrid cell 
line TOV21G and not in TOV112D, however both of the cell lines are non-
serous cell lines which in turn is puzzling.  
The most interesting finding regarding STAG3 was the identification of a 
tSNP within the gene that was responsible for allele specific LOH. SNP 
rs1637001 in the STAG3 gene showed significant non-random allelic specific 
imbalance by LOH analysis in tumours (94% loss of allele A, P=0.015). 
rs1637001 is a SNP located at the 3’UTR of STAG3 gene. This SNP tags 15 
other SNPs within STAG3 gene, 15 of those being in intronic regions or within 
the 3’ UTR, and one located in exon 24. However as mentioned before, LOH 
information is given only about the specific SNP, and the fact that this tags 
others does not gives any information about their LOH status, but just genotype 
information.  
The recorded allele specific LOH for this SNP was found by aCGH to be 
the likely result of amplification of the minor G allele; amplification rather than 
deletion of an allele has previously been suggested as a potential mechanism to 
explain detected LOH at a SNP (LaFramboise et al, 2005). Supporting this 
hypothesis was the observation of STAG3 down-regulation in SOC compared to 
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normal being characterised by a variety of copy number variations the majority 
of them gains (Figure 4.8 F).  
The same SNP in this gene also showed evidence of association with 
disease risk in serous ovarian cancer cases in the parallel association study 
conducted by Lydia Quaye, although this was not confirmed in the imputed data 
from a very large GWAS later performed by our group and collaborators. The 
potential synergy between a putative risk association for a germline genetic 
variant and the preferential somatic amplification of one of the alleles during 
tumour development is intriguing and further investigation would be worthwhile. 
There are several examples in the published literature of allele specific 
imbalance of polymorphic markers in primary tumours. For example, in one 
study, analysis of the DAL1 gene in breast cancer found that 94% of tumours 
showing LOH retained the C allele of the C2166T SNP; in another study, 73% 
of lung tumours with LOH involving the P34 gene retained the G allele of the 
A106G SNP; a third study reported 83% of breast tumours with loss of the Pro 
allele of Arg72Pro in the P53 gene. (Mao et al, 2006, Kittiniyom et al, 2004, 
Wang et al, 2007, Wegman et al, 2009). However, synergy between genetic risk 
alleles and somatic alterations has not been reported before.  
What is unclear for the rs1637001 variant located in the 3’UTR of 
STAG3, is whether or not the preferential allelic amplification targets rs1637001 
or STAG3 specifically. The amplified region detected by aCGH in tumours 
extended across several genes including STAG3; it is not clear that the 
amplification is functionally relevant to ovarian cancer development though. 
More detailed in vitro cell biology studies would be interesting to set up in the 
future to address this. The biological significance of the preferential allele loss 
could also be further evaluated by performing genotype specific gene 
expression analysis using RNA from NOSE and FTE cell line bank that I have 
established. Another way to assess functionality of alleles would be by 
performing protein-DNA binding studies after transfecting with different 
constructs expressing each allele.  
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Conclusion 
In conclusion, in this study I have investigated and found frequent LOH 
for tSNPs across the candidate genes selected from the MMCT-18 project. I 
have identified functional evidence suggesting allele specific imbalance for 
somatic genetic alterations in primary ovarian tumours, for the common allele of 
a SNP in the STAG3 gene. I also found associations of LOH across AXIN2, 
RBBP8, CASP5 and AIFM2 with survival of EOC patients but remained 
significant only for RBBP8 after adjusting for prognostic factors and none 
remained significant after Bonferroni correction. Finally, this study suggests that 
LOH in the candidate MMCT-18 genes AXIN2, BRCA1, RGC32, RBBP8 and 
AKTIP, is a strong indicative marker of EOC stage and/or grade. 
 
 
♣ Publications containing work from this chapter  
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5 Functional analysis of candidate genes and 
SNPs identified from an ovarian cancer 
Genome Wide Association Study 
 
 Introduction 5.1
Over the last few years, genome wide association studies (GWAS) have 
discovered more than 200 new common low-penetrance susceptibility loci for 
several types of cancer. The variants identified confer low risks for disease and 
thus the functional role of the low-risk loci identified in the development of the 
disease is presumably modest. It is a significant challenge to understand how 
these loci contribute to the development of cancer at the biological level and to 
unravel the links between the identified variants and the molecular basis of risk 
etiology. This area of research is part of post-GWAS characterisation of risk loci 
and focuses on understanding the way in which low-risk variants lead to the 
initiation of cancer pathogenesis and will be beneficial for the more effective 
screening, prevention and treatment of the disease.  
An ovarian cancer GWAS performed previously within our lab and 
collaborators has identified 6 susceptibility regions significantly associated with 
susceptibility to ovarian cancer (P< 10-6) (Song et al, 2009, Goode et al, 2010, 
Bolton et al, 2010). The risk variants identified are mapped to loci to 
chromosome loci 2q31, 3q25, 8q24, 9p22, 17q21 and 19p13 (Table 5.1). Most 
of the identified SNPs are non-coding thus do not affect the sequence of any 
target gene’s translated protein. My hypothesis is that the risk variants at these 
loci may be acting as cis-regulatory variants. Cis-regulatory variants are SNPs 
either within a gene or up to 1Mb proximal to the start or up to 1Mb distal to the 
end of the gene. Trans-regulatory variants are SNPs that are located elsewhere 
in the genome. I hypothesised that the identified SNPs in the GWAS may have 
a functional role in ovarian cancer development by regulating in cis the 
transcriptional output of candidate genes located up to a 1Mb region around the 
most significant SNP or the methylation status of the candidate genes. I 
expanded this hypothesis by investigating whether genes mapping in the risk 
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HOXD1
HOXD3
17q21**
1.4×10
-7
6x10-10
7×10
-11
OR      
(95% CI)
P-value
3.8×10
-14
7.1×10
-8
8×10
-15
4.1×10
-21
4.5×10
-14
3.2×10
-7
3.2×10
-9
5.1×10
-19
1.4×10
-6
2×10
-6
1.2     
(1.14-1.25)
1.24   
(1.15-1.34)
0.76   
(0.70-0.81)
0.77   
(0.73-0.81)
1.14   
(1.09-1.20)
1.2     
(1.13-1.27)
1.16           
(1.12-1.21)
1.19        
(1.11-1.27)
0.84        
(0.80-0.89
0.82        
(0.79-0.86)
1.11         
(1.06-1.16)
1.12        
(1.07-1.17)
MERIT40 
rs2363956
Coding, non 
synonymous
ANKRD41
0.96        
(0.89-0.94)
0.96   
(0.89-0.944×10
-7
rs9303542
Gene intron, 
unknown 
function
SKAP1
19p13***
rs8170
Coding, non 
synonymous
9p22* rs3814113
Intergenic non 
coding , 
unknown 
function
BNC2
TIPARP
8q24** rs10088218
Intergenic non 
coding, 
unknown 
function
MYC
2q31** rs2072590
Within non-
coding gene, 
unknown 
3q25 ** rs2665390
Gene intron, 
unknown 
function
Locus
Stages 1, 2 and 3 combined
Associated SNP
SNP Location 
& Function
Gene(s) in 
closest 
proximity to 
associated SNP
All subtypes Serous cases only
OR       
(95% CI)
P-value
loci could be implicated in EOC development using the NOSE & FTE versus 
EOC model established and described in chapter 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.1: SNPs found in association with epithelial ovarian cancer susceptibility and 
genes in closest proximity. OR (95% CI): per allele odds ratio (95% confidence 
interval). The P values presented for all the samples and serous only samples are from 
the combined 3 stages of the GWAS *(Song et al, 2009), ** (Goode et al, 2010), *** 
(Bolton et al, 2010). 
 
Aims and objectives: 
1. A pilot study to test the hypothesis that candidate genes within the 
associated loci may have a role in EOC will be initially performed. For 
this study, the protein coding gene in the closest proximity to each of 
the identified most significant variants will be selected. A follow up 
study using a larger panel of normal (combined NOSE & FTE) and 
EOC cell lines will then be performed to validate the results obtained 
from the pilot study. This will also be an extended study in the sense 
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that the differential expression of more genes within the risk loci 
(located up to 1Mb of associated SNPs) will be assayed.  
2. The functional role of the significantly associated with EOC 
susceptibility SNPs in the transcriptional regulation of the candidate 
genes will be investigated. Initially, I will evaluate gene expression in 
NOSE cell lines for the candidate genes in the closest proximity with 
the associated SNPs relatively to their genotype. In an extended 
study I will investigate genotype specific gene expression using a 
larger number of normal (NOSE & FTE) cell lines for all the additional 
candidate genes selected within 1Mb distance from the associated 
SNPs. 
3. The potential cis-regulatory function of the EOC associated SNPs will 
also be investigated by evaluating whether there are associations 
between SNP genotype and methylation status of the candidate 
genes. Initially a pilot analysis will be performed using methylation 
and genotype data from the blood of healthy individuals. The 
methylation status of CpG islands of the closest to the associated 
SNPs candidate genes will be compared between the different 
genotype groups. A follow up study will then be performed using a 
larger number of samples to validate any genotype specific 
methylation identified and check whether the methylation status of the 
additional candidate genes selected within 1Mb distance from the 
SNPs is associated with their genotype. 
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 Evaluating differential expression of candidate genes 5.2
between NOSE and EOC cell lines - Pilot study 
The most significant low-risk SNPs identified by the GWAS were in the 
closest proximity with the protein coding genes HOXD1 and HOXD3 for locus 
2q31, TIPARP for locus 3q25, MYC for locus 8q24, BNC2 for locus 9p22, 
SKAP1 for locus 17q31 and MERIT40 (or BABAM1) and ANKRD41 (or 
ANKLE1) for locus 19p13  (Figure 5.1). BABAM1 and ANKLE1 are the more 
recently assigned official names for the last genes but the alias names 
MEIRT40 and ANKRD41 will be used in this thesis. 
The known biological function of some of the candidate genes made the 
investigation for their possible role in EOC attractive. HOXD1 and HOXD3 are 
members of the homeobox D family genes that are transcription factors 
regulating genes involved in morphogenesis, differentiation and development. 
TIPARP (TCDD-inducible poly (ADP-ribose) polymerase) is a member of the 
PARP polymerase superfamily and may play role in adaptive response to 
chemical exposure. MYC is a well-established oncogene that activates the 
transcription of growth related genes. BNC2 (basonuclin 2) is a transcription 
factor that is specific for skin keratinocytes and may play a role in differentiation 
of spermatozoa and oocytes. SKAP1 (src kinase associated phosphoprotein 1) 
is positively regulating T-cell receptor signalling by enhancing the MAP kinase 
pathway. MERIT40 (Mediator of RAP80 interactions and targeting subunit of 40 
kDa) has the most relevant interesting reported function as it is a component of 
the BRCA1 interacting complex involved in homologous recombination at the 
sites of DNA double strand breaks (DSBs). ANKRD41 (ankyrin repeat domain 
41) is not well characterised but may be involved at DNA cleavage during DNA 
damage response (http://www.genecards.org). 
The differential expression of the candidate genes in closest proximity to 
the risk variants was assessed between 48 NOSE and 24 EOC cell lines. The 
cell lines were cultured as described in the methods and RNA was extracted. 
The RNA was then reversed transcribed into cDNA and the cDNA amplified 
using Taqman Real time expression assays in the ABI7900 Taqman Sequence 
detection system.   
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Figure 5.1: Mapping of the low-risk susceptibility SNPs identified by the GWAS at 
chromosomes 2, 3, 8, 9, 17 and 19. The genes in closest proximity to those SNPs 
within loci 2q31, 3q25, 8q24, 9p22, 17q21 and 19p13 selected to be investigated are 
illustrated.    
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5.2.1 Quality control and candidate gene expression analysis 
To confirm the linear relationship of expression versus RNA quantity for 
each target probe and endogenous control probe a standard curve was created 
for each assay using serial dilutions of a mix of the cDNAs in the study 5x more 
concentrated than the samples to be run. Data were determined to be reliable if 
an excellent fit (correlation coefficient R2 between 0.95 and 1) of the standard 
curve data to a straight line was observed or at least being able to create a 
suboptimal line (R2>0.8). The standard curves for each of the probes for the 
candidate genes and the 2 endogenous genes are shown at Figure 5.2. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2: Standard curves of the candidate gene and endogenous control probes- 
Pilot study 
To test the reliability of the assay, I initially looked at the relative 
expression of GAPDH normalised to β-actin to exclude the possibility of the 
results being biased by the relative expression of the endogenous controls. The 
expression of the endogenous controls was not different between NOSE and 
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EOC cell lines as shown at Figure 5.3. The assays were performed in two sets 
and alongside each set the endogenous controls were also run. 
The Taqman Real time expression data were analysed using the 
comparative ΔΔCt method and the expression values of all cell lines were 
generated relative to either the lowest or highest expression of a NOSE cell line 
normalized against GAPDH and β-actin. For samples where the standard 
deviation was >0.6 between the replicates, the replicate causing the deviation 
was removed. Differences in the relative expression of each candidate gene 
between EOC cell lines and NOSE cell lines were assessed using the 
nonparametric two sided Wilcoxon Rank sum test using R software and P 
values were generated. Values were considered statistically significant if 
P<0.05.  
 
 
 
 
 
 
 
 
 
Figure 5.3: GAPDH expression in NOSE versus EOC cell lines normalised to β-actin. 
Used as endogenous controls for the assays for a) BNC2, MERIT40, TIPARP, MYC 
genes b) HOXD1, SKAP1, ANKRD41 genes 
 
5.2.2 Results of Real time PCR expression analysis of candidate genes 
The expression data from NOSE versus EOC cell lines were compared 
with publicly available microarray data from the TCGA between serous ovarian 
carcinomas (SOC) and normal fallopian tube tissue (FT) which were analysed 
as previously described in Chapter 3. Additionally, within our group a novel 
EOC transformation model was recently created. Briefly, an immortalised NOSE 
cell line (IOSE) was transformed by introducing MYC and MYC/KRAS 
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(Lawrenson et al, 2011). Thus, I have also compared the differential expression 
between NOSE versus EOC cell lines for the candidate genes with the 
differential expression between IOSE and IOSE-MYC & IOSE-MYC/KRAS cell 
lines from data generated in a microarray analysis performed in the context of 
that project.  
 
Locus 2q31: Candidate genes HOXD3 and HOXD1  
For the 2q31 locus, I tested the expression of both the HOXD3 and 
HOXD1 genes. Both were in the closest proximity with the risk SNP at this 
locus. However, HOXD3 expression in both EOC and NOSE cell lines was too 
low for reliable detection. HOXD1 expression was significantly higher in EOC 
cell lines compared to NOSE cell lines as shown by the boxplots in  Figure 5.4 
A&B (P<10-8). This observation suggests that HOXD1 has a gain of function 
role in EOC development.  This observation was not confirmed in the IOSE 
transformation model. There was no differential expression of HOXD1 between 
the IOSE and IOSE_MYC and ISOS-MYC/KRAS cell lines. The observed gain 
of function role of HOXD1 in ovarian cancer development was also not 
supported by TCGA data where its expression levels did not differ between 
SOC and normal FT (Figure 5.4 C and D respectively).  
 
Locus 3q25: Candidate gene TIPARP 
The TIPARP gene which contains in one of its introns the most 
significant SNP of locus 3q25, exhibited significantly reduced expression in 
EOC compared to NOSE cell lines for both endogenous controls as shown in  
Figure 5.5 A&B (P<10-8). The observed lack of expression for TIPARP in EOC 
cell lines suggests a loss of function role for TIPARP in ovarian cancer 
development. A loss of function role for TIPARP in EOC is also suggested with 
the higher TIPARP expression observed in the IOSE cell line compared to its 
transformed counterparts (Figure 5.5 C).This finding was also supported by a 
significantly reduced expression of the gene in SOC compared to normal FT 
after I performed the analysis of mRNA data available from TCGA (P= 1.11×10-
4, Figure 5.5 D).  
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Locus 8q24: Candidate gene MYC 
SNP rs10088218, the most significant SNP in locus 8q24 is not located 
in very close proximity with any genes but is found in a gene desert. MYC gene, 
which is ~760kb away of rs10088218, was not the gene in closest proximity to 
this SNP but was indeed one of the two genes more closely located to the SNP. 
PVT1 was the other gene, which is a non-protein coding gene. The reason I 
selected to initially investigate MYC is because it is a known oncogene with a 
well-established role in the development of EOC and additionally it is a protein 
coding gene. I found that MYC was significantly over-expressed in EOC 
compared to NOSE cell lines and this observation was consistent with the well-
established role of the gene as an oncogene. (Figure 5.6 A&B). MYC was used 
for the transformation of the IOSE in the EOC transformation model but when 
co-transfected with KRAS its expression decreased to the initial levels of the 
control cell line (Figure 5.6 C) Interestingly, TCGA data showed that MYC 
expression levels didn’t change between SOC and normal FT (Figure 5.6 D). 
 
Locus 9p22: Candidate gene BNC2 
SNP rs3814113 in locus 9p22 was the most significantly associated SNP 
with EOC risk in the GWAS (P= 5.1×10-19). The gene in the closest proximity to 
this SNP was BNC2 (~30kb away). After evaluating the expression in EOC cell 
lines compared to NOSE cell lines, a loss of function role of BNC2 in EOC is 
supported by the findings. The gene was found to be significantly under-
expressed in EOC cell lines compared to NOSE (P= ~1×10-5, Figure 5.7 A&B). 
This is an interesting result supported by the observation of being significantly 
under-expressed in the transformed IOSE cell lines compared to the control 
(P<0.01, Figure 5.7 C). I also found that the expression of BNC2 was 
significantly reduced in SOC compared to normal FT in expression data from 
the TCGA (P= 1.6×10-4).  
 
Locus 17q21: Candidate gene SKAP1 
For chromosome 17, locus 17q21, the most significant SNP rs9303542 is 
located in a SKAP1 intron. I found that there was significantly increased 
expression of SKAP1 in EOC cell lines compared to NOSE cell lines as shown 
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at Figure 5.8 A&B with a P value between 10-4 and 10-6 depending on the 
endogenous control used for normalisation. This trend is indicating a gain of 
function role for SKAP1 in EOC development. Interestingly, a significant 
differential expression was observed between normal FT and SOC but with a 
different trend suggesting a loss of function role in EOC since the expression of 
SKAP1 appears to be reduced in SOC compared to normal FT (Figure 5.8 D).  
 
Locus 19p13: Candidate genes MERIT40 and ANKRD41 
The most significant SNPs of locus 19p13 were rs8170 and rs2363956 
which are located in the coding regions of genes MERIT40 and ANKRD41 
respectively. MERIT40 expression was significantly higher in EOC cell lines 
compared to NOSE cell lines as shown at  Figure 5.9 A&B (P<10-5). These data 
suggest that MERIT40 has a gain of function role in ovarian cancer 
development. This finding was supported by the increased expression I found in 
serous ovarian adenocarcinoma compared to normal FT. MERIT40 did not 
appear differentially expressed in the IOSE transformation model (Figure 5.9 C). 
ANKRD41 expression was not significantly different between EOC and NOSE 
(Figure 5.10 A&B).   
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Figure 5.4: HOXD1 expression in three differential expression models. HOXD1 
expression in EOC versus NOSE cell lines normalised to A) β-actin and B) GAPDH. C) 
HOXD1 expression in the IOSE transformation model. D) HOXD1 expression in SOC 
versus normal FT. 
  
Chapter 5: Post-GWAS characterisation of risk loci 
 
255 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5: TIPARP expression in three differential expression models. TIPARP 
expression in NOSE versus EOC cell lines normalised to A) β-actin and B) GAPDH. C) 
TIPARP expression in the IOSE transformation model. D) TIPARP expression in SOC 
versus normal FT. 
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Figure 5.6: MYC expression in three differential expression models. MYC expression in 
NOSE versus EOC cell lines normalised to A) β-actin and B) GAPDH. C) MYC 
expression in the IOSE transformation model. D) MYC expression in SOC versus 
normal FT. 
. 
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Figure 5.7: BNC2 expression in three differential expression models. BNC2 expression 
in NOSE versus EOC cell lines normalised to A) β-actin and B) GAPDH. C) BNC2 
expression in the IOSE transformation model. D) BNC2 expression in SOC versus 
normal FT. 
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Figure 5.8: SKAP1 expression in three differential expression models. SKAP1 
expression in NOSE versus EOC cell lines normalised to A) β-actin and B) GAPDH. C) 
SKAP1 expression in the IOSE transformation model. D) SKAP1 expression in SOC 
versus normal FT. 
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Figure 5.9: MERIT40 expression in three differential expression models. MERIT40 
expression in NOSE versus EOC cell lines normalised to A) β-actin and B) GAPDH. C) 
MERIT40 expression in the IOSE transformation model. D) MERIT40 expression in 
SOC versus normal FT. 
 
 
 
 
 
 
 
 
 
Figure 5.10: ANKRD41 expression in NOSE versus EOC cell lines. ANKRD41 
expression normalised to A) β-actin and B) GAPDH,    
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15
Candidate 
genes 
selected
12
6
2
2
23
Locus
Associated 
SNP
Position of 
SNP (Genome 
Build 36.3) (bp)
Alleles 
(Major/ 
Minor)
2q31** rs2072590 176750879
9p22* rs3814113 16905021
8q24** rs10088218 129613131
3q25 ** rs2665390 157880443
rs9303542 43766499
19p13*** rs2363956 17255124
17q21** 1025
980
515
1025
1600
Size of 
region for  
selected 
genes (Kb)
1150
T/C
G/T
T/C
G/A
A/G
G/T
 Evaluating differential expression of an extended list of 5.3
candidate genes between normal (NOSE & FTE) and EOC 
cell lines- Extended study 
 
The initial approach of investigating the potential role of candidate genes 
emerging from the GWAS in the development of ovarian cancer was to examine 
the genes that were in the closest proximity to the most significant SNPs at the 
six loci. However, it cannot be ruled out that there are other genes at these 
susceptibility regions that may be functionally important in EOC. Therefore, I 
expanded these studies to include a larger panel of normal (combined NOSE & 
FTE) and EOC cell lines and evaluated additional genes in each region. A map 
for each of the chromosomal loci of interest was established using Genome 
Built 36.3 in Ensemble (http://www.ensembl.org/index.html) and more genes 
around the significant SNPs were selected located in less than 1Mb distance 
away of either side of the SNPs (Table 5.2). 
 
 
 
 
 
 
 
 
 
 
 
Table 5.2: Regions established for selection of candidate genes around the most 
significant EOC risk variants. The number of additional candidate genes selected to 
investigate their differential expression between normal and EOC cell lines is also 
tabulated. 
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5.3.1 Fluidigm study design 
Sixty genes were selected to be investigated in total, 12 at chromosome 
2q31, 6 at chromosome 3q25, 2 at chromosome 8q24, 2 at chromosome 9p22, 
23 at chromosome 17q21, and 15 at chromosome 19p13. A brief description of 
the function of those genes is shown in Table 5.3. Differential mRNA expression 
of the selected genes was evaluated using the cDNA of normal cell lines 
comprised by 59 NOSE and 5 FTE cell lines compared to 45 EOC cell lines. As 
previously described in chapter 3, NOSE217 had not been included in the 
analysis because it was found to express really high levels of FSP in the 
immunofluorescence characterisation, an indication of stromal contamination. 
FT05 cell line was also removed from the analysis as it was found to have an 
abnormal karyotype.  The assays used were Taqman gene expression assays 
by Applied Biosystems run as a multiplex using the 96.96 dynamic array chips 
by Fluidigm. The protocol and assay selection is described in more detail in the 
Methods section of this thesis. The endogenous controls run were β-actin and 
GAPDH as well as TBP. Each sample was run in triplicate. A pooled sample of 
the cell lines used was created to generate standard curves for each of the 
assay also run in triplicate.  The 60 assays were separated run in 3 different 
chips (sets) each including the endogenous control genes for the expression of 
the candidate genes from the relevant chip to be normalised against.  
5.3.2 Quality control analysis  
Extensive quality control (QC) analysis was performed in order to ensure 
that the data were reliable. Firstly, the pass rate for each of the assays was 
calculated using the 64 normal and 45 EOC cell lines (total n= 109). Assays 
where the pass rate was less than 80% were considered as failed. However, 
even if the accuracy of statistical analysis is important, the biological nature of 
the experiment should not be overlooked. Therefore, for assays where the pass 
rate was less than 80% the cell type specific pass rate was calculated 
separately for normal and EOC cell lines. This is justified because a gene may 
be found differentially expressed between normal and EOC cell lines to such an 
extent that there is no detectable expression in one of the cell types. If that is 
the case it will be picked up as a failed assay in the overall quality control 
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analysis. Two assays that had an overall <80% pass rate, for genes HOXD9 
and HOXB9, were found to have a cell type specific expression and these 
genes were not considered as they failed assay pass rate since they 
demonstrated a pass rate of >80% in at least one of the cell types. 36 assays 
remained after removing assays with <80% pass rate. This was not considered 
to be alarming because very low overall pass rates could indicate that a gene is 
not normally expressed neither in normal (NOSE and FTE) nor ovarian cancer 
cell lines and not necessarily mean that the assay failed.   
A standard curve was generated for each of the assays to ensure the 
linear relationship of sample amount and relative gene expression.  Assays for 
which the standard curve had an R2 <0.8 were failed. The standard curves for 
all assays are presented in Appendix 3, Figure 1. Two more assays were 
excluded from the analysis at this step of QC. The standard curves for all 
assays are shown in Appendix 3, Figure 1.  
The reproducibility between the replicates is extremely important for 
testing the reliability of the gene expression data. The standard deviation of the 
Ct values was assessed between the triplicates for each assay. For each 
sample, when the standard deviation was >0.6, the replicate causing the 
deviation was removed as long as two replicates remained to be analysed. 
Samples where only one replicate had worked were failed.  For some samples 
where one of the replicates had failed a standard deviation of <1 was accepted. 
This less stringent cut off for the standard deviation of <1 was used in order to 
keep two replicates in for the analysis and assays that the rate of this occurring 
was more than 15% were failed. 32 assays remained after this final step of 
assay quality control analysis. The quality control analysis for all genes chosen 
to evaluate their differential expression in the six loci is shown in Table 5.4. 
Quality control analysis was also performed for the samples. Samples 
that had a pass rate of <85% were removed.  2 NOSE cell lines and 1 EOC cell 
line were removed. The remaining number of samples after QC was 57 NOSE, 
5 FTE cell lines and 44 EOC cell lines. The endogenous controls assays β-actin 
and GAPDH passed for genes that were run in sets/chips 3 and 4. TBP failed 
for all chips and β-actin failed for set 2.   
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Chromosome Gene Locus  Function
Fluidigm 
Chip
KIAA1715 2q31 May be involved in limb and CNS development Set 3
EVX2 2q31.1 TF for the Homeobox genes Set 2
HOXD13 2q31.1 TF involved in morphogenesis, differentiation and development Set 3
HOXD12 2q31.1 TF involved in morphogenesis, differentiation and development Set 3
HOXD11 2q31.1 TF involved in morphogenesis, differentiation and development Set 3
HOXD10 2q31.1 TF involved in morphogenesis, differentiation and development Set 3
HOXD9 2q31.1 TF involved in morphogenesis, differentiation and development Set 3
HOXD8 2q31.1 TF involved in morphogenesis, differentiation and development Set 3
HOXD4 2q31.1 TF involved in morphogenesis, differentiation and development Set 3
HOXD3 2q31.1 TF involved in morphogenesis, differentiation and development Set 3
HOXD1 2q31.1 TF involved in morphogenesis, differentiation and development Set 4
MTX2 2q31.1 Transporter of proteins into the mitochondrion Set 3
KCNAB1 3q26.1 Accessory potassium channel protein Set 3
SSR3 3q25.31 Associated with protein translocation across the ER membrane. Set 4
TIPARP 3q25.31 May play a role in adaptive response to chemical exposure Set 4
LOC730091 3q25.31 Hypothetical protein Unknown function Set 3
PA2G4P4 3q25.31 Proliferation associated pseudogene with Unknown function Set 3
LEKR1 3q25.31 Unknown function Set 3
MYC 8q24.21 Activates the transcription of growth-related genes Set 3
PVT1 8q24 Potential oncogene Set 4
BNC2 9p22.32 TF specific for skin keratinocytes with a role in the differentiation Set 2
CNTLN 9p22 Unknown function Set 2
SP6 17q21.32 Promotes cell proliferation Set 4
SP2 17q21.32 Binds to GC box promoters elements and selectively activates mRNA synthesis Set 4
PNPO 17q21.32 Catalyzes the oxidation of either PNP or PMP into PLP Set 4
ATAD4 17q21.32 Transmembrane protein of unknown function Set 2
CDK5RAP3 17q21.32 Potential regulator of CDK5 activity. May be involved in cell proliferation. Set 2
COPZ2 17q21.32 Cytosolic protein associated with protein transport from the ER Set 2
NFE2L1 17q21.3 Activates erythroid-specific, globin gene expression Set 3
CBX1 17q21.32 Component of heterochromatin. Involved in epigenetic repression. Set 2
SNX11 17q21.32 May be involved in several stages of intracellular trafficking Set 4
SKAP1 17q21.32 Positively regulates T-cell receptor signalling by enhancing the MAP kinase pathway Set 4
HOXB1 17q21.3 Sequence-specific TF for the developmental regulatory system Set 2
HOXB2 17q21-q22 Sequence-specific TF for the developmental regulatory system Set 3
HOXB3 17q21.3 Sequence-specific TF for the developmental regulatory system Set 3
HOXB4 17q21-q22 Sequence-specific TF for the developmental regulatory system Set 3
HOXB5 17q21.3 Sequence-specific TF for the developmental regulatory system Set 3
HOXB6 17q21.3 Sequence-specific TF for the developmental regulatory system Set 3
LOC404266 17q21.32 Hypothetical protein Unknown function Set 3
HOXB7 17q21.3 Sequence-specific TF for the developmental regulatory system Set 3
HOXB8 17q21.3 Member of the Antp homeobox family TFs involved in development Set 3
HOXB9 17q21.3 Sequence-specific TF for the developmental regulatory system Set 3
PRAC 17q21 May play a regulatory role in the nucleus. Set 4
HOXB13 17q21.2 Sequence-specific TF for the developmental regulatory system Set 2
TTLL6 17q21.32 Glutamylase which preferentially modifies alpha-tubulin Set 4
SIN3B 19p13.11 Transcriptional repressor. Anotagonizes MYC oncogenic activities Set 4
CPAMD8 19p13.11 Belongs to the complement component-3 involved innate immunity and DDR Set 2
HAUS8 19p13.11 Contributes to mitotic spindle assembly Set 4
MYO9B 19p13.1 May be involved in the remodelling of the actin cytoskeleton. Set 3
USE1 19p13.11 May be involved in targeting and fusion of Golgi-derived transport vesicles with the ER Set 4
OCEL1 19p13.11 Unknown function Set 3
NR2F6 19p13.1 Transcriptional repressor mainly involved in modulation of hormonal responses Set 3
USHBP1 19p13 Unknown function Set 4
MERIT40 19p13.11 Component of the BRCA1-A complex. May be involved in DNA damage repair at DSBs Set 2
ANKRD41 19p13.11 May induce DNA cleavage and DNA damage response Set 4
ABHD8 19p13.11 May have catalytic and hydrolase activity involved in metabolic processes Set 2
DDA1 19p13.11 May be involved in ubiquitination and proteasomal degradation of target proteins. Set 2
MRPL34 19p13.1 Assists in protein synthesis within the mitochondrion Set 3
TMEM16H 19p13.11 May act as a calcium-activated chloride channel Set 4
GTPBP3 19p13.11 May play a role in mitochondrial tRNA modification. Set 2
19
17
2
3
8
9
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.3: Selected candidate genes from the six EOC risk associated loci. Genes are 
shown in the order found across the 6 candidate loci (direction pq arm). Highlighted 
in blue are the initially selected genes in the closest proximity to the most significant 
SNPs from the GWAS.   
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Gene 
Assay pass 
rate (%)  
(109 
samples) 
% of samples 
per assay with 
SD>0.6 
R
2  
Standard 
Curve 
Assay failed 
or passed 
2 
KIAA1715 99 0 0.978 PASSED 
EVX2 0 0 FAILED FAILED 
HOXD13 22 5 0.868 FAILED 
HOXD12 5 2 0.921 FAILED 
HOXD11 8 3 FAILED FAILED 
HOXD10 31 10 FAILED FAILED 
HOXD9 73 17 0.876 FAILED 
HOXD8 84 7 0.878 PASSED 
HOXD4 45 13 0.667 FAILED 
HOXD3 61 10 0.828 FAILED 
HOXD1 28 6 0.936 FAILED 
MTX2 99 2 0.805 PASSED 
3 
KCNAB1 42 5 FAILED FAILED 
SSR3 98 0 0.993 PASSED 
TIPARP 98 1 0.936 PASSED 
LOC730091 48 11 0.052 FAILED 
PA2G4P4 97 0 0.956 PASSED 
LEKR1 43 9 0.016 FAILED 
8 
MYC 100 0 0.953 PASSED 
PVT1 95 12 0.834 PASSED 
9 
BNC2 91 1 0.980 PASSED 
CNTLN 99 0 0.944 PASSED 
17 
SP6 32 11 0.189 FAILED 
SP2 98 0 0.991 PASSED 
PNPO 98 0 0.955 PASSED 
ATAD4 14 5 0.991 FAILED 
CDK5RAP3 97 5 0.978 PASSED 
COPZ2 86 3 0.953 PASSED 
NFE2L1 100 0 0.953 PASSED 
CBX1 100 1 0.977 PASSED 
SNX11 97 1 0.963 PASSED 
SKAP1 23 3 0.559 FAILED 
HOXB1 1 1 FAILED FAILED 
HOXB2 78 15 0.205 FAILED 
HOXB3 82 10 0.954 PASSED 
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HOXB4 87 6 0.809 PASSED 
HOXB5 73 13 0.943 FAILED 
HOXB6 84 8 0.925 PASSED 
LOC404266 15 2 0.108 FAILED 
HOXB7 88 4 0.989 PASSED 
HOXB8 30 7 0.050 FAILED 
HOXB9 79 5 0.943 PASSED (*) 
PRAC 6 4 FAILED FAILED 
HOXB13 30 3 0.735 FAILED 
TTLL6 14 5 FAILED FAILED 
19 
SIN3B 98 0 0.990 PASSED 
CPAMD8 14 3 0.653 FAILED 
HAUS8 97 3 0.982 PASSED 
MYO9B 100 0 0.983 PASSED 
USE1 97 1 0.906 PASSED 
OCEL1 95 8 0.890 PASSED 
NR2F6 98 1 0.944 PASSED 
USHBP1 7 5 FAILED FAILED 
MERIT40 100 0 0.960 PASSED 
ANKRD41 68 18 0.717 FAILED 
ABHD8 99 2 0.922 PASSED 
DDA1 100 0 0.938 PASSED 
MRPL34 99 2 0.972 PASSED 
TMEM16H 86 16 0.317 FAILED 
GTPBP3 98 19 0.925 FAILED 
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β-actin SET 2 100 1 0.633 FAILED 
GAPDH SET 2 99 0 0.997 PASSED 
TPB SET 2 100 67 0.091 FAILED 
β-actin SET 3 100 0 0.979 PASSED 
GAPDH SET 3 99 0 0.994 PASSED 
TPB SET 3 98 20 0.707 FAILED 
β-actin SET 4 99 1 0.996 PASSED 
GAPDH SET 4 98 0 0.999 PASSED 
TPB SET 4 96 42 0.863 FAILED 
 
Table 5.4: Quality control analysis performed for the Fluidigm expression data. 
Highlighted in red are the failed assays for a particular quality control criterion. 32 
assays remained to be analysed after quality control. SD: Standard Deviation. 
(*):Assay passed because of an acceptable cell type specific pass rate. 
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5.3.3 Candidate gene expression analysis of the Fluidigm data and 
statistical methods used 
The expression data were analysed as previously described using the 
comparative ΔΔCt method. As a calibrator for the analysis a randomly selected 
NOSE sample that exhibited 100% pass rate was used, NOSE11. Relative 
expression values of all cell lines to NOSE11 expression were generated and 
normalized against the average of GAPDH and β-actin for assays run in 
Fluidigm set 3 and 4 and only against GAPDH for assays run in Fluidigm set 2. 
Extreme outliers were removed when relative expression values were 10× more 
or less than the median of the relative values for each assay but it was checked 
that they would not exceed 5% of the samples. 
Differences in the relative expression of each candidate gene between 
EOC cell lines and normal cell lines were assessed using the nonparametric 
two sided Wilcoxon Rank sum test using R software and P values were 
generated. Additionally, linear regression analysis was performed between 
NOSE, FTE and EOC cell lines. However these results could not be deemed as 
very informative since the number of FTE samples was too small (n=5) and will 
not be discussed. Statistically significant values were considered if P<0.05. 
However, in statistical analysis for many assays, genes can be found to be 
differentially expressed when they are not and these are deemed as false 
positives. Thus, it is vital to re-calculate the statistically significant p-value cut off 
when performing and statistical test on a big group of genes. The incidence of 
false positives is proportional to the number of tests performed. There are 
several multiple testing correction approaches but the more stringent, meaning 
allowing for the less false positive results to appear, is the Bonferroni correction. 
According to this, the statistically significant p-value of 0.05 is divided by the 
number of tests performed and the resulting value serves as the new 
significance level termed as p-value cut off  according to which the results are 
deemed statistically significant or not. According to Bonferroni correction the 
statistically significant cut off value for the current analysis would be 
P<0.05/32=0.0015. 
The differential expression of the endogenous controls that passed the 
QC analysis was compared between the different cell line sets as an additional 
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quality control criterion since their expression should not have been altered 
between EOC and normal cell lines. After correction for multiple testing none of 
the endogenous controls in any of the 3 Fluidigm chips run was found to be 
differentially expressed between EOC and normal cell lines further ensuring the 
reliability of the experiment. 
Finally, it should be noted that the P values of differential expression 
were found to differ in some cases when normalised against β-actin or against 
GAPDH. The total number of assays that passed QC was 32 and out of those 
data were available for β-actin and GAPDH data for 25 assays. The 
concordance rate for the 25 assays when normalised against β-actin compared 
to GAPDH was 72% (18 out of 25). Assays where the P values were or were 
not statistically significant for both β-actin and GAPDH based on the P value 
calculated for Bonferroni correction were classed as being concordant. Out of 
the 7 assays that were not concordant the concordance difference found for 3 
assays was because the comparison was based on the p value after Bonferroni 
correction but still showed the same trend of over or under expression. Because 
of these inconsistencies it was deemed important that the conclusions would be 
drawn from the p values obtained when the genes’ expression normalised 
against the average expression of both the endogenous controls combined. 
Although the separate analyses are presented in the Table 1 of Appendix 3, P 
values presented in this chapter and the discussion will be based on the values 
obtained after the combined endogenous analysis with the exception of some 
genes that were run on Fluidigm chip 2 where only GAPDH passed the QC 
criteria. 
The differential expression of selected candidate genes between EOC 
and normal (combined NOSE & FTE) cell lines in the Fluidigm assay was also 
compared with the differential expression of the genes using mRNA data for 
SOC and normal FT tissue from TCGA as previously described. There were 56 
of the candidate genes with mRNA data available in TCGA. I treated the 
downloaded mRNA expression data as one experiment and have applied 
Bonferroni correction (cut-off P< 8.93x10-4). Additionally, I investigated whether 
any of the candidate genes were found to have any somatic alterations. The 
query was performed in www.cbioportal.org which has the raw data of the 
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TCGA database. I have looked at the frequency of mutations, putative copy 
number (CN) alterations such as amplification or deletions. The sample size 
available for this analysis included 316 serous ovarian cancer samples. A 
summary describing the findings for analysed candidate genes is shown in 
Table 5.5. 
 
5.3.4 Differential expression of candidate genes in locus 2q31 between 
normal and EOC cell lines- Extended study. 
Twelve genes were investigated at locus 2q31 including HOXD1 and 
HOXD3 that were in closest proximity with SNP rs2072590 (Figure 5.11 A). 
Only 3 passed all the steps of QC and their differential expression was 
evaluated between EOC and normal cell lines (Table 5.5). Genes HOXD1 and 
HOXD3 did not pass the QC analysis. Thus the significant differential 
expression for HOXD1 between NOSE and EOC that I previously identified 
could not be assessed in this experiment. According to the analysis performed 
using TCGA mRNA expression data these two genes did not seem to be 
differentially expressed in normal FT and SOC (Appendix 3, Table 1).  
Of the three genes that passed all QC analysis, KIAA1715 has been 
found to be under-expressed in EOC cell lines with a P value of 0.004. 
However, the result though did not remain significant after Bonferroni correction. 
Interestingly, analysis of TCGA data for this gene showed over-expression in 
SOC compared to normal FT with a P value of 1.89×10-4, which remained 
significant after Bonferroni correction and was the most significant result 
amongst the genes tested in that locus according to the TCGA data. MTX was 
found to be over-expressed in EOC cell lines as well as in SOC compared to 
normal but neither result remained significant after Bonferroni correction (Table 
5.5, Figure 5.11, B-E).  
The selected genes were also evaluated for alterations such as 
amplifications, deletions, and somatic mutations. No more than 4.4% of the 
samples (n=316) was found to be altered in any of the selected genes with 
amplifications being the most frequent event as seen in Table 5.5.  
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Table 5.5: Summary of the differential expression for candidate genes in the EOC 
associated loci. Additionally, tabulated is the differential expression evaluated for the 
same genes between SOC and normal FT tissue using TCGA expression data. 
Highlighted in yellow are statistically significant P values using the 0.05 cut-off. 
Highlighted in green are P values that remained statistically significant after Bonferroni 
correction, with a cut-off for the Fluidigm analysis of P<0.0015 and for the TCGA data 
analysis P<0.0008. The trend column indicates whether a gene was found to be over 
or under-expressed in EOC or SOC compared to normal cell lines or normal FT tissue 
respectively (ND: No Differential expression). Finally, identified somatic alterations for 
the candidate genes according to the TCGA are shown. Amp: amplification; HomDel: 
Homozygous Deletion; Mut: somatic mutation; (*) in a sample set of 316 SOC; (**) 
Alterations include Amp, HomDel and Mut.   
C
h
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Gene Cytoband
Normalised 
against
Sample 
number 
(EOC/ 
Normal)
P value Trend P value Trend
Number of 
samples with 
alterations * 
(Amp/ 
HomDel/ 
Mutations) 
Frequency of 
alterations **
KIAA1715 2q31 β-actin & GAPDH 42/59 0.004 ↓ EOC 1.89×10-4 ↑ SOC 11/0/0 3.5%
HOXD8 2q31.1 β-actin & GAPDH 29/59 0.591 ND 0.245 ND 14/0/0 4.4%
MTX2 2q31.1 β-actin & GAPDH 42/59 0.015 ↑ EOC 0.004 ↑ SOC 13/0/1 4.4%
SSR3 3q25.31 β-actin & GAPDH 42/58 0.003 ↓ EOC 0.216 ND 22/0/0 7.0%
TIPARP 3q25.31 β-actin & GAPDH 41/58 4.99×10-9 ↓ EOC 1.11×10-4 ↓ SOC 22/0/1 7.3%
PA2G4P4 3q25.31 β-actin & GAPDH 41/61 2.14×10-5 ↑ EOC 22/0/1 7.3%
MYC 8q24.21 β-actin & GAPDH 40/59 0.085 ND 0.059 ND 97/0/0 30.7%
PVT1 8q24 β-actin & GAPDH 41/59 6.64×10-8 ↑ EOC 102/0/0 32.3%
BNC2 9p22.32 GAPDH 30/58 1.73×10-4 ↓ EOC 1.63×10-4 ↓ SOC 8/2/1 3.5%
CNTLN 9p22 GAPDH 42/58 0.030 ↑ EOC 0.536 ND 4/3/0 2.2%
SP2 17q21.32 β-actin & GAPDH 42/58 5.68×10-10 ↑ EOC 0.049 ↓ SOC 6/0/0 1.9%
PNPO 17q21.32 β-actin & GAPDH 42/58 6.26×10-8 ↑ EOC 0.629 ND 6/0/0 1.9%
CDK5RAP3 17q21.32 GAPDH 42/57 0.023 ↑ EOC 0.143 ND 5/0/0 1.6%
COPZ2 17q21.32 GAPDH 29/57 0.001 ↓ EOC 0.107 ND 5/0/0 1.6%
NFE2L1 17q21.3 β-actin & GAPDH 41/59 0.050 ↓ EOC 1.4×10-5 ↓ SOC 5/0/0 1.6%
CBX1 17q21.32 GAPDH 42/57 1.19×10-5 ↑ EOC 0.018 ↑ SOC 6/0/0 1.9%
SNX11 17q21.32 β-actin & GAPDH 42/58 0.004 ↑ EOC 0.388 ND 5/0/0 1.6%
HOXB3 17q21.3 β-actin & GAPDH 31/51 1.72×10-4 ↑ EOC 5.24×10-4 ↓ SOC 10/0/0 3.2%
HOXB4 17q21-q22 β-actin & GAPDH 35/52 0.001 ↑ EOC 0.026 ↓ SOC 10/0/1 3.5%
HOXB6 17q21.3 β-actin & GAPDH 26/50 4.23×10-7 ↑ EOC 5.25×10-5 ↓ SOC 8/0/0 2.5%
HOXB7 17q21.3 β-actin & GAPDH 35/50 4.62×10-10 ↑ EOC 0.867 ND 8/0/0 2.5%
HOXB9 17q21.3 β-actin & GAPDH 30/46 9.7×10-9 ↑ EOC 0.946 ND 8/0/0 2.5%
SIN3B 19p13.11 β-actin & GAPDH 42/57 0.126 ND 0.019 ↑ SOC 28/0/2 9.5%
HAUS8 19p13.11 β-actin & GAPDH 41/62 1.08×10-6 ↑ EOC 1.48×10-5 ↑ SOC 27/0/1 8.9%
MYO9B 19p13.1 β-actin & GAPDH 42/59 0.010 ↓ EOC 3.69×10-5 ↑ SOC 30/0/2 10.1%
USE1 19p13.11 β-actin & GAPDH 43/60 1.69×10-5 ↑ EOC 0.224 ND 30/0/0 9.5%
OCEL1 19p13.11 β-actin & GAPDH 38/59 0.012 ↑ EOC 0.009 ↓ SOC 30/0/0 9.5%
NR2F6 19p13.1 β-actin & GAPDH 42/60 0.226 ND 0.094 ND 30/0/0 9.5%
MERIT40 19p13.11 GAPDH 42/57 0.005 ↑ EOC 2.09×10-5 ↑ SOC 29/0/1 9.5%
ABHD8 19p13.11 GAPDH 42/58 0.028 ↑ EOC 0.132 ND 27/0/0 8.5%
DDA1 19p13.11 GAPDH 42/58 0.471 ND 2.04×10-4 ↑ SOC 27/0/0 8.5%
MRPL34 19p13.1 β-actin & GAPDH 42/60 0.001 ↑ EOC 0.005 ↑ SOC 27/0/0 8.5%
TMEM16H 19p13.11 β-actin & GAPDH 7.42×10-5 ↑ SOC 26/0/3 9.2%
GTPBP3 19p13.11 GAPDH 1.02×10-5 ↑ SOC 25/0/0 7.9%
19
TCGA mRNA 
epression 
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No data
FAILED
FAILED
Fluidigm gene expression assay
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Figure 5.11: Mapping of SNP rs2072590 on chromosome 2 and expression analyses 
for candidate genes in locus 2q31. A) Location of candidate genes in locus 2q31. 
Differential expression between and EOC and normal cell lines for: B) KIAA1715, D) 
MTX2. Differential expression between SOC and normal FT for: C) KIAA1715, E) 
MTX2.  P Values highlighted in red are the ones that remained significant after 
Bonferroni correction.   
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5.3.5 Differential expression of candidate genes in locus 3q25 between 
normal and EOC cell lines- Extended study   
In locus 3q25, with TIPARP in the closest proximity to SNP rs2665390, 
five more genes were selected to be investigated (Figure 5.12 A). 3 of the 6 
selected genes passed all the steps QC analysis and were further analysed for 
differential expression (Table 5.5).  
TIPARP was found in the pilot study to be significantly under-expressed 
in EOC cell lines (Figure 5.5, P< 10-8), suggesting a loss of function role for this 
gene in EOC development. This result was confirmed in this analysis in a higher 
number of normal and EOC samples (P= 4.99×10-9, Figure 5.12 B), consistent 
with the analysis preformed using TCGA data (P= 1.11×10-4, Figure 5.12 C). 
The pseudogene PA2G4P4 was found to be over-expressed in EOC cell lines 
with a P value of 2.14×10-5 (Figure 5.12 F). This result could not be correlated 
to the expression in SOC and normal FT as there were no mRNA data available 
for this gene in TCGA. For gene SSR3, the expression was not found different 
in normal FT compared to serous carcinoma according to TCGA data. The 
slight under-expression of SSR3 in EOC cell lines compared to normal cell lines 
with a P value of 0.003 did not remain significant after Bonferroni correction 
(Figure 5.12 D&E). TIPARP remains the most significant candidate gene within 
locus 3q25 according to these data. 
A higher frequency of alterations was observed within the selected genes 
of chromosome 3 compared to chromosome 2. Somatic alterations in the genes 
for this locus ranged from 7 to 7.3% of the 316 SOC samples tested. All of the 
altered samples had amplifications for SSR3  and only one of the 23 samples 
with alterations had a somatic mutations for TIPARP and PA2G4P4 (Table 5.5) 
Interestingly, somatic alterations in TIPARP significantly decrease the protein 
levels of CDH2 according to reverse phase protein array (RPPA) data available 
from the TCGA (P= 7.44E×10-5) (www.cbioportal.org). CDH2 (Cadgerin-2) is a 
calcium dependent cell-cell adhesion glycoprotein and may be implicated in 
cancer metastasis when phosphorylated by the scr kinase pathway up-
regulated by cancer cells. 
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Figure 5.12: Mapping of SNP rs2665390 on chromosome 3 and expression analyses 
for candidate genes in locus 3q25. A) Location of candidate genes in locus 3q25. 
Differential expression between EOC and normal cell lines for: B) TIPARP, D) SSR3 
and F) PA2G4P4. Differential expression between SOC and normal FT for: C) TIPARP, 
E) SSR3. G) no mRNA expression data were available for PA2G4P4 in TCGA. P 
Values highlighted in red are the ones that remained significant after Bonferroni 
correction.   
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5.3.6 Differential expression of candidate genes in locus 8q24 between 
normal and EOC cell lines- Extended study   
Gene PVT1 was selected to be investigated in addition to MYC at the 
8q24 locus in proximity to SNP rs10088218 (Figure 5.13 A). This SNP is located 
in an apparent gene desert and these were the only genes in the 1Mb proximity 
of the SNP. Both of the selected genes passed all the steps of quality control 
analysis and were analysed for differential expression (Table 5.5) 
The most interesting finding for this locus was PVT1 which was found to 
be the extremely over-expressed in EOC cell lines suggesting a gain of function 
role for this gene in EOC development (P= 6.64×10-8,  Figure 5.13 D). No 
mRNA data were available in TCGA for this gene. 
MYC, an oncogene involved in the development of EOC and also found 
to be significantly over-expressed in EOC cell lines in the pilot study, was not 
confirmed to be over-expressed in the EOC cell lines in this extended study (P= 
0.085,  Figure 5.13 B). However, it is worth mentioning that the significance 
levels for MYC over-expression in the EOC cell lines found in the pilot study 
was low (ranging from P= 0.001 when normalised to β-actin to P=  0.02 when 
normalised against GAPDH). The expression of MYC was also not significantly 
different between normal FT and SOC (P= 0.059, Table 5.13, Figure 5.13 C). 
A high frequency of amplifications was found for genes MYC and PVT1 based 
on data from TCGA, reached a 32% frequency at the samples tested as seen in 
Table 5.5. All somatic alterations were due to gene amplifications. PVT1 was 
found to have marginally more amplifications than MYC. 
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Figure 5.13: Mapping of SNP rs10088218 on chromosome 8 and expression analyses 
for candidate genes in locus 8q24. A) Location of candidate genes in locus 8q24. 
Differential expression between EOC and normal cell lines for: B) MYC, D) PVT1. 
Differential expression between SOC and normal FT for: C) MYC, E) PVT1. P Values 
highlighted in red are the ones that remained significant after Bonferroni correction. 
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5.3.7 Differential expression of candidate genes in locus 9p22 between 
normal and EOC cell lines- Extended study   
In locus 9p22, with BNC2 in the closest proximity to SNP rs3814113, one 
more gene, CNTLN was selected to be investigated (Figure 5.14 A). Both genes 
passed QC and their differential expression evaluated (Table 5.5). BNC2 was 
previously found in the pilot Taqman gene expression assay to be extremely 
significantly under-expressed in EOC cell lines (Figure 5.7, P<10-4), suggesting 
a loss of function role in EOC development. This result was confirmed in this 
analysis with a higher number of normal and EOC samples (Figure 5.14 B, P= 
1.73×10-4), consistent with the analysis preformed using TCGA data (Figure 
5.14 C, P= 1.63×10-4). The gene CNTLN was not significantly differentially 
expressed between EOC and NOSE cell lines after Bonferroni correction and 
similar results were found between SOC and normal FT (Figure 5.14, D&E). 
BNC2 remains the most interesting candidate gene possibly implicated in EOC 
development within locus 9p22 based on the differential expression between 
EOC and normal cell lines. 
A relatively small frequency of somatic alterations was observed within 
the selected genes of chromosome 9 with the highest frequency a 3.5% of 
tested samples with alterations within BNC2, attributed to amplifications, 
deletions and somatic mutations. Gene CNTLN was found to have equal 
amounts of amplifications and homozygous deletions in 2.2% of the samples 
tested (Table 5.5). I have previously mentioned that alterations in TIPARP affect 
CDH2 protein levels and it is interesting that alterations in BNC2 affect the 
phosphorylation levels of the same protein according to reverse phase protein 
array (RPPA) data available from TCGA (P=  7.44×10-4) (www.cbioportal.org). 
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Figure 5.14: Mapping of SNP rs3814113 on chromosome 9 and expression analyses 
for candidate genes in locus 9p22. A) Location of candidate genes in locus 9p22. 
Differential expression between EOC and normal cell lines for: B) BNC2, D) CNTLN. 
Differential expression between SOC and normal FT for: C) BNC2, E) CNTLN. P 
Values highlighted in red are the ones that remained significant after Bonferroni 
correction.    
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5.3.8 Differential expression of candidate genes in locus 17q21 between 
normal and EOC cell lines- Extended study 
Locus 17q21 is a gene rich region and a total of 23 genes spanning 
1050Kb around the associated SNP were analysed (Figure 5.15 A). SKAP1 was 
the gene in closest proximity with SNP rs9303542 since it is a SKAP1 intronic 
SNP. However, SKAP1 assay failed QC. Several other genes of this locus 
appeared to be differentially expressed between EOC & normal cell lines and 
between SOC and normal FT as shown in Table 5.5. Boxplots representing the 
significant findings for candidate genes from locus 17q21 in EOC versus normal 
cell lines and SOC versus normal FT are shown in Figure 5.15, B-U.  
CBX1 may have a gain of function role in EOC as it was found 
significantly over-expressed in EOC compared to normal cell lines and 
remained significant after Bonferroni correction (P=  1.19×10-5). Following the 
same trend, CBX1 appeared over-expressed in SOC compared to normal FT 
(P= 0.018) but the result did not remain statistically significant after Bonferroni 
correction. COPZ2 expression was significantly lower in EOC compared to 
normal cell lines after Bonferroni correction (P= 0.001), but the gene did not 
appear to be differentially expressed between SOC and normal FT. NFE2L1 
was not differentially expressed between EOC and normal cell lines but was 
significantly under-expressed in SOC compared to normal FT tissue (P= 
1.4×10-5). 
HOXB3 expression was found to be significantly over-expressed in EOC 
compared to normal cell lines (P= 1.72×10-4). Interestingly, HOXB3 appeared to 
be significantly under-expressed in SOC compared to normal FT in contrast to 
the EOC versus normal cell lines model (P= 5.24×10-4).  A similar contradiction 
in expression trends between the two expression models was observed with the 
expression of SKAP1 in the pilot study as well as HOXB4 and HOXB6 in this 
study that were found over-expressed in EOC cell lines but under expressed in 
SOC. HOXB7, HOXB9, PNPO and SP2 were significantly over-expressed in 
EOC compared to normal cell lines (P= 4.64×10-10, P= 9.7×10-9, P= 6.26×10-8, 
P= 5.68×10-10 respectively) but were not differentially expressed between SOC 
and normal FT.  
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Figure 5.15: Mapping of SNP rs9303542 on chromosome 17 and expression analyses 
for candidate genes in locus 17q21. A) Location of candidate genes in locus 17q21. 
Differential expression between EOC (left hand side box) and normal cell lines (right 
hand side box) for: B) CBX1, C) COPZ2. D) HOXB3, E) HOXB4, F) HOXB6, G) 
HOXB7, H) HOXB9, I) NFE2L1, J) PNPO, K) SP2. Differential expression between 
SOC (left hand side box) and normal FT (right hand side box) for: L) CBX1, M) COPZ2. 
N) HOXB3, O) HOXB4, P) HOXB6, Q) HOXB7, R) HOXB9, S) NFE2L1, T) PNPO, U) 
SP2. P Values highlighted in red are the ones that remained significant after Bonferroni 
correction.    
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5.3.9 Differential expression of candidate genes in locus 19p13 between 
normal and EOC cell lines- Extended study 
For chromosome locus 19p13, with MERIT40 and ANKRD41 in the 
closest proximity to SNPs rs8170 and rs2363956 respectively, 14 more genes 
were selected to be investigated (Figure 5.16 A). Five of the selected genes did 
not pass QC. The differential expression of the remaining nine genes was 
assessed and the results are shown in Table 5.5. Boxplots representing the 
significant differential expression found for candidate genes from locus 19p13 
are shown in Figure 5.16, B-O.  
MERIT40 was previously found in the pilot study to be significantly over-
expressed in EOC cell lines (Figure 5.9, P<10-5), suggesting a gain of function 
role in EOC development. This result was confirmed in this analysis with a 
higher number of normal and EOC samples (P= 5×10-3) consistent with the 
analysis preformed using TCGA data (P= 2.09×10-5). However, the EOC versus 
normal result did not remain significant after Bonferroni correction. 
DDA1 and MYO9B(→after Bonferroni) expression were not found 
differentially expressed between EOC and normal cell lines but were 
significantly over-expressed in SOC compared to normal FT (P= 2.09×10-5 and 
P= 3.69×10-5 respectively). In contrast, the expression of USE1 was significantly 
higher in EOC compared to normal cell lines (P= 1.69×10-5) but was not 
differentially expressed between SOC and normal FT tissue. MRPL34 
expression was significantly higher in EOC compared to normal cell lines (P= 
0.001) consistent with a trend of MRPL34 over-expression in SOC compared to 
normal FT (P= 0.005) but the latter not remain significant after Bonferroni 
correction. The most statistically significant finding for this locus was the HAUS8 
over-expression in EOC compared to normal cell lines (P= 1.08×10-6) consistent 
with the SOC and normal FT tissue expression model (P= 1.48×10-5). The 
assays for genes TMEM16H and GTPBP3 did not pass QC but it is worth 
mentioning that they were both found significantly over-expressed in SOC 
compared to normal FT (P=  7.42×10-5 and P=  1.02×10-5 respectively) . 
In conclusion, although at the 19p13 locus HAUS8 is the gene most 
significantly associated with EOC development, MERIT40 remains a very 
attractive candidate because of its functional link to BRCA1 involved in DNA 
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repair, and also because there is strong supporting evidence that the gene is 
frequently altered in ovarian tumour development. MERIT40 was found to be 
amplified in ~9% of the SOC samples tested according to the TCGA (Table 
5.5). TCGA data also suggest that that somatic alterations in MERIT40 cause a 
significant decrease in the phosphorylation levels of the MAPK1/MAPK3 and 
FOXO3 proteins according to reverse phase protein array (RPPA) data 
available from TCGA (P= 0.021 and P= 2.96×10-4 respectively) as well as a 
decrease in MAPK9 protein levels (P= 8.27×10-4) which are proteins involved in 
the MAPK/ERK pathway which when deregulated can lead to uncontrolled cell 
growth and cancer development. 
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Figure 5.16: Mapping of SNPs rs8170 and rs2363956 on chromosome 19 and 
expression analyses for candidate genes selected to be investigated in locus 19p13. A) 
Location of candidate genes in locus 19q13. Differential expression between EOC (left 
hand side box) and normal cell lines (right hand side box) for: B) MERIT40, C) DDA1, 
D) MRPL34, E) MYO9B, F) HAUS8, G) USE1. Differential expression between SOC 
(left hand side box) and normal FT (right hand side box) for: H) MERIT40, I) DDA1, J) 
MRPL34, K) MYO9B, L) HAUS8, M) USE1, N) GTPBP3, O) TMEM16H. P Values 
highlighted in red are the ones that remained significant after Bonferroni correction.   
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 Genotype specific expression of the candidate genes in 5.4
the closest proximity to the EOC associated SNPs- Pilot 
Study 
To test the functional link between the EOC susceptibility SNPs and 
gene expression I evaluated NOSE cell line expression for the candidate genes 
in close proximity with each SNP relatively to the genotype of the most 
significantly risk associated SNPs. DNA of 35 NOSE cell lines was genotyped 
for all the SNPs but due to the small sample size of this study I combined the 
expression data for rare homozygotes and heterozygotes and compared it to 
the expression of the common homozygotes. Gene expression analysis was 
performed as previously described using the comparative ΔΔCt method. Instead 
of using a single cell line as a calibrator sample, on this occasion the expression 
values of all cell lines were generated relative to the averaged Ct values of all 
common homozygotes per SNP. The normalization was performed against 
GAPDH and β-actin. Differences in the relative expression of each candidate 
gene between EOC cell lines and NOSE cell lines were assessed using the 
nonparametric two sided Wilcoxon Rank sum test using R software and P 
values were generated. Statistically significant values were considered if 
P<0.05. I found no evidence of genotype specific expression but the power of 
the study was limited because of the relatively small numbers. The results for 
genotype specific expression analysis are summarized on Table 5.6.  
 
 
 
 
 
 
 
 
 
Table 5.6: Expression of the candidate genes relatively to NOSE cell lines’ genotype of 
the most significant SNPs. CH: Common Homozygotes. RH+H: Rare Homozygotes & 
Heterozygotes combined.  
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 Genotype specific expression of an extended list of 5.5
candidate genes - Extended Study 
Following the pilot study for genotype specific gene expression of the 
genes in closest proximity with the most significant SNPs of the GWAS no 
significant results were obtained. The extended analysis incorporated more 
normal (NOSE & FTE) cell lines increasing the power of this study and was 
performed for all the additional genes across the loci. 
 
5.5.1 Quality control analysis 
Quality control analysis was performed in order to guarantee the 
reliability of the gene expression data to be used for the genotype specific 
expression. All the assays that had a pass rate of <80%, based on the 64 
normal samples on this occasion, were excluded from the analysis. 24 assays 
were excluded with a pass rate <80%. Five assays were excluded for either 
having a standard curve of R2 <0.8 or because more than 15% of the samples 
demonstrated a standard deviation of >0.6. After all three steps of quality 
control analysis 31 assays remained to be analysed. A summary of the quality 
control analysis performed before the genotype specific gene expression 
analysis is shown on Table 5.7. 
Of the 62 normal cell lines that remained after quality control analysis 
described before, 5 more NOSE and 1 more FTE sample were excluded from 
the analysis as there were no available genotyping data for these samples 
bringing the final number of samples to be analysed to 53 normal cell lines. 
Additionally, in order to assess the reliability of the genotyping data, the 
reported/expected minor allele frequency (MAF) from HAPMAP-CEU as found 
in the NCBI database was compared to the observed MAF from the genotyping 
of the NOSE and FTE samples (n=56). The formula that was used for this 
calculation was MAF= (2×r+h)/[2×(r+h+c), (where r= number of rare 
homozygotes, h= number of heterozygotes, c= number of common 
homozygotes). SNP rs2665390 located in chromosome 3 was not genotyped 
for the additional full set of NOSE cell lines but only for 33 in the pilot study. 
Therefore, SNP rs344008, which has an R2=1 with rs2665390, that was 
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genotyped in the full set will also be used in the analysis. The expected and 
observed MAF was closely matched and is shown in Table 5.8. 
 
C
h
ro
m
o
s
o
m
e
 
Gene 
Assay 
pass rate 
(%)       
% of samples 
per assay 
with SD>0.6 
R
2  
Standard 
Curve 
Assay failed or 
passed 
2 
KIAA1715 100 0 0.978 PASSED 
EVX2 0 0 FAILED FAILED 
HOXD13 0 0 0.868 FAILED 
HOXD12 0 0 0.921 FAILED 
HOXD11 8 5 FAILED FAILED 
HOXD10 41 14 FAILED FAILED 
HOXD9 83 26 0.876 FAILED 
HOXD8 97 8 0.878 PASSED 
HOXD4 52 11 0.667 FAILED 
HOXD3 64 12 0.828 FAILED 
HOXD1 11 2 0.936 FAILED 
MTX2 100 0 0.805 PASSED 
3 
KCNAB1 70 8 FAILED FAILED 
SSR3 100 0 0.993 PASSED 
TIPARP 100 0 0.936 PASSED 
LOC730091 52 15 0.052 FAILED 
PA2G4P4 100 0 0.956 PASSED 
LEKR1 39 9 0.016 FAILED 
8 
MYC 100 0 0.953 PASSED 
PVT1 97 17 0.834 FAILED 
9 
BNC2 100 2 0.980 PASSED 
CNTLN 100 0 0.944 PASSED 
17 
SP6 27 9 0.189 FAILED 
SP2 100 0 0.991 PASSED 
PNPO 100 0 0.955 PASSED 
ATAD4 0 0 0.991 FAILED 
CDK5RAP3 100 6 0.978 PASSED 
COPZ2 100 0 0.953 PASSED 
NFE2L1 100 0 0.953 PASSED 
CBX1 100 2 0.977 PASSED 
SNX11 100 0 0.963 PASSED 
SKAP1 11 2 0.559 FAILED 
HOXB1 0 0 FAILED FAILED 
HOXB2 92 20 0.205 FAILED 
HOXB3 86 14 0.954 PASSED 
HOXB4 92 6 0.809 PASSED 
HOXB5 78 20 0.943 FAILED 
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HOXB6 89 11 0.925 PASSED 
LOC404266 9 2 0.108 FAILED 
HOXB7 92 5 0.989 PASSED 
HOXB8 22 6 0.050 FAILED 
HOXB9 80 6 0.943 PASSED 
PRAC 0 0 FAILED FAILED 
HOXB13 2 0 0.735 FAILED 
TTLL6 0 0 FAILED FAILED 
19 
SIN3B 100 0 0.990 PASSED 
CPAMD8 0 0 0.653 FAILED 
HAUS8 100 2 0.982 PASSED 
MYO9B 100 0 0.983 PASSED 
USE1 100 2 0.906 PASSED 
OCEL1 100 6 0.890 PASSED 
NR2F6 100 2 0.944 PASSED 
USHBP1 9 9 FAILED FAILED 
MERIT40 100 0 0.960 PASSED 
ANKRD41 75 23 0.717 FAILED 
ABHD8 100 0 0.922 PASSED 
DDA1 100 0 0.938 PASSED 
MRPL34 100 0 0.972 PASSED 
TMEM16H 89 20 0.317 FAILED 
GTPBP3 98 18 0.925 FAILED 
 
Table 5.7: Quality control analysis performed for genotype specific expression for the 
Fluidigm assay. The quality control was performed based on the normal cell lines 
alone. 31 assays passed quality control. 
 
 
Chromosome SNP       Alleles   
(Major/Minor ) 
MAF 
HAPMAP 
CEU 
MAF in 
normal cell 
lines 
2 rs2072590 G/T 0.362 0.279 
3  
rs2665390 T/C 0.066 0.045 
rs344008 * C/T 0.066 0.066 
8 rs10088218 G/A 0.124 0.139 
9 rs3814113 T/C 0.372 0.350 
17 rs9303542 A/G 0.269 0.279 
19 rs2363956 
T/G 0.451 0.410 
rs8170 C/T 0.183 0.164 
 
Table 5.8: HAPMAP-CEU MAF of EOC risk associated SNPs compared to the 
calculated NOSE and FTE cell line MAF. Highlighted in red are the minor alleles of the 
SNPs. MAF: Minor allele frequency. (*) R2 =1 with rs2665390.  
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5.5.2 Genotype specific gene expression analysis and statistical tests 
performed- Extended study 
The gene expression analysis was performed as previously described 
using the comparative ΔΔCt method. The expression values of all cell lines 
were generated relative to the averaged Ct values of all common homozygotes 
per SNP. The normalization was performed against GAPDH and/or β-actin 
depending on which Fluidigm chip the genes were run.  
Differences in the relative expression of each candidate gene between 
EOC cell lines and NOSE cell lines were assessed using the nonparametric two 
sided Wilcoxon Rank sum test using R software and P values were generated. 
After Bonferroni correction for multiple testing (53 statistical tests throughout the 
6 loci) the cut-off value for statistical significance was 0.0009. Following 
correction for multiple testing none of the results remained significant.  
However, there were some genes that were significantly differentially 
expressed between common and the combined rare and heterozygote samples 
before Bonferroni correction as shown in Table 5.9. In chromosome 2, HOXD1 
was found to be over-expressed in rare homozygotes and heterozygotes 
compared to common homozygotes for SNP rs2072590 (P= 0.041). This finding 
could possibly suggest functional implication of the minor allele to the elevated 
expression of the gene (Figure 5.17 A). The most interesting finding of this 
analysis is the fact that the genotype of rs9303542 seems to be linked to the 
expression of three genes in chromosome 17.  CBX1 was over-expressed in the 
combined rare homozygotes and heterozygotes compared to the common 
homozygotes of this SNP (P value= 0.006, Figure 5.17 B). Both the expression 
of SNX11 and SP2 was higher in the common homozygotes suggesting a role 
of the minor allele of each SNP for down-regulation of these genes (Figure 5.17 
C & D respectively) with a P value of 0.028 and 0.030 respectively. Increasing 
even further the number of normal samples might add more power to the study.  
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Figure 5.17: Boxplots of differential expression of candidate genes relatively to the 
genotype of EOC associated SNPs. A) HOXD1 expression in normal cell lines 
relatively to rs2072590 genotype. B) CBX1, C) SNX11 and D) SP2 expression in 
normal cell lines relatively to rs9303542 genotype. Common: common homozygotes; 
Rare: rare homozygotes; Hets: heterozygotes. 
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Relative expression of common homozygotes compared 
to combined rare homozygotes and heterozygotes  
Sample 
Number 
CH/(RH+H) 
Median of 
Relative 
expression 
Median 
Absolute 
Deviation 
(MAD) 
Wilcoxon 
Rank 
sum test                 
(P value) 
CH RH+H CH RH+H 
2 
rs
2
0
7
2
5
9
0
 
G/T 
KIAA1715 22/28 0.98 1.18 0.35 0.32 0.516 
HOXD8 21/30 1.31 1.43 0.43 0.67 0.629 
HOXD1 (*) 18/20 1.95 3.23 0.91 1.98 0.041 
MTX2 23/28 0.76 0.77 0.21 0.22 0.659 
3 
rs
2
6
6
5
3
9
0
 
T/C 
SSR3 23/3 0.66 0.63 0.17 0.10 0.940 
TIPARP 23/3 0.64 0.79 0.20 0.13 0.395 
PA2G4P4 23/3 0.64 0.80 0.15 0.11 0.352 
rs
3
4
4
0
0
8
  
C/T 
SSR3 42/7 0.72 0.73 0.15 0.04 0.685 
TIPARP 42/7 0.71 0.90 0.17 0.10 0.179 
PA2G4P4 43/7 0.72 0.87 0.25 0.20 0.295 
8 
rs
1
0
0
8
8
2
1
8
 
G/A MYC 39/12 0.77 0.76 0.28 0.21 0.887 
9 
rs
3
8
1
4
1
1
3
 
T/C 
BNC2 22/27 0.87 0.73 0.34 0.29 0.353 
CNTLN 21/27 0.77 0.70 0.37 0.27 0.313 
17 
rs
9
3
0
3
5
4
2
 
A/G 
SP2 26/23 0.89 0.64 0.22 0.13 0.030 
PNPO 26/24 0.84 0.71 0.17 0.21 0.079 
CDK5RAP3 25/24 0.82 0.66 0.46 0.32 0.481 
COPZ2 26/24 0.86 0.41 0.50 0.18 0.360 
NFE2L1 26/25 0.81 0.86 0.24 0.36 0.772 
CBX1 25/24 0.70 0.43 0.19 0.13 0.006 
SNX11 26/24 0.89 0.68 0.16 0.15 0.028 
SKAP1 (*) 22/17 0.88 0.87 0.32 0.42 0.510 
HOXB3 19/23 0.86 0.94 0.53 0.54 0.653 
HOXB4 20/22 1.20 1.73 0.56 0.60 0.071 
HOXB6 20/24 1.12 1.47 0.44 0.68 0.420 
HOXB7 21/22 1.38 1.29 1.04 0.62 0.782 
HOXB9 17/23 0.71 0.87 0.49 0.52 0.705 
19 
rs
2
3
6
3
9
5
6
 
T/G 
SIN3B 18/31 1.14 1.12 0.27 0.28 0.382 
HAUS8 18/36 1.27 1.51 0.65 0.37 0.105 
MYO9B 18/33 0.99 1.12 0.23 0.27 0.395 
USE1 18/32 1.02 1.10 0.27 0.37 0.405 
OCEL1 18/32 0.96 0.96 0.38 0.44 0.772 
NR2F6 18/34 1.04 0.98 0.36 0.37 0.977 
MERIT40 18/32 0.87 0.91 0.42 0.26 0.881 
ABHD8 18/32 1.02 0.93 0.67 0.41 0.865 
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DDA1 18/32 0.87 1.07 0.32 0.40 0.555 
MRPL34 18/34 1.01 1.20 0.27 0.47 0.132 
rs
8
1
7
0
 
C/T 
SIN3B 37/16 0.78 0.75 0.19 0.24 0.752 
HAUS8 35/17 0.96 1.17 0.50 0.63 0.802 
MYO9B 37/16 0.88 0.72 0.37 0.44 0.425 
USE1 35/14 0.76 0.68 0.20 0.24 0.577 
OCEL1 38/16 0.89 0.61 0.38 0.26 0.076 
NR2F6 38/17 1.04 0.61 0.70 0.41 0.290 
MERIT40 36/15 0.70 0.71 0.43 0.39 0.927 
ABHD8 34/15 0.71 0.62 0.44 0.35 0.974 
DDA1 36/15 0.68 0.67 0.40 0.37 0.862 
MRPL34 37/17 0.87 0.61 0.59 0.50 0.605 
 
Table 5.9: Summary of genotype specific gene expression analysis for the extended list 
of candidate genes in the six risk loci. Tabulated are relative expression median values 
for the candidate genes compared between common homozygotes and combined rare 
homozygotes and heterozygotes. Highlighted in blue are the candidate genes initially 
selected with the closest proximity to the most significant SNPs in each locus. 
Highlighted in yellow are P values for assays that were statistically significant before 
application of multiple testing correction cut-off. (*) Genotype specific expression from 
those genes was assayed using the expression data from the pilot study as they failed 
QC in the extended study. CH: Common Homozygotes. RH+H: Rare Homozygotes + 
Heterozygotes combined. 
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 Investigating genotype specific methylation for CpGs in 5.6
the candidate genes- Pilot study 
 
I decided to investigate whether the EOC risk SNPs have a functional 
role in conferring disease susceptibility by regulating the methylation status of 
the candidate genes in healthy individuals. Within our unit a methylation 
analysis has been performed for approximately 27,000 CpGs mapping to 
promoters of 14,000 genes in germline DNA from 148 healthy controls 
(Teschendorff et al, 2009) that were also included as part of Phase II of our 
GWAS and had been genotyped for the SNPs of interest. A limitation of this 
study is that methylation is known to be tissue specific and it would be desirable 
to have methylation data from the cells of origin for EOC. 
I performed an analysis comparing the methylation status in CpG islands 
of the selected candidate genes and the different genotype groups of the 
significant SNPs. There were no methylation data available for CpGs in 
MERIT40 and SKAP1 gene promoters.  Initially, linear regression analysis was 
performed in order to compare methylation status between the 3 genotype 
groups; rare and common homozygotes and heterozygotes. However, because 
the sample size was small the rare homozygotes were further combined with 
the heterozygotes and compared to the common homozygotes. Wilcoxon rank 
sum test was then performed comparing the methylation status of the common 
and the combined heterozygotes & rare homozygotes. I found marginally 
significant associations between hypomethylation of CpG island cg19972619 of 
MYC and the common homozygote genotypes of SNP rs10088218 (P= 0.047). I 
also found association of hypomethylation of cg19001226 near the HOXD1 
gene with the common homozygote genotype of rs2072590 (P= 0.035). The 
results did not remain significant after Bonferroni correction (cut-off P value for 
statistical significance: 0.006 based on 8 statistical tests performed). Table 5.10 
summarises the findings of this analysis for all candidate SNPs. The box plots 
for significant methylation-genotype associations are shown in Figure 5.18 
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Figure 5.18: Genotype specific methylation analysis for CpG sites of HOXD1 and MYC 
genes. (A) Methylation data for cg19001226 of HOXD1 indicate that individuals 
carrying the common GG genotype of rs2072590 were hypomethylated compared to 
the combined rare homozygotes and heterozygotes. (B) Methylation data for 
cg19972619of MYC indicate that individuals carrying the common homozygous 
genotype of rs10088218 were hypomethylated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.10: Summary of genotype specific methylation analysis of candidate genes in 
loci 2q31, 3q25, 8q24 and 9p22 for the EOC risk associated SNPs (Pilot study). 
Tabulated are the CpGs’ median methylation (represented by β-values) of common 
homozygotes compared to the median methylation of combined rare homozygotes and 
heterozygotes. Highlighted in yellow are P values that are significant before Bonferroni 
correction. CH: Common Homozygotes. RH+H: Rare Homozygotes + Heterozygotes. 
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Many studies have shown that methylation status correlates with the age 
of the patients. Therefore, to ensure that the different age groups did not show 
differential methylation, which might have been responsible for the SNP 
associations with methylation I found, I performed linear regression analysis for 
methylation status across 3 age groups 50-59, 60-69 and >70 (Table 5.11). The 
methylation of the analysed CpGs was not affected by age. Thus, none of the 
positive associations I found were biased by age.  
 
 
 
 
 
 
 
 
Table 5.11: Linear regression analysis of candidate gene methylation based on 3 age 
groups. Group 1: 50-59 yrs, Group 2: 60-69 yrs, Group 3: >70 yrs. No significant 
association of age with methylation was found for the CpGs associated with the 
candidate genes.   
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 Genotype specific methylation for CpGs in the extended 5.7
group of candidate genes- Extended study 
I previously performed an analysis comparing methylation status of CpG 
islands in the six genes in closest proximity to the significant SNPs across the 
different genotype groups for the most significant SNPs identified by the GWAS. 
This analysis was performed using methylation and genotyping data from 148 
healthy controls. In that initial study I found significant associations between 
genotypes and methylation status of MYC CpG island cg19972619 for SNP 
rs10088218.  Also methylation in cg19001226 of HOXD1 gene was found to be 
significantly associated with rs2072590. However none of the results remained 
significant after Bonferroni correction. Increasing the sample size of this study 
could increase the power to detect stronger positive associations. 
Therefore, I have expanded this analysis by increasing the sample size 
to 256 healthy controls with an additional 108 healthy individuals available with 
methylation data (Teschendorff et al, 2010). Additionally, I evaluated genotype 
specific methylation for CpG islands in 47 of the candidate genes across the 6 
loci for which methylation data were available. In the initial analysis, because 
the sample size was smaller (n=148), the number of rare homozygotes was 
combined with the heterozygotes that contain the rare allele and Wilcoxon rank 
sum test analysis was performed between the common compared with the 
heterozygotes and rare combined. For the extended analysis, in order to 
compare with the pilot study, I also performed Wilcoxon rank sum test to 
investigate the methylation status of the combined rare homozygotes and 
heterozygotes compared to the common homozygotes’ methylation status. 
However, because the sample size was larger (methylation data from peripheral 
blood DNA from 256 unaffected individuals compared to 148 previously used in 
the pilot study) I also performed linear regression analysis in order to compare 
methylation status between the 3 genotype groups, rare and common 
homozygotes and heterozygotes (Appendix 3, Tables 2-4). 
In the present analysis the statistical significant cut-off P-value was 
0.0007 after Bonferroni correction for multiple testing (statistical tests 
performed=71). A summary of the genotype specific methylation analysis, using 
the Wilcoxon rank sum test analysis, performed for the extended list of genes is 
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presented in Table 5.12 for the risk loci of chromosomes 2, 3, 8, 9 and in Table 
5.13 for the risk loci of chromosomes 17 and 19. The associations found in the 
pilot study did not remain after analysis in the bigger sample size. Significant 
associations were found between methylation status of CpG island cg01405107 
of HOXB5 and genotype of SNP rs9303542 and locus 17q21 (P= 2.11×10-5, 
Figure 5.18 A). In more detail, individuals carrying the common AA genotype of 
SNPs rs9303542 were hypermethylated at the CpG island cg01405107 of 
HOXB5 compared to the heterozygous and rare homozygous individuals. The 
association was also significant when linear regression was performed 
comparing the methylation status across the 3 different genotypes of this SNP 
(P= 5.56×10-6, Appendix 3, Table 3). It is interesting that methylation of 
cg01405107 reduced relatively to the presence of the minor allele with a distinct 
trend of the highest methylation in common homozygotes containing no copies 
of the minor allele, less methylation for the heterozygotes that contain one copy 
of the minor allele and the lowest level of methylation for the rare homozygotes 
containing two copies of the minor allele (Figure 5.19 B). 
 
 
 
 
 
 
 
 
Figure 5.19: Genotype specific methylation analysis for cg01405107 associated with 
HOXB5 gene relative to the genotype of SNP rs9303542. A) Differential methylation of 
cg01405107 of HOXB5 between common homozygotes and the combined rare 
homozygotes & heterozygotes of rs9303542. Wilcoxon rank sum test performed for the 
P value shown B) Differential methylation of cg01405107 of HOXB5 between common 
homozygotes and rare homozygotes and heterozygotes. Linear regression analysis 
was performed for the P value shown.   
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I also found other weak associations that did not remain significant after 
Bonferroni correction. In chromosome 17q21 associations were found between 
methylation status of cg16848873 in HOXB6, cg06760035 in HOXB4 and 
rs9303542 genotype (P= 0.005 and P= 0.031 respectively). Another association 
was observed between methylation status of cg10957151 in HOXD9 and 
genotype of SNP rs2072590 in 2q31 (P= 0.001). Finally, in locus 19p13, I found 
associations between methylation status of cg21435336 in ANKRD41, 
cg22734480 in ABHD8 and rs2363956 genotype (P= 0.004 and P= 0.038 
respectively). All the associations were also significant in linear regression 
analysis performed comparing the methylation between the three genotype 
groups (Appendix 3, Tables 2, 3, ,4). I found no association of methylation 
status of any CpG islands with SNP genotypes for any genes in the risk loci of 
chromosomes 3, 8, and 9.  
Finally, I investigated whether the age of the individuals would be 
associated with methylation status of the studied CpGs and thus driving the 
genotype specific methylation results. Similarly to the pilot study, I performed 
linear regression analysis for methylation status across 3 age groups 50-59, 60-
69 and >70. A summary of the linear regression analysis and P values 
generated to investigate if age affects methylation of the investigated CpGs is 
presented in Table 5.14. The methylation of the analysed CpGs was not 
significantly affected by age when the Bonferroni cut-off P value was used to 
evaluate the results. However, some weak associations were found between 
age and methylation status of CpGs associated with genes HOXD1, HOXD9, 
HOXD8, PVT1, SKAP1, HOXB2 and HOXB4 before Bonferroni correction. 
These results indicate that the most significant association found between 
HOXB5 CpG methylation and rs9303542 was not biased by age. 
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CH RH+H CH RH+H
cg10957151 0.174 0.157 0.020 0.022 0.001
cg14991487 0.053 0.050 0.007 0.009 0.393
cg15520279 0.036 0.033 0.009 0.008 0.350
cg21815667 0.074 0.075 0.009 0.007 0.863
cg00005847 0.150 0.151 0.017 0.015 0.509
cg18702197 0.053 0.054 0.007 0.008 0.663
HOXD1 cg19001226 0.041 0.042 0.006 0.006 0.730
MTX2 cg19280014 0.083 0.084 0.008 0.008 0.353
cg15423862 0.855 0.856 0.010 0.012 0.328
cg23873703 0.695 0.703 0.058 0.062 0.696
SSR3 cg24517609 0.073 0.071 0.006 0.007 0.936
cg22114222 0.022 0.021 0.002 0.002 0.240
cg24262469 0.196 0.208 0.022 0.023 0.199
cg19972619 0.044 0.044 0.004 0.004 0.769
cg27207274 0.071 0.072 0.006 0.006 0.178
cg13052755 0.886 0.886 0.014 0.011 0.428
cg13784855 0.038 0.037 0.003 0.003 0.785
9
rs
3
8
1
4
1
1
3
T/C BNC2 cg24341129 108/148 0.276 0.282 0.035 0.032 0.366
 Median β-value comparison between common 
homozygotes and combined rare homozygotes & 
heterozygotes
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Median Absolute 
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Table 5.12: Summary of genotype specific methylation of CpG islands associated with 
the extended list of candidate genes within loci in chromosomes 2, 3, 8 and 9. 
Tabulated are the CpGs’ median methylation (represented by β-values) of common 
homozygotes compared to the median methylation of combined rare homozygotes and 
heterozygotes. P values were generated using the Wilcoxon rank sum test. Highlighted 
in yellow are P values that are significant before Bonferroni correction. CH: Common 
Homozygotes. RH+H: Rare Homozygotes + Heterozygotes combined. 
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CH RH+H CH RH+H
cg02691091 0.906 0.904 0.007 0.007 0.352
cg14360917 0.530 0.517 0.040 0.027 0.057
cg00177698 0.037 0.036 0.004 0.004 0.085
cg10154655 0.041 0.042 0.004 0.004 0.283
cg03777405 0.062 0.064 0.008 0.007 0.313
cg06740897 0.083 0.086 0.012 0.015 0.745
cg11194725 0.053 0.052 0.005 0.004 0.229
cg17778721 0.040 0.040 0.006 0.006 0.620
cg08413153 0.111 0.116 0.012 0.013 0.207
cg12563480 0.035 0.036 0.006 0.006 0.667
cg05106502 0.368 0.378 0.039 0.034 0.439
cg12513481 0.067 0.067 0.012 0.008 0.705
HOXB2 cg25882366 0.260 0.275 0.044 0.046 0.640
HOXB3 cg12910797 0.841 0.848 0.021 0.017 0.531
cg02422694 0.040 0.040 0.004 0.004 0.907
cg04609859 0.034 0.033 0.005 0.004 0.399
cg06760035 0.033 0.034 0.003 0.003 0.031
cg08089301 0.035 0.035 0.004 0.005 0.901
cg14458834 0.118 0.127 0.019 0.023 0.082
cg21460081 0.078 0.080 0.007 0.008 0.278
cg21546671 0.115 0.120 0.016 0.020 0.607
cg25145670 0.075 0.078 0.010 0.010 0.231
cg01405107 0.273 0.234 0.041 0.054  2.11×10-5
cg16495265 0.081 0.081 0.008 0.009 0.861
HOXB6 cg16848873 0.456 0.498 0.080 0.077 0.005
cg06493080 0.051 0.050 0.008 0.009 0.912
cg09357097 0.062 0.062 0.007 0.007 0.970
cg12370791 0.030 0.031 0.003 0.003 0.559
cg13643585 0.028 0.026 0.003 0.003 0.450
cg00215066 0.949 0.950 0.005 0.005 0.847
cg01103836 0.962 0.963 0.003 0.003 0.869
cg01252496 0.510 0.503 0.015 0.019 0.050
cg08891270 0.035 0.034 0.002 0.003 0.882
cg07242565 0.033 0.033 0.003 0.003 0.705
cg16749578 0.166 0.164 0.022 0.023 0.901
ANKRD41 cg21435336 0.037 0.035 0.003 0.003 0.004
cg08145177 0.117 0.117 0.019 0.024 0.609
cg22734480 0.027 0.025 0.002 0.003 0.038
cg19390148 0.032 0.031 0.005 0.005 0.534
cg21061811 0.747 0.739 0.021 0.024 0.672
MRPL34 cg04914305 0.050 0.050 0.005 0.004 0.538
cg00215066 0.950 0.950 0.005 0.005 0.515
cg01103836 0.962 0.963 0.003 0.003 0.166
cg01252496 0.505 0.505 0.018 0.017 0.598
cg08891270 0.035 0.034 0.003 0.003 0.302
cg07242565 0.033 0.034 0.003 0.003 0.646
cg16749578 0.163 0.166 0.023 0.022 0.674
ANKRD41 cg21435336 0.036 0.036 0.004 0.003 0.276
cg08145177 0.118 0.113 0.022 0.026 0.320
cg22734480 0.025 0.026 0.003 0.003 0.058
cg19390148 0.031 0.031 0.005 0.006 0.405
cg21061811 0.735 0.749 0.027 0.019 0.403
MRPL34 cg04914305 0.050 0.050 0.004 0.004 0.881
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Table 5.13: Summary of genotype specific methylation of CpG islands associated with 
the extended list candidate genes within risk loci in chromosomes 17 and 19. 
Tabulated are the CpGs’ median methylation (represented by β-values) of common 
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homozygotes compared to the median methylation of combined rare homozygotes and 
heterozygotes. P values were generated using the Wilcoxon rank sum test. Highlighted 
in yellow are P values that are significant before Bonferroni correction. Highlighted in 
green are statistically significant associations of methylation status and genotype after 
Bonferroni correction.  CH: Common Homozygotes. RH+H: Rare Homozygotes + 
Heterozygotes combined. 
 
 
Chromosome Gene  CpG site  
Linear regression analysis   
for age affecting methylation 
in healthy controls (P value)  
2 
HOXD9 
cg10957151 0.334 
cg14991487 0.04 
HOXD8 
cg15520279 0.039 
cg21815667 0.842 
HOXD3 
cg00005847 0.295 
cg18702197 0.735 
HOXD1 cg19001226 0.047 
MTX2 cg19280014 0.684 
3 
KCNAB1 
cg15423862 0.827 
cg23873703 0.786 
SSR3 cg24517609 0.776 
TIPARP 
cg22114222 0.721 
cg24262469 0.665 
8 
MYC 
cg19972619 0.094 
cg27207274 0.712 
PVT1 
cg13052755 0.994 
cg13784855 0.008 
9 BNC2 cg24341129 0.249 
17 
SP2 
cg02691091 0.638 
cg14360917 0.487 
PNPO 
cg00177698 0.578 
cg10154655 0.605 
NFE2L1 
cg03777405 0.806 
cg06740897 0.893 
CBX1 
cg11194725 0.268 
cg17778721 0.414 
SNX11 
cg08413153 0.282 
cg12563480 0.985 
SKAP1 
cg05106502 0.647 
cg12513481 0.02 
HOXB2 cg25882366 0.019 
HOXB3 cg12910797 0.408 
HOXB4 cg02422694 0.782 
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cg04609859 0.06 
cg06760035 0.013 
cg08089301 0.208 
cg14458834 0.677 
cg21460081 0.452 
cg21546671 0.744 
cg25145670 0.454 
HOXB5 
cg01405107 0.148 
cg16495265 0.928 
HOXB6 cg16848873 0.173 
HOXB7 
cg06493080 0.229 
cg09357097 0.068 
HOXB9 
cg12370791 0.914 
cg13643585 0.391 
19 
MYO9B 
cg00215066 0.051 
cg01103836 0.311 
USE1 
cg01252496 0.64 
cg08891270 0.174 
NR2F6 
cg07242565 0.46 
cg16749578 0.471 
ANKRD41 cg21435336 0.42 
ABHD8 
cg08145177 0.134 
cg22734480 0.336 
DDA1 
cg19390148 0.699 
cg21061811 0.515 
MRPL34 cg04914305 0.146 
MYO9B 
cg00215066 0.051 
cg01103836 0.311 
USE1 
cg01252496 0.64 
cg08891270 0.174 
NR2F6 
cg07242565 0.46 
cg16749578 0.471 
ANKRD41 cg21435336 0.42 
ABHD8 
cg08145177 0.134 
cg22734480 0.336 
DDA1 
cg19390148 0.699 
cg21061811 0.515 
MRPL34 cg04914305 0.146 
 
Table 5.14: Linear regression analysis of methylation in CpGs associated with the 
extended list of candidate genes’ based on 3 age groups. Group 1: 50-59 yrs, Group 2: 
60-69 yrs, Group 3: >70 yrs. 
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 Discussion 5.8
5.8.1 Functional follow up of moderate risk susceptibility loci emerging 
from GWAS  
Several GWAS have been performed over the last years that have 
identified multiple susceptibility loci for several common disease traits including 
several cancers. Although some risk variants lie in coding sequences, the vast 
majority reside in non-coding regions, including intergenic and intronic regions 
as well as gene deserts. Therefore, the observed associations cannot 
immediately provide us with a full understanding of the genetic mechanism 
underlying disease susceptibility, nor the genes involved. Post-GWAS functional 
characterisation studies in other types of cancer have identified genes that are 
implicated with disease development based on proximity to the risk loci. In 
breast cancer, after the identification of the risk locus 10q26, the gene FGFR2 
was implicated with disease susceptibility and later it was shown that the 
genotype of the risk variant located in the coding region of the FGFR2 affects 
the transcript levels of the gene (Meyer et al, 2008). Several other genes have 
been implicated with cancer development after being investigated as candidates 
emerging form GWAS in breast, prostate, colorectal and lung cancer (Reviewed 
in Freedman et al, 2011). 
So far the ovarian cancer GWAS performed has identified six confirmed 
low/moderate susceptibility loci for EOC. In the present study, I investigated 
whether these loci can provide insights into genes involved in EOC 
development. I have also looked at the mechanisms by which the risk 
associated SNPs may exert their susceptibility effect. These loci contain several 
genes that may be involved in EOC development. I investigated the functional 
relevance of candidate genes within these loci initially choosing the genes in the 
closest proximity with the EOC rick associated SNPs and then expanding the 
investigation to include more genes located up to 1Mb away of these variants. 
For this purpose I examined the differential expression of the selected 
candidate genes between a panel of NOSE and EOC cell lines. I also evaluated 
the functional significance of SNPs at these loci that are associated with EOC 
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susceptibility assessing whether their genotype is regulating in-cis the 
expression and methylation of candidate genes. 
 
5.8.2 Functional role of candidate genes within the risk associated loci in 
EOC development  
There is no reference framework in the research community on how to 
study the function of common low risk susceptibility loci, and so my initial aim 
was to establish the protocol and principles of these studies by investigating 
genes that were in the closest proximity to the most significantly risk associated 
SNP at each locus.  
The first locus identified in the GWAS was locus 2q31 with the most 
significant SNP rs2072590, a non-coding SNP. This SNP is located within a 
non-coding hypothetical gene LOC401022 and there are no known functions for 
this SNP (http://PupaSuite.bioinfo.cipf.es/). This gene is found within the HOXD 
gene cluster between genes HOXD1 and HOXD3 (Goode et al, 2010). The 
HOXD gene cluster presents a family of transcription factors involved in 
morphogenesis, differentiation and development. Genes of this family have 
been previously shown to be implicated in lung adenocarcinomas, melanoma 
(Okubo et al, 2002), colorectal cancer and breast cancer and implicated more 
generally in neoplastic development with a loss of function role. More 
specifically, in colorectal cancer and lung adenocarcinomas a tumour 
suppressor role for HOXD1 has been proposed as it was found to be 
epigenetically silenced through hypermethylation of CpG islands in this locus 
(Jacinto et al, 2007, Shiraishi et al, 2002). A genome wide screen recently 
showed that HOXD1 is frequently hypermethylated and can serve as a reliable 
biomarker to detect early stages of breast cancer (Jeschke et al, 2012). It is 
only in an early study that gain of function role of HOXD1 for neoplastic 
development has been proposed for human neuroblastoma by showing 
increased expression of HOXD1 in human neuroblastoma cell lines (Manohar et 
al, 1996).  
The second locus identified was at 3q25 with the most significant SNP 
rs2665390 (Goode et al, 2010). There are no known functions for this SNP 
which is located within an intron of TIPARP. TIPARP is a gene coding for a 
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poly-ADP-ribose polymerase that may play a role in adaptive response to 
chemical exposure (Diani-Moore et al, 2010). Another member of the PARP 
superfamily is PARP1 which has a role in the DNA repair pathway. It has been 
reported that cells deficient in BRCA1 and/or BRCA2 can survive using the 
PARP pathway as an alternative DNA repair pathway (Farmer et al, 2005).  
PARP1 is also reported to be involved in transcriptional control and cellular 
differentiation (Masutani et al, 2002, Ji et al, 2010). 
The third locus was 8q24 and the most significant risk associated SNP at 
this locus rs10088218. This SNP is an intergenic non-coding SNP with unknown 
function located downstream of MYC but in an apparent gene desert. This could 
be an indication that this SNPs is capable of regulating MYC from a distance or 
possibly that the real gene target regulated by the variant is not MYC. It is worth 
noting that 8q24 locus is rich in miRNA sequences that could be possibly the 
regulated targets for the variants of this locus. Other studies have also reported 
variants at 8q24 associated with susceptibility to several cancer types such as 
breast, prostate, colon and bladder cancers (Tenesa et al, 2008, Ghossaini et 
al, 2008, Kiemeney et al, 2008, Yeager et al, 2009, Al Olama et al, 2009). Most 
of the identified risk variants previously reported are located 5’ of MYC but the 
EOC risk SNP lie 700kb 3’ of MYC. However, I chose to investigate the MYC 
even though it wasn’t the closest in proximity with the risk variant because it is a 
well-established oncogene and to evaluate whether this would be reflected on 
the expression data obtained. 
The fourth locus was 9p22 with the most significant SNP rs3814113, an 
intergenic non-coding SNP with unknown function in close proximity to the gene 
Basonuclin-2 (BNC2) (Song et al, 2009). A recent study found no evidence of 
an association of this SNP with ovarian cancer risk in women with 
endometriosis (Sundqvist et al, 2011) but another study has found an 
association with an increased risk of suspicious abnormal transvaginal 
ultrasounds in women with no ovarian cancer (Wentzensen et al, 2011). BNC2 
codes for a zinc finger DNA binding protein that is highly conserved and is 
suggested to be involved in DNA transcription. BNC2 has been reported to have 
the potential to generate 90,000 different mRNA isoforms to be translated to 
2,000 proteins (Vanhoutteghem et al, 2007). BNC1 and BNC2 have been 
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shown to be implicated in differentiation of oocytes and being highly expressed 
in ovary testis and skin keratinocytes, indicating a role in melanoma (Romano et 
al, 2004). The first report for BNC2 related to cancer was that it has been shown 
in microarray analysis to be over-expressed in basal cell carcinoma compared 
to normal skin (O’Driscoll et al, 2006). BNC2 was proposed to act as a tumour 
suppressor gene after it was shown to be encompassed within a homozygously 
deleted locus and found under-expressed in glioblastoma, and causing growth 
arrest of oesophageal adenocarcinoma cells (Nord et al, 2009, Akaqi et al, 
2009).  
The fifth locus was at 17q21 with the most significant SNP rs9303542. 
There are no known functions for this SNP and it is located within an intron of 
SKAP1. SKAP1 has been shown to regulate mitotic progression at the transition 
from metaphase to anaphase (Fang et al, 2009). Low expression of SKAP1 has 
been implicated with poor prognosis in breast cancer and SKAP1 function is 
proposed to predispose to sensitivity to paclitaxel by maintaining chromosome 
stability and mitotic fidelity (Burell et al, 2009). SKAP1 has recently been shown 
to be involved in regulating the NF-κB pathway during T-cell activation. NF-κB 
activates the expression of genes that keep the cell proliferating (Burbach et al, 
2011).  
The sixth locus was 19p13 with rs8170 and rs2363956 identified initially 
in association with survival in ovarian cancer case but later on also shown to be 
associated with disease risk driven by the serous subtypes (Bolton et al, 2010). 
rs8170 and rs2363956 are non-synonymous coding SNPs with unknown 
function located within MERIT40 and ANKRD41 genes respectively. No known 
function for ANKRD41 is reported in the literature. MERIT40 is a very interesting 
gene as its coded protein has been reported to interact with BRCA1, RAP80, 
BRCC45 and CCDC98. Through this interaction MERIT40 regulates the 
recruitment of BRCA1 at double strand DNA breaks, maintains stability of this 
complex at the sites of DNA damage and has been shown to play a role in cell 
cycle progression (Feng et al, 2009, Shao et al, 2009, Wang et al, 2009). 
In order to evaluate the functional role of the candidate genes at these 
loci in EOC development I compared the expression of each candidate gene in 
48 NOSE versus 24 EOC cell lines. I found that there was significantly higher 
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expression of BNC2 and TIPARP in NOSE cell lines compared to EOC cell lines 
which may indicate a tumour suppressor role for these two genes. On the other 
hand, the expression of HOXD1, MYC, SKAP1 and MERIT40 was significantly 
higher in EOC cell lines compared to NOSE cell lines perhaps suggesting a 
gain of function role for these genes in EOC development, something that is 
already well-established for MYC. HOXD1 is reported to act as a tumour 
suppressor gene in several other cancers and my study is the first one 
supporting an a gain of function role of this gene in carcinogenesis.  
Expression microarray analysis of an in vitro model of neoplastic 
transformation of IOSE cells supported some of the findings from my expression 
analyses; BNC2 and TIPARP expression decreased significantly with each 
additional oncogenic event, as the cells acquired a more neoplastic phenotype.  
The proposed loss of function role for those two genes was also strongly 
supported by showing higher expression in normal FT tissue compared to 
serous ovarian carcinomas. The observed over-expression of SKAP1 in EOC 
cell lines was not consistent with the in vitro IOSE transformation model, where 
it was not statistically significant differentially expressed, although there was a 
trend towards increased expression in progressively transformed IOSE cells. By 
contrast, SKAP1 appeared to be highly expressed in the normal FT from TCGA 
data compared to EOC suggesting instead a tumour suppressor role for this 
gene in EOC development. Additionally, the observed over-expression of MYC 
and HOXD1 in EOC cell lines was not consistent with the TCGA data where 
MYC and HOXD1 did not appear to be differentially expressed between normal 
FT and SOC. Because MYC is a well-established oncogene in EOC 
development; while there was marginal, significant over-expression of the gene 
in EOC cell lines, one might have expected this to be more significant. With 
HOXD1, the observed over-expression in EOC should be treated with more 
caution: Firstly, the expression of the gene in both EOC and NOSE cell lines 
was just marginally detectable; secondly, several previous reports in other types 
of cancer for this gene suggest it acts as a tumour suppressor gene. 
The contradictions between the different models might be attributed to 
the nature of the models analysed or simply chance observations. The IOSE in 
vitro transformation model does not resemble serous events and that might be 
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the explanation for the differences observed since most of the EOC cell lines I 
used were of serous subtype. As previously discussed, the normal FT mRNA 
used by TCGA was obtained from whole fallopian tube tissue rather than from 
the specific cells of origin for EOC, which are the fallopian tube epithelial cells 
probably of secretory lineage. Thus it is conceivable the expression of many 
genes in the epithelial and stromal cells contained in these samples may 
considerably vary and due to the high proportion of stromal cells to provide 
misleading results when compared with SOC samples. Additionally, the EOC 
cell lines used were of several subtypes and may not represent an ideal model 
to study a gene that is involved in development of certain EOC subtypes only. 
Finally, the expression data from TCGA were generated using gene expression 
microarrays and it may be that experimental variation between RT-PCR and 
array approaches can produce different results. Previous research has shown 
that the differential expression of genes from microarray analysis is not always 
in agreement with Real time PCR results (Kothapalli et al, 2002). 
Finally, MERIT40 over-expression observed in EOC cell lines was not 
consistent with the in vitro transformation model of IOSE cells. However, this 
could just mean that MERIT40 and HOXD1 are involved in EOC development 
through another pathway than the MYC/KRAS pathway that was used to 
transform the IOSE cells. MERIT40 was also significantly over-expressed in 
SOC supporting the gain of function role for this gene I propose based on the 
EOC versus NOSE expression model. Additionally, supporting the gain of 
function role for MERIT40, Dr Chris Jones within our group has performed array 
Comparative Genomic Hybridization (aCGH) analysis to evaluate genomic 
alterations at the 19p13 locus containing MERIT40. This analysis revealed copy 
number gain/amplification of the p-arm of chromosome 19 in 45% of 105 tumour 
samples. This may suggest that target genes in this region including MERIT40 
are functionally activated during tumour development. Additionally, according to 
TCGA, SOC samples that were found to have high expression of MERIT40 are 
shown to have copy number gains and amplifications at this locus 
(www.cbioportal.org).  
Initially, I chose candidate genes for analysis that were in close proximity 
to the risk variants within the six loci. Based on the results previously described 
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TIPARP, HOXD1, MYC, BNC2, SKAP1, MERIT40 were proposed to be 
involved in EOC development. However, it is possible that other genes within 
these loci have a higher or an additional significance in the development of 
EOC. Therefore, I performed a multiplex Fluidigm gene expression assay 
investigating several genes in each locus including the ones investigated in the 
initial study in the closest proximity to the risk variants. This also allowed me to 
validate the results of my initial analysis of genes in closest proximity in a larger 
panel of cell lines. I also added fallopian tube epithelial (FTE) cell lines (n=5) to 
the panel given the proposed dual origin for ovarian cancer to comprise the 
normal cell lines that their expression would be compared to a larger panel of 
44 EOC cell lines.  
Of the 62 genes investigated in total 33 only remained after quality 
control analysis. One should not be too concerned regarding the failure of 
almost 50% of the assays in this experiment because it is possible that many of 
the genes investigated did not have a high enough expression in ovarian cell 
lines to be detected as gene expression is tissue specific.  
After analysing the remaining additional candidate genes in locus 2q31, 
MTX2 (Metaxin 2), a gene located 1kb downstream rs2072590, seems to be an 
interesting candidate as it was found over-expressed in EOC cell lines 
compared to normal cell lines consistent with the TCGA expression analysis. 
The result did not remain significant after Bonferroni correction though so 
should be treated cautiously. MTX2 is coding for a protein involved into 
transporting proteins into the mitochondrion. MTX2 abnormal expression has 
been previously reported to be associated with poor prognosis linked to 
resistance in a distinct group of acute myeloid leukaemia (AML) patients that 
have normal cytogenetics and was difficult to identify with conventional 
cytogenetic analysis (Vey et al, 2004).  
The investigation of additional genes in locus 3q25 revealed that TIPARP 
remains the most significantly associated gene with EOC development within 
this locus being very significantly under-expressed in EOC compared to normal 
cell lines (P= 4.99×10-5)  and also in SOC compared to normal FT (P= 1.11×10-
4). Additionally, the gene PA2G4P4 (proliferation associated 2G4 pseudogene) 
was found significantly over-expressed in EOC cell lines compared to normal 
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cell lines (P= 2.14×10-5). This gene has a great homology with the mouse cell 
cycle-protein p38-2G4 involved in proliferation (Lamartine et al, 1997). There is 
no established function reported for this gene or any known implications in 
cancer. 
Interestingly, for locus 8q24 the previously observed slight over-
expression of MYC in EOC cell lines did not remain significant in the extended 
analysis although a similar trend was observed in the boxplot (Figure 5.13 B). 
The other gene studied on this locus, PVT1 (plasmacytoma variant 
translocation 1) is a gene downstream MYC in closer proximity to the risk 
associated SNP and was found to be the most functionally significant gene in 
this region with a very significant over-expression  of the gene observed in EOC 
compared to the normal cell lines (P= 6.6×10-8).  
The exact functional role of PVT1 has been enigmatic for more than two 
decades since the gene was identified because although PVT1 gene directs the 
synthesis of a large transcript no protein product had been identified. A cluster 
of putative micro RNAs (miRNAs) (miR-1204~1208) has been identified within 
the PVT1 genomic locus with a functional role in T lymphomagenesis in Burkitt’s 
lymphomas (Huppi et al, 2008, Beck-Engeser et al, 2008). This gene is reported 
to act as a potential oncogene. It was found to be over-expressed in several 
transformed cell lines such as neuroblastoma cells (Carramusa et al 2007). The 
inactivation of PVT1 has also been shown to restore sensitivity in Gemcitabine 
chemotherapeutic drug in pancreatic cancer (You et al, 2011). It has also been 
shown to from a fusion gene with CDH7 (cadherin 7), coding for a membrane 
protein, which is found amplified in small cell lung cancer (Pleasance et al, 
2010).  
According to TCGA 30-32% of a total of 316 SOC had amplifications in 
the MYC and PVT1 loci (www.cbioportal.org). The observed over-expression for 
PVT1 but not for MYC in the EOC cell lines was puzzling. However, despite the 
long history of MYC as an oncogene there is a lot of recent evidence that shows 
that PVT1 may be the driver gene of the amplifications found in this locus in 
EOC. One study has shown that PVT1 but not MYC is strongly over-expressed 
in ovarian tumours with genomic amplifications compared to normal FT (Haverty 
et al, 2009). It has also been shown that knocking down MYC and PVT1 in 
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ovarian cancer cell lines caused reduced proliferation but only PVT1 knockdown 
caused increased apoptosis. In the same study it was shown that some EOC 
cell lines did not overexpress MYC whereas transcription levels of PVT1 were 
high in all cell lines, and that in EOC cell lines with no amplification of the 8q24 
locus, MYC was not over-expressed but PVT1 was (Guan et al, 2007). Thus, it 
is possible that in the increased number of EOC cell lines used in the extended 
analysis I performed, more cell lines were incorporated with low MYC 
expression and masked the over-expression previously observed in the smaller 
subset.  
The induction of PVT1 transcript synthesis is not clear. Guan and 
colleagues have shown that PVT1 and MYC act independently (Guan et al, 
2007) but other studies have shown that MYC binds to the promoter of PVT1 
activating its transcription (Carramusa et al, 2007) whereas others support that 
PVT1 encoded miRNAs are regulating MYC itself (Huppi et al, 2008). A recent 
study has shown that PVT1 is a p53-inducible target gene (Barsotti et al, 2012). 
A recent review has emphasized the significance of locus 8q24 in 
carcinogenesis as being gene desert rich in non-coding regulatory elements 
such as miRNAs and raises awareness of other transcripts besides MYC in the 
8q24 region as possible candidate genes in malignancy formation (Huppi et al, 
2012). My finding is supported by the relevant research performed for PVT1 
proposing an important role in ovarian cancer development and in other 
malignancies.  
In locus 9p22, BNC2 remained the most significant candidate gene as I 
found it was over-expressed in EOC cell lines compared to normal (P= 6.64×10-
4) confirming the loss of function role proposed for this gene in the pilot study. 
  Locus 17q21 is a gene rich region and several genes were selected to be 
investigated in a region of ~1.2 Mb. The data for the candidate genes of this 
locus were often inconsistent between the EOC versus normal analysis and the 
SOC versus normal FT analysis from TCGA. Three genes of the HOXB 
(homeobox B) cluster of genes were found to be significantly over-expressed in 
EOC cell lines compared to normal but in contrast appeared under-expressed in 
SOC compared to normal FT according to the TCGA expression data analysed. 
The genes with the observed contradicting expression were HOXB3, HOXB4 
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and HOXB6, the results for which remained significant after Bonferroni 
correction for both models studied. HOXB7 and HOXB9 also were found over-
expressed in EOC cell lines but no differential expression was found in the SOC 
compared to normal FT.  
HOXB genes function as transcription factors for the developmental 
regulatory system. HOXB3 and HOXB4 have been previously found to be 
expressed significantly higher in ovarian cancer cell lines compared to normal 
ovaries based on mRNA (Yamashita et al, 2006) and protein expression 
analyses (Hong et al, 2010) in line with the results of this study. HOXB4 has 
been also found to be over-expressed in cervical cancer compared to normal 
adult cervical epithelium (Lopez et al, 2006). HOXB3 has been shown to have 
abundant expression in breast cancer and regulated by miRNAs plays a critical 
role in the epigenetic silencing of tumour suppressor genes inducing the growth 
of transformed cell lines (Li et al, 2012) Additionally, HOXB3 expression has 
been found elevated in acute myeloid leukaemia (AML) (reviewed by Eklund, 
2011) and involved in chemoresistance of AML cases (Kuhnl et al, 2011). There 
are no previous reports for a role of HOXB9 in ovarian cancer. Elevated 
expression of HOXB6 was found to be a common event in ovarian tumours after 
serologic analysis of ovarian tumour antigens (Stone et al, 2003). HOXB7 over-
expression has been shown to increase proliferation of IOSE cell lines and has 
been found expressed in markedly higher levels in ovarian carcinomas 
compared to normal ovarian surface epithelium (Naora et al, 2001). Additionally, 
knocking down HOXB7 in ovarian cancer cell lines has reported to cause an 
85% reduction to their invasion abilities (Yamashita et al, 2006). All the previous 
work proposes an involvement in malignancy formation for all the studied HOXB 
genes in several types of cancers included ovarian cancer suggesting that they 
may act as oncogenes and this is in line with the gain of function role in EOC 
proposed for the HOXB genes in this study.  
Three more genes of this locus were found to be over-expressed in EOC 
compared to normal cell lines, suggesting a possible gain of function role in 
EOC for them, PNPO, SP2 and CBX1. PNPO (pyridoxamine 5'-phosphate 
oxidase) is coding for a protein that is involved in the formation of the active 
form of Vitamin B6 which has been shown to confer sensitivity of breast cancer 
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cells to tamoxifen (Aldhaheri et al, 2006). The functional role of PNPO in 
malignancy formation has not been studied. SP2 is coding for an evolutionary 
conserved transcription factor for genes that are involved in development and 
cell cycle progression and it has been shown that it was required for normal 
progression of embryonic development in mice (Baur et al, 2010). To my 
knowledge there are no extensive evidence suggesting the implication of SP2 
with human cancer development. There is one report suggesting that the 
expression of SP2 is directly correlated with the progression of murine 
squamous cell carcinomas. In this study, the observed SP2 over-expression 
inhibited keratinocyte differentiation rendering those cells susceptible to 
neoplastic development proposing a role for SP2 as an oncogene (Kim et al, 
2010). CBX1 (chromobox homolog 1) is coding for one of the heterochromatin 
proteins that are involved in chromatin packing and gene regulation. An 
important finding regarding CBX1 has been the report that following DNA 
breaks it is mobilized and released from chromatin to initiate DNA damage 
response (Ayoub et al, 2008). Thus, it is attractive to speculate that the CBX1 
over-expression in EOC cell lines may suggest that the gene involved in EOC 
through activation of DNA damage response pathways inducing DNA repair in 
late stages of EOC rendering cancer cells resistant to platinum agents. 
MERIT40 in locus 19p13 was considered a strong candidate gene for 
association with EOC development due to its proposed function in homologous 
recombination as part of the BRCA1 complex and as it was found to be over-
expressed both in the EOC cell lines versus NOSE in the pilot and extended 
studies consistent with over-expression in SOC versus normal FT. The over-
expression of MERIT40 in EOC cell lines may seem as an apparent paradox to 
be linked with EOC susceptibility since BRCA1 is expected to show loss of 
function in its role in the repair or DNA DSBs for EOC initiation. One hypothesis 
would be that over-expression of MERIT40 may ectopically stabilize mutant 
BRCA1 protein into the assembled complex. Since MERIT40 makes cells more 
resistant to ionizing radiation (Shao et al, 2009), MERIT40 over-expression may 
be implicated in EOC initiation by protecting cells with dysfunctional BRCA1 and 
DNA DSB repair activity and enabling them to tolerate more DNA damage. 
However, it is probable that the expression analysis performed could be 
Chapter 5: Post-GWAS characterisation of risk loci 
 
311 
 
unrelated to the susceptibility SNPs and could just be an indication of the 
somatic role of the candidate genes in EOC development rather than 
susceptibility. Thus, the possible functional role of MERIT40 in the initiation of 
serous subtype EOCs and if it is the target susceptibility gene at the 19p13 
locus can only be speculated. Since these results are probably reflecting the 
somatic role of MERIT40 in EOC development the proposed gain of function 
role for this gene in EOC may be exerted by providing cancer cells increased 
ability to repair DNA DSBs caused by spontaneous endogenous stress or 
platinum drugs thus promoting progression and survival in EOC tumours. This 
hypothesis is also supported with previous reports that have shown BRCA1 to 
be reactivated in advanced tumours providing chemoresistance to platinum 
therapy. Future work to elucidate the possible functional role of MERIT40 in 
EOC development seemed very attractive, and this has been pursued in 
chapter 6 of this thesis.  
The most statistically significant difference in expression for this locus, 
were for the genes HAUS8 and USE1. Both were found to be over-expressed in 
EOC compared to normal cell lines indicating a gain of function role for those 
genes in EOC development (P= 2.09E×10-5 and P= 1.08E×10-6 respectively).  
HAUS8 was also found over-expressed in SOC compared to normal FT but 
USE1 was not differentially expressed between them. HAUS8 is a centrosomal 
microtubule-binding protein involved in mitotic spindle assembly and the 
process of cytokinesis (Wu et al, 2009). USE1 function is not very understood 
yet but it may function in the Golgi apparatus and in endosome lysosome 
transport (www.genecards.org). To my knowledge there are no reported 
implications of HAUS8 or USE1 genes with cancer. 
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5.8.3 Evaluating genotype specific gene expression and genotype 
specific methylation for the GWAS candidate genes 
In silico analyses in PupaSuite of risk-associated and strongly-correlated 
SNPs (r2>0.8) failed to find compelling evidence for any functional role. I 
therefore investigated the possible functionality of the SNPs that were found in 
association with EOC susceptibility into regulating in cis the transcriptional 
output of candidate genes in each respective locus. For this, I evaluated 
whether there was any genotype specific expression of the candidate genes 
relative to the genotypes of the significant SNPs.  
Increased DNA methylation and reduced tumour expression implicated 
more than 100 of genes as epigenetically silenced in high grade serous ovarian 
cancer samples compared with fallopian tube controls according to TCGA. 
Increased DNA methylation has been shown to be correlated with reduced gene 
expression across all the samples (The Cancer Genome Atlas Research 
Network, 2011). Thus, based on the critical role methylation status plays in 
gene expression, I investigated whether the genotype of the risk associated 
SNPs affects the expression of the candidate genes and whether there would 
be a link between genotype affecting gene expression and methylation of the 
same genes.  
Initially, in a pilot study I investigated the expression of the seven 
candidate genes I selected on close proximity to the risk associated SNPs 
relative to the genotypes of those SNPs in 35 NOSE cell lines. I found no 
evidence of genotype specific expression for the genes initially analysed. I then 
decided to investigate genotype specific gene expression for the close proximity 
candidate genes in a greater number of genotyped samples for the risk 
associated SNPs (n=56 NOSE and FT samples). Additionally, I extended the 
study and analysed genotype specific gene expression of the whole panel of 
selected candidate genes across the six loci. I did not find any significant 
associations in the pilot study but I found a few in the extended study which 
however did not remain significant after Bonferroni correction for multiple 
testing. Regardless, the results will be discussed assuming that increasing the 
number of tested samples in the future may improve the power of the study.  
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The first genotype association with gene expression I found was between 
expression of HOXD1 and the genotype of the rs2072590 in locus 2q31. 
Individuals carrying the minor allele T (rare homozygotes TT and heterozygotes 
GT) had over-expressed HOXD1 (P= 0.041) compared to individuals carrying 
the common genotype (GG). It is interesting that HOXD1 was found to be over-
expressed in EOC cell lines compared to normal proposing a gain of function 
role in EOC development. This observation together with the fact that the minor 
allele was associated with an increase in the transcript output of HOXD1 may 
suggest that the reported in the GWAS increased risk for susceptibility in EOC 
of the minor allele of rs2072590 might be associated with a functional role of 
this SNP by regulating the expression of a potential oncogene, HOXD1. The 
result should though be validated in the future in a larger sample size.  
Genotype specific methylation analysis was performed to reveal whether 
the mechanism of a potential functional role of rs2072590 is exerted by 
epigenetically regulating the expression of the gene. In the pilot study 
performed to investigate genotype specific methylation I evaluated genotype 
specific methylation of CpGs of 148 healthy individuals in the candidate genes 
in close proximity to the significant SNPs including rs2072590. This analysis 
produced a marginally significant result proposing genotype specific methylation 
for cg19001226 of HOXD1 (P= 0.035) for SNP rs2072590. Individuals carrying 
the common (GG) genotype were found to be hypomethylated in cg19001226 
proposing that the minor allele was associated with hypermethylation of 
cg19001226 which may lead to epigenetically decreased expression of the 
HOXD1. This would pose as a contradiction since the minor allele is the risk 
associated allele and HOXD1 was found over-expressed in EOC cell lines 
posing as a potential oncogene for EOC. However, in the extended study I 
revaluated the methylation status of cg19001226 in 256 healthy individuals the 
rs2072590 genotype association with methylation was not validated which is 
why I conclude that the regulatory role of rs2072590 is probably not exerted by 
epigenetically regulating the expression of the gene.  
SNP rs2072590 is located within the non-protein coding RNA gene 
LOC401022 between HOXD1 and HOXD3. This non-coding gene is also called 
HOXD cluster antisense RNA and is a long antisense non-coding RNA which is 
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a non-coding transcript longer than 200 nucleotides and that is what is 
differentiating this group of non-coding RNAs from small regulatory RNAs such 
as miRNAs. There is no reported function for this non-coding RNA 
(http://lncrnadb.com). Long non-coding RNAs exist in abundance in the human 
genome and may serve as primary transcripts for the production of short RNAs 
(Kapranov et al, 2007). Some have been reported to have a role in the 
regulation of gene transcription by modulating the function of transcription 
factors. For example, the long non-coding RNA Evf-2 is functions as a co-
activator with the homeobox transcription factor Dlx2 (Feng et al, 2006).  
Thinking of the potential mechanism by which rs2072590 exerts its 
regulation on HOXD1 expression one could speculate that it may be through 
regulating the production of LOC401022 which in turn could act as 
transcriptional regulator of HOXD1. The common allele might be responsible for 
producing the antisense transcript that causes post transcriptional regulation of 
both copies of HOXD1 via RNA interference and thus individuals carrying the 
minor/risk allele might deregulate the HOXD1 post-transcriptional inhibition 
which could partially explain the increased risk to EOC susceptibility if we 
accept the proposed role of HOXD1 as an oncogene in EOC. This hypothesis is 
supported by a recent study that has identified associations of miRNAs 
expression and the genotype of rs2072590 (Shan et al, 2012). Following this 
report I have investigated which miRNAs were found to be regulated by 
rs2072590 in this study and have looked in publicly available miRNA function 
databases to try and identify whether any of those miRNAs would be reported to 
target HOXD1. I did not identify exact matches but miRNAlet-7a* (let-7 miRNA 
produced from the 3’ of the transcript) was differentially expressed relative to 
rs2072590 genotype (P= 5×10-4) (Shen et al, 2012) and miRNAlet-7a (let-71 
miRNA produced from the 5’ of the transcript) is reported to target HOXD1 
(http://mirdb.org/miRDB). Increasing research is supporting the involvement of 
non-coding RNA transcripts in human tumorigenesis and non-coding RNAs 
have been found with altered expression in several types of cancer such as 
uterine cancer, hepatocellular carcinomas, leukaemia and ovarian cancer (Calin 
et al, 2007, Mallardo et al, 2008).  
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The most interesting genotype specific gene expression result, though 
not significant after Bonferroni correction, was the effect of rs9303542 genotype 
on the expression of three genes in locus 17q21 CBX1, SNX11 and SP2. 
Individuals with the minor allele (G) that was associated with an increased risk 
for EOC susceptibility in the GWAS, were found to have CBX1 over-expressed 
(P= 0.006). This gene was found over-expressed in EOC cell lines compared to 
normal cell lines and the minor allele might be conferring the increased risk to 
EOC partially by elevating the expression of the potential oncogene CBX1. 
Given the role of CBX1 in triggering DNA damage responses the genotype 
specific gene expression would suggest that rs9303542 may contribute to 
interindividual variability in drug response. Identification of such variants could 
be valuable as they could be used as biomarkers for individualising anticancer 
therapy. However, the latter hypothesis could be under debate since rs9303542 
has not been found associated with survival but only susceptibility in EOC.  
No association of rs9303542 genotype was found with methylation in the 
CBX1 gene locus. However, genotype specific methylation analysis showed 
that rs9303542 genotype was associated with methylation of cg0145107 of 
HOXB5. The minor allele was significantly associated with hypomethylation of 
cg0145107 (P= 2.11×10-5), which could suggest it may also be associated with 
increased expression of HOXB5, assuming there is a correlation between 
expression of HOXB5 and methylation for this CpG island. HOXB5 functions as 
a transcription factor for the developmental regulatory system. HOXB5 was 
found to be implicated with promoting differentiation in alveolar epithelial cell of 
the lung (Fu et al, 2008) and involved in the differentiation of the vascular 
endothelium from precursor cells (Wu et al, 2003). The expression assay for 
HOXB5 failed QC in this study, or the expression is very low in ovarian tissue to 
be detected, and thus I cannot propose a role of the gene in EOC development 
based on differential expression between the EOC and normal cell lines. 
HOXB5 was found under-expressed in SOC (P= 0.002) supporting a loss of 
function role for the gene in EOC development. Additionally, HOXB5 was found 
to be hypermethylated in ovarian carcinomas also suggesting that it may act as 
a tumour suppressor gene (Wu et al, 2007). However, there is a recent report 
though that supports HOXB5 may be acting as an oncogene as it was found 
Chapter 5: Post-GWAS characterisation of risk loci 
 
316 
 
over-expressed in oral squamous cell carcinoma (Tucci et al, 2011). Based on 
other reports and results of this thesis suggesting a potential tumour suppressor 
role of HOXB5 in ovarian cancer it seems a paradox that the risk associated 
minor allele of rs9303542 would be associated with epigenetically activating the 
expression of the gene. However, there is no evidence that this CpG is 
definitely affecting expression levels of the gene and no association of genotype 
and gene expression was found in this study. The biological basis of ovarian 
cancer development is very complicated and more work needs to be performed 
to elucidate the role of HOXB5 in ovarian carcinogenesis and the variants that 
may be regulating its function before drawing any conclusions.  
The rs9303542 minor allele was also found to be associated with the 
decreased expression of SNX11 and SP2 (P= 0.028 and P= 0.03 respectively). 
SNX11 and SP2 were significantly over-expressed in EOC cell lines (P=0.004 
and P= 5.6×10-10 respectively) suggesting a gain of function role for the genes. 
Again, it is puzzling why the allele that is conferring increased risk in ovarian 
cancer susceptibility would be associated with decreased expression of 
candidate oncogenes. It could be possible that allele specific LOH targeting the 
minor allele could be one mechanism involved in the increased expression of 
SP2 observed in EOC cell lines but that should be further investigated. 
Regardless of the difficulties in fully understanding the functional role of 
rs9303542 in the development of EOC it is very intriguing that the genotype of 
this SNP is affecting the expression of three genes and the methylation of 
another. 
Genotype specific methylation has not been extensively studied. There is 
one study that in the attempt to show that DNA methylation is subject to genetic 
control, reports very significant associations of SNPs’ genotype with DNA 
methylation levels near the polymorphism (cis-effects) and also weaker 
associations with DNA methylation in a further locus (trans-effects) (Boks et al, 
2009). Another study has used HapMap derived cell lines and identified 
associations between genotype and DNA methylation and gene expression at a 
genome-wide level. Their most significant finding was that the genotype of 
rs2187102 was associated with methylation status in a CpG in gene HLCS 
which is involved in gene regulation by mediating histone biotinylation. The 
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most interesting point of this study was that they observed a significant overlap 
between regulatory variation that affects both methylation and gene expression. 
Their hypothesis was that since DNA methylation can regulate gene expression 
then SNPs that are regulating methylation often would have effects seen on 
gene expression for the same locus (Bell et al, 2011). I have made a similar 
observation regarding HOXD1 methylation and expression being associated 
with the genotype of rs2072590 but unfortunately the methylation association 
did not remain significant when I increased the power of the study. In order to 
test the hypothesis regarding correlation of genotype specific methylation and 
gene expression, I would be very interested to know the potential genotype 
specific gene expression for HOXB5 for the SNP that was found to affect so 
significantly its methylation but the gene assay failed in the experiment 
performed. 
Several previous studies have also shown evidence of genotype specific 
expression in an attempt to elucidate the possible functional role of genetic 
variants. Keratin1 (KRT1) has been found to have extremely significant 
genotype specific expression in human white blood cells by SNPs that had 
differential affinity for transcription factors modulating KRT1 promoter (Yao et al, 
2006). Another study has shown differential expression of several genes in 
human white blood cells regulated by cis-elements in LD with the SNP of 
interest and proposed allele specific expression of these genes (Pant et al, 
2006). A recent study has showed that the risk allele of rs378854 is associated 
with increased expression of the PVT1 oncogene in locus 8q24. In this study 
they used mapping of DNase I hypersensitive sites in order to prioritise the 
regions that would be interesting to further analyse for their functional role 
(Meyer et al, 2011). In a study for breast cancer, microarray analysis was used 
to identify that the expression of FGFR2 gene is increased in the rare 
homozygote samples. They proposed that two cis-regulatory SNPs alter the 
affinity of transcription factors and synergistically they cause increase 
expression of FGFR2 (Meyer et al, 2008). 
Interestingly, the functional role of the risk associated SNPs that the 
ovarian cancer GWAS identified has been recently studied in regards with their 
associations with miRNAs in ovarian cancer. miRNAs act as post transcriptional 
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regulators by targeting mRNAs and causing gene silencing. Thus, they can 
function as oncogenes or tumour suppressor genes and they have recently 
been implicated with ovarian cancer development. A recent study has studied 
the effect of the genotype of the ovarian cancer GWAS’ identified most 
significant SNPs in 2q31, 3q25, 8q24, 9p22 and  19p13 and reported significant 
association of miRNA expression and the genotype of the EOC risk associated 
SNPs rs3814113 and rs2072590 in loci 9p22 and 2q31 respectively (Shen et al, 
2012). This study offered a new insight into the functional role for risk variants 
emerging from GWAS and they are the first to report that EOC risk assciated 
SNPs regulate miRNas. The associations they found between miRNA 
expression and SNP genotype in this study did not always correlate positively 
with the biological functions of the miRNAs, which is something that I also found 
for several of the functional associations I observed in my study. 
 
5.8.4 Conclusion  
In conclusion, functional analysis of the candidate genes in the EOC risk 
associated loci has provided with information on the genes potential 
involvement in EOC.  I found that PVT1, in locus 8q24, SP2, CBX1, PNPO and 
SKAP1 and several genes of the HOXB family in locus 17q21, HAUS8,  USE1 
and MERIT40 in locus 19p31 are over-expressed in EOC cell lines compared to 
normal NOSE and FTE cell lines suggesting a gain of function role in EOC. 
Additionally, I found TIPAPRP in locus 3q25, BNC2 in locus 9p22 to be under-
expressed in EOC cell lines suggesting a loss of function role for these genes in 
EOC development. Some of these genes such as TIPARP, PVT1, and 
MERIT40 may have an intriguing  role in EOC based on previous reports 
regarding their biological function and should be investigated in more gene 
specific functional assays to further confirm their potential role in EOC 
development.  
This study reports, for the first time, genotype specific gene expression 
and methylation of genes within risk associated loci in ovarian cancer. To 
summarise, weak associations were found between the genotype of rs9303542 
and the expression of CBX1, SNX11 and SP2 genes in locus 17q21 and 
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rs2072590 and HOXD1 expression in locus 2q31. Additionally, methylation of 
HOXB5 was associated with the genotype of rs9303542 in locus 17q21. These 
results suggest that the genes regulated by the genotype of risk associated 
SNPs may be the target susceptibility genes for the relevant loci. 
 An advantage of the study lies in the fact the genotype specific gene 
expression was performed using a proposed cell of origin for EOC, which in turn 
is the limitation for the genotype specific methylation analysis where germline 
DNA was used since expression and methylation are tissue specific. Another 
limitation of the study is the number of the samples used may not have been 
large enough to generate the power to identify association. Another limitation of 
this study regarding the investigation of functional relevance of the risk 
associated SNPs in EOC development is that they are not for sure the true 
causative SNP and another SNP in LD with the associated SNP may be the 
true functional variant. Several questions still pose, such what are the exact 
mechanisms that SNPs are exploiting to be functionally involved with EOC 
development be regulating the expression and methylation of candidate genes. 
Further understanding of the molecular basis of the SNPs mechanisms to affect 
the epigenetic and transcriptional regulation of genes would shed some light 
into the molecular basis of risk etiology.  
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6 Investigation of the potential role of MERIT40 
in EOC development 
 
 Introduction  6.1
Following the identification of the risk associated loci from the GWAS I 
have proposed a functional role for several candidate genes within these loci in 
EOC development. I have chosen to take MERIT40 (recently renamed as 
BABAM1) forward in order to try and elucidate by phenotypic in vitro assays its 
specific potential biological role in EOC. The reason I selected this gene, and 
not some other that was more statistically significant in the differential 
expression analysis between the EOC and normal cell lines, was the intriguing 
role it was recently proposed to have in DNA repair as part of the BRCA1-
Rap80 complex. MERIT40 has been shown to facilitate the localisation of the 
complex in DNA double strand breaks (DSBs) to initiate DNA repair by 
homologous recombination (HR) (Feng et al, 2009, Shao et al 2009). In the 
event of DNA DSBs the cell responds by recruiting various protein complexes to 
the site of the damage in order for HR to repair of the lesion. The tumour 
suppressor protein BRCA1 has an important role in the HR pathway and is 
recruited to the site of a DNA DSB as part of distinct protein complexes involved 
both in DNA DSB recognition and resection. BRCA1 binds to DNA DSBs 
through its association with the Abraxas(CCDC98)-Rap80-BRCC36 complex 
which associates with ubiquitinated histones at DNA DSBs following 
phosphorylation of histone γH2AX. Recent studies have reported that MERIT40 
interacts with Rap80 through its CCDC98 interacting region and in order to 
facilitate the BRCA1-Rap80-CCDC98 complex integrity and DNA DSB 
localisation. These studies showed that MERIT40 is essential for the G2 
checkpoint and for cellular resistance to ionising radiation through facilitating the 
recruitment of BRCA1 to the DNA damage foci (Shao et al, 2009, Feng et al, 
2009). The expression of MERIT40 has been interlinked with maintaining the 
levels of components of the BRCA1-CCDC98-Rap80-RCC36 complex (Hu et al, 
2011). 
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Homologous recombination is a DDR pathway commonly deregulated in 
epithelial ovarian tumours with inactivating BRCA1 mutations. Tumours with 
such mutations respond well to platinum therapy such as cisplatin and 
carboplatin (Agarwal and Kaye, 2003). Cisplatin induced DNA damage is 
activating a number of pathways that lead to apoptosis and death of the cancer 
cell. The cytotoxicity of cisplatin is attributed to its ability to interact with purine 
bases on the DNA backbone leading to the formation of DNA-protein and DNA-
DNA interstrand and intrastrand crosslinks. The interstrand DNA adducts 
formed are initiating a sequence of steps leading to the completion of the 
cytotoxic process, namely apoptosis (Pinto and Lippard, 1985). The DNA 
damage is recognised by proteins that bind to physical distortions in the DNA 
induced by the platinum adducts and transduce DNA damage signals to 
downstream effectors to prevent transcription and replication and lead to 
apoptosis (McCabe et al, 2009, reviewed in Siddik, 2003). The main DDR 
pathways involved in the repair of platinum adducts are the NER and HR 
pathways. This repair is a multistep process where firstly an endonucleolytic 
excision takes place in one strand, followed by translesion synthesis across the 
interstrand crosslink and removal by excision. The resulting DNA DSBs should 
then be resected to generate ssDNAs followed by repair by HR. BRCA1 has 
been shown to be involved in transcription coupled NER (Gowen et al, 1998) 
and has a central role in HR. Thus in BRCA1 deficient cells these mechanisms 
are defective rendering the cells hypersensitive to platinum agents.  
Although defective DNA repair causes for an initial good response after 
treatment of EOC with platinum agents, restoration of DNA repair results to an 
acquired resistance to these drugs. Previous work has shown that secondary 
activating mutations on BRCA1 and BRCA2 are found in ovarian carcinomas 
with platinum resistance (Swisher et al, 2008). 
Based on the role of MERIT40 being a BRCA1 associated protein 
involved in DNA repair, I hypothesised that potentially the gain in function role I 
proposed in EOC development for MERIT40 may be exerted by providing the 
cancer cells with tolerance against DNA damage and increased resistance to 
platinum drugs. I also investigated whether MERIT40 would have another 
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biological relevance to the development of EOC as an oncogene by regulating 
cell cycle regulation, proliferation or migration. 
 
Aims of this chapter: 
1. Create EOC cell lines with stably silenced MERIT40 
2. Investigate whether silencing MERIT40 in EOC cell lines will be 
correlated with increased cell death after introducing DNA DSBs after X-
Ray irradiation. I will also investigate whether MERIT40 silencing is 
causing an increased accumulation of spontaneous DNA DSBs by using 
immunoconjugates that target γH2AX to monitor DNA damage.  
3. Evaluate the chemoresistance to cisplatin and carboplatin of EOC cell 
lines with silenced MERIT40 compared to the parental EOC cell lines. 
4.  Investigate whether MERIT40 knockdown in EOC cell lines would affect: 
A) cell cycle progression using FACS analysis  
B) anchorage dependent proliferation using MTT assays  
C) anchorage independent growth using soft agar assays 
D) the ability of cells to migrate using transwell migration assays 
5. Evaluate the expression of genes involved in cell cycle progression, 
proliferation, apoptosis, proliferation, chromosomal segregation and DNA 
repair pathways after MERIT40 knockdown in EOC cell lines, by 
performing a Fluidigm gene expression experiment.   
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 Evaluation of MERIT40 knockdown effect in platinum 6.2
response and DNA damage repair ability of EOC cell 
lines 
Cisplatin binds to the DNA backbone and causes the formation of 
interstrand crosslink adducts. The physical distortions created on the DNA 
induced by those intrastrand platinum adducts are recognised by DNA damage 
recognition proteins which in turn are transducing DNA damage signals to 
downstream effectors and if DNA repair pathways are defected apoptosis is 
triggered. To evaluate the role of MERIT40 as part of the BRCA1 complex 
involved in HR triggered after DNA damage by platinum agents, my goal was to 
select EOC cell lines, knock down MERIT40, confirm the knockdown of the 
protein and monitor the cell death caused by cisplatin administration in the 
presence or absence of MERIT40. 
 
6.2.1 Selection of EOC cell lines for MERIT40 knockdown 
In order to select at least two EOC cell lines to knockdown MERIT40 and 
evaluate any differences in the chemoresistance I monitored a panel of highly 
expressing MERIT40 EOC cell lines for their sensitivity to cisplatin (also known 
as CCDP), the first of two chemotherapeutic compounds I would use. 
Carboplatin was also used later. 
 
6.2.1.1 Selection of highly expressing MERIT40 EOC cell lines 
Seven EOC cell lines that demonstrated higher MERIT40 expression 
compared to NOSE in the Taqman Real time expression assay in the pilot study 
previously described were chosen to be evaluated for their chemoresistance to 
cisplatin. Additionally, I monitored two pairs of cell lines, A2780CP/A2780 and 
C13/OV2008 which are pairs of cisplatin resistant and sensitive strains of the 
same cell line. A2780 is the cisplatin sensitive strain and A2780CP is the 
cisplatin resistant strain of the same cell line, and OV2008 and C13 are the 
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cisplatin sensitive and resistant strains respectively of the same cell line. The 
histology of the selected EOC cell lines monitored is shown on Table 6.1. 
Because no expression data were available for the cisplatin resistant and 
sensitive pairs and in order to confirm the elevated expression of MERIT40 
compared to NOSE, the 11 cell lines were cultured again and RNA was 
extracted, reverse transcribed and used in a validating MERIT40 Taqman Real 
time expression assay. The expression of MERIT40 in the selected EOC cell 
lines was compared to a small number of NOSE cell lines (Figure 6.1). 
Each of the 11 EOC cell lines exhibited at least a two-fold higher 
MERIT40 expression than NOSE cell lines, thus confirming that they were all 
suitable to take forward in MERIT40 knockdown experiments. MERIT40 
expression was compared the EOC and NOSE cell line by using the Wilcoxon 
Rank sum test. MERIT40’s significant over-expression in EOC cell lines was 
confirmed with no overlap observed between NOSE and EOC cell lines (Figure 
6.2) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6.1: Histological information for the EOC cell lines that were monitored for 
chemoresistance to cisplatin.  
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P= 5.67×10-6  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1: Differential MERIT40 expression between the 11 selected EOC cell lines 
and 10 randomly selected NOSE cell lines normalised to β-actin. (*):  NOSE11 
MERIT40 expression was used as the calibrator sample and the expression of the rest 
of the cell lines was calculated relative to that sample using the ΔΔCt method. A2780-
A2780CP and OV2008-C13 are the cisplatin sensitive-resistant pairs. 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2: Wilcoxon rank sum test for MERIT40 expression in NOSE versus the 
selected 11 EOC cell lines  
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6.2.1.2 Cisplatin dose-response curves for the EOC cell lines with high 
MERIT40 expression 
 
The cisplatin sensitivity for each of the selected cell lines was assessed 
by monitoring their viability in response to dosing with increasing concentrations 
of cisplatin after 72 hours. The viability of cell lines following cisplatin dosing 
was measured by performing an MTT assay as described in the methods 
section. The effectiveness of cisplatin to cause death to each cell line was 
deduced through the production of dose response curves. From these curves 
the IC50 (the half maximal inhibitory concentration) of cisplatin which translates 
to the amount of cisplatin needed (dose) for 50% of the cells to die (response) 
was calculated for each of the selected EOC cell lines. 
Cisplatin dosing and MTT assays were performed for the selected EOC 
cell lines as described in the methods section. Cell line 112D solubilised after 
addition of MTT so it was excluded from the analysis. Each condition was 
repeated in quadruplicate and each assay was repeated twice. In order to 
calculate the cisplatin IC50 for each cell line, GraphPad software was used by 
which non-linear regression with variable slope analysis was performed. The 
dose response curves generated for each cell line and the IC50s generated are 
shown in Figure 6.3 and Table 6.2 respectively. 
The cisplatin IC50 for the sensitive-resistant cell lines A2870 and 
A2780CP was found to be 0.19 M and 8.43 M respectively, showing a 44 fold 
increased resistance to cisplatin for A2780CP. For the other pair, OV2008 and 
C13, the IC50s were found to be 0.17 M and 36.2 M respectively, showing a 
213 fold increased cisplatin resistance for C13.  A2780CP is the resistant 
counterpart of A2780 cell line, but it demonstrated almost ten times less 
resistance to cisplatin than C13, the resistant counterpart of OV2008. The 
cisplatin IC50s for the remaining cell lines ranged from 2.62 M for OAW42 to 
19.28. M for OVCAR3. Cell lines OAW42, SCOV3IP and EFO27 appeared to 
be more sensitive to cisplatin whereas MPSC1, HOC7 and OVCAR3 appeared 
fairly resistant. 
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Figure 6.3: Dose response curves for EOC cell lines after dosing with cisplatin. Viability 
of cells was measured by performing an MTT assay. The difference in IC50s in the two 
sensitive-resistant pairs is obvious from the dose response curves at the top of the 
figure. The steeper the curve is the more efficiently cisplatin kills the cells, thus the 
more sensitive the cell line.  
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EOC cell line Cisplatin IC50 (µM) 
TOV112D  Detached with MTT addition 
OAW42 2.62 
SCOV3IP 3.78 
EFO27 4.51 
MPSC1 8.35 
HOC7 12.7 
OVCAR3 19.28 
A2780 0.19 
A2780CP 8.43 
OV2008 0.17 
C13 36.2 
Table 6.2: Cisplatin IC50s for the selected EOC cell lines. Highlighted in purple are the 
EOC cell lines with high expression of MERIT40 listed in order of increasing resistance 
to cisplatin. Highlighted in yellow and green the two platinum sensitive-resistant pairs. 
 
The purpose for assaying the resistance of these highly expressing 
MERIT40 cell lines to cisplatin was to select the appropriate cell lines for stably 
knocking down MERIT40 and reassessing their resistance to the drug. I 
selected cell lines that would not be over-sensitive to cisplatin because I wanted 
to have a large enough window to observe decreased resistance to cisplatin 
after knocking down MERIT40. That ruled out the two cell lines that showed the 
lowest sensitivity to cisplatin, OAW42 and SCOV3IP. Additionally, due to the 
heterogeneity in ovarian cancer, I decided to carry the knockdown of MERIT40 
in cell lines representing different subtypes. According to these selection 
criteria, the cell lines that were selected for MERIT40 knockdown were EFO27 
(Mucinous, Cisplatin IC50= 4.52), MPSC1 (Low grade serous, Cisplatin IC50= 
8.35), OVCAR3 (High grade serous, Cisplatin IC50= 19.28) and A2780CP 
(Undifferentiated, Cisplatin IC50= 8.43). A summary of the features of the cell 
lines selected to knockdown MERIT40 is shown in Table 6.3. 
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EOC cell line Histology 
Cisplatin 
IC50 (µM) 
95% CI 
EFO27 Mucinous papillary adenocarcinoma 4.51 3.44- 5.9 
MPSC1 Low grade serous carcinoma 8.35 6.47- 10.77 
OVCAR3 High grade serous adenocarcinoma 19.28 15.18- 24.47 
A2780CP Undifferentiated adenocarcinoma 8.43 7.12- 9.98 
Table 6.3: EOC cell lines selected for MERIT40 knockdown. EOC cell lines represent 
four different subtypes of EOC and they demonstrated a cisplatin IC50 large enough to 
provide a window to observe decrease in cisplatin resistance after MERIT40 was 
knocked down. 
 
6.2.2 Generating EOC cell lines with stable MERIT40 knockdown 
According to the real time expression data for MERIT40 expression and 
the cisplatin IC50s generated by dose response curves, four cell lines were 
selected to perform stable knockdown of MERIT40. The four EOC cell lines 
selected (EFO27, MPSC1, OVCAR3 and A2780CP) were infected with 
lentiviruses containing an empty GIPZ plasmid or GIPZ with non-silencing 
shRNA as negative controls, shRNA against GAPDH as positive control to 
assess the effectiveness of the viruses, and three different shRNAs targeting 
MERIT40 (M1, M2, M3). The plasmids all contained a GFP (Green Fluorescent 
protein) gene and a puromycin gene for selection. After large scale preparation 
of the plasmids, they were sequenced to confirm their sequence targeting the 
intended MERIT40 loci. Plasmids M1 and M3 demonstrated the right hairpin 
sequences but plasmid M2 had a base substitution. However, infection with a 
virus containing the M2 plasmid was performed anyway as this base 
substitution might not influence the effectiveness of the shRNA to silence 
MERIT40. The infection was performed at MOI=1 (multiplicity of infection 
meaning lentiviral units per cell) after titration of each virus as described in the 
methods section to establish the TU for each virus. To ensure that 100% 
infected cells would be used in my subsequent phenotypic assays selection with 
puromycin was performed until the relative control-uninfected cell line was killed 
off. The infected cell lines were constantly kept under puromycin selection in 
subsequent culturing. The stable MERIT40 knockdown cell lines were then 
used to generate RNA and protein to assess the knockdown levels of MERIT40 
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at the mRNA and protein level respectively. The process of generating the 
stable MERIT40 silenced EOC cell lines is presented in Figure 6.4.  
The next step was to check the GAPDH expression of the cell lines that 
were infected with lentivirus containing the shRNA against GAPDH. The 
expression of GAPDH in infected cell lines was calibrated to the expression of 
the Empty GIPZ infected cell line. The best MERIT40 knockdown was achieved 
in EFO27 cell line with 74% GAPDH knockdown and in MPSCI with 47% 
knockdown. Cell lines A2780CP and OVCAR3 demonstrated only 20-24% 
knockdown indicating that they were more difficult cell lines to stably infect. The 
expression levels of GAPDH in the different cell lines are shown in Figure 6.5. 
The level of MERIT40 knockdown on the mRNA level was checked in all 
four cell lines (Figure 6.6). Construct M1 appeared to be the one that caused 
the most efficient knockdown of MERIT40 after analysing mRNA expression 
levels of the gene by Taqman. The M3 shRNA caused partial MERIT40 
knockdown but not more than two-fold in any of the four cell lines apart from 
EFO27_M3. No MERIT40 knockdown was achieved with the M2 shRNA so the 
cell lines infected with this virus were not included in subsequent experiments.  
To ensure that the observed decrease in MERIT40 mRNA correlated 
with depleted MERIT40 protein, I then generated protein lysates for all the 
infected and control cell lines. The western blots were generated using those 
lysates in USC (University of South California) by Dr Kate Lawrenson using a 
custom made antibody. The protein levels confirmed the gene silencing 
observed by the Real time gene expression assay on the mRNA level, similarly 
indicating that the most efficient knockdown was caused by MERIT40 shRNA 
M1 (Figure 6.6, B).  
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Figure 6.4: Generation of four EOC cell lines with stably silenced MERIT40. The 
generation of the stable cell lines was achieved using lentiviruses containing GIPZ-
shRNA plasmids. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.5: GAPDH expression of infected EOC cell lines. The histograms represent 
GAPDH expression normalised to β-actin and calibrated against the expression of the 
Empty GIPZ infected cell line. EFO27 and MPSC1 showed the most efficient 
knockdown but knockdown of GAPDH in A2780CP and OVACR3 was not as 
successful.  
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Figure 6.6: Confirmation of MERIT40 knockdown in stably infected EOC cell lines. A) 
MERIT40 knockdown of the stably infected EOC cell lines confirmed on the mRNA 
level. The histograms show MERIT40 expression normalised to β-actin and calibrated 
against the expression of the Empty GIPZ infected cell line. All four EOC cell lines 
showed the most efficient knockdown with MERIT40 shRNA M1. Partial knockdown of 
MERIT40 was achieved with MERIT40 shRNA M3. B) Western blots showing MERIT40 
protein expression in control and MERIT40 knockdown EOC cell lines. Ponceau 
staining was used as loading control. All four EOC cell lines showed the most efficient 
knockdown with MERIT40 shRNA M1.   
A) 
B) 
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6.2.3 Response of EOC cell lines to chemotherapeutic agents following 
MERIT40 knockdown 
The hypothesis behind this was that with MERIT40 involved in the 
BRCA1-Rap80 complex, cells with absent MERIT40 would have impaired HR 
machinery and would be unable to repair DNA DSBs induced by platinum 
agents and ionising radiation, thus increased cell death would be observed. The 
control and the MERIT40 shRNA M1 and M3 stably infected cell lines were then 
used to perform dose response curves and generate IC50s in order to assess if 
there was a potential role of MERIT40 in conferring chemoresistance. I 
performed the dose response assays in duplicate for all cell lines. The 
chemotherapeutic agents that I used were cisplatin (CCDP) and carboplatin and 
the cells were subjected to dosing of cisplatin for 72 hours (Figure 6.8) and 
carboplatin for 96 hours (Figure 6.9). Carboplatin dosing was also performed for 
72 hours but the doses required were extremely high and even in the highest 
dosing the 100% cell death could not be achieved in any of the cell lines at the 
72 hour timeframe.   
Only EFO27 with M1 (EFO27_M1) MERIT40 knockdown showed a minor 
decrease (less than two-fold) in the cisplatin IC50 compared to the 
EFO27_Empty negative control after dosing for 72 hours. The rest of the cell 
lines with MERIT40 knockdown did not show any increased sensitivity to 
cisplatin. None of the cell lines showed increased resistance to carboplatin 
when MERIT40 was knocked down. The summarised data of the dose 
response assays to cisplatin and carboplatin for all the cell lines are shown in 
Table 6.4 and Figure 6.7.  
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Cell lines Cisplatin IC50 (µM) 
[(95% CI]_72 hours  
Carboplatin IC50(µM) 
[(95% CI]_96 hours 
EFO27 
EFO27 7.96 [7.39-8.58] 17.26 [14.40-20.70] 
EFO27_Empty 9.92 [9.45-10.42] 32.25 [25.65-40.54] 
EFO27_Non 8.69 [8.06-9.37] 29.44 [20.95-41.36] 
EFO27_M1 5.34 [4.55- 6.28] 39.8 [35.57- 44.54] 
EFO27_M3 7.63 [ 6.41-9.09] 32.31 [25.42-41.06] 
MPSC1 
MPSC1 15.47 [14.77-16.19] 48.94 [42.76-56.01] 
MPSC1_Empty 15.58 [14.91-16.28] 58.43 [43.23-78.97] 
MPSC1_Non 15.06 [14.49-15.64] 42.25 [35.57-50.20] 
MPSC1_M1 13.94 [13.37-14.53] 53.48 [34.76-82.27] 
MPSC1_M3 14.28 [13.62-14.97] 44.25 [40.47-48.40] 
A2780CP 
A2780CP 6.81 [5.81-7.98] 72.72 [54.67-96.73] 
A2780CP_Empty 10.13 [8.822 -11.63] 62.22 [55.83-69.35] 
A2780CP_Non 9.81 [8.88-10.83] 57.92 [53.03-63.25] 
A2780CP_M1 10.76 [9.76-11.87] 52.2 [43.42-62.74] 
A2780CP_M3 7.85 [6.85-9.01] 79.62 [60.04-105.6] 
A2780 A2780 0.41 [0.052-3.19] 12.47 [11.11-14.00] 
OVCAR3 
OVCAR3 20.25 [17.8-23.04] 22.94 [19.28-27.28] 
OVCAR3_Empty 23.53 [18.51-29.92] 59.36 [11.29-312] 
OVCAR3_Non 29.01 [24.46-34.3] 62.25 [11.46-338.3] 
OVCAR3_M1 31.91 [28.77-35.41] 18.84 [15.24-23.30] 
OVCAR3_M3 43.52 [38.52-49.43] 38.91 [24.53-61.71] 
 
Table 6.4: Cisplatin and carboplatin IC50s and 95% confidence intervals (CI) for the 
selected EOC control and MERIT40  knockdown cell lines.  
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Figure 6.7: Histogram showing the IC50s of all control and MERIT40 knockdown cell lines for the two chemotherapeutic drugs tested, cisplatin 
and carboplatin. There were no cell lines that showed a twofold or higher decrease in the IC50 when MERIT40 is knocked down. The error 
bars are representing the 95% confidence intervals for the calculated IC50s as calculated in PRISM using non-linear regression. 
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Figure 6.8: Dose response curves of EOC control and MERIT40 knockdown cell lines after cisplatin dosing. Viability of the cells was measured 
by performing an MTT assay 72 hours later. For the A2780CP derived stable cell lines the cisplatin sensitive counterpart A2780 was used as a 
control and showed the expected increased sensitivity to cisplatin compared to A2780CP. 
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Dose response curve of MPSC1 control & MERIT40
 knockdown cell lines to carboplatin
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Figure 6.9:  Dose response curves of EOC control and MERIT40 knockdown cell lines after carboplatin dosing. Viability of the cells was 
measured by performing an MTT assay 96 hours later. A2780 showed the expected increased sensitivity to carboplatin compared to 
A2780CP. 
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6.2.4 Evaluating the effect of silencing MERIT40 in EOC cell lines on their 
efficiency to repair DNA DSBs caused by endogenous or 
exogenous stress. 
It has been recently shown that MERIT40 is recruited to sites of DNA 
DSBs resulting from endogenous and exogenous genotoxic stress and is 
conferring resistance to HeLa cells subjected to ionising radiation by facilitating 
the association of the deubiquinating agent BRCC36 with BRCA1-Rap80 and 
the localisation of the complex at the DNA DSBs (Shao et al, 2009). I have 
evaluated whether the controls and MERIT40 knockdown EFO27 EOC cell lines 
show any difference in sensitivity to ionising radiation. I have applied increasing 
concentrations of irradiation (IR measured in Gray) and measured the cell 
viability after 72 hours in culture by performing an MTT assay. The % of cell 
viability for EFO27 cells when MERIT40 was knocked down compared to the 
controls decreased after exposure to increasing doses of ionising radiation as 
shown in Figure 6.10.  The IC50s for each cell line in response to IR were 
calculated using Prism performing a logIR versus response dose response 
inhibition analysis.  I observed an at least 2 fold decrease in the IC50s for 
EFO27_M1 and EFO27_M3 compared to the controls indicating that depleting 
MERIT40 sensitised the ovarian cancer cells to DNA damage caused by 
irradiation (Table 6.5). However, it should be noted that the 95% confidence 
intervals calculated for the IC50s where quite large so the observed result 
should be treated with caution. 
Additionally, to find out just how essential the role of MERIT40 is in DNA 
repair in EOC cell lines, I investigated whether after knocking down MERIT40 
the cells would be more susceptible to spontaneous DNA damage under normal 
culturing conditions. As a marker I used phosphorylated γH2AX which localises 
in the nucleus in response to DNA damage and its presence would be indicative 
of accumulated unrepaired DNA damage. After culturing of the cell line for 48 
hours I found an increase on the localisation of phosphorylated γH2AX in the 
nuclei of the EFO27_M1 cell line. Cells were sparsely seeded on coverslips and 
cultured for 48 hours, then fixed and immunofluorescence was performed using 
an antibody against phosphorylated γH2AX. Following the staining, 80-100 cells 
were captured and the cells with no, low or high γH2AX expression were 
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counted. The % of cells with high γH2AX expression was increased by 20% (2 
fold increase) when MERIT40 was absent, a difference mainly attributed to a 
significant reduction in the number of cells with no γH2AX and a smaller 
reduction in the number of cells with low γH2AX (Figure 6.11). This observation 
indicates that when MERIT40 is absent the accumulation of unrepaired 
spontaneous DNA damage is increased.  
 
 
 
 
 
 
 
 
 
 
Figure 6.10: Dose response curves for EFO27 MERIT40 knockdown and control cell 
lines after subjecting them to increasing doses of X-Ray. The % of cell viability was 
measured by measuring the absorbance of cells after the addition of MTT and DMSO 
after 72 hours of incubation. 
 
Cell line IR IC50 (Gray) [(95% CI]_72 hours  
EFO27 40.29 [27.52-58.99] 
EFO27_Empty 69.02 [38.57-123.5] 
EFO27_Non 70.32 [46.51-106.3] 
EFO27_M1 26.86 [16.27-44.36] 
EFO27_M3 15.89 [10.24-24.66] 
Table 6.5: Calculated IC50s for the EFO27 control and MERIT40 knockdown cell lines 
in response to increasing doses of irradiation. 95% CI: 95% confidence intervals.  
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Figure 6.11: Immunofluorescent staining and quantification of phosphorylated γH2AX in 
EFO27 control and MERIT40 knockdown cells. Staining for γH2AX was performed in 
order to evaluate the cell lines’ efficiency for DNA repair in response to spontaneous 
endogenous damage. The blue colour is DAPI staining for visualisation of the cell 
nuclei. The pink staining represents the γH2AX expression in the nuclei. The 
corresponding pie charts are representing in blue the % of cells with no γH2AX 
expression, in pink and red the % of cells with low and high γH2AX expression 
respectively.  
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 Phenotypic analysis following MERIT40 knockdown in 6.3
EOC cell lines 
MERIT40 was found to be over-expressed in EOC cell lines indicating a 
gain of function role in ovarian cancer development. This may involve function 
of MERIT40 in other pathways than the DDR pathway. For the development of 
neoplastic transformation leading to malignant tumorigenesis cells are 
subjected to several phenotypic changes ranging from unregulated cell cycle 
progression, proliferation in anchorage independent and anchorage dependent 
manner, increased ability of cells to migrate or invade through extracellular 
matrix. The elevated expression of MERIT40 in EOC compared to NOSE cells 
was a significant observation and I decided to investigate further whether some 
of the phenotypic changes indicative of neoplastic transformation were linked to 
the elevated expression of this gene. By knocking down MERIT40 in EOC cell 
lines and assaying the parental and MERIT40 silenced cell lines for reversal of 
neoplastic phenotype I aimed to shed some light in the role of the gene in 
ovarian cancer development.    
 
6.3.1 Investigating the potential role of MERIT40 in cell cycle progression 
and proliferation 
The process of cell division by which a single cell forms two daughter 
cells is divided into G1, S and G2/M phases that collectively constitute the cell 
cycle. The phases of the cell cycle are distinguished according to the amount of 
DNA a single cell has. The cells in G1 phase have a 2N DNA content, then 
during the S phase the content of DNA steadily increases until the G2 phase 
when the cell has 4N DNA content where completely duplicated DNA is 
reached. Each phase is characterised by certain activities that are required for 
proliferation to proceed to the next phase. During cancer development, 
activation of oncogenes has been shown to regulate the progression of the cell 
cycle by promoting cell proliferation.  
The gain-of-function role of MERIT40 attributed by over-expression of the 
gene in EOC cell lines compared to NOSE & FTE cell lines might be translated 
in an involvement of MERIT40 in regulating cell cycle progression and 
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proliferation. Parental, control and MERIT40 silenced cell lines were cultured in 
duplicates, harvested and stained with a DNA intercalating agent Propidium 
Iodide (PI) that indicates the DNA content of the cells. Cell cycle profiles were 
generated by FACS analysis to investigate any effect MERIT40 knockdown may 
have on the original EOC cell line’s cell cycle. The analysis was performed 
using the Summit v4.3 software.  An approximate 15-20% decrease of the cells 
in G2/M phase was observed for cell line EFO27_M1 and EFO27_M3 in the 
duplicate experiments (Figure 6.12). No cell cycle arrests were observed for any 
of the other EOC cell lines (Figure 6.12). An interesting observation is the 50% 
decrease in cells with 8N content found for cell lines EFO27_M1 and 
EFO27_M3. The cell cycle profiles generated by FACS clearly show the cell 
cycle arrests observed (Figure 6.13).  
Cells were arrested in G1 phase when MERIT40 was not expressed for 
EFO27. A reduction in the cells with 8N DNA content may suggest that the 
arrest observed was not due to reduced proliferation but due to reduction in 
ploidy. No differences in the cell cycle profiles were observed for the other EOC 
cell lines with silenced MERIT40 (Appendix, Figure 1). The histological diversity 
of ovarian cancer is reflected in the EOC cell lines selected to knock down 
MERIT40 and it should come as no surprise that different molecular changes 
might have contributed to neoplastic development across the different subtypes.  
A cell that appears to have a 4N content could be a cell in G2 phase but 
could also be a tetraploid cell on G1 phase or even an anaploid cell that has 
abnormal chromosomes. Often cancer cell lines are not diploid, as normal cell 
lines are, but tetraploid, anaploid or octaploid. In fact EFO27 has been shown to 
be hypotetraploid (Lambros et al, 2005). I prepared DNA metaphase spreads of 
EFO27 and its MERIT40 knockdown derivatives to examine if there was any 
reduction in ploidy by counting the chromosomes. I found that more cells in 
EFO27 appeared to be polyploid (with 4N or 8N DNA content) and found no 
polyploid cells in the EFO27_M1 cell line metaphase preparations (Figure 6.14). 
The number of cells available to be analysed in the metaphase preparations 
was too small to assess statistical significance of the observation. Thus, the 
absence of polyploid cells could be due to chance. 
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Figure 6.12: Histograms representing the amount of MERIT40 knockdown and control EOC cells in the different cell cycle phases. Cell cycle 
analysis was performed using PI and the amount of cells in each phase was quantified using the Summit 4.3 software. The red arrows are 
showing the decrease of cell accumulation observed for the G2/M phase and for cells with 8n DNA content.
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Figure 6.13: Cell cycle profiles of EFO27 control and MERIT40 knockdown cell lines. The y axis corresponds to the counts, meaning the 
numbers of cells counted, and the x axis corresponds to the DNA content which is measured by the amount of PI incorporation in the DNA of 
the live single cells counted. The first peak in each profile, annotated as R3, indicates cells that are in G1 phase of the cell cycle, with a 2N 
DNA content. The second peak in each profile, annotated as R6, indicates cells that are in G2/M phase of the cell cycle with a 4N DNA 
content. The areas annotated as R7, correspond to cells with 8N or higher DNA content. 
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Figure 6.14: Metaphase spreads and chromosome count of EFO27 control and 
MERIT40 silenced cell lines. A) Representative pictures of DAPI stained metaphase 
spreads for one of the EFO27 control cells found to have abnormally high chromosome 
numbers (LEFT) and an EFO27_M1 cell found to have normal chromosome count (2N) 
(RIGHT). The pictures were obtained under the 100x oil objective lense of an 
immunofluorescent microscope. B) Table showing the numbers of diploid and polyploid 
cells found per cell line examined. No polyploid cells were observed in the EFO27 with 
knocked down MERIT40.  
 
The proliferation of the EOC cell lines with active or silenced MERIT40 
was then assessed by performing an MTT assay as described in the methods 
section. The proliferation of EFO27_M1 and EFO27_M3 was found to be 
significantly reduced by ~4 fold and ~3 fold respectively compared to the 
parental EFO27 EOC cell line. The reduction was statistically significant in a 
two-tailed paired student t-test (P= 3.4×10-5 for EFO27_M1 and P= P= 6.9×10
-5 
for EFO27_M3). A significant 2 fold reduction was also observed in the 
proliferation of MPSC1_M1 (P= 7.9×10-4, Figure 6.15). An interesting 
observation was that in both cell lines the amount of proliferation reduction 
closely resembled the amount of MERIT40 knockdown. In the case of EFO27 
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the reduction in proliferation was higher in EFO27_M1 that demonstrated a 
higher efficiency of MERIT40 silencing compared to EFO27_M3 (Figure 6.6).  
MERIT40 knockdown did not seem to cause any decrease in the proliferation of 
A2780CP and OVCAR3 EOC cell lines (Figure 6.15). 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.15: MTT proliferation assay of EOC control cell lines and MERIT40 
knockdown cell lines. The percentage of proliferation for each cell line was normalised 
against the proliferation of the cell line infected with a virus containing the empty GIPZ 
plasmid. A two tailed t-test was performed to calculate the significance of the observed 
decreases in proliferation and the P values are shown at the graphs.  
 
Assessing the proliferation of cell lines using an MTT assay is a widely 
used and generally reliable method. However, it does not offer a precise “snap-
shot” of the proliferative ability of a cell line such as would be provided by 
assessing the number of cells that are accumulated in the S phase of the cell 
cycle. I have previously performed a cell cycle analysis using PI staining, but 
the calculation of cells in S phase proved very difficult and inaccurate with just 
PI staining as the peak representative of S phase tends to fuse with G1 and 
G2/M phase peaks making the differentiation almost impossible and massively 
inaccurate.    
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Therefore, I decided to assess the proliferation ability of the cell lines with 
knocked down MERIT40 by performing a Bromodeoxyuridine (BrDU) 
proliferation analysis that can provide a “snap-shot” window into the cell line 
proliferative ability by accurately quantifying the cells located on the S phase of 
the cell cycle. For this assay, BrDU was added to 80% confluent cultured cells 
for 1 hour and it incorporated into the newly synthesised DNA of replicating cells 
during the S phase of the cell cycle. The cells were fixed in ethanol and a FITC-
labelled anti-BrDU antibody was used to stain all the proliferating cells. FACS 
analysis was used to quantify the amount of FITC stained cells, indicative of the 
cells in S phase.  
Interestingly, the observations resulting from the BrDU assay 
contradicted the observations of reduced proliferation found by the MTT assay. 
The amount of cells with incorporated BrDU, indicative of them being in S 
phase, was not different between the parental and the MERIT40 silenced cell 
lines for any of the four EOC cell lines tested. The FACS profiles and quantified 
cells in S phase for the parental and control EOC cell lines compared to their 
MERIT40 knockdown counterparts are shown in Figures 6.16, 6.17, 6.18, 6.19. 
There might be several explanations for this outcome. The simplest one could 
be that the optimal BrDU incubation period may vary from cell line to cell line 
depending on how fast the cells go through the cell cycle to capture the cells 
entering S phase. The one hour incubation period used might not have provided 
a large enough window for changes to be captured. Further work would be 
required to investigate this. Alternatively, it could be that the BrDU proliferation 
assay actually provided the more accurate result. MTT is an assay that is used 
to assay proliferation as a first line assay but it does not really provide a 
snapshot in the proliferation, so the result observed could be due to increased 
apoptosis. Future work investigating the role of MERIT40 in apoptosis 
regulation would be interesting and could elucidate the conflicting observations.   
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Figure 6.16:  FACS proliferation assay of EFO27 control cell lines and MERIT40 
knockdown cell lines using BrDU. BrDU incorporates in the DNA of cells in the S phase 
of the cell cycle. A FITC linked anti-BrDU antibody was used to label the BrDU 
incorporating cells. A) Histogram showing the % of cells in the S phase, B) FACS 
profiles where the cells in S phase are gated (gate denoted as R5). The x axis is a 
measure of PI and the y axis a measure of the BrDU incorporation. According to this 
experiment the amount of cells in the S phase corresponding to their proliferation 
efficiency did not change when MERIT40 was knocked down in EFO27.  
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Figure 6.17:  FACS proliferation assay of MPSC1 control cell lines and MERIT40 
knockdown cell lines using BrDU. A FITC linked anti-BrDU antibody was used to label 
the BrDU incorporating cells. A) Histogram showing the % of cells in the S phase, B) 
FACS profiles where the cells in S phase are gated (gate denoted as R5). The x axis is 
a measure of PI and the y axis a measure of the FITC accounting for BrDU 
incorporation.  
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Figure 6.18:  FACS proliferation assay of OVCAR3 control cell lines and MERIT40 
knockdown cell lines using BrDU. A FITC linked anti-BrDU antibody was used to label 
the BrDU incorporating cells. A) Histogram showing the % of cells in the S phase, B) 
FACS profiles where the cells in S phase are gated (gate denoted as R5). The x axis is 
a measure of PI and the y axis a measure of the FITC accounting for BrDU 
incorporation.  
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Figure 6.19:  FACS proliferation assay of A2780CP control cell lines and MERIT40 
knockdown cell lines using BrDU. A FITC linked anti-BrDU antibody was used to label 
the BrDU incorporating cells. A) Histogram showing the % of cells in the S phase, B) 
FACS profiles where the cells in S phase are gated (gate denoted as R5). The x axis is 
a measure of PI and the y axis a measure of the FITC accounting for BrDU 
incorporation.  
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6.3.2 Effect of MERIT40 knockdown on EOC cell lines on anchorage 
independent growth and migration efficiency of the cell lines. 
A common phenotypic characteristic of neoplastic transformation is the 
ability of cancer cells to proliferate independently of signals that restrain growth 
such as contact inhibition responses. Soft agar colony formation assay is a 
common method to monitor anchorage independent growth and is considered 
an accurate in vitro assay for detection of malignant transformation of cells. I 
have performed soft agar colony formation assays for the EOC cell lines and 
their MERIT40 knockdown derivatives to investigate whether the silencing of 
MERIT40 would cause a reversal of the particular neoplastic phenotype of 
anchorage independent growth. The ability for anchorage independent growth 
was measured by the colony forming efficiency (CFE) of each cell line over a 
period of 4 weeks in soft agar after seeding 500, 2500 and 5000 cells in 
triplicate per cell line as described in the methods section. As a positive control 
for anchorage independent growth I used the EOC cell line TOV112D which has 
been previously shown to have a high colony forming efficiency in soft agar in 
Chapter 2. 
I found that the colony forming efficiency of OVCAR3_M1 and M3 was 
reduced by ~7 fold compared to the average of the control cell lines (P= 0.034 
and P=0.026 respectively, Figure 6.20). However it should be noted that 
although the number of colonies was not significantly reduced for 
OVCAR3_Non cell lines compared of the other controls, the size of the colonies 
was significantly reduced as seen on Figure 6.20. Thus, this result should be 
treated with caution. MPSC1 did not have the ability for anchorage independent 
growth as no more that 10-20 colonies in all the capture planes could be 
counted. None of the other two EOC cell lines showed a reduction in anchorage 
independent growth when MERIT40 was knocked down. The summary of the 
averaged CFE of the three replicates per numbers of cells seeded per cell line 
is shown on Table 6.6 and the average of the CFE of all the number of cells 
seeded for each cell line is presented by the histograms in Figure 6.20,A. 
Representative pictures of the soft agars for A2780CP, MSPC1 and EFO27 are 
shown in Appendix 4, Figure 2.  
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  Colony forming efficiency (CFE) 
Number of 
cells 
seeded EFO27 EFO27_Empty EFO27_Non EFO27_M1 EFO27_M3 
5000 3 6 5 5 6 
2500 3 6 5 4 6 
500 4 8 6 6 6 
CFE 
average % 4 7 5 5 6 
  Colony forming efficiency (CFE) 
Number of 
cells 
seeded MPSC1 MPSC1_Empty MPSC1_Non MPSC1_M1 MPSC1_M3 
5000 0.33 0.35 0.36 0.49 0.47 
2500 0.27 0.36 0.45 0.69 0.67 
500 0.67 0.73  N/A  N/A  N/A 
CFE 
average % 0.42 0.48 0.41 0.59 0.57 
  Colony forming efficiency (CFE) 
Number of 
cells 
seeded OVCAR3 OVCAR3_Empty OVCAR3_Non OVCAR3_M1 OVCAR3_M3 
5000 9 6 4 0 1 
2500 12 7 6 1 0 
500 7  N/A  N/A 1 0 
CFE 
average % 9 7 5 0.70 0.64 
  Colony forming efficiency (CFE) 
Number of 
cells 
seeded A2780CP A2780CP_Empty A2780CP_Non A2780CP_M1 A2780CP_M3 
5000 19 13 16 15 22 
2500 22 20 20 11 24 
500 55 41 48 27 51 
CFE 
average % 32 25 28 18 32 
 
Table 6.6: Colony forming efficiency of control and MERIT40 knockdown EOC cell lines 
in soft agar assays. Summarised are the averaged CFE of the three replicates for the 
three numbers of cells plated for each EOC control cell lines and their MERIT40 
knockdown derivatives. N/A: not applicable: these are conditions where either there 
was contamination or after staining the colonies were not visible enough to be reliably 
counted.  
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Figure 6.20: Anchorage independent growth assays for control and MERIT40 
knockdown EOC cell lines. A) Histograms representing the average colony forming 
efficiency for the control EOC cell lines compared to the MERIT40 knockdown cell 
lines. There was a significant reduction observed in the anchorage independent growth 
ability of OVCAR3 when MERIT40 was knocked down by both the M1 and M3 
constructs. B) Representative pictures of colonies grown for the OVCAR3 controls and 
MERIT40 silenced OVCAR3 cell lines after seeding of 5000 cells in soft agar over 4 
weeks. 
 
Another phenotypic characteristic of malignant cells is their increased 
ability to migrate. A popular way to test this is by performing trans-well assays, 
where the cells are plated on a membrane of a well that is positioned on top of a 
well filled with chemoattractant such as foetal bovine serum. The migration 
ability is assessed on the basis of the ability of the cells to migrate through the 
membrane towards the chemoattractant. I have performed the migration assay 
for the EOC cell line EFO27 compared to the EFO27 MERIT40 knockdown cell 
lines and found no difference in the migration ability of the cells line when 
B) 
A) 
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MERIT40 was knocked down. The migration assay was performed over 20 
hours and 3 replicates of each cell line were prepared and 5 pictures per 
replicate were captured, the migrated cells were counted and averaged. There 
was no difference observed in the ability of the cell line to migrate when 
MERIT40 was knocked down. The summarised graph and representative 
pictures for the migration assay performed for EFO27 cell line are shown in 
Figure 6.21. The migration assays were not performed for the other cell lines 
due to the cost of the trans-wells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.21: Migration efficiency of EFO27 control and MERIT40 knockdown cell lines. 
(TOP) Histogram summarising the migration efficiency of EFO27 control and MERIT40 
knockdown cell lines. Below the histogram are shown representative pictures for the 
membranes of each of the EFO27 cell line.  
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6.3.3 Evaluating the effects of MERIT40 knockdown on regulating other 
pathways involved in tumorigenesis 
I have investigated in EOC cell lines with knocked down MERIT40 the 
mRNA expression of 55 genes involved in pathways implicated with cell cycle 
progression, chromosome segregation, cell differentiation, apoptosis, DNA 
damage repair as well as MERIT40 interacting proteins in the BRCA1 DNA 
repair complex. I also investigated if the expression of other genes closely 
located to the MERIT40 chromosomal locus (19p13) would be affected by the 
knockdown of MERIT40. A total of 55 genes were chosen to be investigated 
and the pathways they are involved are summarised on Table 6.7. The mRNA 
expression of the selected genes was analysed by performing a Fluidigm gene 
expression experiment using Taqman Real Time PCR assays. The assays were 
multiplexed in 7 different chips/sets with endogenous controls GAPDH and β-
actin included in each chip for the mRNA expression of the selected genes to 
be normalised against.  
The total number of samples in this experiment was 16 (Parental, Empty, 
Non-silencing, M1 and M3 conditions per EOC cell line MPCS1, EFO27, 
OVCAR3 and A2780CP). The following quality control analysis was performed. 
Assays with a pass rate of less than 80% were excluded from the analysis. 
However, the four groups of cell lines for each of the infected EOC cell lines 
were also analysed separately. Thus in cases that all conditions of one EOC 
cell line failed bringing the statistical value of the overall assay pass rate to less 
than 80%, the rest of the groups were analysed regardless (for example for 
CDKN2A expression assay all MSPC1 control and MERIT40 knockdown cell 
lines, Table 6.7). Samples with <85% pass rate were also excluded. Control 
EOC cell line A2780CP was excluded, therefore I have used as a calibrator the 
control cell lines EOC_Empty for all stable MERIT40 knockdown cell lines 
generated and used in this experiment. The cut-off for accepted standard 
deviation between the three replicates was <0.6 otherwise the outlier replicate 
was excluded from the analysis as long there would be two replicates 
remaining. In rare cases to keep two replicates in, a standard deviation between 
0.6 and 1 was accepted but in assays where this occurred in more than 15% of 
the samples the assay was excluded. Finally, a standard curve was generated 
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for each of the assays and if any assay exhibited an R2 <0.9 it was failed. The 
standard curve graphs for all the assays performed are shown in Appendix 4, 
Figure 3. After quality control analysis 8 assays were excluded and β-actin for 
set 2 was also excluded. A summary of the assays that were excluded from the 
analysis and the reasons for excluding them are shown in Table 6.8. 
 
Gene name Pathway involved/ Reason for selection 
CCNE1 Cell cycle control, G1/S transition 
CDKN1A Cell cycle control, G1/S transition 
CDKN2A Cell cycle control/arrest in G1 and G2 
PTEN Cell cycle control 
RB1 Cell cycle progression inhibitor 
BUBR1 Cell cycle Mitotic checkpoint control. Kinetochore localisation 
MAD1 Cell cycle Mitotic checkpoint control. Kinetochore localisation 
MAD2L1 Cell cycle Mitotic checkpoint control. Kinetochore localisation 
MAD2L2 Cell cycle Mitotic checkpoint control. Kinetochore localisation 
CHK1 Cell cycle control, entry to mitosis 
CHK2 Cell cycle control, entry to mitosis 
BUB1 Chromosome segregation 
BUB3 Chromosome segregation 
ATM Activates checkpoint signalling upon DNA double strand breaks (DSBs) 
FANCD2 DNA damage response by HR. 
PARP1 DNA damage response by HR. 
RAD51 DNA damage response by HR. 
RAD51C DNA damage response by HR. 
RAD51D  DNA damage response by HR. 
BARD1 DNA damage response by HR 
BRCA1 DNA damage response by HR. 
BRCA2 DNA damage response by HR. 
MERIT40 DNA damage response by HR. BRCA1 complex 
BRE DNA damage response by HR. MERIT40 interacting 
CCDC98 DNA damage response by HR. MERIT40 interacting 
RAP80 DNA damage response by HR. MERIT40 interacting 
BRCC3 DNA damage response by HR. MERIT40 interacting 
ERCC1 DNA damage response. Nucleotide excision repair 
ERCC2 DNA damage response. Nucleotide excision repair 
XPA DNA damage response. Nucleotide excision repair 
XRCC5 DNA damage response. Nucleotide excision repair 
XRCC6 DNA damage response. Nucleotide excision repair 
POLB DNA damage response by base excision repair 
MLH1 DNA damage signalling. Involved in mismatch repair 
MSH2 DNA damage signalling. Involved in mismatch repair 
PMS1 DNA damage signalling. Involved in mismatch repair 
PIK3CA Cell proliferation regulator 
KRAS Cell growth and proliferation 
BRAF Cell proliferation, differentiation, apoptosis. MAPK/ERK signalling 
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HOXA10 Cell differentiation 
CDK12 Cell proliferation, cell differentiation, apoptosis 
BAD Apoptosis regulator 
TP53 Apoptosis regulator 
ABHD8 locus 19p13 
CPAMD8 locus 19p13 
DDA1 locus 19p13 
GTPBP3 locus 19p13 
MRPL34 locus 19p13 
MYO9B locus 19p13 
NR2F6 locus 19p13 
OCEL1 locus 19p13 
USHBP1 locus 19p13 
ANKRD41 locus 19p13 
TMEM16H locus 19p13 
USE1 locus 19p13 
Table 6.7: List of the genes their expression to be investigated when MERIT40 was 
knocked down in EOC cell lines. Summarised in the table is a brief summary of the 
genes’ function. The function of genes at locus 19p13 have been described in chapter 
5.  
 
Gene 
Fluidigm 
Chip 
Assay 
pass rate  
% 
% of samples 
with >0.6SD 
R
2
 
Standard 
Curve 
Assay 
passed 
or failed 
CCNE1 Chip 1 100 0 0.991 PASSED 
CDKN1A Chip 5 100 0 0.992 PASSED 
CDKN2A Chip 5 75 * 0 0.998 PASSED 
PTEN Chip 5 100 0 0.954 PASSED 
RB1 Chip 7 100 0 0.997 PASSED 
BUBR1 Chip 4 100 0 0.967 PASSED 
MAD1 Chip 5 100 6.25 0.921 PASSED 
MAD2L1 Chip 5 100 0 0.982 PASSED 
MAD2L2 Chip 5 100 0 0.986 PASSED 
CHK1 Chip 5 100 0 0.993 PASSED 
CHK2 Chip 5 75 * 8.3 0.997 PASSED 
BUB1 Chip 4 100 0 0.965 PASSED 
BUB3 Chip 4 100 0 0.998 PASSED 
ATM Chip 4 100 0 0.981 PASSED 
FANCD2 Chip 5 100 0 0.947 PASSED 
PARP1 Chip 5 100 0 0.997 PASSED 
RAD51 Chip 5 100 0 0.946 PASSED 
RAD51C Chip 5 100 0 0.969 PASSED 
RAD51D  Chip 5 100 0 0.971 PASSED 
BARD1 Chip 5 100 0 0.942 PASSED 
BRCA1 Chip 4 100 0 0.997 PASSED 
BRCA2 Chip 4 100 0 0.998 PASSED 
MERIT40 Chip 2 100 0 0.960 PASSED 
BRE Chip 4 100 0 0.997 PASSED 
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CCDC98 Chip 4 100 0 0.982 PASSED 
RAP80 Chip 5 100 0 0.987 PASSED 
BRCC3 Chip 1 100 0 0.992 PASSED 
ERCC1 Chip 5 100 0 0.998 PASSED 
ERCC2 Chip 5 100 0 0.977 PASSED 
XPA Chip 5 75 ** 31.25 0.626 FAILED 
XRCC5 Chip 5 100 0 0.997 PASSED 
XRCC6 Chip 5 100 0 0.989 PASSED 
POLB Chip 5 100 0 0.939 PASSED 
MLH1 Chip 5 50 *** 0 0.976 PASSED 
MSH2 Chip 5 100 0 0.993 PASSED 
PMS1 Chip 5 100 12.5 0.932 PASSED 
PIK3CA Chip 5 100 0 0.984 PASSED 
KRAS Chip 5 100 0 0.972 PASSED 
BRAF Chip 4 100 0 0.967 PASSED 
HOXA10 Chip 5 50 *** 0 0.488 FAILED 
CDK12 Chip 6 100 0 0.996 PASSED 
BAD Chip 4 50 31.5 0.585 FAILED 
TP53 Chip 5 100 0 0.995 PASSED 
ABHD8 Chip 2 100 0 0.922 PASSED 
CPAMD8 Chip 2 0 N/A 0.653 FAILED 
DDA1 Chip 2 100 0 0.938 PASSED 
GTPBP3 Chip 2 100 0 0.925 PASSED 
MRPL34 Chip 3 100 0 0.972 PASSED 
MYO9B Chip 3 100 0 0.983 PASSED 
NR2F6 Chip 3 100 0 0.944 PASSED 
OCEL1 Chip 3 100 0 0.890 FAILED 
USHBP1 Chip 4 68.8 50 FAILED FAILED 
ANKRD41 Chip 4 100 6.25 0.717 FAILED 
TMEM16H Chip 4 100 12.5 0.317 FAILED 
USE1 Chip 4 100 0 0.906 PASSED 
β-actin SET 1 Chip 1 100 0 0.998 PASSED 
GAPDH SET 1 Chip 1 100 0 0.996 PASSED 
β-actin SET 2 Chip 2 100 6.25 0.633 FAILED 
GAPDH SET 2 Chip 2 100 0 0.997 PASSED 
β-actin SET 3 Chip 3 100 0 0.979 PASSED 
GAPDH SET 3 Chip 3 100 0 0.994 PASSED 
β-actin SET 4 Chip 4 100 0 0.996 PASSED 
GAPDH SET 4 Chip 4 100 0 0.999 PASSED 
β-actin SET 5 Chip 5 100 0 0.994 PASSED 
GAPDH SET 5 Chip 5 100 0 0.996 PASSED 
β-actin SET 6 Chip 6 100 0 0.997 PASSED 
GAPDH SET 6 Chip 6 100 0 0.997 PASSED 
GAPDH SET 7 Chip 7 100 0 0.995 PASSED 
 
Table 6.8: Quality control analysis for Fluidigm gene expression experiment for the 
control EOC and MERIT40 knockdown cell lines. Highlighted in red are the failed 
assays for a particular quality control criterion. (*) only failed for OVCAR3 control and 
MERIT40 knockdown cell lines. (**) only failed for MPSC1 control and MERIT40 
knockdown cell lines. (***) only failed for OVCAR3 and A2780CP control and MERIT40 
knockdown cell lines.  
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The expression of the selected genes in EOC cell lines with knocked 
down MERIT40 was then calculated using the relative ΔΔCt method and 
calibrated against the expression of the respective EOC cell lines infected with 
a virus containing the Empty vector normalised against the appropriate 
endogenous control(s). For a difference in expression to be biologically 
meaningful at least a two-fold increase or decrease would have to be observed. 
The fold change was calculated as the ratio of the expression in the knockdown 
versus the expression of the EOC_Empty calibrator sample. A fold change of 
<0.5 indicates a two-fold under-expression of the gene and a fold change of >2 
indicated a two-fold over-expression of the gene.  Although the EOC_Empty cell 
lines were used as the calibrator sample, the EOC_Non samples were also 
serving as controls for additional quality control. The fold change between the 
EOC_Empty and the EOC_Non samples was also calculated and if was found 
to have be <0.5 or >2 the assay was deemed as having a fold change 
discordance and any observed fold changes observed between the controls and 
knockdown samples were not considered reliable. Similarly, if a biologically 
significant fold change was observed between EOC_Empty and knockdown cell 
lines and was not observed between EOC_Non and the respective knockdown 
cell line it was classed as having a fold change discordance and the positive 
result was also disregarded. Finally, it is possible that a biologically significant 
observed fold change would not be statistically significant. Fold change 
calculations are calculated using the mean relative expressions and do not take 
into account the diversity in the expression of the replicates. Thus, in cases 
were significant fold changes were observed, a two tailed paired student t-test 
was performed further to judge on whether the observed fold change would also 
be statistically significant (P<0.05). 
The MERIT40 knockdown efficiency of the different shRNA hairpins 
observed previously (Figure 6.6) was confirmed in the present Fluidigm gene 
expression experiment, further indicating the robustness of the assay. For 
EFO27 both M1 and M3 showed a sufficient 9-15 and 2-3 fold decrease 
respectively in MERIT40 expression confirming the 14 and 2.5 fold decrease 
observed in the Taqman gene expression assay (Figure 6.6). For MPSC1 and 
A2780CP only M1 achieved a sufficient decrease of MERIT40 expression of 8-9 
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and 2-2.5 fold decrease respectively which was similar to the calculated 8 and 3 
fold decrease of observed in the Taqman gene expression assay.  For OVCAR3 
M1 showed a 7-9 fold decrease of MERIT40 expression similar to the 7 fold 
decrease found by the Taqman gene expression assay. Also confirming the 
previous observations, M3 did not achieve a more than two-fold decrease of the 
gene’s expression. Figure 6.22 presents the differential expression of MERIT40 
in the EOC and MERIT40 knockdown cell lines according to the Fluidigm gene 
expression assay.  The biologically significant fold change in the expression of 
MERIT40 was also strengthened by statistical significance after performing a 
student’s t-test (Figure 6.22). 
The differential expression of the selected genes between the control 
and MERIT40 knockdown cell lines was evaluated. A summary of the 
expression values for all the genes in the different cell lines is presented in 
Appendix 4, Tables 1, 2, 3 and 4. The results are presented in the 4 different 
cell lines separately as they are representing difference subtypes of ovarian 
cancer and they showed different behaviours in some of the phenotypic assays 
previously performed. An interesting gene to evaluate was PARP1. PARP1 
pathway could be an alternative repair mechanism the cells employ when 
MERIT40 assisted HR is defected to defend themselves against DNA damage 
caused by platinum drugs. No differences were observed in the PARP1 mRNA 
expression for any of the 4 cell lines studied between the controls and their 
MERIT40 knockdown counterparts.  
For EFO27, none of the genes was differentially expressed in the 
presence or absence of MERIT40 (Table 6.9). I have previously observed a 
reduction of cells in the G2/M phase and reduction in the cells with 4N content 
for the EFO27_M1 and M3 compared to the parental. This observation could 
not be linked to any differences in the expression of genes involved in the cell 
cycle regulation or chromosome segregation when MERIT40 was knocked 
down in the EFO27 EOC cell line. The fold changes of all the selected genes 
between the control and MERIT40 knockdown EFO27 cell lines are presented 
in Table 6.9. 
For MSPC1 cell line two genes were found to be under-expressed when 
MERIT40 was knocked down by the M1 construct. One of those genes was 
Chapter 6: Functional analysis of MERIT40 
362 
 
BRE, coding for a component of the BRCA1 complex which is required for the 
integrity of the BRCA1 complex and localisation of the site of DNA DSBs. BRE 
was found to be 2 fold under-expressed in the MSCP1_M1 cell line compared to 
the controls. The result was not of statistical significance though with P 
values>0.05 (Figure 6.23). The second gene found with a 2 fold under-
expression in the MPSC1_M1 and M3 cell lines compared to the controls was 
BRAF, which is involved in cell proliferation, with a statistically significant P 
value of <0.05 (Figure 6.23). The fold changes of all the selected genes 
between the control and MERIT40 knockdown MPSC1 cell lines are presented 
in Table 6.10. 
For OVCAR3 cell line two genes were found to be under-expressed 
when MERIT40 was knocked down by the M1 construct. One of those genes 
was RAD51D, coding for a protein involved in HR and is part of the RAD51 
complex responsible for searching the genome for an intact copy of the 
damaged DNA on the sister chromatid. RAD51D was found to be 2 fold under-
expressed (with P<0.05) in the OVCAR3 _M1 cell line compared to the controls. 
The second gene with a 2.5 fold under-expression in the OVCAR3 _M1 cell line 
was ABHD8, which is a gene located in chromosome 19 in close proximity to 
the MERIT40 locus.  ABHD8 may have catalytic and hydrolase activity and 
might be involved in metabolic processes. Another gene was found to be 2-3 
fold over-expressed (with P<0.05) when MERIT40 was knocked down in 
OVCAR3 cell line was GTPBP3, which is another gene in close proximity to 
MERIT40 in chromosome 19. According to the QC criteria this result should be 
taken with caution as a 2 fold change was observed between OVCAR3_Empty 
and OVCAR3_Non but with a trend of under-expression for OVCAR_Non 
compared to OVCAR3_Empty. However, the expression difference observed 
between the OVCAR3_Empty and OVCAR3_Non was not statistically 
significant with a P value of >0.05 and the expression differences between the 
control and knockdown cell lines were statistically significant (Figure 6.23). The 
fold changes of all the selected genes between the control and MERIT40 
knockdown OVCAR3 cell lines are presented in Table 6.11. 
For cell line A2780CP, BARD1, a gene involved in DDR in the G1/S 
checkpoint in response to ionising radiation (Roy et al, 2012), was found to be 
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2.5 fold over-expressed when MERIT40 was knocked down (P< 0.05, Figure 
6.23). The fold changes of all the selected genes between the control and 
MERIT40 knockdown A2780CP cell lines are presented in Table 6.12. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.22: Validation of differential expression of MERIT40 between the EOC control 
and MERIT40 knockdown cell lines in the Fluidigm experiment. The P values of <0.05 
show the statistically significant differential expression observed between the control 
and knockdown cell lines.  
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Figure 6.23: Histograms representing the expression of genes that were found to be 
differentially expressed between control and MERIT40 knockdown cell lines. The 
histograms in purple are showing differential expression observed for BRE and BRAF 
genes between the MPSC1 control and knockdown cell lines. In pink differential 
expression observed for ABHD8, GTPBP3 and RAD51D genes between the OVCAR3 
control and knockdown cell lines. In red showing the differential expression observed 
for BARD1 between the A2780CP control and knockdown cell lines. For those genes 
that showed a significant fold difference, the P values were calculated to check whether 
the change would be statistically significant and annotated by the graphs. All fold 
changes observed were statistically significant apart for the one observed for the gene 
BRE in the MPSC1 cell line.  
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Non vs E  M1 vs E M3 vs E  M1 vs Non M3 vs Non
CCNE1 Chip 1 β-actin & GAPDH 1.9 1.85 2.03 0.97 1.07 NO
CDKN1A Chip 5 β-actin & GAPDH 1.21 0.65 1.12 0.54 0.93 YES
CDKN2A Chip 5 β-actin & GAPDH 1.4 1.06 1.51 0.76 1.08 YES
PTEN Chip 5 β-actin & GAPDH 0.93 1.04 1.17 1.12 1.26 YES
RB1 Chip 7 β-actin & GAPDH 1.01 0.85 0.8 0.84 0.79 YES
BUBR1 Chip 4 β-actin & GAPDH 1.03 0.97 0.95 0.94 0.92 YES
MAD1 Chip 5 β-actin & GAPDH 0.99 0.57 0.69 0.58 0.70 YES
MAD2L1 Chip 5 β-actin & GAPDH 1.6 0.92 1.14 0.58 0.71 YES
MAD2L2 Chip 5 β-actin & GAPDH 1.19 1.16 1.2 0.97 1.01 YES
CHK1 Chip 5 β-actin & GAPDH 1.22 1.12 1.12 0.92 0.92 YES
CHK2 Chip 5 β-actin & GAPDH 1.53 0.76 1.54 0.50 1.01 NO
BUB1 Chip 4 β-actin & GAPDH 1.22 1.04 1.22 0.85 1.00 YES
BUB3 Chip 4 β-actin & GAPDH 0.96 0.97 1.1 1.01 1.15 YES
ATM Chip 4 β-actin & GAPDH 0.8 0.99 0.88 1.24 1.10 YES
FANCD2 Chip 5 β-actin & GAPDH 1.5 1.54 1.23 1.03 0.82 YES
PARP1 Chip 5 β-actin & GAPDH 1.57 1.23 1.5 0.78 0.96 YES
RAD51 Chip 5 β-actin & GAPDH 1.74 1.35 1.1 0.78 0.63 YES
RAD51C Chip 5 β-actin & GAPDH 1.94 1.38 1.27 0.71 0.65 YES
RAD51D Chip 5 β-actin & GAPDH 1.57 1.66 1.5 1.06 0.96 YES
BARD1 Chip 5 β-actin & GAPDH 0.83 1.03 1.9 1.24 2.29 NO
BRCA1 Chip 4 β-actin & GAPDH 1.06 0.92 1.01 0.87 0.95 YES
BRCA2 Chip 4 β-actin & GAPDH 0.89 1.04 1 1.17 1.12 YES
MERIT40 Chip 2 β-actin 1.65 0.11 0.49 0.07 0.30 YES
BRE Chip 4 β-actin & GAPDH 0.76 0.89 0.98 1.17 1.29 YES
CCDC98 Chip 4 β-actin & GAPDH 0.97 0.6 0.96 0.62 0.99 YES
RAP80 Chip 5 β-actin & GAPDH 1.68 1.22 1.36 0.73 0.81 YES
BRCC3 Chip 1 β-actin & GAPDH 1.56 1.05 1.29 0.67 0.83 YES
ERCC1 Chip 5 β-actin & GAPDH 1.09 0.94 1.32 0.86 1.21 YES
ERCC2 Chip 5 β-actin & GAPDH 1.43 1.39 1.29 0.97 0.90 YES
XRCC5 Chip 5 β-actin & GAPDH 1.33 0.94 1.25 0.71 0.94 YES
XRCC6 Chip 5 β-actin & GAPDH 1.32 1.26 1.2 0.95 0.91 YES
POLB Chip 5 β-actin & GAPDH 1.81 2.34 1.64 1.29 0.91 NO
MLH1 Chip 5 β-actin & GAPDH 1.81 1.34 1.55 0.74 0.86 YES
MSH2 Chip 5 β-actin & GAPDH 1.38 1.25 1.22 0.91 0.88 YES
PMS1 Chip 5 β-actin & GAPDH 2.82 2.89 1.18 1.02 0.42 NO
PIK3CA Chip 5 β-actin & GAPDH 1.43 1.32 0.96 0.92 0.67 YES
KRAS Chip 5 β-actin & GAPDH 1.53 1.33 1.22 0.87 0.80 YES
BRAF Chip 4 β-actin & GAPDH 0.6 1.08 1.12 1.80 1.87 YES
CDK12 Chip 6 β-actin & GAPDH 0.76 0.54 0.72 0.71 0.95 YES
TP53 Chip 5 β-actin & GAPDH 1.04 1 0.96 0.96 0.92 YES
ABHD8 Chip 2 β-actin 1.31 0.92 1.06 0.70 0.81 YES
DDA1 Chip 2 β-actin 1.11 1.12 1.27 1.01 1.14 YES
GTPBP3 Chip 2 β-actin 0.82 1.26 1.81 1.54 2.21 NO
MRPL34 Chip 3 β-actin & GAPDH 0.95 1.11 1.4 1.17 1.47 YES
MYO9B Chip 3 β-actin & GAPDH 1.18 0.97 0.95 0.82 0.81 YES
NR2F6 Chip 3 β-actin & GAPDH 0.65 0.85 1.39 1.31 2.14 NO
USE1 Chip 4 β-actin & GAPDH 1.23 1.63 1.83 1.33 1.49 YES
Gene 
Fluidigm 
Chip
Normalised 
against
Fold Change
Fold change 
concordance
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6.9: Summary of fold changes for the selected genes in the EFO27 and silenced 
MERIT40 counterpart cell lines. Highlighted in green are 2 fold changes or higher. 
Higher than 2 fold changes indicated over-expression of the gene and lower than 0.5 
fold changed indicate under-expression of the genes. The column on the far right 
namely fold change concordance is indicating whether the fold changes observed are 
concordant or not.    
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Non vs E  M1 vs E M3 vs E  M1 vs Non M3 vs Non
CCNE1 Chip 1 β-actin & GAPDH 0.88 0.73 0.94 0.83 1.07 YES
CDKN1A Chip 5 β-actin & GAPDH 0.97 0.86 0.96 0.89 0.99 YES
CDKN2A Chip 5 β-actin & GAPDH N/A N/A N/A N/A N/A YES
PTEN Chip 5 β-actin & GAPDH 0.86 0.81 0.92 0.94 1.07 YES
RB1 Chip 7 β-actin & GAPDH 0.99 1.01 0.99 1.02 1.00 YES
BUBR1 Chip 4 β-actin & GAPDH 1.09 0.64 1.27 0.59 1.17 YES
MAD1 Chip 5 β-actin & GAPDH 0.91 0.95 1.24 1.04 1.36 YES
MAD2L1 Chip 5 β-actin & GAPDH 1.03 0.83 1.23 0.81 1.19 YES
MAD2L2 Chip 5 β-actin & GAPDH 1.05 0.93 1.34 0.89 1.28 YES
CHK1 Chip 5 β-actin & GAPDH 1.22 0.96 1.52 0.79 1.25 YES
CHK2 Chip 5 β-actin & GAPDH 1.77 1.11 1.46 0.63 0.82 YES
BUB1 Chip 4 β-actin & GAPDH 1.26 0.58 1.24 0.46 0.98 NO
BUB3 Chip 4 β-actin & GAPDH 1.3 0.72 1.17 0.55 0.90 YES
ATM Chip 4 β-actin & GAPDH 1.52 0.93 1.09 0.61 0.72 YES
FANCD2 Chip 5 β-actin & GAPDH 0.93 1.03 1.29 1.11 1.39 YES
PARP1 Chip 5 β-actin & GAPDH 1.01 0.96 1.42 0.95 1.41 YES
RAD51 Chip 5 β-actin & GAPDH 1.13 0.96 1.01 0.85 0.89 YES
RAD51C Chip 5 β-actin & GAPDH 0.69 0.86 1.67 1.25 2.42 NO
RAD51D Chip 5 β-actin & GAPDH 0.78 0.72 0.88 0.92 1.13 YES
BARD1 Chip 5 β-actin & GAPDH 0.76 0.86 0.89 1.13 1.17 YES
BRCA1 Chip 4 β-actin & GAPDH 1.17 0.62 1.04 0.53 0.89 YES
BRCA2 Chip 4 β-actin & GAPDH 1.35 0.89 1 0.66 0.74 YES
MERIT40 Chip 2 β-actin 1.07 0.12 0.51 0.11 0.48 YES
BRE Chip 4 β-actin & GAPDH 0.94 0.46 0.65 0.49 0.69 YES
CCDC98 Chip 4 β-actin & GAPDH 1.07 0.7 0.93 0.65 0.87 YES
RAP80 Chip 5 β-actin & GAPDH 1.3 0.96 1.68 0.74 1.29 YES
BRCC3 Chip 1 β-actin & GAPDH 1.43 1 0.99 0.70 0.69 YES
ERCC1 Chip 5 β-actin & GAPDH 0.81 0.71 0.66 0.88 0.81 YES
ERCC2 Chip 5 β-actin & GAPDH 0.98 1.01 1.25 1.03 1.28 YES
XRCC5 Chip 5 β-actin & GAPDH 1.07 0.96 1.41 0.90 1.32 YES
XRCC6 Chip 5 β-actin & GAPDH 1.1 1.07 1.57 0.97 1.43 YES
POLB Chip 5 β-actin & GAPDH 0.95 0.83 1.24 0.87 1.31 YES
MLH1 Chip 5 β-actin & GAPDH 1.01 1.03 1.03 1.02 1.02 YES
MSH2 Chip 5 β-actin & GAPDH 1.03 0.84 1.49 0.82 1.45 YES
PMS1 Chip 5 β-actin & GAPDH 0.9 1.38 1.44 1.53 1.60 YES
PIK3CA Chip 5 β-actin & GAPDH 0.99 0.73 0.91 0.74 0.92 YES
KRAS Chip 5 β-actin & GAPDH 0.98 0.79 0.93 0.81 0.95 YES
BRAF Chip 4 β-actin & GAPDH 1.16 0.51 0.4 0.44 0.34 YES
CDK12 Chip 6 β-actin & GAPDH 1.16 1.06 1.06 0.91 0.91 YES
TP53 Chip 5 β-actin & GAPDH 1.09 1.08 1.06 0.99 0.97 YES
ABHD8 Chip 2 β-actin 1.24 0.83 0.55 0.67 0.44 NO
DDA1 Chip 2 β-actin 1.25 0.91 0.6 0.73 0.48 NO
GTPBP3 Chip 2 β-actin 1.28 0.95 0.79 0.74 0.62 YES
MRPL34 Chip 3 β-actin & GAPDH 3.11 1.15 0.71 0.37 0.23 NO
MYO9B Chip 3 β-actin & GAPDH 1.29 1.15 0.78 0.89 0.60 YES
NR2F6 Chip 3 β-actin & GAPDH 1.9 1.08 0.78 0.57 0.41 NO
USE1 Chip 4 β-actin & GAPDH 0.88 0.45 0.88 0.51 1.00 NO
Gene 
Fluidigm 
Chip
Normalised 
against
Fold Change
Fold change 
concordance
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6.10: Summary of the fold changes for the selected genes in the MPSC1 and 
silenced MERIT40 counterpart cell lines. Highlighted in green are 2 fold changes or 
more. Higher than 2 fold changes indicated over-expression of the gene and lower than 
0.5 fold changed indicate under-expression of the genes. The column on the far right 
namely fold change concordance is indicating whether the fold changes observed are 
concordant or not.  
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Non vs E  M1 vs E M3 vs E  M1 vs Non M3 vs Non
CCNE1 Chip 1 β-actin & GAPDH 0.89 1.14 0.65 1.28 0.73 YES
CDKN1A Chip 5 β-actin & GAPDH 0.87 0.65 0.5 0.75 0.57 YES
CDKN2A Chip 5 β-actin & GAPDH 0.74 0.47 0.58 0.64 0.78 NO
PTEN Chip 5 β-actin & GAPDH 0.93 0.63 1 0.68 1.08 YES
RB1 Chip 7 β-actin & GAPDH 0.89 0.78 0.79 0.88 0.89 YES
BUBR1 Chip 4 β-actin & GAPDH 0.93 1.14 1.55 1.23 1.67 YES
MAD1 Chip 5 β-actin & GAPDH 1.33 0.74 1.03 0.56 0.77 YES
MAD2L1 Chip 5 β-actin & GAPDH 0.86 0.89 1.01 1.03 1.17 YES
MAD2L2 Chip 5 β-actin & GAPDH 0.8 0.75 0.84 0.94 1.05 YES
CHK1 Chip 5 β-actin & GAPDH 1 0.82 1.11 0.82 1.11 YES
CHK2 Chip 5 β-actin & GAPDH N/A N/A N/A N/A N/A N/A
BUB1 Chip 4 β-actin & GAPDH 0.75 0.68 1.05 0.91 1.40 YES
BUB3 Chip 4 β-actin & GAPDH 0.92 0.89 1.36 0.97 1.48 YES
ATM Chip 4 β-actin & GAPDH 1.26 1.02 1.52 0.81 1.21 YES
FANCD2 Chip 5 β-actin & GAPDH 1 0.5 0.79 0.50 0.79 YES
PARP1 Chip 5 β-actin & GAPDH 1.15 0.61 0.82 0.53 0.71 YES
RAD51 Chip 5 β-actin & GAPDH 0.98 0.99 0.84 1.01 0.86 YES
RAD51C Chip 5 β-actin & GAPDH 0.78 0.92 1.2 1.18 1.54 YES
RAD51D Chip 5 β-actin & GAPDH 1.27 0.45 1.05 0.35 0.83 YES
BARD1 Chip 5 β-actin & GAPDH 0.67 1.03 0.77 1.54 1.15 YES
BRCA1 Chip 4 β-actin & GAPDH 0.96 1.18 1.63 1.23 1.70 YES
BRCA2 Chip 4 β-actin & GAPDH 0.86 0.99 1.09 1.15 1.27 YES
MERIT40 Chip 2 β-actin 0.86 0.11 0.61 0.13 0.71 YES
BRE Chip 4 β-actin & GAPDH 0.87 0.8 1.53 0.92 1.76 YES
CCDC98 Chip 4 β-actin & GAPDH 0.92 0.49 1.26 0.53 1.37 NO
RAP80 Chip 5 β-actin & GAPDH 0.82 0.63 0.77 0.77 0.94 YES
BRCC3 Chip 1 β-actin & GAPDH 0.84 0.95 0.94 1.13 1.12 YES
ERCC1 Chip 5 β-actin & GAPDH 0.55 0.41 0.55 0.75 1.00 NO
ERCC2 Chip 5 β-actin & GAPDH 1.17 0.75 0.94 0.64 0.80 YES
XRCC5 Chip 5 β-actin & GAPDH 0.8 0.62 0.96 0.78 1.20 YES
XRCC6 Chip 5 β-actin & GAPDH 1.25 0.7 1.04 0.56 0.83 YES
POLB Chip 5 β-actin & GAPDH 1.25 0.77 0.97 0.62 0.78 YES
MLH1 Chip 5 β-actin & GAPDH N/A N/A N/A N/A N/A N/A
MSH2 Chip 5 β-actin & GAPDH 1.44 0.91 1.13 0.63 0.78 YES
PMS1 Chip 5 β-actin & GAPDH 0.34 0.59 0.76 1.74 2.24 NO
PIK3CA Chip 5 β-actin & GAPDH 0.91 0.56 0.78 0.62 0.86 YES
KRAS Chip 5 β-actin & GAPDH 0.84 0.62 0.75 0.74 0.89 YES
BRAF Chip 4 β-actin & GAPDH 1.09 1.45 1.25 1.33 1.15 YES
CDK12 Chip 6 β-actin & GAPDH 1.07 0.83 1.09 0.78 1.02 YES
TP53 Chip 5 β-actin & GAPDH 0.94 0.62 0.73 0.66 0.78 YES
ABHD8 Chip 2 β-actin 0.89 0.38 0.62 0.43 0.70 YES
DDA1 Chip 2 β-actin 0.73 1.22 1.55 1.67 2.12 NO
GTPBP3 Chip 2 β-actin 0.4 2.09 3.05 5.23 7.63 NO
MRPL34 Chip 3 β-actin & GAPDH 1.03 1.96 4.26 1.90 4.14 YES
MYO9B Chip 3 β-actin & GAPDH 1.05 0.82 1.02 0.78 0.97 YES
NR2F6 Chip 3 β-actin & GAPDH 0.79 1.99 3.48 2.52 4.41 YES
USE1 Chip 4 β-actin & GAPDH 0.65 1.05 0.9 1.62 1.38 YES
Gene 
Fluidigm 
Chip
Normalised against
Fold Change
Fold change 
concordance
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6.11: Summary of the fold changes for the selected genes in the OVCAR3 and 
silenced MERIT40 counterpart cell lines. Highlighted in green are 2 fold changes of 
more. Higher than 2 fold changes indicated over-expression of the gene and lower than 
0.5 fold changed indicate under-expression of the genes. The column on the far right 
namely fold change concordance is indicating whether the fold changes observed are 
concordant or not. If not concordant they are highlighted in red.   
Chapter 6: Functional analysis of MERIT40 
368 
 
Non vs E  M1 vs E M3 vs E  M1 vs Non M3 vs Non
CCNE1 Chip 1 β-actin & GAPDH 0.97 1.01 1.3 1.04 1.34 YES
CDKN1A Chip 5 β-actin & GAPDH 0.19 1.23 0.41 6.47 2.16 NO
CDKN2A Chip 5 β-actin & GAPDH 0.76 0.97 0.58 1.28 0.76 YES
PTEN Chip 5 β-actin & GAPDH 0.66 0.83 0.71 1.26 1.08 YES
RB1 Chip 7 β-actin & GAPDH 0.8 1.02 1.15 1.28 1.44 YES
BUBR1 Chip 4 β-actin & GAPDH 1.06 0.76 0.77 0.72 0.73 YES
MAD1 Chip 5 β-actin & GAPDH 0.54 1.22 0.68 2.26 1.26 NO
MAD2L1 Chip 5 β-actin & GAPDH 0.97 1.26 1.15 1.30 1.19 YES
MAD2L2 Chip 5 β-actin & GAPDH 0.61 0.93 0.57 1.52 0.93 YES
CHK1 Chip 5 β-actin & GAPDH 0.78 0.72 0.88 0.92 1.13 YES
CHK2 Chip 5 β-actin & GAPDH 0.82 0.93 1.13 1.13 1.38 YES
BUB1 Chip 4 β-actin & GAPDH 0.82 0.59 0.76 0.72 0.93 YES
BUB3 Chip 4 β-actin & GAPDH 0.79 0.71 0.59 0.90 0.75 YES
ATM Chip 4 β-actin & GAPDH 1.15 0.87 1.18 0.76 1.03 YES
FANCD2 Chip 5 β-actin & GAPDH 0.76 0.81 0.72 1.07 0.95 YES
PARP1 Chip 5 β-actin & GAPDH 0.7 0.79 0.79 1.13 1.13 YES
RAD51 Chip 5 β-actin & GAPDH 0.96 0.95 0.89 0.99 0.93 YES
RAD51C Chip 5 β-actin & GAPDH 0.73 0.94 1.02 1.29 1.40 YES
RAD51D Chip 5 β-actin & GAPDH 0.42 0.79 0.49 1.88 1.17 NO
BARD1 Chip 5 β-actin & GAPDH 1.17 2.4 0.81 2.05 0.69 YES
BRCA1 Chip 4 β-actin & GAPDH 1.01 0.68 0.89 0.67 0.88 YES
BRCA2 Chip 4 β-actin & GAPDH 0.89 0.83 0.9 0.93 1.01 YES
MERIT40 Chip 2 β-actin 1.04 0.44 0.66 0.42 0.63 YES
BRE Chip 4 β-actin & GAPDH 1.06 0.81 1 0.76 0.94 YES
CCDC98 Chip 4 β-actin & GAPDH 1.1 0.59 0.87 0.54 0.79 YES
RAP80 Chip 5 β-actin & GAPDH 0.6 0.75 0.6 1.25 1.00 YES
BRCC3 Chip 1 β-actin & GAPDH 1.25 0.88 1.21 0.70 0.97 YES
ERCC1 Chip 5 β-actin & GAPDH 0.55 1.17 0.66 2.13 1.20 NO
ERCC2 Chip 5 β-actin & GAPDH 1.01 0.75 1.4 0.74 1.39 YES
XRCC5 Chip 5 β-actin & GAPDH 0.93 1.05 1.04 1.13 1.12 YES
XRCC6 Chip 5 β-actin & GAPDH 0.63 0.73 0.63 1.16 1.00 YES
POLB Chip 5 β-actin & GAPDH 0.69 1.28 0.56 1.86 0.81 YES
MLH1 Chip 5 β-actin & GAPDH N/A N/A N/A N/A N/A N/A
MSH2 Chip 5 β-actin & GAPDH 0.56 0.83 0.68 1.48 1.21 YES
PMS1 Chip 5 β-actin & GAPDH 0.77 0.78 0.85 1.01 1.10 YES
PIK3CA Chip 5 β-actin & GAPDH 0.47 0.61 0.5 1.30 1.06 NO
KRAS Chip 5 β-actin & GAPDH 0.94 0.82 1.05 0.87 1.12 YES
BRAF Chip 4 β-actin & GAPDH 1.06 0.8 0.83 0.75 0.78 YES
CDK12 Chip 6 β-actin & GAPDH 1.22 1.03 0.9 0.84 0.74 YES
TP53 Chip 5 β-actin & GAPDH 0.64 0.93 0.75 1.45 1.17 YES
ABHD8 Chip 2 β-actin 0.46 1.04 0.59 2.26 1.28 NO
DDA1 Chip 2 β-actin 0.53 1.08 0.79 2.04 1.49 NO
GTPBP3 Chip 2 β-actin 0.59 1.21 0.79 2.05 1.34 NO
MRPL34 Chip 3 β-actin & GAPDH 0.36 0.91 0.73 2.53 2.03 NO
MYO9B Chip 3 β-actin & GAPDH 0.9 0.82 0.76 0.91 0.84 YES
NR2F6 Chip 3 β-actin & GAPDH 0.55 1.14 0.79 2.07 1.44 NO
USE1 Chip 4 β-actin & GAPDH 0.88 0.69 0.67 0.78 0.76 YES
Gene 
Fluidigm 
Chip
Normalised 
against
Fold Change
Fold change 
concordance
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6.12: Summary of the fold changes for the selected genes in the A2780CP and 
silenced MERIT40 counterpart cell lines. Highlighted in green are 2 fold changes or 
more. Higher than 2 fold changes indicated over-expression of the gene and lower than 
0.5 fold changed indicate under-expression of the genes. The column on the far right 
namely fold change concordance is indicating whether the fold changes observed are 
concordant or not.   
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 Discussion 6.4
Platinum based chemotherapy is the first line treatment for ovarian 
cancer patients. Although initial treatment is effective especially in patients that 
carry BRCA1 mutations most of the patients develop chemoresistance to the 
drugs and relapse. There are two types of chemoresistance; the intrinsic and 
the acquired chemoresistance. In ovarian cancer the chemoresistance is likely 
due to acquired chemoresistance. This mechanism of acquired 
chemoresistance can include the genetic or epigenetic alterations of oncogenes 
or tumour suppressor genes.  Since MERIT40 is a BRCA1 associated protein 
involved in DNA repair, I hypothesised that the gain in function role I proposed 
in EOC development for MERIT40 may be exerted by the encoded protein of 
the gene providing the cancer cells with tolerance against DNA damage and 
increased resistance to platinum drugs. I also investigated whether MERIT40 
would have another biological relevance to the development of EOC as an 
oncogene by regulating cell cycle progression, proliferation or migration. 
6.4.1 Investigation of MERIT40 function in chemoresistance and DNA 
repair in ovarian cancer 
Treatment of the EOC control and MERIT40 knocked down cell lines with 
cisplatin and carboplatin did not reveal any significant differences in drug 
sensitivity according to the IC50s generated from the dose response curves. A 
slight decrease of the IC50 was observed for EFO27_M1 compared with the 
controls when dosed with cisplatin. It could be argued that a main limitation of 
this experiment was the end point MTT readout to evaluate cell viability due to 
cisplatin cytotoxicity might not be sensitive enough to pick up changes in cell 
viability when monitoring effects on DNA damage. Previous research evaluating 
the sensitivity of cells to DNA damage caused by irradiation when MERIT40 is 
knocked down uses clonogenic assays in order to assay the effects on cell 
viability (Wang et al, 2009). Because of the high toxicity of cisplatin and the 
extreme precautions required when working with it and the numerous samples 
and replicates included in my study, performing clonogenic assays for this study 
would have been extremely difficult.   
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The effectiveness of cisplatin in inhibiting cell viability after MERIT40 
knockdown was assayed by calculating the IC50 based on the dose response 
curves generated after dosing with increasing concentrations of cisplatin. The 
IC50 represents the amount of cisplatin needed to kill 50% of the cells. Though  
comparisons of IC50s is a conventional method to assay for the effect of an 
inhibitor in cell growth and viability, closer step-wise inspections of the curves 
could reveal mechanistic information about the pathway studied providing 
different insights than the IC50 provides. There are no reports to my knowledge 
of such observations by inspecting part of dose response curves but the 
majority of the other studies are using 4-7 doses of platinum drugs (Fajac et al, 
1996, Sevin et al, 1997, Perego et al, 1998, Asselin et al, 2001, Katano et al, 
2002, Li et al, 2009, Wei et al, 2009) whereas in the present study I have 
performed 20 doses of cisplatin making possible the closer examination of 
smaller parts of the dose response curve as the doses slowly increase. 
I have hypothesised that some populations of cells within the same EOC 
cell line could respond differently to cisplatin based on an initial observation of 
some patterns in dose response curves of the different EOC cell lines that were 
used to test cisplatin chemoresistance initially in order to select the cell lines to 
knock down MERIT40. It was apparent that dose response curves consistently 
showed ‘humps’ particularly in the small cisplatin doses for cell lines C13, 
EFO27, OVCAR3 and SCOV3IP. These patterns were consistent and 
reproducible between experiments and observed at exactly the same positions 
corresponding to specific cisplatin concentrations. These patterns were not 
correlated with any of the experimental conditions, such as position on the plate 
reader. These ‘humps’ could be indicative of a cell population within the cell 
lines that may have a different molecular mechanism for response to DNA 
damage caused by cisplatin.  
Additionally, for cell lines SCOV3IP and EFO27 it is interesting that even 
though judging from their IC50 they appear to be quite sensitive to cisplatin, at 
very high cisplatin concentrations a population of cells remains resistant with 
the curve reaching a plateau. This may suggest that heterogeneity in EOC is 
responsible for the development of chemoresistance in patients and may 
suggest that intratumour heterogeneity has a role in acquired chemoresistance. 
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Cell lines SCOV3IP and EFO27 were closely examined under the microscope 
and the heterogeneity observed was compared to the rest of the EOC cell lines 
tested.  SCOV3IP and EFO27 had at least 5-6 morphologically distinct clones 
observed (Data not shown). It will be interesting in the future to examine 
subclonal resistance for the different subtypes of EOC cell lines by sparsely 
seeding the cell lines and picking morphologically distinct colonies to test their 
resistance to chemotherapeutic drugs such as cisplatin. 
Whether the observed differential response to cisplatin within EOC cell 
lines has to do with cancer stem cells (CSC) which have been suggested to 
have a role in intrinsic chemoresistance in several cancers (Liu et al, 2012) or 
different molecular switches activating different DDR pathways or a combination 
of both, should be further investigated. A recent study has shown that side 
population cells, which have the characteristics of cancer stem cells, in 
OVCAR3 showed increased resistance to cisplatin and other chemotherapeutic 
drugs exposed (Luo et al, 2012). 
Inspecting the dose response curves for small, medium and high 
cisplatin concentrations for the EFO27 control and MERIT40 knockdown cell 
lines I observed that up to 10μM of cisplatin dosing, MERIT40 deficient cell line 
EFO27_M1 was more sensitive to cisplatin compared to the controls (Figure 
6.24). In higher dosing of cisplatin the sensitivity to cisplatin between control 
and knockdown cell lines was not different anymore and the dose response 
curves coincided. The same was not observed with the EFO27_M3 but it is not 
surprising as greater knockdown levels of MERIT40 might be required for that 
response to take place.  Similarly, A2780CP_M1 cell line seems to be more 
sensitive to cisplatin between 0 and 7.5 μM of cisplatin doses than the controls 
but in a more subtle manner than the one observed in EFO27 and should be 
treated with caution as the error bars were too large (Appendix 4, Figure 4). 
MPSCI and OVCAR3 did not show any sensitivity to cisplatin at any point of the 
dose response curves.  
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Figure 6.24: Close inspection of cisplatin dose response curves for EFO27 control and 
MERIT40 knockdown cell lines. A) Dose response curve of EFO27 control and 
MERIT40 knockdown cell lines for increasing doses of cisplatin up to 150μM did not 
show any differences in the cisplatin sensitivity. B) Close inspection of the initial part of 
the curve clearly shows the difference of the EFO27_M1 cells response up to 10μM of 
cisplatin dosing. The error bars are showing the standard error of mean (SEM) 
representing how accurate the estimate of the mean cell viability is for each cisplatin 
concentration.   
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The observation that different cisplatin concentrations seem to trigger a 
different response from one EOC cell line in the MERIT40 knockdown model 
resemble the ‘humps’ of different cisplatin response observed before in EOC 
cell lines. Maybe they are caused by different cell populations within the cell 
lines responding in a different way to MERIT40 depletion. More importantly, 
another possible explanation would be that an alternative DNA pathway could 
be employed when the cells are ‘threatened’ with higher doses of cisplatin. The 
cancer cell is constantly exploiting various mechanisms in order to overcome 
stress and adapt to threats such as chemotherapeutic drugs. The possibility of 
the cell employing another DDR response to deal with damage caused by 
platinum drugs is very possible. PARP is participating in Base Excision Repair 
(BER) pathway but it has been previously shown that cells that have defects in 
HR they rely on PARP and BER to maintain genome integrity and repair the 
DNA DSBs caused by exogenous stress (reviewed by Wang and Weaver, 
2012).  When the BER pathway is blocked by PARP1 inhibitors in BRCA1 and 
BRCA2 mutant cells, which have defected HR, it results in cell death and this 
demonstrates the cooperation of the two different pathways to repair damage 
(Farmer et al, 2005). Based on the principle of compensating alternative 
mechanisms being employed as a response to platinum triggered DNA 
damage, it would be intriguing to find out whether dosing MERIT40 deficient 
cells with a combination of cisplatin and PARP1 inhibitors would cause 
increased cell death compared to treating the controls EOC cell lines with 
PARP1 inhibitors alone. 
The gene expression assay I performed did not identify any differential 
expression of PARP1 between the cell lines when MERIT40 was depleted or 
not. However I found PARP1 to be significantly over-expressed in EOC cell 
lines compared to NOSE & FTE cell lines (P=1.6×10-9), (Appendix 4, Figure 5).  
It would be interesting to assay PARP1 expression in the EOC control and EOC 
MERIT40 knockdown cell lines after they are treated with doses of cisplatin 
corresponding to before and after the dose response curves start to coincide. If 
PARP1 is employed an as alternative DNA repair pathway after certain doses of 
cisplatin then it may be more highly expressed at the doses where the dose 
response curves were found to coincide. It has been shown that in the event of 
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DNA SSBs and DSBs the catalytic activity of PARP1 is increased by 100fold 
(Bouchard et al, 2003) but to my knowledge there are no reports on whether the 
transcript output for PARP1 increases too. 
Another question raised by this study is why these EOC cell lines 
respond differently to cisplatin when MERIT40 was knocked down and one 
answer could be because they represent different EOC subtypes. It is 
interesting that high and low grade serous cell lines, MPSC1 and OVCAR3 
respectively, did not show any increased sensitivity to cisplatin when MERIT40 
was knocked down but the mucinous cell line EFO27 did show that initial 
improved response to low doses of cisplatin and also a small decrease in the 
IC50 when MERIT40 is knocked down compared to the controls however with 
very large 95% confidence intervals. A small initial response up to 7.5μM was 
also shown by A2780CP which is an undifferentiated tumour cell line. It is 
curious that the EOC risk association found by the GWAS in chromosome 19 
with a coding SNP within MERIT40 was driven by serous subtypes only (Bolton 
et al, 2010). Therefore it would be expected that any functional role of MERIT40 
would have been more apparent in serous EOC cell lines. However, as 
previously discussed, a SNP in MERIT40 associated with susceptibility for 
serous EOC does not necessarily indicate that the gene is not somatically 
involved in EOC development, progression and survival of the disease in other 
subtypes. I investigated the publicly and in house available information for these 
four EOC cell lines to see if I could find any differences.  I have evaluated the 
expression of BRCA1 between the four EOC cell lines (data not shown) and I 
found no differences. PARP1 expression between them also did not differ.  
p53 is known to be involved in drug induced apoptosis and has been 
previously shown to suppress HR by transcriptionally regulating RAD51 (Lopez 
et al, 2006). Thus cells with depleted p53 could be more resistant in cisplatin 
induced cytotoxicity avoiding apoptosis of unrepaired damage caused by the 
drugs. Additionally, mutations in TP53 have been shown to have a role in 
cisplatin resistance in ovarian cancer (Perego et al, 1996). This raises questions 
regarding the role of p53 in the response of cancer cell lines to DNA 
crosslinking cytotoxic agents. Recent work has shown that whereas cells that 
are p53 deficient have suppressed HR activity, when treated with an intrastrand 
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crosslinking agent mitomycin C, their deficiency in p53 did not impair the cells 
ability to use HR for the removal of DBS (Sirbu et al, 2011). An older study in 
ovarian cancer, however, has shown that cells deficient in p53 demonstrate 
resistance to cisplatin but when treated with a novel platinum agent DACH-
aceto-Pt the p53 protein production was induced and drug related apoptosis 
was triggered (Hagopian et al, 1999).  Mutational analyses performed for those 
cell lines report TP53, PTEN and MSH2 mutations in EFO27. TP53 mutations 
were present also in the OVCAR3 cell line (www.sanger.ac.uk). A2780CP has 
been shown to harbour TP53 mutations (Song et al, 1997) which result in the 
expression of mutant conformations of p53 that are transcriptionally inactive. 
Based on that information it could be suggested that the p53 status of the cell 
lines EFO27, OVCAR3 and A2780CP did not seem to be the differentiating 
factor for the subtle differences they showed in cisplatin sensitivity when 
MERIT40 was knocked down. 
Collectively, the known or observed information I have on the 4 EOC cell 
lines used in this study, do not provide any compelling discriminating 
characteristics on why they should be more sensitive to cisplatin when 
MERIT40 is knocked down. The only difference is the mutation in MSH2 found 
only in EFO27 that could be treated as a discriminating factor. Therefore, I 
investigated this further. In the expression assay I performed I found that 
whereas MSH2 was significantly over-expressed in EOC compared to NOSE 
cell lines (P=2.5×10-9), EFO27 had at least two fold less expression of MSH2 
compared to the other 3 cell lines that were used to knock down MERIT40 
(Appendix 4, Figure 6 A & B respectively). However, this finding does not 
correlate with known information regarding the role of MSH2 in 
chemoresistance for it to be deemed responsible for the observed difference in 
response to low doses of cisplatin between the 4 cell lines. Platinum complexes 
have been shown in some cancer types to interfere with normal activity of the 
mismatch repair (MMR) and prevent the DDR leading to apoptosis. The MMR 
has been previously shown to be implicated with repair of DNA damage caused 
by cisplatin as the loss of MMR activity conferred resistance to cisplatin to 
endometrial and colon cancer cells (Aebi et al, 1996, Fink et al, 1998). In 
ovarian cancer the role of MMR protein in cisplatin resistance is more 
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controversial. In a study of 75 ovarian carcinomas for microsatellite instability 
and mRNA expression of members of the MMR pathway, loss of MSH2 and 
other members of the pathway, was not correlated with cisplatin resistance 
(Helleman et al, 2006). Additionally, the immunohistochemical expression of 
MLH1 and MSH2 proteins was not different between platinum resistant and 
platinum sensitive ovarian cancer patients (Magnowska et al, 2008).  Other 
studies have reported however that ovarian cancer cells that overexpress MMR 
proteins are sensitive to cisplatin (Martin et al, 2008).  
It should be noted that observed differences in results from different 
studies using EOC cell lines may have resulted from mutations and other 
alterations that could have occurred during serial propagation of cells in culture 
leading to cell lines no longer representing reliable models of their original 
source material. Such alterations have been previously shown for EOC cell 
lines (Hughes et al, 2007). This is a limitation that should be mentioned for all 
the studies that used EOC cell lines including this study.  
Based on all these data, unfortunately, in this study I have not managed 
to fully unravel the role of MERIT40 in DNA repair triggered by cisplatin, but the 
findings suggest that alternative pathways may be activated by the cell when a 
DDR pathway is depleted and that a sub-population of cells may be conferring 
increased resistance in EOC.  
I have also investigated the role of MERIT40 in DNA damage repair 
caused by ionising irradiation (IR) and spontaneous damage caused during 
replication. To my knowledge this is the first study that reports that MERIT40 
knockdown in mucinous ovarian cancer cells contributes to increased cell death 
after ionizing radiation although the result is moderate and should be treated 
with caution. More importantly, I observed that unrepaired DNA from 
spontaneous damage during replication was significantly increased as indicated 
by increased levels of phosphorylated γH2AX nuclear foci when MERIT40 was 
knocked down in the EFO27 mucinous EOC cell line. It is likely that MERIT40 
may be more importantly involved in HR employed by the cancer cell for 
surviving replication errors rather than for surviving aggressive exogenous DNA 
damage induced by platinum drugs, in which case alternative repair pathways 
may be used.   
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6.4.2 Investigation of MERIT40 gain of function role in EOC development 
Based on the indication that MERIT40 may contribute in EOC 
development as part of the HR response to replication induced DNA DSBs 
rather than chemoresistance I wanted to see if MERIT40 is involved through 
another function in oncogenesis. Previous work has shown that only a fraction 
of cellular BRE/MERIT40 and BRCC36 localizes to the sites of DNA breaks, 
raising the possibility that BRE/ MERIT40 and BRCC36 may also have other 
functions in the cell (Feng et al, 2009). I have therefore chosen to investigate 
whether silencing of MERIT40 in EOC cell lines would cause the reversal of 
neoplastic phenotypes. I investigated the effect of MERIT40 knockdown on cell 
cycle regulation, proliferation, migration and anchorage independent growth.  
The most significant finding was the decrease of cells in G2/M phase 
observed in mucinous cell line EFO27 with depleted MERIT40. An interesting 
observation is the 50% decrease observed in cell lines EFO27_M1 and 
EFO27_M3 for the cells with 8N content. A reduction in the cells with 8N DNA 
content may suggest that the arrest observed was not due to reduced 
proliferation but due to reduction in ploidy. In fact EFO27 has been shown to be 
hypotretraploid (Lambros et al, 2005). In a follow up analysing metaphase 
spreads I have found that the amount of polyploid cells decreases when 
MERIT40 is knocked down but the amount of cells available to analyse was not 
sufficient to suggest significance for the observed difference. Recent work has 
demonstrated that polyploid cells need intact DDR pathways to overcome 
replication stress induced barriers for tumour progression. This showed that 
polyploidy in cells is causing the over-expression of DNA repair genes including 
BRCA1 (Zheng et al, 2012). Thus it is possible that the reduction in ploidy 
and/or arrest of EFO27 cells with depleted MERIT40 in cell cycle checkpoints 
are a result of defective DNA repair caused by the absence of MERIT40. 
Another characteristic of transformed cells is their ability to grow in an 
anchorage independent manner. I have therefore investigated whether 
MERIT40 has a role in ovarian cancer development by promoting malignant 
transformation of cells after increasing their capability to proliferate 
independently of external and internal signals losing the normal contact 
inhibition response.  Knocking down MERIT40 did not cause a reduction in the 
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anchorage independent growth ability for cell lines EFO27, MPSC1 and 
A2780CP.  I have observed a small reduction in the number of colonies formed 
when MERIT40 was knocked down in the high grade serous EOC cell line 
OVCAR3. Previous work in breast cancer has identified a negative regulator of 
BRCA1 that when it is over-expressed is associated with anchorage 
independent growth thus associating the over-expression of BRCA1 with 
increased ability to proliferate anchorage independently (Welcsh et al, 2001). 
However, I found that the expression for BRCA1 in OVCAR3 control and 
MERIT40 knockdown cell lines was not different (data not shown) so it is more 
possible that MERIT40 could promote anchorage independent growth by 
regulating another pathway involved in the generation of that particular 
neoplastic phenotype. According to the TCGA database, amplifications in the 
MERIT40 locus, that may correlate to higher expression of the gene have a 
significant effect on the levels of several proteins with the most significant being 
a large reduction in the protein levels of MAPK9 (alternatively named JNK2) (P= 
0.0008). That may form an interesting correlation with the decreased growth in 
soft agar observed in OVCAR3 EOC cell lines with depleted MERIT40. In a 
study investigating non-small cell lung carcinoma tumorigenesis it was shown 
that cells deficient in the α isoform of MAPK9 had decreased anchorage 
independent growth (Nitta et al, 2011). It is possible that MERIT40 acts as a 
regulator of the activity of MAPK9, thus dysregulation of MERIT40 expression 
levels may cause increased activity of MAPK9 leading to the cells becoming 
less dependent on ECM adhesion and able to grow in an anchorage 
independent manner leading to tumorigenesis in serous EOC. 
 
6.4.3 Evaluating the effects of MERIT40 knockdown on regulating other 
pathways involved in tumorigenesis 
In an attempt to identify additional pathways that MERIT40 may be 
regulating, I have chosen to investigate whether knocking down MERIT40 
would affect the mRNA expression levels of several genes that are involved in 
cell cycle regulation, chromosome segregation, proliferation, differentiation and 
DNA repair pathways.   
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For EFO27 cell line none of the selected genes was found to be 
differentially expressed when MERIT40 was depleted thus I propose that the 
phenotypic effect that MERIT40 may have in cell cycle regulation is exerted by 
its own role in DNA repair and not via regulating another pathway, at least not 
by being involved in the transcriptional regulation of components involved in 
malignant transformation pathways.  
For MPSC1 I found that BRAF expression was significantly reduced 
when MERIT40 was depleted. That was a very interesting observation because 
the low grade serous EOC cell line MPSC1 is already reported to have 
activating BRAF mutations (www.sanger.ac.uk). BRAF mutations have been 
implicated with early EOC development and these mutations are associated 
with the MAPK pathway in ovarian low grade serous tumours and the 
constitutive activation of the MAPK pathway plays a key role in the development 
of low grade serous tumours containing mutant KRAS or BRAF (Pohl et al, 
2005). It is conceivable that MERIT40 somehow attenuates the increased 
expression of BRAF in low grade serous tumours with activating mutations of 
BRAF and contributing in such way to activation of the MAPK pathway leading 
to increased proliferation and decreased apoptosis. The decreased expression 
of BRAF in MPSC1 with depleted MERIT40 did not relate to any of the 
phenotypic assays performed to assess for reversal of the neoplastic 
phenotype. I have not found that knocking down MERIT40 in MPSC1 had any 
effects reducing the proliferation after evaluating the cells in the S phase of the 
cell cycle based on BrDU incorporation for the control and knockdown cell lines. 
However, a decrease in the proliferation was assumed in the initial evaluation of 
cell proliferation with the MTT assay. The fact that this was not validated by the 
more specific BrDU analysis may be explained by the possibility that the 
observation with MTT was not due to an effect of MERIT40 in the proliferative 
ability for the cells but in their ability to undergo apoptosis. Additional work 
researching the effect of MERIT40 knockdown in apoptosis could be beneficial 
into understanding the possible role of MERIT40 in EOC development by 
attenuating the expression of BRAF leading to activation of the MARK pathway. 
For OVCAR3 I found that when MERIT40 was depleted GTPBP3 
expression was significantly increased and ABHD8 was significantly reduced 
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compared to the control cell line. Both of those genes are located in locus 
19p13 within 100kb downstream of MERIT40 and to my knowledge they have 
not been implicated with any functions in carcinogenesis. Their function is not 
clearly understood yet but is believed that ABHD8 may code for a protein that 
has catalytic and hydrolase activity involved in metabolic processes and 
GTPBP3 for a protein that may play a role in mitochondrial tRNA modification 
(www.genecards.org). 
The significant reduction in RAD51D expression when MERIT40 was 
knocked down in the OVCAR3 cell line was an interesting observation. RAD51D 
is involved in HR as part of the RAD51 complex which searches the genome for 
an intact copy of the damaged DNA on the sister chromatid for HR to take 
place. MERIT40 is implicated in HR by stabilising the BRCA1-Rap80-Abraxas 
complex in DNA DSBs and has mainly been shown to be involved in the 
recognition and initiation of the process as previously described. My observation 
could indicate an additional role of MERIT40 in HR by positively regulating the 
crucial scanning function of RAD51. Recently RAD51 has been proposed to be 
a gene that confers moderate risk for the development of EOC. Inactivating 
mutations in RAD51D have been shown to confer susceptibility to ovarian 
cancer and mutations of this gene have also been found in ovarian cancer 
families with no BRCA1 or BRCA2 mutations (Loveday et al, 2011, Osher et al, 
2012). Additionally, cells that are deficient in RAD41D have been shown to be 
sensitive to treatment with PARP inhibitors (Loveday et al, 2011).  
Hypothesising that the activity of RAD51D may be regulated by MERIT40 levels 
it would be interesting to investigate whether OVCAR3 with depleted MERIT40 
would be more sensitive to PARP inhibitors compared to the control cell line. 
Finally, I found that A2780CP with MERIT40 knocked down, had 
increased expression of BARD1. BARD1 is involved in DNA repair and HR by 
forming a complex with BRCA1 which is involved in the activation of the G1/S, 
S-phase and G2/M checkpoints but is a process that is not yet well 
characterised. When the complex BRCA1-BARD1 is depleted then the 
activation of the G1/S checkpoints in response to damage by ionising radiation 
is compromised (Fabbro et al, 2004). Additionally, the G2/M checkpoint was 
also found defective in cells lacking BARD1 (reviewed in Roy et al, 2012). My 
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observation could be indicative of MERIT40 being involved in checkpoint 
control, possibly the G2/M checkpoint, by negatively regulating BARD1 causing 
the cells to avoid arresting in checkpoint controls where they would undergo 
apoptosis but continue to proliferate uncontrollably leading to neoplastic 
transformation in EOC. However, this hypothesis was not reflected by any of the 
phenotypic assays performed. One limitation of this study is that the expression 
of genes at the mRNA level does not guarantee that an active protein is 
produced such is the case previously mentioned with A2780CP expressing 
TP53 on the mRNA level but the protein expressed is inactive. Thus the results 
should be treated with caution and can only be used to speculate possible 
interactions of MERIT40 with other neoplastic pathways. 
6.4.4 Conclusion  
I observed that in low doses of cisplatin EFO27 mucinous EOC cell line 
became more sensitive when MERIT40 was depleted. That could be due to 
either a subpopulation of cells that respond differently to cisplatin and/or 
alternative repair pathways being employed by the cancer cell to ensure that it 
would regain resistance towards higher doses of cisplatin. Additionally, I 
propose that MERIT40 may be involved in HR employed for the DNA repair of 
DSBs induced during replication and that might show a potential role for the 
gene in EOC early stages of development rather than chemoresistance. 
Consistent with this hypothesis is the observation that knocking down MERIT40 
caused cell cycle arrest and reduction of ploidy for the EFO27 cell line which 
may be just another response to unrepaired DNA damage caused by replicative 
stress. It could be interesting in the future to use NOSE and FTE 3D in vitro 
models and overexpress MERIT40 in the absence and presence of p53 in order 
to study the potential effect of this gene in the early stages of EOC 
development. 
Undoubtedly, the DDR pathways that contribute towards the cytotoxicity 
to cisplatin and the mechanisms which are employed by the cancer cell are 
several. These alternative mechanisms can modulate the cellular response to 
cisplatin induced DNA damage in a tightly coordinated manner and may also 
vary between the different subtypes of EOC. The possibility of MERIT40 
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knockdown contributing to deficiency in HR leading to increased EOC cell death 
after cisplatin exposure remains a point of debate and should be further 
investigated in relation to alternative DDR pathways. Further research 
investigating the mechanisms that are responsible for the collaboration of all the 
recognised DDR pathways in cisplatin resistance for the different subtypes of 
EOC would be valuable and could lead and even more complex and 
individualised combination therapies to overcome resistance to chemotherapy.  
Finally, it still remains under debate whether MERIT40 has other 
functions in the cell than being involved with DNA repair. Over-expression of 
MERIT40 being apparent in EOC cell lines suggests that MERIT40 may 
contribute to EOC development through other pathways leading to neoplastic 
transformation. However, I did not find any really compelling information 
supporting this hypothesis. Additional work investigating other oncogenic 
pathways that MERIT40 may be involved for the development of different EOC 
subtypes would be critical to fully understand the function of that gene in EOC 
development. 
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7 Conclusions and Future work 
Epithelial ovarian cancer (EOC) is the most common cause of 
gynaecological cancer deaths but is still poorly understood. The origin of 
ovarian cancer has been considered to be the normal Ovarian Surface 
Epithelium (NOSE), but a proportion of ovarian cancers may also originate from 
Fallopian Tube Epithelial (FTE) cells. Additionally, the known high risk 
susceptibility genes for EOC do not explain all the heritable components of 
EOC’s. Pathway based association studies and genome wide association 
studies aim to identify alleles of low/moderate risk that may account for the 
development of the remaining familial cases and sporadic EOC. 
The aim of this study was to investigate the functional role of 
low/moderate susceptibility SNPs and candidate genes that emerge from 
candidate gene approaches and GWAS using appropriate tissue and cell line 
models. Part of this study focused in establishing and characterising a NOSE 
primary cell bank (n= 57), and 5 primary FTE cell lines to compare their 
expression with EOC cell lines in post-GWAS functional characterisation 
studies. Additionally, I have established 3D FTE cultures for in vitro models to 
study EOC transformation. I found that FTE3D cultures are a better biological in 
vitro model than 2D as they better reflect the in vivo architecture than 2D 
cultures. Both FTE and NOSE 3D models could be used to impose defined 
genetic modifications that are characteristic for different subtypes of EOC in 
order to elucidate the molecular events that take place for EOC initiation and 
development to occur. 
  A candidate gene approach identified nine genes (AIFM2, AKTIP, AXIN2, 
CASP5, FILIP1L, RBBP8, RGC32, RUVBL1 and STAG3) using an in vitro 
model of microcell mediated chromosome 18 transfer. I tested 301 invasive 
EOC tumours and found frequent LOH for tagging SNPs in those genes with the 
highest frequencies identified for AXIN2, AKTIP and RGC32 and one SNP 
(rs1637001) in STAG3 showed significant preferential loss of the common 
allele. Also, patients with LOH in genes AXIN2, CASP5, RRBBP8 and AIFM2 
had significantly worse survival than cases without LOH but the result was 
associated with stage in AXIN2, CASP5 and AIFM2. 
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Six loci - 2q31, 3q25, 17q21, 8q24, 9p22 and 19p13 - containing 
susceptibility SNPs were identified in an ovarian cancer GWAS and I compared 
the expression of candidate genes within the risk associated loci between 
normal (NOSE & FTE) and EOC cell lines and found compelling evidence for 
the somatic role of some of these genes in EOC development. These genes 
included PVT1, SP2, CBX1, PNPO, HAUS8, USE1, SKAP1, MERIT40 and 
members of the HOXB family of genes with an observed gain of function role  
and TIPARP and BNC2 with an observed loss of function role in EOC 
development. Additionally I have investigated whether the associated SNPs 
would have a functional regulatory role in EOC and found weak associations for 
the rs9303542 genotype with expression of genes CBX1, SNX11 and SP2 and 
for the rs2072590 genotype with HOXD1 expression. Additionally, I found 
compelling evidence for the rs9303542 genotype being associated with HOXB5 
methylation in a cohort of 256 healthy controls. These results indicate that those 
genes may be the susceptibility targets of these loci regulated by the identified 
variants. Collectively these results also suggest the use of the NOSE & FTE 
versus EOC cell lines expression model as a reliable first line tool for evaluation 
of candidate genes’ role in EOC.  
I further knocked down MERIT40 in 4 EOC cell lines and studied their 
chemosensitivity towards cisplatin and carboplatin, but did not find compelling 
evidence of a role or MERIT40 in drug resistance. However, I have found that 
MERIT40 depletion leads to increased accumulation of spontaneous DNA 
damage and cell cycle arrest characterised by reduction in ploidy of the 
mucinous EOC cell line EFO27 
Most association studies report associated SNPs with disease but no 
evidence to suggest which candidate gene in a region may be functionally 
important as a target. This study has provided substantial evidence that GWAS 
are an incredibly powerful tool for understanding the relationship between 
carcinogenesis and genetic markers. Additionally, that a methodical approach 
conducting post-GWAS functional characterization of the cancer risk loci is now 
essential to provide us with valuable biological insights that can only be 
beneficial for creating more effective strategies for the screening, prevention 
and treatment of the disease. The post-GWAS functional characterisation 
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performed in this study has only looked at a small number of possible functions 
for the candidate genes and variants in the associated loci and much more can 
be investigated.  
Several questions remain unanswered and require large collaborative 
efforts to form a conclusive picture. In the first instance, ongoing work is being 
carried out by members of the OCAC, including my group, to fine map the 
candidate loci. This involves large scale genotyping of samples using the 1000 
Genomes project data in order to identify other SNPs in LD with the original 
SNPs in the regions of the EOC associated loci that may confer higher risk of 
EOC susceptibility. A well-structured approach to study the function of the 
candidate SNPs and fine mapping SNPs in more detail could be performed 
based on the findings from this thesis and additional research in the following 
way: 
In case a SNP is a non synonymous SNP changing the amino acid 
sequence of a protein, further bioinformatics analysis can be performed to 
identify whether the changed amino acid influences protein-protein interactions, 
DNA binding, and if the SNP is within or likely to affect activation domains. 
Bionformatic analysis can be performed to determine whether coding and non 
coding variants are located in known promoter regions, or within splicing 
regions, or in regions exhibiting copy number variations. Furthermore, the SNPs 
could affect miRNA binding sites. 
The next step is to evaluate the potential cis-regulatory effects of the 
identified variants by investigating whether the SNP affects transcriptional 
output or methylation of genes within close proximity (1Mb from start or distal 
end). In this study I have established that a reliable assay to investigate function 
of the candidate SNPs is looking at gene expression differences relative to NSP 
genotype, using the cells of origin for EOC (NOSE&FTE) since gene expression 
is tissue specific. However, although using such a model is the most 
appropriate way for reliable results its limitation was in the number of the 
samples. Additional work is being performed by my supervisors, Dr Susan 
Ramus and Prof Simon Gayther at USC, and collaborators using SNPs from the 
original GWAS and fine mapping SNPs, to establish whether there are gene 
expression differences between the genotypes of SNPs after genotyping the 
Chapter 7: Conclusions and future work 
386 
 
NOSE & FT cells established in this project as well as DNA from lymphoblastoid 
cell lines to increase the power of the study to detect significant associations. 
The expression of miRNAs in the regions of susceptibility should also be 
examined relative to the genotype of candidate SNPs as the variants may 
regulate gene expression via miRNA regulation. Allele specific LOH could also 
be investigated for candidate SNPs that were found associated with gene 
expression and could provide insights to the mechanisms by which a risk allele 
may affect the transcriptional output of an oncogene or tumour suppressor gene 
based on the differential expression observed in normal versus EOC cell lines. 
Finally, genotype specific expression of alternative splice variants of candidate 
genes could be evaluated to test whether these SNPs are regulating the genes 
by affecting their splicing patterns. 
Furthermore, the trans effects of the candidate SNPs could be 
investigated in the future by performing microarray analysis for global gene 
expression in NOSE and FTE cell lines as well as evaluating the methylation of 
genes using genome wide methylation data relative to the genotypes of the 
candidate SNPs. 
In post GWAS-characterisation the genes that are regulated by the 
genotype of candidate SNPs may be the target susceptibility genes. However 
genes may have a somatic role in EOC development. This study has 
demonstrated that by evaluating the differential expression of candidate genes 
within the identified loci between normal (NOSE &FTE) and EOC cell lines it is 
possible to suggest a loss or gain of function role for these genes in EOC 
development. This could be validated in the future by investigating the protein 
expression for those genes by performing immunohistochemistry in tissue 
arrays and comparing between primary ovarian tumours and normal OSE and 
FTE tissues. Further mutational and copy number variation for this genes is now 
available by TCGA and could be used to correlate the findings of the expression 
differences observed.  
It should be noted that the differential expression model used in this 
study mainly indicates the somatic role of the candidate genes in EOC 
development but probably is not indicative of the genes’ function in early 
oncogenesis. Once the best candidate genes are established, from this study 
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and after the fine mapping approach, a coordinated study studying the 
functional role of these genes in the appropriate FTE, NOSE or EOC in vitro 
models would be essential to identify what are the molecular pathways these 
genes are using to lead to neoplastic transformation and also in regards to 
earlier or later stages of oncogenesis for the different subtypes. Knocking down 
potential oncogenes in different subtypes of EOC cell lines and assaying for 
neoplastic phenotype reversal can provide information about the candidate 
genes’ function in the development and progression of the different EOC 
subtypes. Overexpressing potential oncogenes or knocking down potential 
tumour suppressor genes in 3D NOSE (Lawrenson et al, 2011) and the FTE 3D 
in vitro model established in his study and assaying for neoplastic 
transformation could provide information about development of the different 
EOC subtypes in early stages of transformation. 
The necessity to use the appropriate in vitro models to study early or late 
stages of EOC development is strengthened by an interesting and puzzling 
observation made in this study regarding the role of tumour suppressor genes in 
EOC. Tumour suppressor genes such as BRCA1, BRCA2 and TP53, all known 
to have a role in DNA repair and cell cycle regulation, were found to be over-
expressed in EOC cells consistent with a similar trend for BRCA1 and BRCA2 
observed in SOC based on TCGA data analysed. This could be an indication 
that the results obtained from the NOSE&FTE versus EOC differential 
expression model may describe later stages in EOC development, where the 
cancer cell has employed mechanisms that traditionally the cell uses to avoid 
neoplastic transformation, in order to overcome DNA damage from endogenous 
or exogenous stress such as replication errors or cytotoxic drugs respectively. 
Thus, tumour suppressor genes involved in such pathways may be found over 
expressed in cancer cells during these stages of cancer development. Based on 
such hypothesis the same tumour suppressor gene conferring protection to the 
cell before cancer initiation, is then deactivated by a somatic alteration which 
favours neoplastic development and later, somehow the cancer cell manages to 
restore its function to promote its growth and avoid DNA damage triggered 
apoptosis. Thus, it may be conceivable that to study the function of such a 
tumour suppressor genes in later stages of EOC may require knocking it down 
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in EOC cell lines. This hypothesis is consistent with some studies that have 
shown findings to support this theory, including BRCA1 secondary activating 
mutations in cisplatin resistant tumours (Swisher et al, 2008) and BRCA1 over-
expression promoting cisplatin resistance in ovarian cancer cells (Chock et al, 
2010). I therefore hypothesise that tumour suppressor genes may adopt 
“oncogenic”-like properties in cancer development by being reactivated and 
promoting the survival of the cancer cell may be one of the hallmarks for cancer 
progression. Studying the mechanisms by which such a fundamental functional 
switch could be achieved may provide valuable insights on cancer cells’ ability 
to acquire chemoresistance or progress into more advances stages. Further 
research elucidating the role of such TSGs in later stages of cancer progression 
may be the key to provide novel individualised therapeutic targets and for better 
prognosis of late stage diagnosed EOC patients. 
 
To conclude, I propose that the functional investigation of GWAS 
identified risk or survival associated loci using the models described in a step 
wise process that I have established in this study should lead to a better 
understanding of the molecular players involved in EOC initiation, development 
and survival and could lead to more reliable screening and individualised 
treatments for EOC. 
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Appendix 1: NOSE & FTE in vitro models 
 
  
Appendix 1 
 
426 
  
Figure 1: NOSE cell line expression of AE1:AE3, CK7, CA125, FSP, FVII as captured under a 
fluorescent microscope (Images at 200×). 
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Patient 
Number
Patient 
age Histopatholgical diagnosis
Brushing 
Collected
Histopathology 
report (Right 
ovary)
Histopathology 
report (Left 
Ovary)
3 62 Grade 1 endometrioid endometrial carcinoma (R) OSE Free of tumour N/A
9 62 Grade 2 endometrioid adenocarcinoma. (R) OSE Free of tumour N/A
11 49 Severe complex atypical hyperplasia of endometrium. OSE Free of tumour Free of tumour
13 66 Endometrioid clear cell carcinoma OSE Free of tumour Free of tumour
18 62 Not specif ied (L) OSE Free of tumour Free of tumour
24 69 Grade 2 endometrioid endometrial adenocarcinoma (R) OSE Free of tumour N/A
175 74 High grade carcinosarcoma (R), (L) OSE Free of tumour Free of tumour
176 59 Grade 1 endometrial adenocarcinoma, FIGO stage 1B  (L) OSE Free of tumour Free of tumour
179 68 Grade 2 endometrial serous papillary adenocarcinoma (R), (L) OSE Free of tumour Free of tumour
181 61 Grade 2 endometrial endometriod adenocarcinoma (R), (L) OSE Free of tumour Free of tumour
185 81 Grade 2 endometrioid endometrial adenocarcinoma (R) OSE Free of tumour N/A
189 46 Grade 1 endometrioid adenocarcinoma (R), (L) OSE Free of tumour Free of tumour
190 76 Grade 3 endometrial carcinoma (R), (L) OSE Free of tumour Free of tumour
191 79 Moderate-poorly differentiated adenocarcinoma (R), (L) OSE Free of tumour Free of tumour
192 82 High Grade serous endometrial adenocarcinoma (R), (L) OSE TUMOUR deposit TUMOUR deposit
194 56 Grade 1, endometrioid adenocarcinoma (R), (L) OSE Free of tumour Free of tumour
197 88 Grade 2 endometrioid endometrial adenocarcinoma (R), (L) OSE Free of tumour Free of tumour
198 81 Grade 2 endometrial endometrioid adenocarcinoma (R), (L) OSE Free of tumour Free of tumour
200 84 Grade 2 endometrioid adenocarcinoma (R), (L) OSE Free of tumour Free of tumour
205 86 Grade 2 endometrial endometrioid adenocarcinoma (L) OSE N/A Free of tumour
206 56 Simple hyperplasia w ith not atypia. (L) OSE N/A Free of tumour
208 49 Papillary serous ovarian cystadenoma (L) OSE N/A Serous cystadenoma
211 83 Grade 3 mixed clear cell and endometrioid carcinoma (L) OSE N/A Free of tumour
216 71 Grade 3 endometrial endometrioid adenocarcinoma (R), (L) OSE Free of tumour Free of tumour
217 65 Grade 2 endometrial endometriod adenocarcinoma (R), (L) OSE Free of tumour Free of tumour
218 67 Grade 3 mixed endometriod/clear cell adenocarcinoma (R), (L) OSE Free of tumour Free of tumour
221 61 Grade 2 endometrioid endometrial adenocarcinoma (R), (L) OSE Free of tumour Free of tumour
222 40 Grade 3 endometrioid, endometrial adenocarcinoma (L) OSE N/A TUMOUR deposit
223 84 Grade 2 endometrioid adenocarcinoma (R), (L) OSE Free of tumour Free of tumour
224 75 Grade 2 endometrial Endometrioid adenocarcinoma (R), (L) OSE Free of tumour Free of tumour
225 59 Grade 2 endometrioid endometrial adenocarcinoma (R) OSE Free of tumour N/A
226 63 Grade 2 endometrioid endometrial adenocarcinoma (R), (L) OSE Free of tumour Free of tumour
228 62 Grade 2 endometrioid endometrial adenocarcinoma (R), (L) OSE Free of tumour Free of tumour
229 70 Grade 2 endometrioid endometrial adenocarcinoma (R), (L) OSE Free of tumour Free of tumour
230 59 Grade 2 endometrioid endometrial adenocarcinoma (R), (L) OSE Free of tumour Free of tumour
231 74 Carcinoma w ith heterologous elements, FIGO 1B (R), (L) OSE Free of tumour Free of tumour
232 62 Carcinosarcma w ith heterologous elements, FIGO 1B (R), (L) OSE Free of tumour Free of tumour
236 62 Grade 2 endometrial Endometrioid adenocarcinoma (R), (L) OSE Free of tumour Free of tumour
237 80 High grade  endometrial carcinosarcoma (R), (L) OSE Free of tumour Free of tumour
238 73 Grade 2 endometrioid endometrial adenocarcinoma (R), (L) OSE Free of tumour Free of tumour
239 82 High grade papillary serous endometrial carcinoma (R), (L) OSE Free of tumour Free of tumour
241 75 Grade 3 endometriod adenocarcinoma (L) OSE N/A Free of tumour
243 57 Invasive polypoid endometrial stromal tumour (R) OSE Free of tumour N/A
245 70 Grade 3 endometrioid carcinoma. (R), (L) OSE Free of tumour Free of tumour
246 75 Grade 3 poorly differentiated adenocarcinoma (R), (L) OSE Free of tumour Free of tumour
250 66 Grade 3 endometrioid endometrial adenocarcinoma (R), (L) OSE Free of tumour Free of tumour
252 40 Grade 2 mixed mucinus and endometrioid adenocarcinoma (R), (L) OSE Free of tumour Free of tumour
253 60 Grade 2 endometrioid adenocarcinoma (R), (L) OSE Free of tumour Free of tumour
254 70 Carcinosarcoma w ith heterologous differentiation (R), (L) OSE Free of tumour Free of tumour
255 67 Grade 3 poorly differentiated adenocarcinoma (R), (L) OSE Free of tumour Free of tumour
257 78 Grade 2 Endometrial endometrioid adenocarcinoma (L) OSE N/A Free of tumour
258 70 Grade 3 endometrioid endometrial adenocarcinoma (R), (L) OSE Free of tumour Free of tumour
261 81 High Grade papillary serous carcinoma of endometrium (R), (L) OSE Metastatic tumour Free of tumour
265 63 CIN (Cervival intraepithelial neoplasia) 3 of cervix. (R), (L) OSE Free of tumour Free of tumour
266 70 Grade 2 endometrioid endometrial carcinoma. (R), (L) OSE Free of tumour Free of tumour
267 70 Grade 2 endometrioid adenocarcinoma into parametrium (R) OSE Free of tumour N/A
268 77 Grade 3 endometrioid endometrial adenocarcinoma (L) OSE N/A Free of tumour
270 65 Atypical complex hyperplasia (R), (L) OSE Free of tumour Free of tumour
273 57 Grade 2 Endometrial endometrioid adenocarcinoma (R), (L) OSE Free of tumour Free of tumour
274 52 Grade 1 w ell differentiated endometrioid adenocarcinoma (R), (L) OSE Free of tumour Free of tumour
277 54 Grade 3 poorly differentiated endometrioid adenocarcinoma (R), (L) OSE Free of tumour Free of tumour
278 63 Grade 2 endometrioid adenocarcinoma (R), (L) OSE Free of tumour Free of tumour
279 72 Grade 2 endometrioid adenocarcinoma (R), (L) OSE Free of tumour Free of tumour
280 69 Grade 3 endometrioid endometrial adenocarcinoma (R), (L) OSE Free of tumour Free of tumour
283 65 Grade 2 endometrioid endometrial adenocarcinoma (R), (L) OSE Free of tumour Free of tumour
284 60 Grade 2 endometrioid endometrial adenocarcinoma (R), (L) OSE Free of tumour Free of tumour
286 71 Grade 2 endometrioid endometrial adenocarcinoma (R), (L) OSE Free of tumour Free of tumour
NOSE FT02 50 Leiomyomas in uterus (R) OSE Free of tumour N/A
NOSE FT05 54 Autolysed endometrium. Benign leiomyomas (R), (L) OSE Free of tumour Free of tumour
1M R 44 Benign leiomyomas and ademonyosis (R) OSE Free of tumour N/A
2M R 47 Uterus w ith multiple f ibroids. (R) OSE Free of tumour N/A
Table 1: NOSE primary cell line collection with patient information such as age, 
diagnosis, histopathological examination of samples is presented. Ovarian surface 
epithelium brushings (OSE) were confirmed as normal (NOSE) after reported free of 
tumour by a pathologist. Samples highlighted in red were not taken forward due to 
malignancy. Samples highlighted in yellow were lost because of bacterial 
contamination. Sample highlighted in grey were not grown. (N/A= not applicable, where 
brushing was not collected). 
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Table 2:  Colony counts in soft agar for FT cell lines after 4 weeks of seeding 5000, 10000 and 20000 cells in 3 replicates each. The EOC cell line 112D was 
used as a positive control for the experiment.  The colony forming efficiency for each replicate was calculated and averaged. 
 
 
Number of cells 
seeded   FT01, p8, 4wks FT02, p8, 4wks FT03, p5, 4wks FT05, p5, 4wks FT283, p8, 4wks FT284, p8, 4wks 112D 1000 cells 
5000 
Number of 
colonies 
Replicate 1 496 312 668 1740 328 660 608 
Replicate 2 564 352 596 1848 392 548 556 
Replicate 3 604 404 760 1712 424 612 592 
Average 555 356 675 1767 381 607 585 
Colony 
forming 
efficiency 
CFE 1 10 6 13 35 7 13 61 
CFE 2 11 7 12 37 8 11 56 
CFE 3 12 8 15 34 8 12 59 
CFE 
average 11 7 13 35 8 12 59 
10000 
Number of 
colonies 
Replicate 1 936 752 1384 3688 584 1192 
  
Replicate 2 1140 708 1248 3592 612 1024 
Replicate 3 1028 732 1420 3872 544 1216 
Average 1035 731 1351 3717 580 1144 
Colony 
forming 
efficiency 
CFE 1 9 8 14 37 6 12 
CFE 2 11 7 12 36 6 10 
CFE 3 10 7 14 39 5 12 
CFE 
average 10 7 14 37 6 11 
20000 
Number of 
colonies 
Replicate 1 1988 1204 2696 6608 836 2372 
Replicate 2 2248 1156 2316 6848 924 2268 
Replicate 3 2132 1408 2472 6968 848 2016 
Average 2123 1256 2495 6808 869 2219 
Colony 
forming 
efficiency 
CFE 1 10 6 13 33 4 12 
CFE 2 11 6 12 34 5 11 
CFE 3 11 7 12 35 4 10 
CFE 
average 11 6 12 34 4 11 
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Table 3: Commercially available EOC cell lines cultured to extract RNA from. The subtypes of 
these cell lines are shown. However as the collection of these cell lines spans over several 
years the terminology of histopathological examination has varied. The term “unknown 
histology” is referring to cell lines that their subtypes is probably serous but collected long ago 
before the subtypes were well differentiated from pathologists.  
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Table 4: Genotyping information for the established primary NOSE cell lines for 7 SNPs 
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Appendix 2: Functional analysis of MMCT-19 
genes and tNSPs 
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Gene SNP
Order in 
gene Plex
Number of 
samples
Genomic Call 
Rate %
% Genomic 
Concordances
Heterozygous 
duplicate 
samples
LOH in duplicate 
samples 
(Concordant/ 
discordant)
% of LOH 
concordance Reason for excluding
AIFM2 rs2394655 1 28plex 301 100 100 1 0/1 0 LOH discordances
AIFM2 rs7908957 2 28plex 301 99 100 1 0/1 0 LOH discordances
AIFM2 rs1053495 3 33plex 239 100 100 9 8/1 89 PASSED
AIFM2 rs2271695 4 33plex Non polymorphic
AIFM2 rs2894111 5 28plex PCR failed
AIFM2 rs2394656 6 28plex 301 100 100 1 1/0 100 PASSED
AIFM2 rs6480440 7 33plex 239 96 100 26 25/1 96 PASSED
AIFM2 rs2280201 8 28plex 301 100 100 0 N/A N/A PASSED
AIFM2 rs10999147 9 33plex 239 100 100 15 15/0 100 PASSED
AIFM2 rs3750772 10 28plex 301 100 100 0 N/A N/A PASSED
AIFM2 rs4295944 11 33plex 239 100 100 39 26/13 67 LOH discordances
AIFM2 rs2394644 12 33plex N/A 0 Genomic call rate
AIFM2 rs10999152 13 28plex 301 97 100 2 2/0 100 PASSED
AKTIP rs9931702 1 28plex 301 100 100 3 3/0 100 PASSED
AKTIP rs17801966 2 28plex 301 98 100 1 1/0 100 PASSED
AKTIP rs7189819 3 28plex 301 99 100 7 3/4 0 PASSED
AKTIP rs3743772 4 33plex 239 94 100 6 5/1 83 PASSED
AXIN2 rs11868547 1 28plex 301 99 100 2 2/0 100 PASSED
AXIN2 rs7591 2 33plex 239 100 100 44 41/3 95 PASSED
AXIN2 rs7210356 3 33plex 239 100 100 43 21/22 95 PASSED
AXIN2 rs11655966 4 28plex N/A 0 Genomic call rate
AXIN2 rs4541111 5 28plex 301 100 85 Genomic discordances
AXIN2 rs4791171 6 33plex 239 100 100 29 28/1 97 PASSED
AXIN2 rs11079571 7 33plex 239 0 Genomic call rate
AXIN2 rs3923086 8 28plex 301 100 100 6 6/0 100 PASSED
CASP5 rs518604 1 33plex 239 99 100 63 60/3 95 PASSED
CASP5 rs523104 2 33plex 239 0 Genomic call rate
CASP5 rs3181328 3 28plex 301 100 100 0 N/A N/A PASSED
CASP5 rs17446518 4 28plex 301 99 77 Genomic discordances
CASP5 rs9651713 5 28plex 301 100 100 1 1/0 100 PASSED
CASP5 rs3181175 6 33plex 239 100 100 0 N/A N/A PASSED
CASP5 rs3181174 7 33plex 239 100 100 14 11/3 78 LOH discordances
CASP5 rs2282657 8 33plex 239 100 100 0 N/A N/A PASSED
FILIP1L rs796977 1 33plex 239 99 100 40 40/0 98 PASSED
FILIP1L rs793477 2 28plex 301 99 100 0 N/A N/A PASSED
FILIP1L rs793446 3 33plex 239 100 100 41 29/12 71 LOH discordances
FILIP1L rs17338680 4 33plex 239 100 69 Genomic discordances
FILIP1L rs9864437 5 33plex 239 100 100 27 25/2 93 PASSED
FILIP1L rs6788750 6 28plex 301 100 100 4 4/0 100 PASSED
FILIP1L rs12494994 7 33plex 239 99 100 22 21/1 95 PASSED
RBBP8 rs7239066 1 28plex 301 100 100 0 N/A N/A PASSED
RBBP8 rs11082221 2 28plex 301 100 100 0 N/A N/A PASSED
RBBP8 rs9304261 3 33plex 239 99 100 0 N/A N/A PASSED
RGC32 rs3783194 1 28plex 239 76 Genomic call rate
RGC32 rs11618371 2 33plex 239 100 100 25 22/3 88 PASSED
RGC32 rs995845 3 33plex 239 100 100 31 30/1 97 PASSED
RGC32 rs975590 4 28plex 301 100 100 3 3/0 100 PASSED
RGC32 rs3783197 5 33plex 239 100 70 Genomic discordances
RUVBL1 rs9860614 1 33plex 239 99 100 4 3/1 75 LOH discordances
RUVBL1 rs13063604 2 28plex 301 76 69 Genomic call rate
RUVBL1 rs3732402 3 33plex 239 100 100 46 38/8 83 PASSED
RUVBL1 rs13091198 4 33plex 239 93 100 5 3/2 60 LOH discordances
RUVBL1 rs7650365 5 28plex 301 78 Genomic call rate
RUVBL1 rs4857836 6 33plex 239 100 100 37 35/2 95 PASSED
RUVBL1 rs9821568 7 28plex 301 100 100 2 2/0 100 PASSED
STAG3 rs11762932 1 33plex 239 100 100 29 27/2 96 PASSED
STAG3 rs2246713 2 28plex 301 100 77 Genomic discordances
STAG3 rs1637001 3 33plex 239 100 100 25 24/1 99 PASSED
BRCA1 rs799917 28plex 301 97 100 4 3/1 75 LOH discordances
BRCA2 rs144848 28plex 301 100 100 3 2/1 67 LOH discordances
N/A
N/A
Non polymorphic
PCR failed
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Table 1: Summary of quality control analysis for the SNPs selected to investigate allele specific 
LOH. Highlighted in red are the SNPs that failed. LOH= Loss of Heterozygosity. N/A: when 
analysis was not performed due to having failed sample QC or not having enough informative 
samples.  
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Figure 1: Standard Curves for assays run in the Fluidigm assay for gene expression analysis 
between EOC and normal (NOSE & FT ) cell lines 
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C
h
ro
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o
m
e
Gene Locus
Sample 
number 
(EOC/ 
Normal)
P value
Sample 
number 
(EOC/ 
Normal)
P value
Sample 
number 
(EOC/ 
Normal)
P value P value
Number of 
samples with 
alterations * 
(Amp/ 
HomDel/ 
Mutations) 
Frequency of 
alterations      
**
KIAA1715 2q31 44/62 0.094 42/58 0.038 42/59 0.004 1.89×10-4 11/0/0 3.5%
EVX2 2q31.1 FAILED FAILED FAILED FAILED FAILED FAILED 0.003 11/0/1 3.8%
HOXD13 2q31.1 FAILED FAILED FAILED FAILED FAILED FAILED 0.007 12/0/0 3.8%
HOXD12 2q31.1 FAILED FAILED FAILED FAILED FAILED FAILED 0.151 12/0/1 4.1%
HOXD11 2q31.1 FAILED FAILED FAILED FAILED FAILED FAILED 0.378 12/0/0 3.8%
HOXD10 2q31.1 FAILED FAILED FAILED FAILED FAILED FAILED 0.024 12/0/3 4.7%
HOXD9 2q31.1 FAILED FAILED FAILED FAILED FAILED FAILED 0.489 12/0/0 3.8%
HOXD8 2q31.1 30/61 0.185 28/56 0.692 29/59 0.591 0.245 14/0/0 4.4%
HOXD4 2q31.1 FAILED FAILED FAILED FAILED FAILED FAILED 0.663 13/0/0 4.1%
HOXD3 2q31.1 FAILED FAILED FAILED FAILED FAILED FAILED 0.362 14/0/0 4.4%
HOXD1 2q31.1 FAILED FAILED FAILED FAILED FAILED FAILED 0.912 13/0/0 4.1%
MTX2 2q31.1 44/62 0.001 42/58 0.083 42/59 0.015 0.004 13/0/1 4.4%
KCNAB1 3q26.1 FAILED FAILED FAILED FAILED FAILED FAILED 2.38×10-4 22/0/2 7.6%
SSR3 3q25.31 44/62 0.180 42/58 3.04×10-4 42/58 0.003 0.216 22/0/0 7.0%
TIPARP 3q25.31 41/62 9.4×10-6 42/58 6.57×10-11 41/58 4.99×10-9 1.11×10-4 22/0/1 7.3%
LOC730091 3q25.31 FAILED FAILED FAILED FAILED FAILED FAILED No data 0/0/0 0.0%
PA2G4P4 3q25.31 43/62 8.5×10-8 42/58 3.64×10-5 41/61 2.14×10-5 No data 22/0/1 7.3%
LEKR1 3q25.31 FAILED FAILED FAILED FAILED FAILED FAILED 0.006 23/0/1 7.6%
MYC 8q24.21 44/62 0.028 39/57 0.079 40/59 0.085 0.059 97/0/0 30.7%
PVT1 8q24 42/62 9.7×10-11 41/56 3.28×10-8 41/59 6.64×10-8 No data 102/0/0 32.3%
BNC2 9p22.32 35/62 N/A * 30/58 1.73×10-4 32/58 N/A * 1.63×10-4 8/2/1 3.5%
CNTLN 9p22 44/62 N/A * 42/58 0.030 42/59 N/A * 0.536 4/3/0 2.2%
SP6 17q21.32 FAILED FAILED FAILED FAILED FAILED FAILED 0.005 7/0/0 2.2%
SP2 17q21.32 44/62 1.69×10-12 42/57 2.33×10-6 42/58 5.68×10-10 0.049 6/0/0 1.9%
PNPO 17q21.32 44/62 8.59×10-10 42/57 8.21×10-5 42/58 6.26×10-8 0.629 6/0/0 1.9%
ATAD4 17q21.32 FAILED FAILED FAILED FAILED FAILED FAILED 0.210 6/0/1 2.2%
CDK5RAP3 17q21.32 44/62 N/A * 42/57 0.023 42/51 N/A * 0.143 5/0/0 1.6%
COPZ2 17q21.32 30/62 N/A * 29/57 0.001 29/58 N/A * 0.107 5/0/0 1.6%
NFE2L1 17q21.3 44/62 0.465 42/58 0.088 41/59 0.050 1.4×10-5 5/0/0 1.6%
CBX1 17q21.32 44/62 N/A * 42/57 1.19×10-5 42/58 N/A * 0.018 6/0/0 1.9%
SNX11 17q21.32 43/62 3.77×10-7 42/58 0.532 42/58 0.004 0.388 5/0/0 1.6%
SKAP1 17q21.32 FAILED FAILED FAILED FAILED FAILED FAILED 0.001 10/1/0 3.5%
HOXB1 17q21.3 FAILED FAILED FAILED FAILED FAILED FAILED 0.024 10/0/1 3.5%
HOXB2 17q21-q22 FAILED FAILED FAILED FAILED FAILED FAILED 0.047 9/0/0 2.8%
HOXB3 17q21.3 34/52 0.002 28/47 1.54×10-5 31/51 1.72×10-4 5.24×10-4 10/0/0 3.2%
HOXB4 17q21-q22 34/54 6.8×10-7 33/49 4.9×10-4 35/52 0.001 0.026 10/0/1 3.5%
HOXB5 17q21.3 FAILED FAILED FAILED FAILED FAILED FAILED 0.002 9/0/0 2.8%
HOXB6 17q21.3 27/54 1.31×10-4 21/49 4.76×10-5 26/50 4.23×10-7 5.25×10-5 8/0/0 2.5%
LOC404266 17q21.32 FAILED FAILED FAILED FAILED FAILED FAILED No data 0/0/0 0.0%
HOXB7 17q21.3 35/54 5.12×10-11 35/52 4.08×10-9 35/50 4.62×10-10 0.867 8/0/0 2.5%
HOXB8 17q21.3 FAILED FAILED FAILED FAILED FAILED FAILED 0.001 8/0/0 2.5%
HOXB9 17q21.3 29/47 3.84×10-10 27/46 1.05×10-8 30/46 9.7×10-9 0.946 8/0/0 2.5%
PRAC 17q21 FAILED FAILED FAILED FAILED FAILED FAILED 0.184 7/0/0 2.2%
HOXB13 17q21.2 FAILED FAILED FAILED FAILED FAILED FAILED 0.003 7/0/0 2.2%
TTLL6 17q21.32 FAILED FAILED FAILED FAILED FAILED FAILED 2.12×10-6 7/0/0 2.2%
SIN3B 19p13.11 44/62 8.57×10-5 42/57 0.864 42/57 0.126 0.019 28/0/2 9.5%
CPAMD8 19p13.11 FAILED FAILED FAILED FAILED FAILED FAILED 0.398 28/0/6 10.8%
HAUS8 19p13.11 43/62 2.7×10-11 42/51/6 1.02×10-4 41/62 1.08×10-6 1.48×10-5 27/0/1 8.9%
MYO9B 19p13.1 44/62 0.071 42/58 0.082 42/59 0.010 3.69×10-5 30/0/2 10.1%
USE1 19p13.11 44/62 8.52×10-9 42/58 0.002 43/60 1.69×10-5 0.224 30/0/0 9.5%
OCEL1 19p13.11 39/62 0.002 39/59 0.037 38/59 0.012 0.009 30/0/0 9.5%
NR2F6 19p13.1 42/62 0.075 40/58 0.562 42/60 0.226 0.094 30/0/0 9.5%
USHBP1 19p13 FAILED FAILED FAILED FAILED FAILED FAILED 0.014 30/0/1 9.8%
MERIT40 19p13.11 44/62 N/A * 42/57 0.005 42/58 N/A * 2.09×10-5 29/0/1 9.5%
ANKRD41 19p13.11 FAILED FAILED FAILED FAILED FAILED FAILED 0.234 28/0/0 8.9%
ABHD8 19p13.11 44/62 N/A * 42/58 0.028 42/58 N/A * 0.132 27/0/0 8.5%
DDA1 19p13.11 44/62 N/A * 42/58 0.471 42/60 N/A * 2.04×10-4 27/0/0 8.5%
MRPL34 19p13.1 43/62 3.34×10-5 42/58 0.003 42/60 0.001 0.005 27/0/0 8.5%
TMEM16H 19p13.11 FAILED FAILED FAILED FAILED FAILED FAILED 7.42×10-5 26/0/3 9.2%
GTPBP3 19p13.11 FAILED FAILED FAILED FAILED FAILED FAILED 1.02×10-5 25/0/0 7.9%
19
TCGA analysis for somatic 
alterations
2
3
8
9
17
Fluidigm gene expression assay TCGA data 
epression 
analysis
Normalised against 
β-actin
Normalised against 
GAPDH
Normalised against β-
actin & GAPDH
Table 1: Summary of the P values generated for expression of the candidate genes normalised  
to β-actin and GAPDH  separately and combined. Included in this table are genes that failed QC 
for the Fluidigm assay and their expression between SOC and normal FT from TCGA data as 
well as reported somatic alterations. 
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Table 2: Summary of genotype specific methylation of CpG islands associated with the 
candidate genes within risk loci in chromosomes 2, 3, 8 and 9 (Linear regression analysis). 
Tabulated are the CpGs’ median methylation (represented by β-values) compared between the 
3 genotype groups of the risk EOC associated SNPs. P values were generated with linear 
regression analysis. 
 
 
 
 
 
 
 
 
 
 
CH H RH CH H RH
cg10957151 0.174 0.157 0.157 0.020 0.022 0.017 0.003
cg14991487 0.053 0.050 0.049 0.007 0.009 0.009 0.332
cg15520279 0.036 0.033 0.033 0.009 0.008 0.008 0.455
cg21815667 0.074 0.075 0.074 0.009 0.007 0.007 0.901
cg00005847 0.150 0.150 0.153 0.017 0.016 0.013 0.186
cg18702197 0.053 0.054 0.047 0.007 0.007 0.008 0.621
HOXD1 cg19001226 0.041 0.043 0.036 0.006 0.006 0.005 0.616
MTX2 cg19280014 0.083 0.084 0.086 0.008 0.009 0.006 0.447
cg15423862 0.855 0.855 0.883 0.010 0.011 0.009 0.083
cg23873703 0.695 0.703 0.721 0.058 0.062 0.069 0.489
SSR3 cg24517609 0.073 0.071 0.072 0.006 0.006 0.010 0.977
cg22114222 0.022 0.021 0.021 0.002 0.002 0.001 0.389
cg24262469 0.196 0.208 0.205 0.022 0.025 0.015 0.304
cg19972619 0.044 0.044 0.048 0.004 0.003 0.003 0.817
cg27207274 0.071 0.072 0.072 0.006 0.006 0.005 0.222
cg13052755 0.886 0.887 0.884 0.014 0.011 0.008 0.415
cg13784855 0.038 0.037 0.038 0.003 0.003 0.002 0.993
9
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 Median β-value comparison between common homozygotes and 
combined rare homozygotes & heterozygotes
Sample 
number 
CH/H/RH
Linear 
regression 
analysis   
(P value)
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CH H RH CH H RH
cg02691091 0.906 0.904 0.907 0.007 0.008 0.008 0.646
cg14360917 0.530 0.517 0.532 0.040 0.027 0.030 0.151
cg00177698 0.037 0.035 0.037 0.004 0.004 0.002 0.760
cg10154655 0.041 0.042 0.041 0.004 0.003 0.003 0.185
cg03777405 0.062 0.064 0.066 0.008 0.007 0.013 0.262
cg06740897 0.083 0.086 0.080 0.012 0.015 0.014 0.665
cg11194725 0.053 0.052 0.052 0.005 0.005 0.004 0.271
cg17778721 0.040 0.040 0.040 0.006 0.006 0.007 0.719
cg08413153 0.111 0.116 0.116 0.012 0.013 0.010 0.340
cg12563480 0.035 0.036 0.035 0.006 0.006 0.005 0.601
cg05106502 0.368 0.380 0.374 0.039 0.033 0.034 0.763
cg12513481 0.067 0.067 0.066 0.012 0.008 0.014 0.917
HOXB2 cg25882366 0.260 0.272 0.278 0.044 0.052 0.037 0.604
HOXB3 cg12910797 0.841 0.847 0.849 0.021 0.016 0.021 0.998
cg02422694 0.040 0.040 0.040 0.004 0.004 0.003 0.798
cg04609859 0.034 0.033 0.034 0.005 0.004 0.005 0.677
cg06760035 0.033 0.034 0.036 0.003 0.003 0.005 0.005
cg08089301 0.035 0.036 0.034 0.004 0.005 0.006 0.496
cg14458834 0.118 0.127 0.126 0.019 0.021 0.028 0.320
cg21460081 0.078 0.080 0.081 0.007 0.008 0.009 0.437
cg21546671 0.115 0.120 0.115 0.016 0.022 0.020 0.969
cg25145670 0.075 0.076 0.091 0.010 0.009 0.013 0.013
cg01405107 0.273 0.239 0.219 0.041 0.051 0.040  5.56×10-6
cg16495265 0.081 0.082 0.079 0.008 0.008 0.008 0.451
HOXB6 cg16848873 0.456 0.493 0.562 0.080 0.072 0.079 0.006
cg06493080 0.051 0.051 0.048 0.008 0.010 0.007 0.948
cg09357097 0.062 0.062 0.062 0.007 0.007 0.008 0.772
cg12370791 0.030 0.031 0.029 0.003 0.003 0.003 0.972
cg13643585 0.028 0.027 0.026 0.003 0.003 0.004 0.335
Median of β-values 
Median Absolute 
Deviation (MAD)
HOXB7
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Table 3: Summary of genotype specific methylation of CpG islands associated with the 
candidate genes within loci in chromosome 17 (Linear regression analysis). Tabulated are the 
CpGs’ median methylation (represented by β-values) compared between the 3 genotype groups 
of the risk EOC associated SNPs. P values were generated with linear regression analysis. 
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CH H RH CH H RH
cg00215066 0.949 0.950 0.950 0.005 0.005 0.005 0.728
cg01103836 0.962 0.963 0.962 0.003 0.003 0.004 0.195
cg01252496 0.510 0.505 0.500 0.015 0.019 0.020 0.092
cg08891270 0.035 0.034 0.034 0.002 0.003 0.003 0.584
cg07242565 0.033 0.033 0.033 0.003 0.003 0.003 0.892
cg16749578 0.166 0.166 0.160 0.022 0.024 0.020 0.442
ANKRD41 cg21435336 0.037 0.035 0.035 0.003 0.003 0.003 0.045
cg08145177 0.117 0.120 0.110 0.019 0.030 0.020 0.666
cg22734480 0.027 0.025 0.026 0.002 0.003 0.003 0.041
cg19390148 0.032 0.031 0.030 0.005 0.005 0.004 0.425
cg21061811 0.747 0.740 0.735 0.021 0.022 0.028 0.397
MRPL34 cg04914305 0.050 0.050 0.050 0.005 0.004 0.004 0.242
cg00215066 0.949 0.950 0.950 0.005 0.005 0.005 0.728
cg01103836 0.962 0.963 0.962 0.003 0.003 0.004 0.195
cg01252496 0.510 0.505 0.500 0.015 0.019 0.020 0.092
cg08891270 0.035 0.034 0.034 0.002 0.003 0.003 0.584
cg07242565 0.033 0.033 0.033 0.003 0.003 0.003 0.892
cg16749578 0.166 0.166 0.160 0.022 0.024 0.020 0.442
ANKRD41 cg21435336 0.037 0.035 0.035 0.003 0.003 0.003 0.045
cg08145177 0.117 0.120 0.110 0.019 0.030 0.020 0.666
cg22734480 0.027 0.025 0.026 0.002 0.003 0.003 0.041
cg19390148 0.032 0.031 0.030 0.005 0.005 0.004 0.425
cg21061811 0.747 0.740 0.735 0.021 0.022 0.028 0.397
MRPL34 cg04914305 0.050 0.050 0.050 0.005 0.004 0.004 0.242
 Median β-value comparison between common homozygotes and 
combined rare homozygotes & heterozygotes
Sample 
number 
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Table 4: Summary of genotype specific methylation of CpG islands associated with the 
candidate genes within loci in chromosome 19 (Linear regression analysis). Tabulated are the 
CpGs’ median methylation (represented by β-values) compared between the 3 genotype groups 
of the risk EOC associated SNPs. P values were generated with linear regression analysis. 
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Appendix 4: Functional analysis of MERIT40 
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Figure 1: Cell cycle profiles of A2780CP, MPSC1, OVCAR3 control and MERIT40 knockdown 
cell lines 
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Figure 2: Representative soft agar assays of EFO27, A2780CP and MPSC1 control and 
MERIT40 knockdown cell lines. The pictured were taken after seeding 5000 cells and 
incubating for 4 weeks. 112D EOC cell line was used as a positive control cell line. 
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Figure 3: Standard Curves for assays run in the Fluidigm assay for gene expression analysis 
between EOC control and MERIT40 knockdown cell lines 
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Figure 4: Close inspection of cisplatin dose response curve for A2780CP control and MERIT40 
knockdown cell lines. The dose response curve for increasing doses of cisplatin up to 150μM 
did not show any differences in the cell lines’ cisplatin sensitivity. Close inspection of the curve 
clearly shows the difference of the A2780CP _M1 cells response up to 7.5um of cisplatin 
dosing. The error bars are showing the SEM (standard error of mean) which is the standard 
error of the mean representing how accurate the estimate of the mean cell viability is for each 
cisplatin concentration.  
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Figure 5: Differential expression of PARP1 in EOC and normal cell lines 
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Figure 6: MSH2 expression in normal and EOC cell lines A) Differential expression of MSH2 
between EOC and normal cell lines, B) Differential expression of MSH2 between the 4 EOC cell 
lines selected to knock down MERIT40 
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Empty Non-silencing M1 M3
CCNE1 Chip 1 β-actin & GAPDH 100 [116-86] 190 [222-165] 185 [234-152] 203 [251-165]
CDKN1A Chip 5 β-actin & GAPDH 100 [125-80] 121 [148-99] 65 [81-53] 112 [147-85]
CDKN2A Chip 5 β-actin & GAPDH 100 [110-91] 140 [166-118] 106 [164-71] 151 [186-123]
PTEN Chip 5 β-actin & GAPDH 100 [117-86] 93 [129-67] 104 [135-82] 117 [136-101]
RB1 Chip 7 β-actin & GAPDH 100 [129-77] 101 [123-83] 85 [101-72] 80 [89-72]
BUBR1 Chip 4 β-actin & GAPDH 100 [113-89] 103 [115-93] 97 [117-82] 95 [115-79]
MAD1 Chip 5 β-actin & GAPDH 100 [122-82] 99 [122-81] 57 [73-45] 69 [117-41]
MAD2L1 Chip 5 β-actin & GAPDH 100 [147-68] 160 [202-127] 92 [131-67] 114 [167-78]
MAD2L2 Chip 5 β-actin & GAPDH 100 [112-89] 119 [137-104] 116 [147-93] 120 [153-94]
CHK1 Chip 5 β-actin & GAPDH 100 [113-89] 122 [136-110] 112 [138-92] 112 [126-99]
CHK2 Chip 5 β-actin & GAPDH 100 [113-88] 153 [193-122] 76 [153-40] 154 [217-109]
BUB1 Chip 4 β-actin & GAPDH 100 [134-75] 122 [147-102] 104 [144-77] 122 [148-101]
BUB3 Chip 4 β-actin & GAPDH 100 [112-89] 96 [112-83] 97 [122-79] 110 [135-90]
ATM Chip 4 β-actin & GAPDH 100 [124-81] 80 [95-68] 99 [123-81] 88 [109-72]
FANCD2 Chip 5 β-actin & GAPDH 100 [118-85] 150 [176-128] 154 [196-124] 123 [162-94]
PARP1 Chip 5 β-actin & GAPDH 100 [131-76] 157 [199-124] 123 [150-102] 150 [181-125]
RAD51 Chip 5 β-actin & GAPDH 100 [117-86] 174 [209-145] 135 [188-99] 110 [139-87]
RAD51C Chip 5 β-actin & GAPDH 100 [153-65] 194 [281-134] 138 [212-93] 127 [189-85]
RAD51D Chip 5 β-actin & GAPDH 100 [138-73] 157 [194-127] 166 [221-128] 150 [174-129]
BARD1 Chip 5 β-actin & GAPDH 100 [115-87] 83 [115-60] 103 [144-75] 190 [245-147]
BRCA1 Chip 4 β-actin & GAPDH 100 [121-83] 106 [120-94] 92 [115-75] 101 [152-68]
BRCA2 Chip 4 β-actin & GAPDH 100 [138-72] 89 [100-80] 104 [129-85] 100 [141-72]
MERIT40 Chip 2 β-actin 100 [113-89] 165 [185-147] 11 [16-7] 49 [60-40]
BRE Chip 4 β-actin & GAPDH 100 [116-86] 76 [98-60] 89 [106-76] 98 [123-79]
CCDC98 Chip 4 β-actin & GAPDH 100 [126-79] 97 [123-77] 60 [73-50] 96 [116-80]
RAP80 Chip 5 β-actin & GAPDH 100 [127-79] 168 [188-151] 122 [189-82] 136 [160-115]
BRCC3 Chip 1 β-actin & GAPDH 100 [109-92] 156 [189-130] 105 [172-69] 129 [166-100]
ERCC1 Chip 5 β-actin & GAPDH 100 [140-71] 109 [160-75] 94 [143-64] 132 [162-107]
ERCC2 Chip 5 β-actin & GAPDH 100 [111-90] 143 [169-121] 139 [176-112] 129 [155-108]
XRCC5 Chip 5 β-actin & GAPDH 100 [132-76] 133 [176-101] 94 [126-72] 125 [156-100]
XRCC6 Chip 5 β-actin & GAPDH 100 [119-84] 132 [164-106] 126 [183-89] 120 [162-89]
POLB Chip 5 β-actin & GAPDH 100 [138-72] 181 [213-154] 234 [284-196] 164 [226-119]
MLH1 Chip 5 β-actin & GAPDH 100 [112-89] 181 [212-155] 134 [171-107] 155 [187-128]
MSH2 Chip 5 β-actin & GAPDH 100 [114-87] 138 [180-106] 125 [177-91] 122 [173-86]
PMS1 Chip 5 β-actin & GAPDH 100 [178-56] 282 [525-152] 289 [403-213] 118 [136-103]
PIK3CA Chip 5 β-actin & GAPDH 100 [115-87] 143 [186-110] 132 [163-109] 96 [112-82]
KRAS Chip 5 β-actin & GAPDH 100 [132-76] 153 [187-126] 133 [175-103] 122 [162-92]
BRAF Chip 4 β-actin & GAPDH 100 [120-83] 60 [90-41] 108 [143-83] 112 [157-81]
CDK12 Chip 6 β-actin & GAPDH 100 [116-86] 76 [89-65] 54 [66-45] 72 [94-54]
TP53 Chip 5 β-actin & GAPDH 100 [112-89] 104 [117-93] 100 [128-80] 96 [119-77]
ABHD8 Chip 2 β-actin 100 [143-70] 131 [146-117] 92 [128-66] 106 [131-86]
DDA1 Chip 2 β-actin 100 [117-85] 111 [130-95] 112 [149-84] 127 [165-98]
GTPBP3 Chip 2 β-actin 100 [128-78] 82 [113-59] 126 [139-114] 181 [266-123]
MRPL34 Chip 3 β-actin & GAPDH 100 [112-89] 95 [124-74] 111 [134-95] 140 [151-130]
MYO9B Chip 3 β-actin & GAPDH 100 [103-97] 118 [135-104] 97 [102-93] 95 [101-89]
NR2F6 Chip 3 β-actin & GAPDH 100 [112-90] 65 [99-44] 85 [111-67] 139 [149-129]
USE1 Chip 4 β-actin & GAPDH 100 [150-67] 123 [155-99] 163 [231-119] 183 [222-152]
β-actin SET 1 Chip 1 GAPDH 100 [115-87] 114 [140-93] 151 [183-124] 103 [129-83]
GAPDH SET 1 Chip 1 β-actin 100 [115-87] 87 [107-71] 66 [80-54] 97 [121-78]
GAPDH SET 2 Chip 2 N/A (β-actin failed) N/A N/A N/A N/A
β-actin SET 3 Chip 3 GAPDH 100 [110-91] 120 [135-107] 143 [150-136] 95 [106-85]
GAPDH SET 3 Chip 3 β-actin 100 [110-91] 83 [93-74] 70 [73-67] 105 [117-94]
β-actin SET 4 Chip 4 GAPDH 100 [118-85] 113 [128-100] 123 [150-101] 109 [141-84]
GAPDH SET 4 Chip 4 β-actin 100 [118-85] 89 [101-79] 81 [99-66] 92 [119-71]
β-actin SET 5 Chip 5 GAPDH 100 [122-82] 102 [134-77] 121 [160-91] 100 [130-77]
GAPDH SET 5 Chip 5 β-actin 100 [122-82] 98 [129-75] 83 [110-63] 100 [130-77]
β-actin SET 6 Chip 6 GAPDH 100 [122-82] 99 [130-76] 144 [158-131] 76 [95-61]
GAPDH SET 6 Chip 6 β-actin 100 [122-82] 101 [132-77] 70 [77-64] 132 [165-105]
GAPDH SET 7 Chip 7 N/A (β-actin failed) N/A N/A N/A N/A
EFO27
Normalised against
Fluidigm 
Chip
Gene 
% Relative expresion [Confidence intervals]
Table 1: Summary of relative expression (%) of selected genes in control and MERIT40 
knockdown EFO27 cell lines. The confidence intervals were calculated from +/- error of relative 
expression. 
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Empty Non-silencing M1 M3
CCNE1 Chip 1 β-actin & GAPDH 100 [123-81] 88 [131-59] 73 [88-62] 94 [114-78]
CDKN1A Chip 5 β-actin & GAPDH 100 [135-74] 97 [127-74] 86 [95-77] 96 [111-83]
CDKN2A Chip 5 β-actin & GAPDH FAILED FAILED FAILED FAILED
PTEN Chip 5 β-actin & GAPDH 100 [129-78] 86 [117-63] 81 [98-67] 92 [119-71]
RB1 Chip 7 β-actin & GAPDH 100 [115-87] 99 [108-91] 101 [130-79] 99 [129-76]
BUBR1 Chip 4 β-actin & GAPDH 100 [110-91] 109 [134-89] 64 [86-48] 127 [145-111]
MAD1 Chip 5 β-actin & GAPDH 100 [141-71] 91 [109-76] 95 [114-79] 124 [172-90]
MAD2L1 Chip 5 β-actin & GAPDH 100 [140-71] 103 [140-76] 83 [101-68] 123 [169-90]
MAD2L2 Chip 5 β-actin & GAPDH 100 [140-72] 105 [134-82] 93 [116-75] 134 [150-119]
CHK1 Chip 5 β-actin & GAPDH 100 [137-73] 122 [139-107] 96 [111-83] 152 [171-135]
CHK2 Chip 5 β-actin & GAPDH 100 [129-78] 177 [253-124] 111 [163-76] 146 [204-105]
BUB1 Chip 4 β-actin & GAPDH 100 [111-90] 126 [172-92] 58 [73-46] 124 [146-105]
BUB3 Chip 4 β-actin & GAPDH 100 [123-82] 130 [161-105] 72 [84-61] 117 [133-103]
ATM Chip 4 β-actin & GAPDH 100 [116-86] 152 [217-106] 93 [131-66] 109 [158-75]
FANCD2 Chip 5 β-actin & GAPDH 100 [159-63] 93 [129-67] 103 [114-93] 129 [152-110]
PARP1 Chip 5 β-actin & GAPDH 100 [141-71] 101 [114-89] 96 [129-71] 142 [178-113]
RAD51 Chip 5 β-actin & GAPDH 100 [136-73] 113 [129-99] 96 [127-72] 101 [115-89]
RAD51C Chip 5 β-actin & GAPDH 100 [147-68] 69 [78-61] 86 [165-45] 167 [237-117]
RAD51D Chip 5 β-actin & GAPDH 100 [150-67] 78 [101-60] 72 [85-61] 88 [108-71]
BARD1 Chip 5 β-actin & GAPDH 100 [132-76] 76 [87-66] 86 [102-73] 89 [107-74]
BRCA1 Chip 4 β-actin & GAPDH 100 [119-84] 117 [146-94] 62 [71-54] 104 [116-93]
BRCA2 Chip 4 β-actin & GAPDH 100 [113-89] 135 [176-104] 89 [131-60] 100 [128-78]
MERIT40 Chip 2 β-actin 100 [110-91] 107 [129-88] 12 [16-9] 51 [62-42]
BRE Chip 4 β-actin & GAPDH 100 [132-76] 94 [132-67] 46 [66-32] 65 [83-51]
CCDC98 Chip 4 β-actin & GAPDH 100 [140-72] 107 [166-69] 70 [90-55] 93 [107-81]
RAP80 Chip 5 β-actin & GAPDH 100 [129-78] 130 [172-99] 96 [118-78] 168 [187-151]
BRCC3 Chip 1 β-actin & GAPDH 100 [126-79] 143 [191-107] 100 [135-74] 99 [143-68]
ERCC1 Chip 5 β-actin & GAPDH 100 [130-77] 81 [116-56] 71 [108-47] 66 [100-43]
ERCC2 Chip 5 β-actin & GAPDH 100 [131-77] 98 [113-85] 101 [112-91] 125 [141-111]
XRCC5 Chip 5 β-actin & GAPDH 100 [147-68] 107 [133-86] 96 [132-70] 141 [176-113]
XRCC6 Chip 5 β-actin & GAPDH 100 [133-75] 110 [142-85] 107 [136-84] 157 [196-126]
POLB Chip 5 β-actin & GAPDH 100 [135-74] 95 [109-82] 83 [102-67] 124 [164-94]
MLH1 Chip 5 β-actin & GAPDH 100 [136-74] 101 [120-85] 103 [114-93] 103 [132-80]
MSH2 Chip 5 β-actin & GAPDH 100 [142-70] 103 [143-74] 84 [95-74] 149 [196-114]
PMS1 Chip 5 β-actin & GAPDH 100 [155-65] 90 [116-70] 138 [161-118] 144 [163-127]
PIK3CA Chip 5 β-actin & GAPDH 100 [134-75] 99 [112-88] 73 [103-52] 91 [119-69]
KRAS Chip 5 β-actin & GAPDH 100 [135-74] 98 [112-86] 79 [92-68] 93 [104-83]
BRAF Chip 4 β-actin & GAPDH 100 [109-91] 116 [143-94] 51 [65-40] 40 [52-31]
CDK12 Chip 6 β-actin & GAPDH 100 [148-68] 116 [152-89] 106 [139-81] 106 [146-77]
TP53 Chip 5 β-actin & GAPDH 100 [134-75] 109 [125-95] 108 [123-95] 106 [148-76]
ABHD8 Chip 2 β-actin 100 [122-82] 124 [154-100] 83 [105-65] 55 [60-50]
DDA1 Chip 2 β-actin 100 [122-82] 125 [155-101] 91 [110-75] 60 [81-44]
GTPBP3 Chip 2 β-actin 100 [109-92] 128 [190-86] 95 [115-79] 79 [86-73]
MRPL34 Chip 3 β-actin & GAPDH 100 [112-90] 311 [411-235] 115 [139-95] 71 [93-54]
MYO9B Chip 3 β-actin & GAPDH 100 [114-88] 129 [167-99] 115 [148-89] 78 [96-63]
NR2F6 Chip 3 β-actin & GAPDH 100 [118-85] 190 [250-144] 108 [132-88] 78 [105-58]
USE1 Chip 4 β-actin & GAPDH 100 [106-94] 88 [131-59] 45 [65-31] 88 [118-66]
β-actin SET 1 Chip 1 GAPDH 100 [129-77] 87 [128-59] 111 [128-97] 93 [118-73]
GAPDH SET 1 Chip 1 β-actin 100 [129-77] 115 [169-78] 90 [103-78] 107 [135-85]
GAPDH SET 2 Chip 2 N/A (β-actin failed) N/A N/A N/A N/A
β-actin SET 3 Chip 3 GAPDH 100 [123-81] 71 [103-49] 102 [135-77] 106 [143-79]
GAPDH SET 3 Chip 3 β-actin 100 [123-81] 141 [203-98] 98 [130-74] 94 [127-70]
β-actin SET 4 Chip 4 GAPDH 100 [137-73] 118 [170-82] 199 [238-166] 149 [170-131]
GAPDH SET 4 Chip 4 β-actin 100 [137-73] 84 [121-58] 50 [60-42] 67 [76-59]
β-actin SET 5 Chip 5 GAPDH 100 [144-70] 89 [110-72] 74 [91-60] 83 [104-66]
GAPDH SET 5 Chip 5 β-actin 100 [144-70] 113 [139-92] 136 [167-111] 121 [151-97]
β-actin SET 6 Chip 6 GAPDH 100 [147-68] 101 [143-71] 113 [142-90] 118 [151-92]
GAPDH SET 6 Chip 6 β-actin 100 [147-68] 99 [140-70] 89 [112-71] 85 [109-67]
GAPDH SET 7 Chip 7 N/A (β-actin failed) N/A N/A N/A N/A
MPSC1
% Relative expresion [Confidence intervals]
Gene 
Fluidigm 
Chip
Normalised against
Table 2: Summary of relative expression (%) of selected genes in control and MERIT40 
knockdown MPSC1 cell lines. The confidence intervals were calculated from +/- error of relative 
expression.  
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Empty Non-silencing M1 M3
CCNE1 Chip 1 β-actin & GAPDH 100 [111-90] 89 [112-70] 114 [125-104] 65 [83-51]
CDKN1A Chip 5 β-actin & GAPDH 100 [116-86] 87 [127-60] 65 [81-52] 50 [64-39]
CDKN2A Chip 5 β-actin & GAPDH 100 [119-84] 74 [107-51] 47 [67-33] 58 [79-43]
PTEN Chip 5 β-actin & GAPDH 100 [141-71] 93 [135-64] 63 [73-55] 100 [119-84]
RB1 Chip 7 β-actin & GAPDH 100 [116-86] 89 [101-79] 78 [93-66] 79 [97-65]
BUBR1 Chip 4 β-actin & GAPDH 100 [119-84] 93 [104-83] 114 [134-97] 155 [193-125]
MAD1 Chip 5 β-actin & GAPDH 100 [146-68] 133 [198-89] 74 [84-65] 103 [134-79]
MAD2L1 Chip 5 β-actin & GAPDH 100 [127-78] 86 [135-55] 89 [116-68] 101 [131-78]
MAD2L2 Chip 5 β-actin & GAPDH 100 [125-80] 80 [121-53] 75 [101-56] 84 [105-67]
CHK1 Chip 5 β-actin & GAPDH 100 [114-88] 100 [146-68] 82 [96-70] 111 [136-91]
CHK2 Chip 5 β-actin & GAPDH FAILED FAILED FAILED FAILED
BUB1 Chip 4 β-actin & GAPDH 100 [118-85] 75 [97-58] 68 [79-58] 105 [125-88]
BUB3 Chip 4 β-actin & GAPDH 100 [112-89] 92 [100-84] 89 [100-79] 136 [161-115]
ATM Chip 4 β-actin & GAPDH 100 [113-89] 126 [145-110] 102 [118-88] 152 [193-120]
FANCD2 Chip 5 β-actin & GAPDH 100 [112-89] 100 [147-68] 50 [58-43] 79 [95-66]
PARP1 Chip 5 β-actin & GAPDH 100 [125-80] 115 [169-78] 61 [71-53] 82 [110-61]
RAD51 Chip 5 β-actin & GAPDH 100 [118-85] 98 [151-64] 99 [114-86] 84 [119-59]
RAD51C Chip 5 β-actin & GAPDH 100 [131-76] 78 [121-50] 92 [125-68] 120 [179-81]
RAD51D Chip 5 β-actin & GAPDH 100 [129-78] 127 [189-85] 45 [51-40] 105 [131-84]
BARD1 Chip 5 β-actin & GAPDH 100 [111-90] 67 [100-45] 103 [120-88] 77 [98-61]
BRCA1 Chip 4 β-actin & GAPDH 100 [115-87] 96 [126-73] 118 [150-93] 163 [203-131]
BRCA2 Chip 4 β-actin & GAPDH 100 [116-86] 86 [109-68] 99 [112-88] 109 [133-89]
MERIT40 Chip 2 β-actin 100 [119-84] 86 [103-72] 11 [16-8] 61 [80-46]
BRE Chip 4 β-actin & GAPDH 100 [122-82] 87 [99-77] 80 [94-68] 153 [186-126]
CCDC98 Chip 4 β-actin & GAPDH 100 [125-80] 92 [106-80] 49 [62-39] 126 [146-109]
RAP80 Chip 5 β-actin & GAPDH 100 [133-75] 82 [124-54] 63 [73-54] 77 [101-59]
BRCC3 Chip 1 β-actin & GAPDH 100 [130-77] 84 [88-80] 95 [114-79] 94 [113-78]
ERCC1 Chip 5 β-actin & GAPDH 100 [148-68] 55 [86-35] 41 [60-28] 55 [81-37]
ERCC2 Chip 5 β-actin & GAPDH 100 [112-90] 117 [169-81] 75 [89-64] 94 [120-74]
XRCC5 Chip 5 β-actin & GAPDH 100 [123-81] 80 [124-52] 62 [75-51] 96 [122-76]
XRCC6 Chip 5 β-actin & GAPDH 100 [130-77] 125 [190-82] 70 [84-58] 104 [132-82]
POLB Chip 5 β-actin & GAPDH 100 [122-82] 125 [192-81] 77 [92-64] 97 [134-70]
MLH1 Chip 5 β-actin & GAPDH FAILED FAILED FAILED FAILED
MSH2 Chip 5 β-actin & GAPDH 100 [123-81] 144 [213-97] 91 [109-76] 113 [140-91]
PMS1 Chip 5 β-actin & GAPDH 100 [130-77] 34 [54-21] 59 [76-46] 76 [116-50]
PIK3CA Chip 5 β-actin & GAPDH 100 [129-77] 91 [133-62] 56 [71-44] 78 [101-60]
KRAS Chip 5 β-actin & GAPDH 100 [132-75] 84 [121-58] 62 [73-52] 75 [89-64]
BRAF Chip 4 β-actin & GAPDH 100 [152-66] 109 [136-87] 145 [171-123] 125 [179-87]
CDK12 Chip 6 β-actin & GAPDH 100 [120-83] 107 [151-76] 83 [107-64] 109 [139-86]
TP53 Chip 5 β-actin & GAPDH 100 [115-87] 94 [136-65] 62 [76-51] 73 [94-57]
ABHD8 Chip 2 β-actin 100 [120-83] 89 [110-72] 38 [45-32] 62 [78-49]
DDA1 Chip 2 β-actin 100 [129-78] 73 [83-64] 122 [137-109] 155 [201-119]
GTPBP3 Chip 2 β-actin 100 [113-89] 40 [56-29] 209 [233-187] 305 [379-245]
MRPL34 Chip 3 β-actin & GAPDH 100 [126-80] 103 [110-97] 196 [230-167] 426 [472-385]
MYO9B Chip 3 β-actin & GAPDH 100 [123-81] 105 [113-98] 82 [98-69] 102 [111-93]
NR2F6 Chip 3 β-actin & GAPDH 100 [120-83] 79 [82-76] 199 [245-162] 348 [392-309]
USE1 Chip 4 β-actin & GAPDH 100 [139-72] 65 [75-56] 105 [129-85] 90 [102-80]
β-actin SET 1 Chip 1 GAPDH 100 [113-89] 97 [104-90] 65 [78-54] 103 [130-82]
GAPDH SET 1 Chip 1 β-actin 100 [113-89] 103 [110-96] 154 [184-129] 97 [122-77]
GAPDH SET 2 Chip 2 N/A (β-actin failed) N/A N/A N/A N/A
β-actin SET 3 Chip 3 GAPDH 100 [127-79] 88 [94-83] 79 [99-63] 87 [103-73]
GAPDH SET 3 Chip 3 β-actin 100 [127-79] 114 [122-107] 127 [160-101] 114 [135-96]
β-actin SET 4 Chip 4 GAPDH 100 [120-83] 79 [89-70] 64 [70-58] 60 [67-54]
GAPDH SET 4 Chip 4 β-actin 100 [120-83] 126 [141-112] 157 [173-142] 168 [187-151]
β-actin SET 5 Chip 5 GAPDH 100 [120-83] 74 [125-44] 62 [81-47] 100 [130-77]
GAPDH SET 5 Chip 5 β-actin 100 [120-83] 134 [226-79] 160 [209-123] 100 [130-77]
β-actin SET 6 Chip 6 GAPDH 100 [125-80] 93 [129-67] 73 [94-57] 89 [102-77]
GAPDH SET 6 Chip 6 β-actin 100 [125-80] 108 [150-78] 136 [175-106] 113 [130-98]
GAPDH SET 7 Chip 7 N/A (β-actin failed) N/A N/A N/A N/A
OVCAR3
Gene 
Fluidigm 
Chip
Normalised against
% Relative expresion [Confidence intervals]
Table 3: Summary of relative expression (%) of selected genes in control and MERIT40 
knockdown OVCAR3 cell lines. The confidence intervals were calculated from +/- error of 
relative expression. 
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Empty Non-silencing M1 M3
CCNE1 Chip 1 β-actin & GAPDH 100 [123-81] 97 [127-74] 101 [118-87] 130 [167-102]
CDKN1A Chip 5 β-actin & GAPDH 100 [158-63] 19 [26-14] 123 [153-99] 41 [56-30]
CDKN2A Chip 5 β-actin & GAPDH 100 [154-65] 76 [92-63] 97 [105-90] 58 [86-39]
PTEN Chip 5 β-actin & GAPDH 100 [143-70] 66 [70-63] 83 [90-76] 71 [85-59]
RB1 Chip 7 β-actin & GAPDH 100 [122-82] 80 [102-63] 102 [122-85] 115 [167-79]
BUBR1 Chip 4 β-actin & GAPDH 100 [119-84] 106 [130-86] 76 [89-65] 77 [99-60]
MAD1 Chip 5 β-actin & GAPDH 100 [147-68] 54 [67-43] 122 [158-94] 68 [92-50]
MAD2L1 Chip 5 β-actin & GAPDH 100 [139-72] 97 [122-77] 126 [184-86] 115 [137-96]
MAD2L2 Chip 5 β-actin & GAPDH 100 [128-78] 61 [71-52] 93 [114-76] 57 [64-51]
CHK1 Chip 5 β-actin & GAPDH 100 [131-76] 78 [94-65] 72 [85-61] 88 [103-75]
CHK2 Chip 5 β-actin & GAPDH 100 [156-64] 82 [103-65] 93 [100-86] 113 [162-79]
BUB1 Chip 4 β-actin & GAPDH 100 [119-84] 82 [107-63] 59 [81-43] 76 [92-63]
BUB3 Chip 4 β-actin & GAPDH 100 [122-82] 79 [100-63] 71 [88-58] 59 [70-50]
ATM Chip 4 β-actin & GAPDH 100 [127-79] 115 [148-90] 87 [123-61] 118 [156-89]
FANCD2 Chip 5 β-actin & GAPDH 100 [142-70] 76 [82-71] 81 [94-70] 72 [80-65]
PARP1 Chip 5 β-actin & GAPDH 100 [141-71] 70 [82-59] 79 [93-67] 79 [96-65]
RAD51 Chip 5 β-actin & GAPDH 100 [150-67] 96 [105-88] 95 [118-77] 89 [113-70]
RAD51C Chip 5 β-actin & GAPDH 100 [158-63] 73 [107-50] 94 [116-76] 102 [145-71]
RAD51D Chip 5 β-actin & GAPDH 100 [129-78] 42 [50-35] 79 [86-72] 49 [64-38]
BARD1 Chip 5 β-actin & GAPDH 100 [156-64] 117 [126-108] 240 [279-207] 81 [90-73]
BRCA1 Chip 4 β-actin & GAPDH 100 [127-79] 101 [123-83] 68 [83-56] 89 [111-71]
BRCA2 Chip 4 β-actin & GAPDH 100 [121-82] 89 [110-72] 83 [104-66] 90 [120-67]
MERIT40 Chip 2 β-actin 100 [121-83] 104 [130-83] 44 [56-35] 66 [74-59]
BRE Chip 4 β-actin & GAPDH 100 [125-80] 106 [145-77] 81 [103-64] 100 [138-72]
CCDC98 Chip 4 β-actin & GAPDH 100 [155-65] 110 [139-87] 59 [73-48] 87 [106-72]
RAP80 Chip 5 β-actin & GAPDH 100 [129-78] 60 [66-54] 75 [100-56] 60 [76-48]
BRCC3 Chip 1 β-actin & GAPDH 100 [122-82] 125 [154-102] 88 [100-77] 121 [160-91]
ERCC1 Chip 5 β-actin & GAPDH 100 [145-69] 55 [75-41] 117 [126-108] 66 [99-44]
ERCC2 Chip 5 β-actin & GAPDH 100 [130-77] 101 [114-90] 75 [84-67] 140 [162-121]
XRCC5 Chip 5 β-actin & GAPDH 100 [134-74] 93 [113-76] 105 [131-84] 104 [125-87]
XRCC6 Chip 5 β-actin & GAPDH 100 [133-75] 63 [73-54] 73 [84-63] 63 [76-52]
POLB Chip 5 β-actin & GAPDH 100 [133-75] 69 [78-61] 128 [141-117] 56 [67-47]
MLH1 Chip 5 β-actin & GAPDH FAILED FAILED FAILED FAILED
MSH2 Chip 5 β-actin & GAPDH 100 [145-69] 56 [78-40] 83 [108-64] 68 [82-56]
PMS1 Chip 5 β-actin & GAPDH 100 [137-73] 77 [106-56] 78 [98-62] 85 [103-70]
PIK3CA Chip 5 β-actin & GAPDH 100 [133-75] 47 [63-35] 61 [75-50] 50 [59-42]
KRAS Chip 5 β-actin & GAPDH 100 [136-73] 94 [106-84] 82 [96-70] 105 [126-87]
BRAF Chip 4 β-actin & GAPDH 100 [128-78] 106 [158-71] 80 [116-55] 83 [127-54]
CDK12 Chip 6 β-actin & GAPDH 100 [121-82] 122 [160-93] 103 [115-93] 90 [94-86]
TP53 Chip 5 β-actin & GAPDH 100 [135-74] 64 [71-57] 93 [115-75] 75 [90-62]
ABHD8 Chip 2 β-actin 100 [126-79] 46 [63-33] 104 [140-77] 59 [69-50]
DDA1 Chip 2 β-actin 100 [128-78] 53 [67-42] 108 [141-82] 79 [98-64]
GTPBP3 Chip 2 β-actin 100 [122-82] 59 [73-47] 121 [149-98] 79 [91-69]
MRPL34 Chip 3 β-actin & GAPDH 100 [125-80] 36 [54-24] 91 [106-78] 73 [89-60]
MYO9B Chip 3 β-actin & GAPDH 100 [129-78] 90 [117-69] 82 [98-69] 76 [83-69]
NR2F6 Chip 3 β-actin & GAPDH 100 [128-78] 55 [72-42] 114 [143-91] 79 [89-70]
USE1 Chip 4 β-actin & GAPDH 100 [119-84] 88 [124-62] 69 [79-60] 67 [101-45]
β-actin SET 1 Chip 1 GAPDH 100 [131-76] 79 [104-60] 103 [126-85] 102 [131-79]
GAPDH SET 1 Chip 1 β-actin 100 [131-76] 126 [166-96] 97 [118-80] 98 [126-76]
GAPDH SET 2 Chip 2 N/A (β-actin failed) N/A N/A N/A N/A
β-actin SET 3 Chip 3 GAPDH 100 [138-73] 92 [132-64] 123 [157-96] 143 [168-122]
GAPDH SET 3 Chip 3 β-actin 100 [138-73] 108 [155-75] 81 [103-63] 70 [82-60]
β-actin SET 4 Chip 4 GAPDH 100 [127-79] 81 [107-61] 153 [186-126] 130 [162-104]
GAPDH SET 4 Chip 4 β-actin 100 [127-79] 127 [161-100] 65 [79-53] 77 [96-62]
β-actin SET 5 Chip 5 GAPDH 100 [144-69] 116 [148-91] 124 [147-105] 100 [130-77]
GAPDH SET 5 Chip 5 β-actin 100 [144-69] 86 [110-68] 81 [96-69] 100 [129-77]
β-actin SET 6 Chip 6 GAPDH 100 [123-81] 86 [109-68] 128 [149-110] 135 [161-113]
GAPDH SET 6 Chip 6 β-actin 100 [123-81] 117 [149-92] 78 [91-67] 74 [88-62]
GAPDH SET 7 Chip 7 N/A (β-actin failed) N/A N/A N/A N/A
% Relative expresion [Confidence intervals]
A2780CP
Gene 
Fluidigm 
Chip
Normalised against
Table 4: Summary of relative expression (%) of selected genes in control and MERIT40 
knockdown A2780CP cell lines. The confidence intervals were calculated from +/- error of 
relative expression. 
 
 
 
 
 
 
